

# ***A. INCIDENCE*** of reported ESRD therapy

**Tables numbered A.30 and higher are not included in the paper edition of the ADR, but are available on the USRDS Web site (<http://www.med.umich.edu/usrds>) and on the USRDS ADR CD.**

Incidence in this report is defined as patients reported as starting renal replacement therapy for ESRD during the calendar year. This definition excludes:

- persons with acute, as opposed to chronic or end stage, renal failure
- persons with chronic renal failure who die before receiving ESRD treatment
- ESRD treatments which are not reported through HCFA. Most ESRD patients not covered by Medicare were not reported to HCFA prior to 1995. Beginning in 1995, all ESRD patients should have HCFA 2728 "Medical Evidence" forms filed with HCFA and should be included in the database.

Chapter XIII and the *Researcher's Guide* discuss these limitations in more detail.

Since the U.S. population figures used for this report (see Section J) include only residents of the 50 states and the District of Columbia, only these residents are included in most of the patient counts and rates in this section. The exceptions are: 1) Table A.1, where counts for Puerto Rico and the Territories are reported separately; 2) Table A.2, where counts for Puerto Rico and the Territories are reported; 3) Tables A.13 and A.14 of median and mean ages; and 4) Tables A.15 through A.22 which report counts (but not rates) by detailed disease group.

Age is computed as of time of start of ESRD therapy.

Race categories. Race in the USRDS database is categorized as follows:

Black  
White  
Native American/Alaskan Native  
Asian/Pacific Islander  
Other  
Unknown

The race of each patient is determined by combining the race code reported on the Chronic Renal Disease Medical Evidence Report, HCFA-2728-U4 (HCFA-2728) with the race code recorded in the HCFA Medicare Health Insurance Master file. The resulting race code indicates "other" or "unknown" in less than 2 percent of all new cases in recent years.

The Native American/Alaskan Native and the Asian/Pacific Islander race categories were added to the HCFA-2728 form in 1981. The proportion of new patients in the "other" and

"unknown" race categories drops from about 5 percent before 1981 to about 1 percent from 1982 to 1986. The proportion in the "other" category increases in 1987 and 1988 due to a large increase in the proportion of this category in the Health Insurance Master file, but the combined proportion of "other" and "unknown" remains under 2 percent.

In 1991, the Medicare Health Insurance Master File added the categories of Native American/Alaskan Native, Asian/Pacific Islander, and Hispanic to its race categories for new patients entering the system. This change allows patients for whom there is no Medical Evidence form to be classified as Native American or Asian. However, it also adds Hispanic as a race category, which is inconsistent with the categories on the Medical Evidence Form and those used by the Census Bureau. If a patient is classified as Hispanic in the Health Insurance Master File and has no Medical Evidence Form, then that patient is classified as "Other" race in the USRDS database.

The Census population estimates used in computing incidence rates use the four race groups of White, Black, Asian and Native American, and all persons are placed in one of these groups. Thus the 2 percent of patients in the USRDS database with race coded "other" or "unknown" do not have a corresponding Census population base for computation of rates. This means that all incidence rates involving race will be slightly low.

In summary, there are two distinct problems with race data. The first is the discontinuity in the coding of race before and after 1982. This results in a lack of comparability before and after 1982. The second is that the patients with race "other" and "unknown" (under 2 percent in recent years) have no corresponding category in the Census population data used as the denominator in computing and adjusting rates. This results in a downward bias in the rates by race.

Treatment of race in reference tables. The discontinuity in the coding of race and the lack of Census population counts corresponding to the "other" and "unknown" categories complicates the computation and presentation of rates of ESRD incidence per million population. We have adopted the following scheme:

Table A.1 presents counts by age, race, sex, and primary disease by year. It shows all of the race categories, including "other" and "unknown."

Table A.3 presents unadjusted incidence rates per million population by age, race, sex, and primary disease. Rates by race are presented only by Black, White, and other. The discontinuity in race coding in 1982 means that even the rates for Blacks and Whites before 1982 must be treated with caution or, preferably, not used at all. The rates by primary disease should also be treated with caution since the proportion of cases with missing primary disease code is much higher before 1982.

In Tables A.4 through A.12 and tables A.30 through A.35, which report incidence rates by race or adjusted for race, we drop the roughly 2 percent of patients with race "other" or "unknown." This means that all rates will be slightly low in these tables. In order to quantify the

effects of this procedure, Table A.4 shows the number of patients remaining after the "other" and "unknown" race patients are dropped and Table A.5 shows the percentage of patients dropped. Both tables show years starting with 1988 and show the same age, sex, and primary disease categories used in Table A.1.

The percentage dropped figures in Table A.5 help to identify any biases which may be introduced by this procedure. Note that patients with disease "missing" are disproportionately represented among those dropped. These are patients for whom a Medical Evidence form was not received. The effect on the unadjusted rates per million of dropping the patients with race "other" and "unknown" can be seen by comparing the crude rates from Tables A.3 and A.6.

Table A.6 corresponds to Table A.3 but shows rates adjusted for age, race, and sex. All four race groups are used in the rate adjustment process. Chapter XIII, "Analytical Methods," describes the adjustment process.

Tables A.13 and A.14 reports median and mean ages by year and race, including the "other" and "unknown" race groups. Tables A.15 through A.22 report incidence counts by detailed disease group including all patients in the "other" and "unknown" race groups. These tables show percents by race only for Blacks and Whites.

Tables A.23 through A.29 show incidence counts and adjusted rates by state and ESRD Network including all race groups. Rates are adjusted for race using three race groups, White and Black, and "other".

Population bases for rates. Rates are computed using U.S. resident population on July 1 of each year, as published by the Bureau of the Census. The population counts are tabulated in Section J of the Reference Tables. Adjustment of rates uses July 1, 1996, U.S. resident population by age, race, and sex as the standard population. See Chapter XIII, "Analytical Methods," for a discussion of the database and of the methodologies used.

Primary disease causing ESRD. Primary disease is recorded on the HCFA-2728. A new list of primary disease choices was introduced in 1995; these codes are reflected in the primary disease tables (A.15 through A.22). A substantial effort has been made to reconcile codes reported before the change was made with the codes available presently, but there may be some discontinuity in primary disease distribution around the year 1995. Changes in primary disease coding are described in more detail in Chapter II of the 1997 Annual Data Report.

Below is an explanation of one of the more complex table formats used in this section:

**Specific Rates By Sex, By Race, By Age  
And Rates Adjusted for Age, Race, and Sex**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female		
0- 4	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D	
5- 9	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D	
10-14	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D	
75-79	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D	
80-84	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D	
85 plus	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D	
All Age	A	A	A	A	A	A	A	A	B	B	B	B	C	C	D	
Age Adj	E	E	E	E	E	E	E	E	F	F	F	F	G	G	H	

- A Specific rates by age by race by sex, with no adjustment.
- B Rates for age by race groups, adjusted for sex.
- C Rates for age by sex groups, adjusted for race.
- D Rates for age groups, adjusted for race and sex.
- E Rates for sex by race groups, adjusted for age.
- F Rates for race groups, adjusted for age and sex.
- G Rates for sex groups, adjusted for age and race.
- H Overall rate adjusted for age, race, and sex.

Standard error tables show the standard errors of the adjusted rates in the corresponding cells of the rates table.

Table A.1  
 U.S. Incidence Counts of Reported ESRD Therapy  
 by Year, Age, Race, Sex, and Primary Disease Causing ESRD

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
<b>AGE AT ESRD</b>										
0- 4	120	130	123	136	121	144	128	185	193	181
5- 9	90	112	138	119	107	114	152	157	141	135
10- 14	200	188	207	217	209	217	233	281	260	267
15- 19	443	502	466	416	457	451	503	550	566	486
20- 24	814	807	828	856	931	886	945	1030	1017	887
25- 29	1306	1467	1468	1486	1492	1496	1671	1660	1661	1571
30- 34	1747	1968	1988	2041	2133	2156	2386	2511	2444	2262
35- 39	2077	2206	2340	2488	2749	2667	3084	3331	3347	3113
40- 44	2131	2443	2744	3064	3229	3173	3542	4139	4284	3967
45- 49	2304	2727	2804	3171	3526	3721	4360	4959	5247	5041
50- 54	2878	3123	3319	3504	3999	4125	5047	5544	5696	5895
55- 59	3562	3922	4155	4464	4905	4912	5969	6504	6700	6848
60- 64	4672	5178	5528	6055	6379	6471	7352	8151	8346	8469
65- 69	5345	6443	7086	7632	8271	8556	9403	9659	10025	10759
70- 74	4559	5535	6117	6996	7900	8408	9387	9694	10475	11297
75- 79	3409	4187	4577	5295	5945	6214	7045	7455	8218	9439
80- 84	1657	2099	2401	2698	3199	3435	3979	4325	4831	5800
85 plus	592	804	962	1098	1274	1478	1613	1854	2197	2685
	37906	43841	47251	51736	56826	58624	66799	71989	75648	79102
<b>RACE</b>										
White	25208	29138	31626	34439	37543	38420	42948	45276	47654	51171
Black	10824	12924	13629	15094	16729	17331	20108	21756	22574	22926
Asian	1120	957	1159	1307	1448	1701	2174	2470	2584	2383
Native Amer.	494	583	640	684	847	780	967	1188	1315	928
Other	163	121	92	99	114	193	370	1139	1387	1558
Unknown	97	118	105	113	145	199	232	160	134	136
	37906	43841	47251	51736	56826	58624	66799	71989	75648	79102
<b>SEX</b>										
Male	20494	23660	25606	27797	30268	31336	35351	37962	40535	42129
Female	17412	20181	21645	23939	26558	27288	31448	34027	35113	36973
	37906	43841	47251	51736	56826	58624	66799	71989	75648	79102
<b>PRIMARY DIAGNOSIS</b>										
Diabetes	11818	14404	16261	18671	20800	21319	25656	29149	31643	33096
Hypertension	10788	12786	14033	15626	17549	17333	20286	18670	19296	20066
Glomeruloneph.	5393	5863	6067	6152	6396	6439	7314	7817	7967	7390
Cystic Kidney	1282	1307	1458	1526	1620	1624	1777	1925	1815	1772
Other Urologic	693	772	804	891	887	888	1035	1344	1507	1388
Other Cause	3922	4453	4540	5016	5436	5400	6358	8043	8368	8284
Unknown Cause	2427	2209	2289	2551	2885	2621	2794	2646	2946	2920
Missing Cause	1583	2047	1799	1303	1253	3000	1579	2395	2106	4186
	37906	43841	47251	51736	56826	58624	66799	71989	75648	79102
<b>Geography</b>										
U. S.	37739	43660	47077	51499	56520	58135	65666	71658	75518	79030
Presumed U. S.	167	181	174	237	306	489	1133	331	130	72
Puerto Rico	477	550	554	604	707	666	846	848	937	979
Other non-U. S.	49	58	68	75	77	88	104	123	131	167
	38432	44449	47873	52415	57610	59378	67749	72960	76716	80248

Age is as of start of ESRD therapy.

Table A.2  
 1997 Incidence Counts of Reported ESRD Therapy  
 by Age, Sex, and Primary Disease Causing ESRD  
 for Patients Residing Outside 50 States and D.C.

	Count	Count	%
ALL PATIENTS	979	167	
AGE AT ESRD			
0-19	13	1	
20-44	127	34	
45-64	440	69	
65-74	226	54	
75 plus	173	9	
SEX			
Male	573	86	
Female	406	81	
PRIMARY DIAGNOSIS			
Diabetes	540	91	
Hypertension	154	35	
Glomeruloneph.	111	7	
Cystic Kidney	19	4	
Other Urologic	29	2	
Other Cause	63	11	
Unknown Cause	25	4	
Missing Cause	38	13	

Age is as of start of ESRD therapy.

**Table A.3**  
**Incidence Rates per Million Population of Reported ESRD Therapy**  
**by Year, Age, Race, Sex, and Primary Disease Causing ESRD**  
**Unadjusted**

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
<b>AGE AT ESRD</b>										
0- 4	7	7	7	7	6	7	6	9	10	9
5- 9	5	6	8	7	6	6	8	8	7	7
10- 14	12	11	12	12	12	12	12	15	14	14
15- 19	24	28	26	24	27	26	28	30	30	25
20- 24	41	42	43	45	49	47	51	57	58	51
25- 29	60	68	69	72	74	76	87	88	87	83
30- 34	82	91	91	92	96	97	108	115	115	109
35- 39	109	113	117	121	130	123	140	149	148	138
40- 44	132	144	154	163	172	165	180	204	206	186
45- 49	178	203	203	225	230	234	261	284	285	273
50- 54	262	279	292	301	332	324	382	406	409	389
55- 59	332	372	397	428	468	460	546	586	590	582
60- 64	433	484	521	572	611	632	729	811	835	842
65- 69	544	647	703	761	829	855	944	973	1013	1102
70- 74	584	700	762	849	933	976	1075	1098	1193	1293
75- 79	577	695	745	844	930	960	1072	1115	1196	1336
80- 84	447	549	610	669	774	809	915	968	1060	1249
85 plus	205	271	316	345	385	431	455	507	584	694
0- 19	12	13	13	12	12	13	14	16	15	14
20- 44	82	90	94	98	104	102	115	125	126	117
45- 64	295	326	342	368	389	388	447	481	484	473
65- 74	562	671	730	801	877	911	1005	1032	1098	1192
75 plus	453	553	605	674	753	786	874	920	1003	1151
<b>RACE</b>										
White	122	140	151	163	176	179	198	208	217	231
Black	364	429	446	485	528	539	616	657	674	675
Other	217	195	209	220	244	265	333	427	452	405
<b>SEX</b>										
Male	172	197	211	226	243	249	278	295	312	322
Female	139	159	169	185	204	207	236	253	259	271
<b>PRIMARY DIAGNOSIS</b>										
Diabetes	48	58	65	74	82	83	99	111	119	124
Hypertension	44	52	56	62	69	67	78	71	73	75
Glomeruloneph.	22	24	24	24	25	25	28	30	30	28
Cystic Kidney	5	5	6	6	6	6	7	7	7	7
Other Urologic	3	3	3	4	3	3	4	5	6	5
Other Cause	16	18	18	20	21	21	24	31	32	31
Unknown Cause	10	9	9	10	11	10	11	10	11	11
Missing Cause	6	8	7	5	5	12	6	9	8	16
<b>CRUDE RATE</b>	<b>155</b>	<b>178</b>	<b>189</b>	<b>205</b>	<b>223</b>	<b>227</b>	<b>257</b>	<b>274</b>	<b>285</b>	<b>296</b>

Includes residents of 50 states and District of Columbia only.

The reporting and coding of race changed in 1982. Rates are not reported for some race categories for reasons discussed in notes at beginning of this Section.

The population base is U.S. resident population on July 1 of each year.

Age is as of start of ESRD therapy.

See Tables A.6 and following for rates adjusted for age, race, and sex.

Table A.4  
Incidence Counts of Reported ESRD Therapy  
by Year, Age, Race, Sex, and Primary Disease Causing ESRD  
after Dropping Patients With Race "Other" and "Unknown"

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
<b>AGE AT ESRD</b>										
0- 4	116	124	121	132	115	138	121	169	177	167
5- 9	90	110	132	117	100	109	147	149	132	129
10- 14	195	180	203	211	200	212	225	271	245	254
15- 19	435	499	455	410	447	440	490	533	543	450
20- 24	802	795	817	844	919	867	926	994	977	837
25- 29	1281	1442	1454	1466	1476	1478	1638	1615	1609	1504
30- 34	1728	1948	1975	2023	2114	2122	2354	2444	2357	2191
35- 39	2056	2186	2324	2466	2730	2651	3028	3270	3262	3024
40- 44	2116	2430	2724	3048	3210	3144	3492	4048	4160	3857
45- 49	2276	2714	2783	3154	3507	3690	4313	4844	5120	4902
50- 54	2858	3110	3302	3492	3979	4090	4996	5404	5558	5712
55- 59	3542	3905	4144	4445	4892	4896	5906	6348	6519	6662
60- 64	4653	5154	5515	6044	6359	6438	7277	7989	8138	8255
65- 69	5326	6419	7072	7613	8248	8512	9343	9488	9878	10563
70- 74	4538	5518	6102	6980	7877	8369	9351	9617	10351	11145
75- 79	3392	4172	4570	5291	5928	6190	7019	7389	8132	9349
80- 84	1651	2093	2399	2693	3195	3418	3965	4279	4791	5754
85 plus	591	803	962	1095	1271	1468	1606	1839	2178	2653
	37646	43602	47054	51524	56567	58232	66197	70690	74127	77408
<b>RACE</b>										
White	25208	29138	31626	34439	37543	38420	42948	45276	47654	51171
Black	10824	12924	13629	15094	16729	17331	20108	21756	22574	22926
Asian	1120	957	1159	1307	1448	1701	2174	2470	2584	2383
Native Amer.	494	583	640	684	847	780	967	1188	1315	928
	37646	43602	47054	51524	56567	58232	66197	70690	74127	77408
<b>SEX</b>										
Male	20361	23509	25497	27677	30131	31127	35044	37270	39763	41261
Female	17285	20093	21557	23847	26436	27105	31153	33420	34364	36147
	37646	43602	47054	51524	56567	58232	66197	70690	74127	77408
<b>PRIMARY DIAGNOSIS</b>										
Diabetes	11773	14384	16238	18640	20752	21229	25448	28581	30937	32351
Hypertension	10761	12755	14011	15609	17522	17293	20155	18465	19077	19808
Glomeruloneph.	5347	5833	6040	6131	6374	6406	7241	7643	7792	7209
Cystic kidney	1276	1305	1456	1521	1620	1617	1762	1899	1789	1750
Other Urologic	690	772	802	889	886	883	1025	1328	1486	1369
Other Cause	3907	4440	4532	5003	5421	5380	6290	7920	8225	8156
Unknown Cause	2411	2195	2279	2540	2869	2608	2764	2598	2879	2854
Missing Cause	1481	1918	1696	1191	1123	2816	1512	2256	1942	3911
	37646	43602	47054	51524	56567	58232	66197	70690	74127	77408

Includes residents of 50 states and District of Columbia only.

This table reports cases which are excluded in most of the following tables because race is "Other" or "Unknown."

Note that the "missing" disease group is disproportionately represented.



**Table A.5**  
**Percent Decrease In Incidence Counts of Reported ESRD Therapy**  
**by Year, Age, Race, Sex, and Primary Disease Causing ESRD**  
**after Dropping Patients with Race "Other" and "Unknown"**

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
<b>AGE AT ESRD</b>										
0- 4	3.3	4.6	1.6	2.9	5.0	4.2	5.5	8.6	8.3	7.7
5- 9	0.0	1.8	4.3	1.7	6.5	4.4	3.3	5.1	6.4	4.4
10- 14	2.5	4.3	1.9	2.8	4.3	2.3	3.4	3.6	5.8	4.9
15- 19	1.8	0.6	2.4	1.4	2.2	2.4	2.6	3.1	4.1	7.4
20- 24	1.5	1.5	1.3	1.4	1.3	2.1	2.0	3.5	3.9	5.6
25- 29	1.9	1.7	1.0	1.3	1.1	1.2	2.0	2.7	3.1	4.3
30- 34	1.1	1.0	0.7	0.9	0.9	1.6	1.3	2.7	3.6	3.1
35- 39	1.0	0.9	0.7	0.9	0.7	0.6	1.8	1.8	2.5	2.9
40- 44	0.7	0.5	0.7	0.5	0.6	0.9	1.4	2.2	2.9	2.8
45- 49	1.2	0.5	0.7	0.5	0.5	0.8	1.1	2.3	2.4	2.8
50- 54	0.7	0.4	0.5	0.3	0.5	0.8	1.0	2.5	2.4	3.1
55- 59	0.6	0.4	0.3	0.4	0.3	0.3	1.1	2.4	2.7	2.7
60- 64	0.4	0.5	0.2	0.2	0.3	0.5	1.0	2.0	2.5	2.5
65- 69	0.4	0.4	0.2	0.2	0.3	0.5	0.6	1.8	1.5	1.8
70- 74	0.5	0.3	0.2	0.2	0.3	0.5	0.4	0.8	1.2	1.3
75- 79	0.5	0.4	0.2	0.1	0.3	0.4	0.4	0.9	1.0	1.0
80- 84	0.4	0.3	0.1	0.2	0.1	0.5	0.4	1.1	0.8	0.8
85 plus	0.2	0.1	0.0	0.3	0.2	0.7	0.4	0.8	0.9	1.2
	0.7	0.5	0.4	0.4	0.5	0.7	0.9	1.8	2.0	2.1
<b>SEX</b>										
Male	0.6	0.6	0.4	0.4	0.5	0.7	0.9	1.8	1.9	2.1
Female	0.7	0.4	0.4	0.4	0.5	0.7	0.9	1.8	2.1	2.2
	0.7	0.5	0.4	0.4	0.5	0.7	0.9	1.8	2.0	2.1
<b>PRIMARY DIAGNOSIS</b>										
Diabetes	0.4	0.1	0.1	0.2	0.2	0.4	0.8	1.9	2.2	2.3
Hypertension	0.3	0.2	0.2	0.1	0.2	0.2	0.6	1.1	1.1	1.3
Glomeruloneph.	0.9	0.5	0.4	0.3	0.3	0.5	1.0	2.2	2.2	2.4
Cystic Kidney	0.5	0.2	0.1	0.3	0.0	0.4	0.8	1.4	1.4	1.2
Other Urologic	0.4	0.0	0.2	0.2	0.1	0.6	1.0	1.2	1.4	1.4
Other Cause	0.4	0.3	0.2	0.3	0.3	0.4	1.1	1.5	1.7	1.5
Unknown Cause	0.7	0.6	0.4	0.4	0.6	0.5	1.1	1.8	2.3	2.3
Missing Cause	6.4	6.3	5.7	8.6	10.4	6.1	4.2	5.8	7.8	6.6
	0.7	0.5	0.4	0.4	0.5	0.7	0.9	1.8	2.0	2.1

Includes residents of 50 states and District of Columbia only.

This table reports cases which are excluded in most of the following tables because race is "Other" or "Unknown."

Note that the "missing" disease group is disproportionately represented.

Table A.6  
Incidence Rates per Million Population of Reported ESRD Therapy  
by Year, Age, Race, Sex, and Primary Disease Causing ESRD  
Adjusted for Age, Race, and Sex

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
<b>AGE AT ESRD</b>										
0- 4	6	7	6	7	6	7	6	8	9	8
5- 9	5	6	7	6	5	6	8	8	7	6
10- 14	12	11	12	12	11	11	12	14	13	13
15- 19	23	26	25	23	25	24	26	28	28	23
20- 24	40	40	42	43	47	44	48	52	53	45
25- 29	59	66	68	70	72	74	83	83	82	77
30- 34	82	90	90	92	95	95	106	111	109	104
35- 39	111	115	119	122	131	124	139	147	145	133
40- 44	140	153	162	170	177	169	183	205	205	184
45- 49	188	217	216	240	247	250	278	297	295	278
50- 54	280	298	311	322	354	347	411	430	433	410
55- 59	365	403	431	463	506	496	583	617	621	608
60- 64	482	538	577	627	671	688	784	864	879	884
65- 69	613	721	788	849	920	943	1032	1045	1089	1167
70- 74	668	800	863	952	1047	1102	1209	1238	1328	1425
75- 79	677	801	871	978	1075	1097	1241	1282	1369	1505
80- 84	553	681	751	830	947	985	1108	1162	1278	1476
85 plus	306	363	438	480	525	565	614	667	790	897
0- 19	11	12	12	12	12	12	13	14	14	13
20- 44	86	93	96	99	104	101	112	120	119	109
45- 64	329	364	384	413	444	445	514	552	557	545
65- 74	640	760	825	901	983	1023	1120	1142	1209	1296
75 plus	512	615	687	763	849	882	988	1037	1146	1292
<b>RACE</b>										
White	120	137	147	158	170	172	190	198	206	218
Black	477	564	588	641	696	708	802	846	865	873
Asian	252	197	232	244	256	289	348	383	387	344
Native Amer.	397	465	490	507	629	563	657	782	849	586
<b>SEX</b>										
Male	196	223	239	256	274	278	308	321	339	348
Female	133	152	161	175	191	192	218	231	234	242
<b>PRIMARY DIAGNOSIS</b>										
Diabetes	50	60	67	76	83	84	99	109	117	120
Hypertension	47	54	59	64	71	69	79	71	72	73
Glomeruloneph.	23	24	25	25	26	25	28	29	29	27
Cystic Kidney	6	6	6	6	7	6	7	7	7	6
Other Urologic	3	3	3	4	4	3	4	5	6	5
Other Cause	16	18	19	20	22	21	24	30	31	30
Unknown Cause	10	9	9	10	11	10	11	10	11	11
Missing Cause	6	8	7	5	4	11	6	9	7	15
<b>CRUDE RATE</b>	154	177	189	204	222	226	254	269	280	289
<b>ADJUSTED RATE</b>	161	183	195	210	227	230	257	271	280	287

Includes residents of 50 states and District of Columbia only.

Cases where race is "Other" or "Unknown" are excluded from this table.

See tables A.4 and A.5 and notes at beginning of this Section.

All rates are therefore slightly low but are consistently defined and are comparable.

The bias introduced by excluding the cases with race "Other" or "Unknown" is unpredictable.

Age is as of start of ESRD therapy.

The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population.

Rates by age are adjusted for race and sex.

Rates by sex are adjusted for race and age.

Rates by race adjusted for sex and age.

Rates by primary disease and "adjusted rate" row adjusted for age, race, and sex.

The "crude rate" row is not adjusted.

Table A.7  
Incidence Counts  
of Reported ESRD Therapy  
by Age, Sex, and Race

1992-1994

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0- 4	190	44	*	*	237	109	18	*	*	137	299	62	11	*	374
5- 9	163	45	10	*	223	104	21	*	*	133	267	66	14	*	356
10- 14	229	74	16	*	322	230	67	13	*	315	459	141	29	*	637
15- 19	424	273	31	12	740	383	208	34	12	637	807	481	65	24	1377
20- 24	846	584	70	14	1514	661	464	53	20	1198	1507	1048	123	34	2712
25- 29	1463	1015	79	24	2581	1198	724	65	24	2011	2661	1739	144	48	4592
30- 34	2218	1499	127	33	3877	1602	971	112	28	2713	3820	2470	239	61	6590
35- 39	2782	2182	139	66	5169	1796	1285	118	41	3240	4578	3467	257	107	8409
40- 44	3205	2467	161	96	5929	2146	1534	168	69	3917	5351	4001	329	165	9846
45- 49	3867	2482	211	142	6702	2688	1843	171	106	4808	6555	4325	382	248	11510
50- 54	4234	2561	218	129	7142	3270	2341	172	140	5923	7504	4902	390	269	13065
55- 59	5121	2649	238	158	8166	4222	2916	232	158	7528	9343	5565	470	316	15694
60- 64	6861	2815	260	166	10102	5978	3508	260	226	9972	12839	6323	520	392	20074
65- 69	9641	2832	384	147	13004	8333	4171	383	212	13099	17974	7003	767	359	26103
70- 74	10287	2247	354	112	13000	8551	3540	343	163	12597	18838	5787	697	275	25597
75- 79	8274	1465	251	70	10060	6395	2347	241	94	9077	14669	3812	492	164	19137
80- 84	4506	755	146	37	5444	3678	1269	137	50	5134	8184	2024	283	87	10578
85 plus	1677	336	66	11	2090	1579	616	45	15	2255	3256	952	111	26	4345
All Age	65988	26325	2763	1226	96302	52923	27843	2560	1368	84694	118911	54168	5323	2594	180996

1995-1997

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0- 4	228	68	14	*	313	138	48	10	*	200	366	116	24	*	513
5- 9	170	56	*	*	234	133	33	*	*	176	303	89	13	*	410
10- 14	274	117	10	*	406	237	98	22	*	364	511	215	32	12	770
15- 19	540	307	32	*	888	374	220	34	10	638	914	527	66	19	1526
20- 24	807	637	61	21	1526	637	561	60	24	1282	1444	1198	121	45	2808
25- 29	1410	1084	84	27	2605	1116	896	73	38	2123	2526	1980	157	65	4728
30- 34	2226	1692	110	53	4081	1503	1257	101	50	2911	3729	2949	211	103	6992
35- 39	3011	2450	154	93	5708	1917	1700	160	71	3848	4928	4150	314	164	9556
40- 44	3848	3099	176	134	7257	2425	2104	185	94	4808	6273	5203	361	228	12065
45- 49	4647	3484	245	185	8561	3396	2520	225	164	6305	8043	6004	470	349	14866
50- 54	5472	3199	329	191	9191	4114	2898	260	211	7483	9586	6097	589	402	16674
55- 59	6277	3303	351	214	10145	5172	3653	302	257	9384	11449	6956	653	471	19529
60- 64	8204	3453	422	184	12263	7083	4378	401	257	12119	15287	7831	823	441	24382
65- 69	11081	3216	501	167	14965	9422	4714	544	284	14964	20503	7930	1045	451	29929
70- 74	12706	2733	473	121	16033	10009	4318	530	223	15080	22715	7051	1003	344	31113
75- 79	10770	1923	432	83	13208	8197	2937	411	117	11662	18967	4860	843	200	24870
80- 84	6366	999	248	27	7640	5173	1712	238	61	7184	11539	2711	486	88	14824
85 plus	2665	473	117	15	3270	2353	916	109	22	3400	5018	1389	226	37	6670
All Age	80702	32293	3765	1534	118294	63399	34963	3672	1897	103931	144101	67256	7437	3431	222225

Includes residents of 50 states and District of Columbia only.  
Cases where race is "Other" or "Unknown" are excluded from this table.  
See tables A.4 and A.5 and notes at beginning of this Section.  
\* Values for cells with fewer than 10 patients are suppressed.

**Table A.8**  
**Incidence Rates per Million Population of Reported ESRD Therapy**  
**Specific Rates by Sex, Race, and Age, and Rates Adjusted for Age, Race, and Sex**

**1992-1994**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0- 4	*	*	*	*	*	*	*	*	*	*	*	*	*	*	*
5- 9	*	10	*	*	*	*	*	*	*	*	*	*	*	*	*
10- 14	10	17	15	*	11	16	13	*	10	17	14	*	11	12	11
15- 19	20	67	32	41	19	52	37	43	19	59	34	42	26	24	25
20- 24	36	147	59	47	30	113	47	74	33	130	53	61	51	41	46
25- 29	60	265	69	86	51	173	54	90	55	219	61	88	87	67	76
30- 34	80	379	106	118	59	216	88	99	69	296	96	108	119	80	99
35- 39	103	586	124	263	67	303	97	156	85	441	110	208	166	99	131
40- 44	132	799	166	448	88	428	151	305	110	608	158	374	220	135	176
45- 49	190	1107	282	845	130	690	203	598	159	891	241	714	314	207	259
50- 54	264	1461	391	1021	197	1091	284	1025	229	1269	335	1026	426	320	371
55- 59	381	1850	556	1604	295	1600	475	1466	337	1721	512	1532	583	476	528
60- 64	538	2213	769	2120	424	2086	590	2534	480	2148	673	2332	772	658	714
65- 69	803	2492	1403	2360	575	2706	1029	2845	687	2600	1205	2607	1052	880	965
70- 74	1021	2709	1672	2454	653	2873	1281	2769	832	2791	1462	2613	1269	974	1119
75- 79	1167	2638	1927	2405	609	2517	1437	2232	882	2575	1664	2319	1390	894	1137
80- 84	1099	2393	1904	2164	491	2077	1522	1803	787	2229	1698	2009	1299	739	1014
85 plus	650	1485	1347	860	233	1125	657	591	436	1300	987	711	781	364	568
All Age	209	575	218	377	161	549	192	415	185	561	205	396	255	214	234
Age Adj	221	808	346	623	144	667	262	610	177	735	298	616	287	201	238

**1995-1997**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0- 4	*	15	11	*	*	11	*	*	*	13	*	*	10	*	*
5- 9	*	12	*	*	*	*	*	*	*	*	*	*	*	*	*
10- 14	12	26	*	*	11	23	20	*	11	25	14	17	14	13	13
15- 19	23	70	30	*	17	51	33	32	20	60	32	31	30	22	26
20- 24	37	164	52	73	31	141	52	88	34	153	52	80	54	46	50
25- 29	61	290	67	92	49	220	54	141	55	254	60	117	90	72	81
30- 34	84	429	87	189	58	282	74	181	71	354	80	184	129	88	108
35- 39	107	615	125	345	69	378	120	259	88	494	123	301	174	112	142
40- 44	147	893	159	571	93	528	148	379	120	708	154	475	246	153	198
45- 49	203	1286	267	971	147	782	212	818	174	1030	241	896	349	235	290
50- 54	303	1661	489	1349	220	1223	348	1382	261	1439	419	1371	491	362	424
55- 59	440	2146	685	2013	342	1853	530	2182	390	1997	610	2105	678	556	615
60- 64	660	2694	1073	2217	520	2566	822	2714	588	2628	947	2475	946	808	876
65- 69	930	2699	1629	2578	673	2955	1268	3650	799	2829	1445	3130	1194	1009	1100
70- 74	1233	3191	1940	2371	756	3431	1616	3527	990	3312	1775	2962	1516	1150	1330
75- 79	1405	3175	2792	2521	749	3028	1945	2515	1068	3095	2367	2542	1685	1096	1385
80- 84	1398	3047	2724	1315	656	2691	2032	1954	1017	2863	2370	1643	1650	974	1305
85 plus	925	1894	1842	917	320	1512	1193	650	614	1694	1502	790	1077	504	785
All Age	249	677	267	450	189	662	245	549	219	669	256	500	304	256	279
Age Adj	261	935	427	691	168	793	331	776	207	862	371	739	336	236	279

Includes residents of 50 states and District of Columbia only.  
 Cases where race is "Other" or "Unknown" are excluded from this table.  
 See tables A.4 and A.5 and notes at beginning of this Section.  
 The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

**Table A.9**  
**Standard Errors for Adjusted Incidence Rates per Million Population**  
**of Reported ESRD Therapy by Sex, Race, and Age,**  
**Adjusted for Age, Race, and Sex**

**1992-1994**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0- 4	0.6	1.4	*	*	0.5	0.9	*	*	0.4	0.8	1.5	*	0.5	0.4	0.3
5- 9	0.6	1.5	3.1	*	0.5	1.1	*	*	0.4	0.9	1.8	*	0.5	0.4	0.3
10- 14	0.7	2.0	3.8	*	0.7	2.0	3.6	*	0.5	1.4	2.6	*	0.6	0.7	0.5
15- 19	1.0	4.0	5.7	11.9	1.0	3.6	6.3	12.3	0.7	2.7	4.3	8.6	1.0	1.0	0.7
20- 24	1.2	6.1	7.1	12.6	1.2	5.3	6.4	16.5	0.9	4.0	4.8	10.4	1.3	1.2	0.9
25- 29	1.6	8.3	7.8	17.5	1.5	6.4	6.7	18.4	1.1	5.2	5.1	12.7	1.7	1.5	1.1
30- 34	1.7	9.8	9.4	20.6	1.5	6.9	8.3	18.7	1.1	6.0	6.2	13.9	1.9	1.5	1.2
35- 39	1.9	12.5	10.5	32.3	1.6	8.5	8.9	24.4	1.2	7.5	6.9	20.1	2.3	1.7	1.4
40- 44	2.3	16.1	13.1	45.7	1.9	10.9	11.7	36.7	1.5	9.6	8.7	29.1	2.9	2.2	1.8
45- 49	3.0	22.2	19.4	70.9	2.5	16.1	15.5	58.1	2.0	13.6	12.4	45.3	3.9	3.0	2.4
50- 54	4.1	28.9	26.5	89.9	3.4	22.6	21.7	86.6	2.6	18.2	17.0	62.6	5.1	4.2	3.3
55- 59	5.3	36.0	36.1	127.6	4.5	29.6	31.2	116.6	3.5	23.2	23.7	86.2	6.6	5.5	4.3
60- 64	6.5	41.7	47.7	164.6	5.5	35.2	36.6	168.6	4.2	27.2	29.7	117.9	7.9	6.7	5.1
65- 69	8.2	46.8	71.6	194.7	6.3	41.9	52.6	195.4	5.1	31.3	43.9	137.9	9.5	7.9	6.1
70- 74	10.1	57.2	88.9	231.8	7.1	48.3	69.2	216.9	6.1	37.3	55.7	158.5	11.7	9.0	7.3
75- 79	12.8	68.9	121.6	287.4	7.6	52.0	92.6	230.2	7.4	42.9	75.5	183.5	14.6	9.9	8.8
80- 84	16.4	87.1	157.6	355.7	8.1	58.3	130.1	255.0	9.0	51.9	101.3	221.4	18.6	11.2	10.7
85 plus	15.9	81.0	165.8	259.3	5.9	45.3	97.9	152.6	8.3	45.9	94.8	146.9	17.8	8.4	9.7
Age Adj	0.9	5.2	7.1	19.0	0.6	4.0	5.5	16.9	0.5	3.2	4.4	12.6	0.9	0.7	0.6

**1995-1997**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0- 4	0.6	1.8	2.9	*	0.5	1.6	2.5	*	0.4	1.2	1.9	*	0.6	0.5	0.4
5- 9	0.6	1.6	*	*	0.5	1.3	*	*	0.4	1.0	1.6	*	0.5	0.5	0.3
10- 14	0.7	2.4	2.7	*	0.7	2.3	4.2	*	0.5	1.7	2.6	4.9	0.7	0.7	0.5
15- 19	1.0	4.0	5.3	*	0.9	3.5	5.6	10.1	0.7	2.6	3.9	7.0	1.0	0.9	0.7
20- 24	1.3	6.5	6.7	15.9	1.2	6.0	6.8	17.9	0.9	4.4	4.8	12.0	1.4	1.3	0.9
25- 29	1.6	8.8	7.3	17.8	1.5	7.4	6.3	22.9	1.1	5.7	4.8	14.6	1.8	1.6	1.2
30- 34	1.8	10.4	8.3	25.9	1.5	8.0	7.4	25.6	1.2	6.5	5.5	18.2	2.0	1.6	1.3
35- 39	1.9	12.4	10.1	35.8	1.6	9.2	9.5	30.8	1.2	7.7	6.9	23.5	2.3	1.8	1.5
40- 44	2.4	16.0	11.9	49.4	1.9	11.5	10.9	39.1	1.5	9.8	8.1	31.5	2.9	2.2	1.8
45- 49	3.0	21.8	17.1	71.4	2.5	15.6	14.2	63.9	1.9	13.3	11.1	48.0	3.8	3.0	2.4
50- 54	4.1	29.4	27.0	97.6	3.4	22.7	21.6	95.1	2.7	18.5	17.3	68.5	5.2	4.2	3.3
55- 59	5.6	37.3	36.6	137.6	4.8	30.7	30.5	136.1	3.6	24.1	23.9	97.0	6.8	5.8	4.4
60- 64	7.3	45.8	52.2	163.5	6.2	38.8	41.1	169.3	4.8	29.9	33.2	118.0	8.7	7.4	5.7
65- 69	8.8	47.6	72.8	199.5	6.9	43.0	54.4	216.6	5.6	32.0	45.2	147.7	10.0	8.4	6.5
70- 74	10.9	61.0	89.2	215.6	7.6	52.2	70.2	236.2	6.6	40.0	56.5	160.3	12.5	9.7	7.8
75- 79	13.5	72.4	134.3	276.7	8.3	55.9	95.9	232.5	7.8	45.4	82.3	182.0	15.4	10.6	9.3
80- 84	17.5	96.4	173.0	253.1	9.1	65.0	131.7	250.2	9.7	57.7	108.2	178.3	20.1	12.3	11.6
85 plus	17.9	87.1	170.3	236.8	6.6	50.0	114.2	138.6	9.4	49.5	101.4	137.6	19.5	9.4	10.7
Age Adj	0.9	5.4	7.5	18.6	0.7	4.3	5.7	18.2	0.5	3.4	4.6	13.1	1.0	0.7	0.6

Includes residents of 50 states and District of Columbia only.  
 Cases where race is "Other" or "Unknown" are excluded from this table.  
 See tables A.4 and A.5 and notes at beginning of this Section.  
 The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

**Table A.10**  
**Incidence Counts of Reported ESRD Therapy**  
**by Age, Sex, Race and Primary Disease Causing ESRD**  
**1994-1997**

**Diabetes**

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0- 4	*	*	*	*	12	*	*	*	0	10	11	*	*	*	22
5- 9	*	0	0	0	*	*	*	0	0	*	*	*	0	0	*
10-14	*	*	0	0	*	*	*	0	0	*	*	*	0	0	*
15-19	10	*	0	0	15	11	*	*	0	21	21	14	*	0	36
20-24	96	58	*	0	156	128	88	*	*	225	224	146	*	*	381
25-29	547	196	*	*	754	577	242	*	12	837	1124	438	12	17	1591
30-34	1303	334	19	21	1677	905	300	23	23	1251	2208	634	42	44	2928
35-39	1793	492	41	43	2369	1089	503	30	40	1662	2882	995	71	83	4031
40-44	2206	835	70	95	3206	1405	785	50	75	2315	3611	1620	120	170	5521
45-49	2877	1320	127	167	4491	2135	1393	96	154	3778	5012	2713	223	321	8269
50-54	3573	1728	201	170	5672	2832	2087	146	205	5270	6405	3815	347	375	10942
55-59	4233	2037	257	207	6734	3914	2771	220	251	7156	8147	4808	477	458	13890
60-64	5113	2069	289	176	7647	5393	3414	310	266	9383	10506	5483	599	442	17030
65-69	6075	1906	342	142	8465	6636	3614	422	288	10960	12711	5520	764	430	19425
70-74	5640	1425	279	104	7448	6058	2924	381	197	9560	11698	4349	660	301	17008
75-79	3511	799	221	48	4579	3741	1712	246	93	5792	7252	2511	467	141	10371
80-84	1501	333	99	*	1940	1641	765	121	45	2572	3142	1098	220	52	4512
85 plus	400	103	41	*	549	494	245	44	15	798	894	348	85	20	1347
All Age	38887	13646	1995	1191	55719	36967	20861	2101	1669	61598	75854	34507	4096	2860	117317

**Hypertension**

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0- 4	*	*	0	0	11	*	*	0	*	14	*	15	0	*	25
5- 9	*	*	0	0	*	*	*	0	0	*	*	*	0	0	*
10-14	*	*	0	0	10	10	*	*	0	14	14	*	*	0	24
15-19	26	57	*	*	87	26	24	*	*	54	52	81	*	*	141
20-24	90	260	10	*	367	45	131	*	*	188	135	391	14	15	555
25-29	209	449	19	*	683	97	262	*	*	371	306	711	27	10	1054
30-34	255	732	29	11	1027	155	418	21	*	597	410	1150	50	14	1624
35-39	355	1186	35	20	1596	168	651	24	12	855	523	1837	59	32	2451
40-44	574	1507	40	25	2146	258	828	48	19	1153	832	2335	88	44	3299
45-49	719	1686	65	34	2504	399	900	52	14	1365	1118	2586	117	48	3869
50-54	915	1491	79	25	2510	529	967	70	19	1585	1444	2458	149	44	4095
55-59	1312	1357	84	27	2780	799	1180	64	25	2068	2111	2537	148	52	4848
60-64	2269	1480	119	28	3896	1405	1452	106	25	2988	3674	2932	225	53	6884
65-69	3941	1506	144	29	5620	2595	1818	144	35	4592	6536	3324	288	64	10212
70-74	5611	1401	185	28	7225	3586	1992	138	47	5763	9197	3393	323	75	12988
75-79	5600	1159	189	27	6975	3778	1570	169	32	5549	9378	2729	358	59	12524
80-84	3754	612	130	17	4513	2976	1071	100	20	4167	6730	1683	230	37	8680
85 plus	1627	335	56	*	2026	1465	667	55	10	2197	3092	1002	111	18	4223
All Age	27268	15231	1186	294	43979	18297	13945	1008	276	33526	45565	29176	2194	570	77505

(CONTINUED)

Includes residents of 50 states and District of Columbia only.  
 Incident cases for 1994 through 1997 are combined to produce larger cell sizes.  
 Cases where race is "Other" or "Unknown" are excluded from this table.  
 See tables A. 4 and A. 5 and notes at beginning of this Section.  
 \* Values for cells with fewer than 10 patients are suppressed.

Table A.10(Continued)  
Incidence Counts of Reported ESRD Therapy  
by Age, Sex, Race and Primary Disease Causing ESRD  
1994-1997

**Glomeruloneph.**

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0- 4	25	*	*	0	37	25	*	*	0	35	50	14	*	0	72
5- 9	48	17	*	*	73	45	12	*	*	61	93	29	*	*	134
10-14	80	29	*	*	118	86	51	*	*	151	166	80	15	*	269
15-19	236	195	22	*	456	186	101	12	*	304	422	296	34	*	760
20-24	392	291	41	11	735	267	202	36	*	513	659	493	77	19	1248
25-29	537	327	53	15	932	299	229	45	13	586	836	556	98	28	1518
30-34	639	373	76	16	1104	336	302	53	24	715	975	675	129	40	1819
35-39	743	497	70	21	1331	421	327	102	18	868	1164	824	172	39	2199
40-44	793	581	79	29	1482	440	337	88	14	879	1233	918	167	43	2361
45-49	905	487	76	23	1491	502	272	75	18	867	1407	759	151	41	2358
50-54	888	345	77	16	1326	516	216	42	*	780	1404	561	119	22	2106
55-59	944	286	56	15	1301	536	220	57	13	826	1480	506	113	28	2127
60-64	1127	254	37	11	1429	629	188	42	19	878	1756	442	79	30	2307
65-69	1399	198	83	14	1694	828	217	52	15	1112	2227	415	135	29	2806
70-74	1582	172	76	13	1843	956	200	57	*	1222	2538	372	133	22	3065
75-79	1321	109	64	11	1505	848	129	39	11	1027	2169	238	103	22	2532
80-84	826	57	29	*	915	508	67	36	*	615	1334	124	65	*	1530
85 plus	313	27	17	*	358	256	51	*	0	316	569	78	26	*	674
All Age	12798	4254	870	208	18130	7684	3126	761	184	11755	20482	7380	1631	392	29885

**Cystic Kidney**

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0- 4	23	*	0	0	25	23	*	*	0	28	46	*	*	0	53
5- 9	14	*	*	*	20	18	*	0	0	21	32	*	*	*	41
10-14	17	*	*	*	23	19	*	*	0	27	36	10	*	*	50
15-19	14	*	0	*	20	14	*	*	0	19	28	*	*	*	39
20-24	16	*	0	0	18	16	*	*	0	20	32	*	*	0	38
25-29	23	*	0	*	30	30	*	*	*	35	53	*	*	*	65
30-34	73	19	*	*	95	52	18	*	*	72	125	37	*	*	167
35-39	187	31	*	*	228	128	32	*	*	166	315	63	13	*	394
40-44	373	60	*	*	443	236	63	11	0	310	609	123	17	*	753
45-49	499	74	12	*	586	385	78	12	*	479	884	152	24	*	1065
50-54	516	57	19	*	595	406	75	*	*	493	922	132	28	*	1088
55-59	375	42	14	*	433	347	55	*	*	414	722	97	21	*	847
60-64	276	44	10	*	334	281	43	*	*	334	557	87	18	*	668
65-69	312	38	10	*	361	299	39	*	*	347	611	77	16	*	708
70-74	247	29	*	0	284	259	45	*	0	311	506	74	15	0	595
75-79	157	24	*	0	184	153	24	*	0	180	310	48	*	0	364
80-84	79	20	*	*	103	73	11	*	*	88	152	31	*	*	191
85 plus	34	*	*	*	43	24	*	0	0	31	58	14	*	*	74
All Age	3235	468	98	24	3825	2763	512	78	22	3375	5998	980	176	46	7200

(CONTINUED)

Includes residents of 50 states and District of Columbia only.  
Incident cases for 1994 through 1997 are combined to produce larger cell sizes.  
Cases where race is "Other" or "Unknown" are excluded from this table.  
See tables A. 4 and A. 5 and notes at beginning of this Section.  
\* Values for cells with fewer than 10 patients are suppressed.

Table A.10(Continued)  
 Incidence Counts of Reported ESRD Therapy  
 by Age, Sex, Race and Primary Disease Causing ESRD  
**1994-1997**

**Other Urologic**

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0- 4	16	*	0	0	23	*	*	0	0	*	22	*	0	0	30
5- 9	15	*	0	0	19	13	*	0	0	17	28	*	0	0	36
10- 14	41	*	0	0	47	30	*	*	*	34	71	*	*	*	81
15- 19	39	16	0	0	55	34	*	*	*	42	73	22	*	*	97
20- 24	53	*	*	0	63	56	*	*	*	69	109	15	*	*	132
25- 29	75	14	*	*	92	65	14	0	0	79	140	28	*	*	171
30- 34	72	13	*	*	91	79	*	*	*	94	151	22	*	*	185
35- 39	99	18	*	*	127	100	12	*	*	116	199	30	*	*	243
40- 44	99	19	*	*	120	83	28	*	0	119	182	47	*	*	239
45- 49	96	25	*	*	127	95	17	*	0	118	191	42	11	*	245
50- 54	109	23	*	*	137	110	18	*	*	135	219	41	*	*	272
55- 59	150	33	*	*	190	115	26	11	0	152	265	59	15	*	342
60- 64	218	52	13	*	286	126	24	*	*	157	344	76	18	*	443
65- 69	315	77	10	*	406	171	32	12	*	216	486	109	22	*	622
70- 74	408	68	*	*	487	191	25	12	*	229	599	93	20	*	716
75- 79	417	43	*	*	472	164	15	*	*	185	581	58	11	*	657
80- 84	297	45	*	*	350	81	21	*	0	105	378	66	*	*	455
85 plus	156	19	*	0	180	50	10	*	0	62	206	29	*	0	242
All Age	2675	489	74	34	3272	1569	272	82	13	1936	4244	761	156	47	5208

**Other Cause**

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0- 4	169	50	*	*	230	84	26	*	*	117	253	76	13	*	347
5- 9	117	36	*	0	157	66	15	*	*	87	183	51	*	*	244
10- 14	172	67	*	*	247	113	38	*	*	163	285	105	15	*	410
15- 19	266	86	14	*	372	179	85	18	*	287	445	171	32	11	659
20- 24	254	142	11	*	411	238	232	29	*	506	492	374	40	11	917
25- 29	331	303	12	*	652	293	327	29	11	660	624	630	41	17	1312
30- 34	361	551	13	*	932	333	471	30	*	838	694	1022	43	11	1770
35- 39	457	699	13	23	1192	436	525	19	15	995	893	1224	32	38	2187
40- 44	499	697	16	13	1225	499	454	33	12	998	998	1151	49	25	2223
45- 49	546	520	18	12	1096	588	342	27	16	973	1134	862	45	28	2069
50- 54	668	300	19	14	1001	621	270	26	11	928	1289	570	45	25	1929
55- 59	760	249	22	12	1043	679	225	25	13	942	1439	474	47	25	1985
60- 64	1037	245	27	10	1319	906	235	20	14	1175	1943	480	47	24	2494
65- 69	1491	226	31	13	1761	1167	201	37	11	1416	2658	427	68	24	3177
70- 74	1662	202	24	*	1896	1264	196	33	11	1504	2926	398	57	19	3400
75- 79	1493	174	34	*	1708	1074	154	21	*	1254	2567	328	55	12	2962
80- 84	839	99	16	*	956	662	105	12	*	782	1501	204	28	*	1738
85 plus	371	47	10	*	433	273	55	*	*	335	644	102	16	*	768
All Age	11493	4693	298	147	16631	9475	3956	382	147	13960	20968	8649	680	294	30591

(CONTINUED)

Includes residents of 50 states and District of Columbia only.  
 Incident cases for 1994 through 1997 are combined to produce larger cell sizes.  
 Cases where race is "Other" or "Unknown" are excluded from this table.  
 See tables A. 4 and A. 5 and notes at beginning of this Section.  
 \* Values for cells with fewer than 10 patients are suppressed.



Table A.10(Continued)  
 Incidence Counts of Reported ESRD Therapy  
 by Age, Sex, Race and Primary Disease Causing ESRD  
**1994-1997**

**Unknown Cause**

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0- 4	13	*	0	0	14	*	*	0	0	*	19	*	0	0	23
5- 9	*	*	0	0	13	13	*	*	*	17	22	*	*	*	30
10- 14	*	16	*	*	27	26	15	*	0	42	34	31	*	*	69
15- 19	53	27	*	*	82	43	23	*	*	72	96	50	*	*	154
20- 24	108	49	*	*	168	59	33	*	*	99	167	82	13	*	267
25- 29	101	73	11	*	187	77	37	*	*	121	178	110	16	*	308
30- 34	121	116	*	*	243	67	59	11	*	140	188	175	15	*	383
35- 39	142	145	19	*	313	109	63	14	*	187	251	208	33	*	500
40- 44	163	138	13	*	320	103	91	12	*	211	266	229	25	11	531
45- 49	177	132	14	*	330	136	81	15	*	234	313	213	29	*	564
50- 54	201	88	10	*	301	138	75	18	*	235	339	163	28	*	536
55- 59	251	123	12	*	392	195	94	14	*	309	446	217	26	12	701
60- 64	368	112	21	*	506	257	98	25	*	385	625	210	46	10	891
65- 69	511	118	27	11	667	409	124	20	*	561	920	242	47	19	1228
70- 74	808	108	20	*	941	484	143	31	*	666	1292	251	51	13	1607
75- 79	784	93	31	*	914	492	101	18	*	615	1276	194	49	10	1529
80- 84	544	62	19	*	626	409	81	16	*	508	953	143	35	*	1134
85 plus	272	32	10	0	314	257	60	*	*	326	529	92	17	*	640
All Age	4634	1437	223	64	6358	3280	1183	217	57	4737	7914	2620	440	121	11095

**Missing Cause**

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0- 4	26	*	*	0	35	21	*	*	0	27	47	10	*	0	62
5- 9	26	*	*	0	34	17	*	*	0	23	43	11	*	0	57
10- 14	33	14	0	*	48	23	11	*	0	37	56	25	*	*	85
15- 19	51	23	*	0	77	27	24	*	*	53	78	47	*	*	130
20- 24	64	43	*	*	116	42	34	*	0	80	106	77	11	*	196
25- 29	92	85	*	*	189	85	63	*	*	158	177	148	17	*	347
30- 34	139	121	*	*	270	124	69	*	*	200	263	190	13	*	470
35- 39	185	156	14	*	358	109	104	*	*	221	294	260	20	*	579
40- 44	199	179	11	*	390	126	109	*	0	240	325	288	16	*	630
45- 49	232	222	11	*	466	144	113	12	*	274	376	335	23	*	740
50- 54	246	153	12	*	417	160	108	13	*	285	406	261	25	10	702
55- 59	229	153	*	*	393	144	154	*	*	302	373	307	11	*	695
60- 64	282	187	16	*	487	248	195	*	*	455	530	382	23	*	942
65- 69	413	131	10	*	555	339	179	13	*	539	752	310	23	*	1094
70- 74	471	117	*	*	598	328	148	*	*	487	799	265	15	*	1085
75- 79	455	75	*	*	539	299	104	*	*	411	754	179	12	*	950
80- 84	245	47	*	*	297	175	74	*	0	252	420	121	*	*	549
85 plus	123	27	*	*	155	102	48	*	0	153	225	75	*	*	308
All Age	3511	1746	136	31	5424	2513	1545	102	37	4197	6024	3291	238	68	9621

Includes residents of 50 states and District of Columbia only.  
 Incident cases for 1994 through 1997 are combined to produce larger cell sizes.  
 Cases where race is "Other" or "Unknown" are excluded from this table.  
 See tables A. 4 and A. 5 and notes at beginning of this Section.  
 \* Values for cells with fewer than 10 patients are suppressed.

**Table A.11**  
**Incidence Rates per Ten Million Population**  
**of Reported ESRD Therapy by Primary Disease Causing ESRD**  
**Specific Rates by Sex, Race, and Age, and Rates Adjusted for Age, Race, and Sex**  
**1994-1997**

**Diabetes**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	*	*	*	*	*	*	*	0	*	*	*	*	*	*	*	
5- 9	*	0	0	0	*	*	0	0	*	*	0	0	*	*	*	
10-14	*	*	0	0	*	*	0	0	*	*	0	0	*	*	*	
15-19	*	*	0	0	*	*	*	0	*	12	*	0	*	*	*	
20-24	33	112	*	0	46	165	*	*	40	139	*	*	42	61	52	
25-29	176	393	*	*	191	445	*	337	183	420	35	235	198	218	208	
30-34	366	634	113	560	259	504	128	621	310	567	121	592	391	288	338	
35-39	480	935	253	1210	296	845	172	1103	386	889	211	1158	536	368	450	
40-44	642	1839	483	3082	410	1502	306	2301	523	1668	395	2686	808	561	681	
45-49	960	3769	1070	6711	703	3342	703	5874	829	3546	892	6314	1368	1081	1221	
50-54	1512	6834	2312	9179	1158	6715	1514	10254	1328	6777	1905	9704	2277	1950	2110	
55-59	2247	10050	3867	14774	1958	10679	2970	16218	2098	10348	3431	15484	3396	3217	3306	
60-64	3082	12129	5650	16081	2958	15064	4841	21291	3020	13620	5224	18758	4431	4714	4581	
65-69	3819	12075	8512	16542	3532	17083	7531	27980	3675	14615	7992	22385	5142	5602	5386	
70-74	4109	12549	8733	15536	3433	17473	8978	23599	3765	15048	8830	19621	5441	5582	5523	
75-79	3483	10060	11050	11191	2586	13363	9066	15271	3009	11715	9957	13369	4629	4283	4460	
80-84	2516	7649	8383	*	1572	9050	8067	10987	2020	8349	8171	6853	3360	2825	3090	
85 plus	1060	3144	5040	*	511	3083	3781	3475	774	3075	4282	2946	1463	971	1212	
All Age	904	2158	1081	2643	830	2981	1071	3649	866	2590	1076	3150	1079	1142	1111	
Age Adj	920	3118	1752	4093	747	3644	1491	5260	825	3414	1609	4752	1169	1061	1112	

**Hypertension**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	*	*	0	0	*	*	0	*	*	13	0	*	*	*	*	
5- 9	*	*	0	0	*	*	0	0	*	*	0	0	*	*	*	
10-14	*	*	0	0	*	*	*	0	*	*	*	0	*	*	*	
15-19	*	98	*	*	*	43	*	*	*	70	*	*	21	14	17	
20-24	31	501	64	*	16	246	*	*	23	371	45	201	92	47	69	
25-29	67	900	116	*	32	482	*	*	49	687	80	135	175	90	131	
30-34	72	1389	173	293	44	702	117	*	58	1037	145	184	243	130	184	
35-39	95	2254	216	563	46	1094	137	331	70	1664	177	444	377	184	276	
40-44	167	3318	276	811	75	1585	294	583	120	2440	286	702	577	279	422	
45-49	240	4814	548	1366	131	2159	381	534	185	3474	467	943	843	402	613	
50-54	387	5897	909	1350	216	3111	726	950	302	4489	825	1150	1116	610	853	
55-59	697	6695	1264	1927	400	4548	864	1615	546	5616	1064	1783	1490	954	1213	
60-64	1368	8676	2326	2558	771	6407	1655	2001	1062	7518	1997	2278	2337	1526	1920	
65-69	2477	9541	3584	3378	1381	8594	2570	3400	1917	9066	3073	3401	3420	2355	2876	
70-74	4088	12338	5790	4183	2032	11904	3252	5630	3039	12120	4493	4945	5195	3356	4259	
75-79	5555	14592	9450	6295	2611	12255	6228	5255	4051	13386	7845	5804	6844	3986	5385	
80-84	6292	14057	11008	6383	2852	12670	6667	4883	4528	13344	8731	5651	7433	4246	5809	
85 plus	4310	10227	6883	*	1514	8392	4726	2316	2870	9268	5747	3108	5129	2498	3787	
All Age	634	2409	642	652	411	1993	514	603	520	2190	576	628	852	622	734	
Age Adj	694	3462	1154	1105	341	2451	763	911	487	2931	926	998	986	554	737	

(CONTINUED)

Includes residents of 50 states and District of Columbia only.  
 Incident cases for 1994 through 1997 are combined to produce larger cell sizes.  
 Cases where race is "Other" or "Unknown" are excluded from this table.  
 See tables A.4 and A.5 and notes at beginning of this Section.  
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.  
 The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

Table A.11(Continued)  
Incidence Rates per Ten Million Population  
of Reported ESRD Therapy by Primary Disease Causing ESRD  
Specific Rates by Sex, Race, and Age, and Rates Adjusted for Age, Race, and Sex  
**1994-1997**

**Glomeruloneph.**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	*	*	*	0	*	*	*	0	*	12	*	0	*	*	*	
5- 9	15	27	*	*	15	20	*	*	15	24	*	*	18	16	17	
10- 14	26	49	*	*	29	90	*	*	28	70	51	*	30	39	35	
15- 19	78	336	157	*	66	179	89	*	72	257	123	*	114	82	97	
20- 24	133	560	262	285	96	380	235	*	114	467	247	252	193	138	165	
25- 29	173	656	323	389	99	421	255	365	135	536	289	378	241	148	193	
30- 34	179	708	454	427	96	507	294	648	137	605	373	540	258	160	208	
35- 39	199	945	432	591	114	549	583	496	156	743	511	543	305	190	246	
40- 44	231	1279	545	941	128	645	538	429	178	957	548	681	381	212	294	
45- 49	302	1390	641	924	165	653	549	687	232	1014	599	795	458	245	348	
50- 54	376	1364	886	864	211	695	436	*	293	1023	659	584	525	282	400	
55- 59	501	1411	843	1071	268	848	769	840	382	1124	808	954	634	365	496	
60- 64	679	1489	723	1005	345	830	656	1521	509	1152	691	1268	787	428	603	
65- 69	879	1254	2066	1631	441	1026	928	1457	655	1138	1490	1545	977	541	755	
70- 74	1153	1515	2379	1942	542	1195	1343	*	841	1351	1854	1509	1250	659	948	
75- 79	1310	1372	3200	2565	586	1007	1437	1806	940	1182	2311	2186	1397	681	1032	
80- 84	1385	1309	2456	*	487	793	2400	*	925	1047	2428	*	1410	600	997	
85 plus	829	824	2090	*	265	642	*	0	539	731	1406	*	869	327	593	
All Age	297	673	471	462	173	447	388	402	234	554	428	432	351	218	283	
Age Adj	308	804	641	632	158	491	453	499	225	642	534	560	378	207	284	

**Cystic Kidney**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	*	*	0	0	*	*	*	0	*	*	*	0	*	*	*	
5- 9	*	*	*	*	*	*	0	0	*	*	*	*	*	*	*	
10- 14	*	*	*	*	*	*	*	0	*	*	*	*	*	*	*	
15- 19	*	*	0	*	*	*	*	0	*	*	*	*	*	*	*	
20- 24	*	*	0	0	*	*	*	0	*	*	*	0	*	*	*	
25- 29	*	*	0	*	*	*	*	*	*	*	*	*	*	*	*	
30- 34	21	36	*	*	15	30	*	*	18	33	*	*	22	17	19	
35- 39	50	59	*	*	35	54	*	*	42	56	39	*	51	37	44	
40- 44	109	132	*	*	69	121	67	0	88	126	55	*	109	75	92	
45- 49	167	211	101	*	127	187	88	*	147	200	93	*	169	134	151	
50- 54	218	225	219	*	166	241	*	*	192	233	153	*	219	173	196	
55- 59	199	207	211	*	174	212	*	*	186	210	155	*	200	177	188	
60- 64	166	258	195	*	154	190	*	*	160	223	160	*	181	158	169	
65- 69	196	241	249	*	159	184	*	*	177	212	175	*	203	161	182	
70- 74	180	255	*	0	147	269	*	0	163	262	204	0	190	161	176	
75- 79	156	302	*	0	106	187	*	0	130	241	*	0	173	116	143	
80- 84	132	459	*	*	70	130	*	*	101	290	*	*	180	84	130	
85 plus	90	*	*	*	25	*	0	0	57	149	*	*	110	31	70	
All Age	75	74	53	53	62	73	40	48	69	74	46	51	74	63	68	
Age Adj	76	102	72	72	58	85	46	63	66	92	58	66	78	61	69	

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

Incident cases for 1994 through 1997 are combined to produce larger cell sizes.

Cases where race is "Other" or "Unknown" are excluded from this table.

See tables A.4 and A.5 and notes at beginning of this Section.

Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.

The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996,

U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

**Table A.11(Continued)**  
**Incidence Rates per Ten Million Population**  
**of Reported ESRD Therapy by Primary Disease Causing ESRD**  
**Specific Rates by Sex, Race, and Age, and Rates Adjusted for Age, Race, and Sex**  
**1994-1997**

**Other Urologic**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0- 4	*	*	0	0	*	*	0	0	*	*	0	0	*	*	*
5- 9	*	*	0	0	*	*	0	0	*	*	0	0	*	*	*
10- 14	13	*	0	0	10	*	*	*	12	*	*	*	12	*	11
15- 19	13	28	0	0	12	*	*	*	13	19	*	*	14	12	13
20- 24	18	*	*	0	20	*	*	*	19	14	*	*	17	20	19
25- 29	24	28	*	*	21	26	0	0	23	27	*	*	24	21	23
30- 34	20	25	*	*	23	*	*	*	22	20	*	*	21	22	22
35- 39	27	34	*	*	27	20	*	*	27	27	*	*	29	26	27
40- 44	29	42	*	*	24	54	*	0	26	48	*	*	30	28	29
45- 49	32	71	*	*	31	41	*	0	31	56	45	*	37	33	35
50- 54	46	91	*	*	45	58	*	*	46	75	*	*	52	47	50
55- 59	80	163	*	*	58	100	148	0	68	131	106	*	90	66	78
60- 64	131	305	254	*	69	106	*	*	100	203	165	*	159	75	116
65- 69	198	488	249	*	91	151	214	*	144	315	232	*	239	103	169
70- 74	297	599	*	*	108	149	283	*	201	368	265	*	334	120	224
75- 79	414	541	*	*	113	117	*	*	259	323	247	*	433	117	271
80- 84	498	1034	*	*	78	248	*	0	282	633	*	*	566	102	328
85 plus	413	580	*	0	52	126	*	0	226	350	*	0	435	65	245
All Age	62	77	40	75	35	39	42	28	48	57	41	52	63	36	49
Age Adj	67	121	67	132	33	45	53	34	46	77	57	76	72	34	49

**Other Cause**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0- 4	54	82	*	*	28	44	*	*	41	63	38	*	57	30	43
5- 9	37	58	*	0	22	25	*	*	30	41	*	*	39	23	31
10- 14	56	114	*	*	39	67	*	*	47	90	51	*	63	43	53
15- 19	88	148	100	*	63	151	133	*	75	150	117	133	96	77	87
20- 24	86	273	70	*	86	436	189	*	86	357	131	148	110	135	123
25- 29	106	608	73	*	97	602	164	309	101	605	120	234	169	165	167
30- 34	101	1046	78	*	95	791	167	*	98	915	124	146	221	186	202
35- 39	122	1328	80	647	118	882	109	414	120	1100	95	527	278	217	246
40- 44	145	1535	110	422	146	869	202	368	145	1194	158	396	322	241	279
45- 49	182	1485	152	482	194	821	198	610	188	1140	173	548	347	276	309
50- 54	283	1186	219	756	254	869	270	550	268	1022	249	657	399	335	365
55- 59	404	1228	331	856	340	867	337	840	370	1043	339	848	509	410	458
60- 64	625	1436	528	914	497	1037	312	1121	560	1231	419	1030	726	564	643
65- 69	937	1432	772	1514	621	950	660	1069	776	1184	715	1287	999	668	830
70- 74	1211	1779	751	*	716	1171	778	1318	959	1465	759	1261	1265	781	1018
75- 79	1481	2191	1700	*	742	1202	774	*	1099	1682	1218	1209	1574	799	1178
80- 84	1406	2274	1355	*	634	1242	800	*	1007	1745	1056	*	1500	717	1099
85 plus	983	1435	1229	*	282	692	*	*	621	1050	867	*	1057	340	691
All Age	267	742	161	326	213	565	195	321	239	649	179	324	322	259	290
Age Adj	280	908	240	472	194	614	226	399	229	750	228	426	352	245	290

(CONTINUED)

Includes residents of 50 states and District of Columbia only.  
 Incident cases for 1994 through 1997 are combined to produce larger cell sizes.  
 Cases where race is "Other" or "Unknown" are excluded from this table.  
 See tables A.4 and A.5 and notes at beginning of this Section.  
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.  
 The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

Table A.11(Continued)  
 Incidence Rates per Ten Million Population  
 of Reported ESRD Therapy by Primary Disease Causing ESRD  
 Specific Rates by Sex, Race, and Age, and Rates Adjusted for Age, Race, and Sex  
**1994-1997**

**Unknown Cause**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	*	*	0	0	*	*	0	0	*	*	0	0	*	*	*	
5- 9	*	*	0	0	*	*	*	*	*	*	*	*	*	*	*	
10- 14	*	27	*	*	*	26	*	0	*	27	*	*	*	11	*	
15- 19	17	47	*	*	15	41	*	*	16	44	*	*	21	19	20	
20- 24	37	94	*	*	21	62	*	*	29	78	42	*	45	27	36	
25- 29	32	146	67	*	25	68	*	*	29	106	48	*	48	31	39	
30- 34	34	220	*	*	19	99	61	*	26	158	43	*	57	31	44	
35- 39	38	276	117	*	30	106	80	*	34	189	99	*	72	41	56	
40- 44	47	304	90	*	30	174	73	*	39	238	82	175	83	51	66	
45- 49	59	377	118	*	45	194	110	*	52	284	117	*	104	66	84	
50- 54	85	348	115	*	56	241	187	*	71	294	151	*	120	86	102	
55- 59	133	607	181	*	98	362	189	*	115	484	189	411	198	137	167	
60- 64	222	657	411	*	141	432	390	*	181	542	401	426	286	189	236	
65- 69	321	748	672	1281	218	586	357	*	268	665	519	1015	396	274	334	
70- 74	589	951	626	*	274	855	731	*	428	902	683	849	638	371	502	
75- 79	778	1171	1550	*	340	788	663	*	553	977	1121	1020	860	411	631	
80- 84	912	1424	1609	*	392	958	1067	*	644	1183	1350	*	994	490	737	
85 plus	721	977	1229	0	266	755	*	*	484	858	880	*	757	339	544	
All Age	108	227	121	142	74	169	111	125	90	197	116	133	123	88	105	
Age Adj	116	311	198	223	64	201	149	173	86	252	168	197	140	80	105	

**Missing Cause**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	*	*	*	0	*	*	*	0	*	*	*	0	*	*	*	
5- 9	*	*	*	0	*	*	*	0	*	*	*	0	*	*	*	
10- 14	11	24	0	*	*	19	*	0	*	22	*	*	12	*	11	
15- 19	17	40	*	0	*	43	*	*	13	41	*	*	20	14	17	
20- 24	22	83	*	*	15	64	*	0	19	74	36	*	31	22	26	
25- 29	30	170	*	*	28	116	*	*	29	142	49	*	49	40	44	
30- 34	39	230	*	*	35	116	*	*	38	172	37	*	64	46	55	
35- 39	50	296	86	*	30	175	*	*	39	233	59	*	82	48	65	
40- 44	58	394	76	*	37	209	*	0	46	294	51	*	99	57	77	
45- 49	77	634	93	*	47	271	88	*	61	435	90	*	145	77	110	
50- 54	104	605	138	*	65	348	135	*	82	467	131	247	167	103	134	
55- 59	122	755	*	*	72	593	*	*	95	667	78	*	200	136	167	
60- 64	170	1096	313	*	136	860	*	*	153	975	205	*	292	229	259	
65- 69	260	830	249	*	180	846	232	*	220	838	242	*	331	272	301	
70- 74	343	1030	*	*	186	884	*	*	263	955	206	*	426	276	350	
75- 79	451	944	*	*	207	812	*	*	323	875	261	*	504	284	392	
80- 84	411	1080	*	*	168	875	*	0	284	973	*	*	488	256	370	
85 plus	326	824	*	*	105	604	*	0	209	710	*	*	390	171	278	
All Age	82	276	74	69	56	221	52	81	69	247	62	75	105	78	91	
Age Adj	85	365	96	96	51	258	60	116	66	309	76	106	115	72	91	

Includes residents of 50 states and District of Columbia only.  
 Incident cases for 1994 through 1997 are combined to produce larger cell sizes.  
 Cases where race is "Other" or "Unknown" are excluded from this table.  
 See tables A.4 and A.5 and notes at beginning of this Section.  
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.  
 The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

**Table A.12**  
**Standard Errors for Adjusted Incidence Rates per Ten Million Population**  
**of Reported ESRD Therapy by Primary Disease Causing ESRD**  
**by Sex, Race, and Age, Adjusted for Age, Race, and Sex**  
**1994-1997**

**Diabetes**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	*	*	*	*	*	*	*	0.0	0.5	*	*	*	0.8	0.8	0.6	
5- 9	*	0.0	0.0	0.0	*	*	0.0	0.0	*	*	0.0	0.0	*	*	*	
10-14	*	*	0.0	0.0	*	*	0.0	0.0	*	*	0.0	0.0	*	*	*	
15-19	1.0	*	0.0	0.0	1.2	*	*	0.0	0.8	3.3	*	0.0	1.0	1.2	0.8	
20-24	3.3	14.7	*	0.0	4.1	17.6	*	*	2.6	11.5	*	*	3.3	4.1	2.7	
25-29	7.5	28.1	*	*	7.9	28.6	*	97.3	5.5	20.1	10.2	57.0	7.2	7.6	5.2	
30-34	10.1	34.7	26.0	122.3	8.6	29.1	26.6	129.5	6.6	22.5	18.7	89.2	9.6	8.1	6.3	
35-39	11.3	42.2	39.6	184.5	9.0	37.7	31.3	174.4	7.2	28.2	25.1	127.1	11.0	9.0	7.1	
40-44	13.7	63.6	57.7	316.2	10.9	53.6	43.3	265.7	8.7	41.5	36.1	206.1	14.3	11.7	9.2	
45-49	17.9	103.7	95.0	519.3	15.2	89.6	71.7	473.4	11.7	68.4	59.9	352.7	20.6	17.6	13.5	
50-54	25.3	164.4	163.1	704.0	21.8	147.0	125.3	716.2	16.6	110.2	102.6	501.7	30.7	27.0	20.4	
55-59	34.5	222.7	241.2	1026.9	31.3	202.9	200.2	1023.7	23.2	150.1	157.4	724.2	42.0	38.2	28.3	
60-64	43.1	266.7	332.3	1212.1	40.3	257.8	275.0	1305.4	29.5	185.3	214.6	893.4	51.6	49.0	35.6	
65-69	49.0	276.6	460.3	1388.2	43.4	284.2	366.6	1648.7	32.7	198.2	292.5	1082.0	57.4	54.4	39.5	
70-74	54.7	332.4	522.8	1523.4	44.1	323.1	460.0	1681.3	35.0	231.5	346.8	1135.7	66.0	59.1	44.2	
75-79	58.8	355.9	743.3	1615.3	42.3	323.0	578.0	1583.5	35.8	239.3	465.8	1140.5	72.6	59.3	46.7	
80-84	64.9	419.2	842.5	*	38.8	327.2	733.4	1637.9	37.2	264.0	555.7	961.8	81.7	60.3	50.3	
85 plus	53.0	309.8	787.1	*	23.0	196.9	569.9	897.2	28.3	179.8	471.9	699.1	65.4	38.0	37.3	
Age Adj	4.7	27.4	41.4	123.4	3.9	25.4	33.7	131.2	3.0	18.6	26.3	91.4	5.0	4.3	3.2	

**Hypertension**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	*	*	0.0	0.0	*	*	0.0	*	*	3.3	0.0	*	0.8	0.9	0.6	
5- 9	*	*	0.0	0.0	*	*	0.0	0.0	*	*	0.0	0.0	*	*	*	
10-14	*	*	0.0	0.0	1.1	*	*	0.0	0.6	*	*	0.0	0.8	1.0	0.6	
15-19	1.7	13.0	*	*	1.8	8.7	*	*	1.2	7.7	*	*	2.2	1.9	1.5	
20-24	3.2	31.1	20.2	*	2.4	21.5	*	*	2.0	18.8	12.0	51.9	4.8	3.5	2.9	
25-29	4.6	42.5	26.6	*	3.3	29.8	*	*	2.8	25.8	15.5	42.8	6.7	4.7	4.0	
30-34	4.5	51.3	32.1	88.5	3.6	34.3	25.4	*	2.8	30.6	20.5	49.2	7.6	5.3	4.6	
35-39	5.0	65.4	36.5	125.8	3.5	42.9	28.0	95.5	3.1	38.8	23.0	78.5	9.4	6.3	5.6	
40-44	7.0	85.5	43.7	162.2	4.7	55.1	42.4	133.7	4.2	50.6	30.6	105.8	12.5	8.2	7.4	
45-49	8.9	117.2	68.0	234.3	6.6	72.0	52.8	142.7	5.5	68.6	43.4	136.3	17.0	10.9	9.9	
50-54	12.8	152.7	102.3	270.0	9.4	100.1	86.8	218.0	8.0	90.9	67.8	173.5	22.6	15.4	13.5	
55-59	19.2	181.7	137.9	370.9	14.1	132.4	108.0	323.1	11.9	112.1	87.6	247.5	28.7	21.1	17.6	
60-64	28.7	225.5	213.3	483.5	20.6	168.1	160.8	400.2	17.5	139.8	133.9	313.3	38.2	28.1	23.5	
65-69	39.5	245.8	298.7	627.3	27.1	201.5	214.1	574.8	23.8	158.5	183.1	426.1	46.7	35.2	29.1	
70-74	54.6	329.6	425.7	790.5	33.9	266.7	276.8	821.2	31.8	211.2	251.9	573.7	63.8	45.6	38.9	
75-79	74.2	428.6	687.4	1211.5	42.5	309.3	479.1	928.9	42.3	262.4	419.4	765.7	86.4	56.1	50.9	
80-84	102.7	568.2	965.5	1548.0	52.3	387.2	666.7	1091.9	56.8	341.1	579.5	947.5	117.4	70.4	67.6	
85 plus	106.9	558.8	919.8	*	39.6	324.9	637.2	732.5	55.8	319.1	556.5	774.1	118.5	57.5	64.8	
Age Adj	4.2	29.3	35.8	69.3	2.5	20.9	25.2	56.2	2.3	17.5	20.9	43.6	4.8	3.0	2.6	

(CONTINUED)

Includes residents of 50 states and District of Columbia only.  
 Incident cases for 1994 through 1997 are combined to produce larger cell sizes.  
 Cases where race is "Other" or "Unknown" are excluded from this table.  
 See tables A.4 and A.5 and notes at beginning of this Section.  
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.  
 The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

Table A.12(Continued)  
 Standard Errors for Adjusted Incidence Rates per Ten Million Population  
 of Reported ESRD Therapy by Primary Disease Causing ESRD  
 by Sex, Race, and Age, Adjusted for Age, Race, and Sex  
**1994-1997**

**Glomeruloneph.**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	1.6	*	*	0.0	1.7	*	*	0.0	1.2	3.1	*	0.0	1.5	1.5	1.1	
5- 9	2.2	6.7	*	*	2.3	5.8	*	*	1.6	4.4	*	*	2.1	2.1	1.5	
10-14	2.9	9.2	*	*	3.2	12.5	*	*	2.2	7.8	13.2	*	2.8	3.2	2.1	
15-19	5.1	24.1	33.5	*	4.8	17.9	25.6	*	3.5	15.0	21.2	*	5.4	4.7	3.6	
20-24	6.7	32.9	40.9	85.9	5.9	26.7	39.1	*	4.5	21.1	28.2	57.8	7.1	6.1	4.7	
25-29	7.4	36.3	44.4	100.5	5.7	27.8	38.0	101.3	4.7	22.7	29.3	71.5	7.9	6.1	5.0	
30-34	7.1	36.6	52.0	106.7	5.2	29.2	40.4	132.3	4.4	23.3	32.9	85.5	7.8	6.0	4.9	
35-39	7.3	42.4	51.7	128.9	5.6	30.4	57.7	117.0	4.6	25.9	39.0	86.9	8.4	6.5	5.2	
40-44	8.2	53.1	61.3	174.7	6.1	35.1	57.4	114.8	5.1	31.6	42.5	103.9	9.9	7.1	6.1	
45-49	10.0	63.0	73.5	192.7	7.4	39.6	63.4	161.8	6.2	37.0	49.0	124.3	12.0	8.4	7.2	
50-54	12.6	73.5	100.9	216.0	9.3	47.3	67.2	*	7.8	43.4	60.6	124.7	14.6	10.1	8.8	
55-59	16.3	83.4	112.6	276.4	11.6	57.2	101.9	233.0	9.9	50.3	76.2	180.5	17.8	12.8	10.9	
60-64	20.2	93.4	118.9	303.0	13.8	60.5	101.2	348.9	12.1	55.2	78.2	231.8	21.1	14.5	12.7	
65-69	23.5	89.1	226.7	435.9	15.3	69.6	128.7	376.3	13.9	56.3	129.6	287.7	24.3	16.5	14.6	
70-74	29.0	115.5	272.9	538.6	17.5	84.5	177.9	*	16.8	71.1	162.0	323.2	30.2	19.4	17.8	
75-79	36.1	131.4	400.0	773.3	20.1	88.7	230.2	544.6	20.4	78.5	230.1	471.3	37.8	22.3	21.7	
80-84	48.2	173.4	456.0	*	21.6	96.8	400.0	*	26.0	98.3	303.1	*	48.8	26.6	27.4	
85 plus	46.9	158.6	506.8	*	16.5	89.9	*	0.0	24.4	90.3	279.6	*	47.6	20.0	25.4	
Age Adj	2.7	12.8	23.7	47.3	1.8	8.9	17.3	38.2	1.6	7.6	14.2	29.8	2.8	1.9	1.6	

**Cystic Kidney**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	1.5	*	0.0	0.0	1.6	*	*	0.0	1.1	*	*	0.0	1.3	1.4	1.0	
5- 9	1.2	*	*	*	1.4	*	0.0	0.0	0.9	*	*	*	1.1	1.2	0.8	
10-14	1.3	*	*	*	1.5	*	*	0.0	1.0	2.8	*	*	1.2	1.4	0.9	
15-19	1.2	*	0.0	*	1.3	*	*	0.0	0.9	*	*	*	1.1	1.2	0.8	
20-24	1.4	*	0.0	0.0	1.4	*	*	0.0	1.0	*	*	0.0	1.2	1.3	0.9	
25-29	1.5	*	0.0	*	1.8	*	*	*	1.2	*	*	*	1.4	1.6	1.1	
30-34	2.4	8.3	*	*	2.1	7.1	*	*	1.6	5.4	*	*	2.3	2.0	1.5	
35-39	3.7	10.6	*	*	3.1	9.5	*	*	2.4	7.1	10.7	*	3.4	2.9	2.2	
40-44	5.6	17.1	*	*	4.5	15.2	20.3	0.0	3.6	11.4	13.3	*	5.2	4.3	3.3	
45-49	7.5	24.6	29.2	*	6.5	21.2	25.4	*	4.9	16.3	19.1	*	7.0	6.1	4.6	
50-54	9.6	29.9	50.1	*	8.2	27.9	*	*	6.3	20.4	29.1	*	9.1	7.8	6.0	
55-59	10.3	32.0	56.3	*	9.3	28.6	*	*	6.9	21.4	33.9	*	9.7	8.7	6.5	
60-64	10.0	38.9	61.8	*	9.2	28.9	*	*	6.8	24.1	37.9	*	10.0	8.7	6.6	
65-69	11.1	39.1	78.7	*	9.2	29.5	*	*	7.2	24.3	44.2	*	10.9	8.8	6.9	
70-74	11.5	47.4	*	0.0	9.1	40.1	*	0.0	7.3	30.9	53.2	0.0	11.7	9.4	7.4	
75-79	12.4	61.7	*	0.0	8.5	38.2	*	0.0	7.5	35.5	*	0.0	13.3	9.0	7.9	
80-84	14.9	102.7	*	*	8.2	39.2	*	*	8.4	53.9	*	*	19.0	9.6	10.4	
85 plus	15.4	*	*	*	5.1	*	0.0	0.0	8.0	43.1	*	*	17.5	5.8	9.0	
Age Adj	1.3	4.9	7.8	15.9	1.1	3.8	5.4	13.6	0.9	3.0	4.6	10.0	1.3	1.0	0.8	

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

Incident cases for 1994 through 1997 are combined to produce larger cell sizes.

Cases where race is "Other" or "Unknown" are excluded from this table.

See tables A.4 and A.5 and notes at beginning of this Section.

Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.

The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996,

U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

Table A.12(Continued)  
 Standard Errors for Adjusted Incidence Rates per Ten Million Population  
 of Reported ESRD Therapy by Primary Disease Causing ESRD  
 by Sex, Race, and Age, Adjusted for Age, Race, and Sex  
**1994-1997**

**Other Urologic**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	1.3	*	0.0	0.0	*	*	0.0	0.0	0.7	*	0.0	0.0	1.2	*	0.7	
5- 9	1.2	*	0.0	0.0	1.2	*	0.0	0.0	0.9	*	0.0	0.0	1.1	1.1	0.8	
10-14	2.1	*	0.0	0.0	1.9	*	*	*	1.4	*	*	*	1.8	1.6	1.2	
15-19	2.1	6.9	0.0	0.0	2.1	*	*	*	1.5	4.1	*	*	1.9	1.8	1.3	
20-24	2.5	*	*	0.0	2.7	*	*	*	1.8	3.7	*	*	2.2	2.4	1.6	
25-29	2.8	7.5	*	*	2.7	6.9	0.0	0.0	1.9	5.1	*	*	2.5	2.4	1.7	
30-34	2.4	6.8	*	*	2.5	*	*	*	1.8	4.2	*	*	2.2	2.3	1.6	
35-39	2.7	8.1	*	*	2.7	5.8	*	*	1.9	4.9	*	*	2.5	2.4	1.7	
40-44	2.9	9.6	*	*	2.7	10.1	*	0.0	2.0	7.0	*	*	2.7	2.6	1.9	
45-49	3.3	14.3	*	*	3.2	9.9	*	0.0	2.3	8.7	13.5	*	3.4	3.0	2.2	
50-54	4.4	19.0	*	*	4.3	13.7	*	*	3.1	11.7	*	*	4.5	4.1	3.0	
55-59	6.5	28.3	*	*	5.4	19.7	44.8	0.0	4.2	17.2	27.3	*	6.6	5.3	4.2	
60-64	8.9	42.3	70.5	*	6.2	21.6	*	*	5.4	23.5	39.0	*	9.6	6.0	5.6	
65-69	11.2	55.6	78.7	*	7.0	26.7	61.8	*	6.5	30.4	50.0	*	12.1	7.1	6.9	
70-74	14.7	72.6	*	*	7.8	29.9	81.6	*	8.2	38.6	59.7	*	15.7	8.1	8.7	
75-79	20.3	82.6	*	*	8.9	30.2	*	*	10.8	43.1	76.0	*	20.9	8.9	11.1	
80-84	28.9	154.1	*	*	8.6	54.2	*	0.0	14.7	80.4	*	*	32.0	10.6	16.5	
85 plus	33.1	133.1	*	0.0	7.3	39.8	*	0.0	16.5	68.6	*	0.0	33.5	9.0	17.0	
Age Adj	1.3	5.8	8.5	24.3	0.8	2.8	6.1	10.0	0.7	2.9	4.9	11.8	1.3	0.8	0.7	

**Other Cause**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	4.1	11.6	*	*	3.1	8.6	*	*	2.6	7.2	10.5	*	3.8	2.8	2.4	
5- 9	3.5	9.7	*	0.0	2.7	6.4	*	*	2.2	5.8	*	*	3.2	2.5	2.0	
10-14	4.3	13.9	*	*	3.6	10.8	*	*	2.8	8.8	13.1	*	4.0	3.4	2.6	
15-19	5.4	16.0	26.8	*	4.7	16.4	31.3	*	3.6	11.4	20.7	40.2	5.0	4.6	3.4	
20-24	5.4	23.0	21.2	*	5.6	28.6	35.1	*	3.9	18.4	20.7	44.7	5.4	6.0	4.1	
25-29	5.8	34.9	21.1	*	5.7	33.3	30.5	93.1	4.1	24.1	18.8	56.8	6.6	6.4	4.6	
30-34	5.3	44.5	21.5	*	5.2	36.4	30.4	*	3.7	28.6	18.9	44.0	7.2	6.4	4.8	
35-39	5.7	50.2	22.3	134.9	5.7	38.5	24.9	106.8	4.0	31.5	16.8	85.5	8.1	6.9	5.3	
40-44	6.5	58.1	27.6	117.0	6.5	40.8	35.1	106.3	4.6	35.2	22.6	79.2	9.2	7.6	5.9	
45-49	7.8	65.1	35.8	139.2	8.0	44.4	38.0	152.6	5.6	39.0	25.8	103.7	10.6	8.9	6.8	
50-54	10.9	68.5	50.1	202.0	10.2	52.9	52.9	165.9	7.5	43.0	37.2	131.5	12.8	11.0	8.4	
55-59	14.6	77.9	70.6	247.2	13.0	57.8	67.5	233.0	9.8	48.2	49.5	169.8	16.0	13.4	10.4	
60-64	19.4	91.8	101.6	288.9	16.5	67.6	69.8	299.5	12.7	56.6	61.4	210.5	20.3	16.5	13.0	
65-69	24.3	95.2	138.6	420.0	18.2	67.0	108.5	322.2	15.1	57.7	87.6	263.4	24.3	18.0	15.0	
70-74	29.7	125.2	153.3	*	20.1	83.7	135.4	397.3	17.8	74.5	101.3	290.5	30.0	20.7	18.0	
75-79	38.3	166.1	291.6	*	22.7	96.9	168.9	*	22.0	95.0	165.9	353.7	39.8	23.4	22.8	
80-84	48.6	228.5	338.7	*	24.7	121.2	231.0	*	26.8	127.7	200.5	*	51.0	27.1	28.4	
85 plus	51.0	209.3	388.7	*	17.1	93.3	*	*	26.3	112.5	220.2	*	52.6	20.0	27.6	
Age Adj	2.6	13.9	15.2	42.2	2.0	9.9	12.2	34.1	1.6	8.3	9.3	26.0	2.8	2.1	1.7	

(CONTINUED)

Includes residents of 50 states and District of Columbia only.  
 Incident cases for 1994 through 1997 are combined to produce larger cell sizes.  
 Cases where race is "Other" or "Unknown" are excluded from this table.  
 See tables A.4 and A.5 and notes at beginning of this Section.  
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.  
 The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.



Table A.12(Continued)  
 Standard Errors for Adjusted Incidence Rates per Ten Million Population  
 of Reported ESRD Therapy by Primary Disease Causing ESRD  
 by Sex, Race, and Age, Adjusted for Age, Race, and Sex  
**1994-1997**

**Unknown Cause**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	1.1	*	0.0	0.0	*	*	0.0	0.0	0.7	*	0.0	0.0	1.0	*	0.6	
5- 9	*	*	0.0	0.0	1.2	*	*	*	0.8	*	*	*	0.9	1.1	0.7	
10-14	*	6.8	*	*	1.7	6.8	*	0.0	1.0	4.8	*	*	1.2	1.7	1.0	
15-19	2.4	9.0	*	*	2.3	8.5	*	*	1.7	6.2	*	*	2.3	2.3	1.6	
20-24	3.5	13.5	*	*	2.8	10.8	*	*	2.2	8.6	11.6	*	3.5	2.7	2.2	
25-29	3.2	17.1	20.2	*	2.9	11.2	*	*	2.2	10.2	11.9	*	3.5	2.8	2.3	
30-34	3.1	20.4	*	*	2.3	12.9	18.4	*	1.9	12.0	11.2	*	3.7	2.7	2.2	
35-39	3.2	22.9	26.9	*	2.8	13.3	21.4	*	2.1	13.1	17.2	*	4.1	3.0	2.5	
40-44	3.7	25.9	24.9	*	3.0	18.3	21.2	*	2.4	15.8	16.4	52.6	4.6	3.5	2.9	
45-49	4.4	32.8	31.5	*	3.8	21.6	28.4	*	2.9	19.6	21.7	*	5.8	4.3	3.6	
50-54	6.0	37.1	36.4	*	4.8	27.9	44.0	*	3.8	23.2	28.6	*	7.0	5.6	4.5	
55-59	8.4	54.7	52.1	*	7.0	37.4	50.5	*	5.5	33.0	37.1	118.8	10.1	7.9	6.4	
60-64	11.6	62.0	89.6	*	8.8	43.7	78.1	*	7.2	37.7	59.4	135.1	12.9	9.7	8.0	
65-69	14.2	68.8	129.3	386.4	10.8	52.6	79.8	*	8.9	43.1	76.5	233.4	15.7	11.8	9.8	
70-74	20.7	91.5	140.0	*	12.5	71.5	131.2	*	12.0	57.8	96.4	236.2	21.5	14.8	13.0	
75-79	27.8	121.4	278.4	*	15.3	78.4	156.4	*	15.6	71.8	161.8	326.5	29.9	17.4	17.1	
80-84	39.1	180.9	369.1	*	19.4	106.5	266.7	*	21.5	103.6	229.1	*	41.9	23.5	23.7	
85 plus	43.7	172.7	388.7	0.0	16.6	97.5	*	*	22.8	97.6	216.5	*	44.1	20.2	23.9	
Age Adj	1.7	8.7	14.4	29.8	1.1	5.9	10.7	23.7	1.0	5.0	8.6	18.8	1.8	1.2	1.0	

**Missing Cause**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0- 4	1.6	*	*	0.0	1.5	*	*	0.0	1.1	2.6	*	0.0	1.5	1.4	1.0	
5- 9	1.6	*	*	0.0	1.4	*	*	0.0	1.1	2.7	*	0.0	1.5	1.3	1.0	
10-14	1.9	6.4	0.0	*	1.6	5.8	*	0.0	1.2	4.3	*	*	1.8	1.6	1.2	
15-19	2.4	8.3	*	0.0	1.8	8.7	*	*	1.5	6.0	*	*	2.2	1.9	1.5	
20-24	2.7	12.6	*	*	2.3	11.0	*	0.0	1.8	8.4	10.7	*	2.9	2.5	1.9	
25-29	3.1	18.5	*	*	3.0	14.6	*	*	2.2	11.7	11.9	*	3.5	3.2	2.4	
30-34	3.3	20.9	*	*	3.2	13.9	*	*	2.3	12.5	10.4	*	3.9	3.2	2.5	
35-39	3.6	23.7	23.1	*	2.8	17.1	*	*	2.3	14.5	13.2	*	4.3	3.2	2.7	
40-44	4.1	29.5	22.9	*	3.3	20.0	*	0.0	2.6	17.3	12.9	*	5.0	3.7	3.1	
45-49	5.1	42.5	28.0	*	4.0	25.5	25.4	*	3.2	23.8	18.8	*	6.8	4.6	4.0	
50-54	6.6	48.9	39.9	*	5.2	33.4	37.4	*	4.1	29.0	26.2	78.2	8.3	6.1	5.1	
55-59	8.0	61.0	*	*	6.0	47.8	*	*	4.9	38.3	23.6	*	10.3	7.8	6.4	
60-64	10.1	80.2	78.2	*	8.6	61.6	*	*	6.6	50.3	43.0	*	13.5	10.8	8.6	
65-69	12.8	72.5	78.7	*	9.8	63.2	64.3	*	8.0	48.0	51.0	*	14.4	11.9	9.3	
70-74	15.8	95.3	*	*	10.3	72.7	*	*	9.4	59.6	53.6	*	18.2	12.9	11.0	
75-79	21.2	109.0	*	*	12.0	79.6	*	*	11.9	66.9	75.7	*	22.7	14.6	13.4	
80-84	26.2	157.5	*	*	12.7	101.8	*	0.0	14.2	92.8	*	*	30.1	17.1	17.1	
85 plus	29.4	158.6	*	*	10.4	87.2	*	0.0	15.1	89.4	*	*	32.7	14.8	17.6	
Age Adj	1.4	9.1	9.0	19.0	1.0	6.6	6.3	19.6	0.8	5.5	5.3	13.5	1.6	1.1	0.9	

Includes residents of 50 states and District of Columbia only.  
 Incident cases for 1994 through 1997 are combined to produce larger cell sizes.  
 Cases where race is "Other" or "Unknown" are excluded from this table.  
 See tables A.4 and A.5 and notes at beginning of this Section.  
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.  
 The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

Table A.13  
 Median Age at Start of ESRD Therapy  
 by Year, Age, Race, Sex, and Primary Disease Causing ESRD

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
Age										
0-19	15.0	15.0	14.0	14.0	15.0	14.0	14.0	14.0	14.0	14.0
20-44	35.0	35.0	35.0	36.0	36.0	36.0	36.0	36.0	37.0	37.0
45-64	57.0	57.0	57.0	57.0	57.0	56.0	56.0	56.0	56.0	56.0
65-74	69.0	69.0	69.0	69.0	69.0	69.0	69.0	69.0	70.0	70.0
75 plus	78.0	79.0	79.0	79.0	79.0	79.0	79.0	79.0	79.0	79.0
Disease										
1 Diabetes	59.0	60.0	61.0	61.0	62.0	62.0	62.0	62.0	63.0	64.0
2 Hypertension	67.0	67.0	68.0	68.0	68.0	69.0	68.0	69.0	69.0	71.0
3 Glomeruloneph.	52.0	53.0	53.0	54.0	53.0	54.0	54.0	53.0	54.0	56.0
4 Cystic Kidney	53.0	53.5	54.0	54.0	54.0	53.0	54.0	53.0	53.0	54.0
5 Other Urologic	68.0	68.0	67.0	62.0	64.0	62.0	64.0	65.0	66.0	66.0
6 Other Cause	56.0	57.0	56.0	58.0	58.0	57.0	56.0	56.0	57.0	60.0
7 Unknown Cause	65.0	66.0	65.0	65.0	65.0	65.0	65.0	66.0	66.0	69.0
8 Missing Cause	56.0	62.0	61.0	58.0	61.5	68.0	64.0	61.0	58.0	58.0
Race										
1 Native Amer.	57.0	59.0	57.0	58.0	60.0	60.0	58.0	58.0	57.0	59.0
2 Asian	58.0	59.0	59.0	61.0	60.0	62.0	62.0	62.0	64.0	65.0
3 Black	57.0	58.0	59.0	59.0	59.0	59.0	58.0	57.0	58.0	59.0
4 White	63.0	64.0	64.0	65.0	65.0	66.0	66.0	65.0	66.0	67.0
5 Unknown	40.0	39.0	45.0	41.0	39.0	45.0	49.0	52.0	56.0	52.0
9 Other	54.5	58.0	46.0	50.0	61.0	64.0	57.0	57.0	56.0	57.0
Sex										
Female	62.0	63.0	63.0	64.0	64.0	65.0	64.0	64.0	64.0	65.0
Male	60.0	61.0	61.0	62.0	62.0	63.0	62.0	62.0	62.0	64.0
Total	61.0	62.0	62.0	63.0	63.0	64.0	63.0	63.0	63.0	65.0

Table A.14  
 Mean Age at Start of ESRD Therapy  
 by Year, Age, Race, Sex, and Primary Disease Causing ESRD

	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
Age										
0-19	12.8	12.9	12.6	12.3	12.8	12.4	12.7	12.2	12.3	12.2
20-44	34.2	34.3	34.6	34.9	34.9	34.9	34.9	35.2	35.3	35.4
45-64	56.0	55.9	56.0	56.0	55.9	55.7	55.7	55.6	55.6	55.7
65-74	69.3	69.3	69.3	69.4	69.4	69.4	69.5	69.5	69.6	69.6
75 plus	79.3	79.4	79.6	79.5	79.7	79.7	79.7	79.8	79.9	80.0
Disease										
1 Diabetes	56.8	57.3	58.3	58.9	59.3	59.6	60.0	60.3	61.0	61.9
2 Hypertension	63.5	64.0	64.4	64.8	64.8	65.2	65.0	64.9	65.3	66.9
3 Glomeruloneph.	50.6	51.3	51.6	52.4	52.1	52.3	52.8	52.3	53.2	54.3
4 Cystic Kidney	53.6	53.5	54.0	53.5	54.3	54.1	54.8	53.8	54.3	55.1
5 Other Urologic	61.3	62.0	60.5	55.4	56.7	55.8	56.8	59.4	60.0	60.8
6 Other Cause	51.8	52.3	51.9	53.2	54.0	53.2	53.2	53.3	54.2	55.8
7 Unknown Cause	60.2	60.3	59.7	59.8	59.9	59.1	59.1	61.4	61.4	63.7
8 Missing Cause	52.9	58.0	57.3	55.2	57.3	64.2	58.7	57.4	54.8	56.3
Race										
1 Native Amer.	54.7	56.7	56.2	56.0	58.4	58.3	56.3	56.3	56.5	57.4
2 Asian	55.9	55.1	56.3	57.2	57.1	58.0	58.5	59.6	60.5	61.0
3 Black	54.9	55.4	56.0	56.2	56.4	56.6	56.2	55.7	56.2	57.5
4 White	58.6	59.5	59.9	60.5	61.1	61.6	61.8	61.8	62.4	63.5
5 Unknown	42.8	41.9	44.6	42.4	40.4	45.3	47.6	50.3	51.7	51.7
9 Other	51.5	53.3	45.5	49.2	55.5	58.2	52.9	54.3	54.0	54.9
Sex										
Female	58.3	59.1	59.6	60.2	60.4	61.0	60.8	60.6	61.0	62.2
Male	56.5	57.3	57.7	58.1	58.7	58.9	59.0	58.7	59.4	60.8
Total	57.3	58.1	58.6	59.1	59.5	59.9	59.8	59.6	60.2	61.4

Includes all patients: residents of the 50 states, the District of Columbia, Puerto Rico and the Territories.  
 \* Values for cells with fewer than 10 patients are suppressed.

**Table A.15**  
**Incidence of Reported ESRD Therapy and**  
**Median Age at Incidence by Sex, Race, One Year Transplant and Death Status**  
**and Detailed Primary Disease for All Patients, 1993-1997**

Primary Disease Groups	Total Patients	% Incid	Median Age	% Males	% White	% Black	% Asian	% Amer. Native	% Tran First Year	% Died First Year
All ESRD, (reference)	357,051	100.0	64	53.3	63.9	29.5	3.3	1.5	6.0	22.3
Diabetes	143,448	41.7	63	47.6	63.7	28.5	3.5	2.3	3.8	21.5
. Type 1, juvenile type	41,318	12.0	56	49.9	70.3	24.6	2.4	1.5	8.8	19.2
. Type 2, adult-onset or unspec. type	102,130	29.7	64	46.7	61.0	30.0	3.9	2.7	1.8	22.5
Glomerulonephritis	37,463	10.9	54	60.7	67.5	23.9	5.3	1.2	12.7	12.8
. Focal glomerulosclerosis, focal GN	7,294	2.1	46	62.3	58.6	36.5	2.5	0.9	15.4	9.2
. Membranous nephropathy	1,708	0.5	59	65.4	70.7	24.8	2.3	0.9	11.6	11.1
. Membranoproliferative GN, types 1&2	1,380	0.4	46	58.8	74.3	16.5	5.1	2.0	21.2	9.1
. IgA nephropathy, Bergers disease	1,618	0.5	41	68.4	75.8	7.4	11.2	1.7	28.1	4.8
. IgM nephropathy	175	0.1	43	68.6	77.7	8.0	10.3	0.6	31.4	5.1
. Rapidly progressive GN	1,450	0.4	62	51.3	80.5	12.3	3.9	1.7	9.2	15.8
. Goodpastures Syndrome	659	0.2	62	46.9	88.9	7.0	2.1	1.2	6.7	23.8
. Post infectious GN, SBE	258	0.1	55	61.2	77.5	16.3	3.1	1.6	9.3	15.1
. Glomerulonephritis (GN)	21,809	6.3	58	60.5	67.2	23.1	6.1	1.3	10.3	14.5
. Other proliferative GN	1,112	0.3	53	58.1	73.9	18.1	5.3	1.4	15.8	13.5
Secondary GN/Vasculitis	8,522	2.5	46	32.4	63.2	30.4	3.3	1.2	8.0	18.3
. Lupus erythematosus, (SLE nephritis)	4,301	1.3	38	18.7	47.3	44.1	4.8	1.1	9.9	11.9
. Polyarteritis	188	0.1	64	48.4	83.5	10.6	5.3	0.5	4.3	21.8
. Wegeners granulomatosis	945	0.3	64	58.8	91.9	5.2	1.3	1.0	6.0	23.5
. Henoch-Schonlein syndrome	142	0.0	25	56.3	82.4	7.0	6.3	2.8	29.6	7.0
. Vasculitis and its derivatives	695	0.2	68	47.3	87.5	7.6	1.6	2.0	2.7	26.5
. Scleroderma	756	0.2	57	22.2	77.8	18.8	1.5	1.1	2.1	35.8
. Hemolytic uremic syndrome	718	0.2	49	35.2	80.1	17.4	1.3	0.7	9.6	21.3
. Nephropathy from heroin /related abuse	530	0.2	53	62.8	54.5	40.2	2.3	1.9	5.7	20.4
. Secondary GN, other	247	0.1	52	58.7	58.7	34.8	2.0	2.0	6.5	21.9
Interstitial Nephritis/Pyelonephritis	14,784	4.3	65	56.5	78.8	16.1	2.8	0.9	8.6	21.1
. Chronic pyelonephritis, reflux neph.	1,975	0.6	49	39.2	84.0	10.4	3.3	1.1	18.2	12.6
. Analgesic abuse	567	0.2	66	36.0	76.9	18.7	2.5	0.7	4.1	17.5
. Nephropathy caused by other agents	1,765	0.5	65	66.2	77.4	18.1	2.2	0.6	7.0	26.9
. Nephrolithiasis, Obstruction, Gouty	4,441	1.3	68	73.3	78.3	16.1	3.1	0.7	5.7	24.7
. Nephrocalcinosis	180	0.1	68	52.8	76.7	16.7	3.9	0.6	8.3	21.7
. Chronic interstitial nephritis	5,420	1.6	64	48.6	77.8	17.2	2.7	1.1	8.9	19.0
. Acute interstitial nephritis	436	0.1	68	49.1	82.1	14.4	2.1	0.2	3.0	31.9
Hypertensive/large vessel disease	96,538	28.1	69	57.0	58.3	37.1	2.8	0.7	2.2	25.0
. Hypertension, (no primary ren. dis.)	87,564	25.5	69	56.7	54.8	40.4	2.9	0.7	2.4	23.8
. Renal artery stenosis or occlusion	6,696	1.9	73	57.8	92.3	5.6	1.2	0.5	0.8	36.8
. Cholesterol emboli, renal emboli	2,278	0.7	72	66.1	94.9	3.3	1.1	0.4	0.3	37.1
Cystic/Hereditary/Congenital Diseases	12,027	3.5	51	56.3	81.3	13.7	2.6	0.8	23.6	6.7
. Polycystic kidneys, adult (dominant)	8,788	2.6	54	52.6	82.5	13.1	2.6	0.6	19.0	6.7
. Polycystic, infantile (recessive)	108	0.0	22	47.2	81.5	16.7	1.9	0.0	25.9	11.1
. Medullary cystic, inc nephronophthisis	132	0.0	24	52.3	81.8	12.1	0.8	2.3	43.2	4.5
. Alports, other hereditary/familial dis	781	0.2	33	70.2	84.4	11.0	1.9	1.2	34.4	2.3
. Tuberous sclerosis	125	0.0	60	44.8	76.8	18.4	2.4	1.6	8.8	21.6
. Cystinosis	54	0.0	15	53.7	88.9	7.4	0.0	1.9	53.7	3.7
. Primary oxalosis	86	0.0	53	51.2	90.7	7.0	2.3	0.0	24.4	11.6
. Fabrys disease	71	0.0	41	88.7	90.1	5.6	0.0	2.8	23.9	4.2
. Congenital nephrotic syndrome	130	0.0	21	51.5	65.4	18.5	10.0	2.3	34.6	10.8
. Drash syndrome, mesangial sclerosis	20	0.0	35	60.0	65.0	25.0	0.0	5.0	20.0	0.0
. Congenital obstructive uropathy	917	0.3	26	76.0	75.1	17.2	3.2	0.9	37.0	9.3
. Renal hypoplasia, dysplasia	734	0.2	14	59.4	74.0	19.1	2.0	1.4	43.3	4.6
. Prune belly syndrome	81	0.0	11	97.5	77.8	18.5	1.2	0.0	43.2	3.7
Neoplasms/Tumors	5,971	1.7	68	62.0	78.1	18.7	1.5	0.9	1.0	46.7
. Renal or Urological Neoplasms	1,662	0.5	68	72.6	79.7	17.1	1.3	1.1	1.3	38.1
. Multiple myeloma	2,993	0.9	69	59.2	75.7	20.8	1.7	0.9	0.2	53.6
. Light chain nephropathy	252	0.1	71	61.5	77.0	18.3	3.2	0.4	0.8	42.1
. Amyloidosis	1,064	0.3	66	53.7	82.3	15.0	1.0	0.8	2.9	41.4
Miscellaneous Conditions	10,814	3.1	53	65.3	55.2	41.4	1.1	0.7	3.4	37.4
. Complication post bone marr/other txp	196	0.1	54	62.8	86.2	10.7	1.0	1.0	18.9	24.5
. Sickle cell disease/anemia or trait	374	0.1	38	52.4	5.1	93.0	0.3	1.1	1.6	16.8
. AIDS nephropathy	3,622	1.1	38	74.9	9.1	87.6	0.2	0.6	0.1	43.7
. Traumatic/surgical loss of kidney(s)	247	0.1	66	70.0	81.8	13.0	2.0	1.2	3.2	22.7
. Hepatorenal syndrome	424	0.1	56	69.1	82.5	10.8	1.7	2.6	15.6	49.8
. Tubular necrosis (no recovery)	3,796	1.1	69	59.9	84.1	13.2	1.3	0.4	2.0	37.2
. Post-Partum Fail, Oth Renal Disorders	2,155	0.6	66	60.0	79.3	16.4	2.3	0.7	8.1	31.0
Etiology Uncertain	14,069	4.1	66	57.3	70.3	23.1	3.8	1.0	7.0	25.3
Missing	13,415	.	63	54.8	60.2	30.7	2.1	0.7	20.3	30.0

\* Values for cells with fewer than 10 patients are suppressed.

Includes all patients: residents of the 50 states, the District of Columbia, Puerto Rico and the Territories.

Table A.16  
Incidence of Reported ESRD Therapy by Detailed Primary Disease and Race  
for All Patients, 1993-1997

Primary Disease Groups	Total Patients	#				# Native Amer.	White (%)	Black (%)	Asian (%)	Native Amer. (%)
		White	Black	Asian	Amer.					
All ESRD, (reference)	357,051	228,332	105,177	11,654	5,182	100.0	100.0	100.0	100.0	
Diabetes	143,448	91,309	40,855	4,954	3,366	41.5	40.4	43.5	66.1	
. Type 1, juvenile type	41,318	29,028	10,171	976	622	13.2	10.1	8.6	12.2	
. Type 2, adult-onset or unspec. type	102,130	62,281	30,684	3,978	2,744	28.3	30.4	35.0	53.9	
Glomerulonephritis	37,463	25,304	8,951	1,972	466	11.5	8.9	17.3	9.2	
. Focal glomerulosclerosis, focal GN	7,294	4,274	2,661	184	67	1.9	2.6	1.6	1.3	
. Membranous nephropathy	1,708	1,207	424	40	16	0.5	0.4	0.4	0.3	
. Membranoproliferative GN, types 1&2	1,380	1,026	228	71	28	0.5	0.2	0.6	0.6	
. IgA nephropathy, Bergers disease	1,618	1,226	120	182	27	0.6	0.1	1.6	0.5	
. IgM nephropathy	175	136	14	18	*	0.1	0.0	0.2	0.0	
. Rapidly progressive GN	1,450	1,167	178	56	25	0.5	0.2	0.5	0.5	
. Goodpastures Syndrome	659	586	46	14	*	0.3	0.0	0.1	0.2	
. Post infectious GN, SBE	258	200	42	*	*	0.1	0.0	0.1	0.1	
. Glomerulonephritis (GN)	21,809	14,660	5,037	1,340	274	6.7	5.0	11.8	5.4	
. Other proliferative GN	1,112	822	201	59	16	0.4	0.2	0.5	0.3	
Secondary GN/Vasculitis	8,522	5,383	2,594	285	104	2.4	2.6	2.5	2.0	
. Lupus erythematosus, (SLE nephritis)	4,301	2,036	1,896	206	48	0.9	1.9	1.8	0.9	
. Polyarteritis	188	157	20	10	*	0.1	0.0	0.1	0.0	
. Wegeners granulomatosis	945	868	49	12	*	0.4	0.0	0.1	0.2	
. Henoch-Schonlein syndrome	142	117	10	*	*	0.1	0.0	0.1	0.1	
. Vasculitis and its derivatives	695	608	53	11	14	0.3	0.1	0.1	0.3	
. Scleroderma	756	588	142	11	*	0.3	0.1	0.1	0.2	
. Hemolytic uremic syndrome	718	575	125	*	*	0.3	0.1	0.1	0.1	
. Nephropathy from heroin /related abuse	530	289	213	12	10	0.1	0.2	0.1	0.2	
. Secondary GN, other	247	145	86	*	*	0.1	0.1	0.0	0.1	
Interstitial Nephritis/Pyelonephritis	14,784	11,653	2,373	420	127	5.3	2.3	3.7	2.5	
. Chronic pyelonephritis, reflux neph.	1,975	1,659	205	65	21	0.8	0.2	0.6	0.4	
. Analgesic abuse	567	436	106	14	*	0.2	0.1	0.1	0.1	
. Nephropathy caused by other agents	1,765	1,366	320	39	10	0.6	0.3	0.3	0.2	
. Nephrolithiasis, Obstruction, Gouty	4,441	3,479	715	139	33	1.6	0.7	1.2	0.6	
. Nephrocalcinosis	180	138	30	*	*	0.1	0.0	0.1	0.0	
. Chronic interstitial nephritis	5,420	4,217	934	147	57	1.9	0.9	1.3	1.1	
. Acute interstitial nephritis	436	358	63	*	*	0.2	0.1	0.1	0.0	
Hypertensive/large vessel disease	96,538	56,313	35,810	2,689	670	25.6	35.4	23.6	13.2	
. Hypertension, (no primary ren. dis.)	87,564	47,972	35,356	2,582	629	21.8	35.0	22.7	12.4	
. Renal artery stenosis or occlusion	6,696	6,180	378	83	31	2.8	0.4	0.7	0.6	
. Cholesterol emboli, renal emboli	2,278	2,161	76	24	10	1.0	0.1	0.2	0.2	
Cystic/Hereditary/Congenital Diseases	12,027	9,780	1,647	309	93	4.4	1.6	2.7	1.8	
. Polycystic kidneys, adult (dominant)	8,788	7,246	1,148	228	54	3.3	1.1	2.0	1.1	
. Polycystic, infantile (recessive)	108	88	18	*	0	0.0	0.0	0.0	0.0	
. Medullary cystic, inc nephronophthisis	132	108	16	*	0	0.0	0.0	0.0	0.1	
. Alports, other hereditary/familial dis	781	659	86	15	*	0.3	0.1	0.1	0.2	
. Tuberous sclerosis	125	96	23	*	*	0.0	0.0	0.0	0.0	
. Cystinosis	54	48	*	0	*	0.0	0.0	0.0	0.0	
. Primary oxalosis	86	78	*	*	0	0.0	0.0	0.0	0.0	
. Fabrys disease	71	64	*	0	*	0.0	0.0	0.0	0.0	
. Congenital nephrotic syndrome	130	85	24	13	*	0.0	0.0	0.1	0.1	
. Drash syndrome, mesangial sclerosis	20	13	*	0	*	0.0	0.0	0.0	0.0	
. Congenital obstructive uropathy	917	689	158	29	*	0.3	0.2	0.3	0.2	
. Renal hypoplasia, dysplasia	734	543	140	15	10	0.2	0.1	0.1	0.2	
. Prune belly syndrome	81	63	15	*	0	0.0	0.0	0.0	0.0	
Neoplasms/Tumors	5,971	4,662	1,114	92	53	2.1	1.1	0.8	1.0	
. Renal or Urological Neoplasms	1,662	1,325	285	22	18	0.6	0.3	0.2	0.4	
. Multiple myeloma	2,993	2,267	623	51	26	1.0	0.6	0.4	0.5	
. Light chain nephropathy	252	194	46	*	*	0.1	0.0	0.1	0.0	
. Amyloidosis	1,064	876	160	11	*	0.4	0.2	0.1	0.2	
Miscellaneous Conditions	10,814	5,968	4,475	119	72	2.7	4.4	1.0	1.4	
. Complication post bone marr/other txp	196	169	21	*	*	0.1	0.0	0.0	0.0	
. Sickle cell disease/anemia or trait	374	19	348	*	*	0.0	0.3	0.0	0.1	
. AIDS nephropathy	3,622	328	3,173	*	21	0.1	3.1	0.1	0.4	
. Traumatic/surgical loss of kidney(s)	247	202	32	*	*	0.1	0.0	0.0	0.1	
. Hepatorenal syndrome	424	350	46	*	11	0.2	0.0	0.1	0.2	
. Tubular necrosis (no recovery)	3,796	3,192	501	48	16	1.4	0.5	0.4	0.3	
. Post-Partum Fail, Oth Renal Disorders	2,155	1,708	354	49	15	0.8	0.4	0.4	0.3	
Etiology Uncertain	14,069	9,889	3,244	536	138	4.5	3.2	4.7	2.7	
Missing	13,415	8,071	4,114	278	93	.	.	.	.	

\* Values for cells with fewer than 10 patients are suppressed.

Includes all patients: residents of the 50 states, the District of Columbia, Puerto Rico and the Territories.

Table A.17  
 Incidence of Reported ESRD Therapy and  
 Median Age at Incidence by Sex, Race, One Year Transplant and Death Status,  
 and Detailed Primary Disease, for Patients Age 65 and Over, 1993-1997

Primary Disease Groups	Total Patients	% Incid	Median Age	% Males	% White	% Black	% Asian	% Amer. Native	% Tran First Year	% Died First Year
All ESRD, (reference)	170,127	100.0	73	51.1	72.5	22.1	3.2	1.0	0.4	33.1
Diabetes	63,441	38.7	71	43.5	66.9	25.6	4.1	1.8	0.2	30.8
. Type 1, juvenile type	12,437	7.6	71	42.2	70.5	24.0	3.4	1.1	0.2	31.9
. Type 2, adult-onset or unspec. type	51,004	31.1	71	43.9	66.0	26.0	4.3	1.9	0.2	30.5
Glomerulonephritis	12,977	7.9	73	59.6	83.0	11.3	4.1	0.8	1.1	26.0
. Focal glomerulosclerosis, focal GN	1,756	1.1	72	64.5	83.9	12.6	2.6	0.4	1.9	21.8
. Membranous nephropathy	639	0.4	73	63.4	81.4	14.7	2.7	0.5	1.4	19.9
. Membranoproliferative GN, types 1&2	303	0.2	72	56.8	86.8	9.6	2.0	1.3	3.0	22.1
. IgA nephropathy, Bergers disease	230	0.1	72	71.7	90.4	3.5	4.8	0.4	1.7	21.7
. IgM nephropathy	27	0.0	71	77.8	92.6	3.7	3.7	0.0	3.7	14.8
. Rapidly progressive GN	656	0.4	73	48.3	90.7	5.9	1.8	0.9	0.3	28.7
. Goodpastures Syndrome	304	0.2	73	44.1	93.1	4.6	1.0	1.0	0.3	37.8
. Post infectious GN, SBE	83	0.1	74	62.7	90.4	6.0	2.4	0.0	0.0	27.7
. Glomerulonephritis (GN)	8,637	5.3	74	59.4	81.4	11.9	5.0	0.9	1.0	26.8
. Other proliferative GN	342	0.2	72	57.9	86.5	9.4	3.2	0.6	0.6	29.8
Secondary GN/Vasculitis	2,029	1.2	72	43.2	87.3	9.8	1.6	0.7	0.4	36.8
. Lupus erythematosus, (SLE nephritis)	378	0.2	70	24.6	71.4	24.9	1.9	0.3	0.5	33.1
. Polyarteritis	91	0.1	74	41.8	90.1	6.6	3.3	0.0	1.1	29.7
. Wegeners granulomatosis	466	0.3	72	56.4	96.4	2.1	0.9	0.6	0.2	36.7
. Henoch-Schonlein syndrome	12	0.0	74	50.0	83.3	8.3	8.3	0.0	0.0	33.3
. Vasculitis and its derivatives	403	0.2	74	49.6	92.8	3.5	1.7	1.5	0.5	33.5
. Scleroderma	244	0.1	71	23.8	89.3	7.8	2.0	0.4	0.0	51.6
. Hemolytic uremic syndrome	171	0.1	72	34.5	89.5	9.4	0.0	0.6	0.0	40.9
. Nephropathy from heroin /related abuse	185	0.1	75	61.6	80.0	17.3	1.6	1.1	0.0	31.9
. Secondary GN, other	79	0.0	73	58.2	86.1	8.9	3.8	1.3	2.5	36.7
Interstitial Nephritis/Pyelonephritis	7,430	4.5	74	59.9	83.5	12.7	2.6	0.5	0.8	31.0
. Chronic pyelonephritis, reflux neph.	589	0.4	74	37.0	85.4	10.0	3.4	0.5	1.0	30.2
. Analgesic abuse	318	0.2	73	38.7	82.1	13.2	3.1	0.6	1.3	23.0
. Nephropathy caused by other agents	900	0.5	74	68.6	82.2	14.1	2.3	0.3	0.8	36.2
. Nephrolithiasis, Obstruction, Gouty	2,639	1.6	75	77.1	82.0	13.6	2.6	0.6	0.5	33.3
. Nephrocalcinosis	96	0.1	75	56.3	80.2	15.6	3.1	0.0	2.1	31.3
. Chronic interstitial nephritis	2,630	1.6	74	48.4	84.7	12.0	2.4	0.4	1.1	27.1
. Acute interstitial nephritis	258	0.2	75	50.0	88.0	9.3	2.3	0.0	0.4	42.2
Hypertensive/large vessel disease	60,192	36.7	75	54.4	71.4	24.8	2.6	0.5	0.3	33.8
. Hypertension, (no primary ren. dis.)	52,731	32.2	75	53.6	68.1	27.7	2.9	0.5	0.3	33.0
. Renal artery stenosis or occlusion	5,550	3.4	74	57.7	93.6	4.6	1.2	0.3	0.1	39.4
. Cholesterol emboli, renal emboli	1,911	1.2	74	65.1	95.4	2.9	1.0	0.4	0.1	39.1
Cystic/Hereditary/Congenital Diseases	2,748	1.7	72	51.3	83.8	12.5	2.6	0.4	2.5	17.4
. Polycystic kidneys, adult (dominant)	2,355	1.4	72	49.8	83.9	12.4	2.6	0.4	2.9	15.9
. Polycystic, infantile (recessive)	*	0.0	72	55.6	77.8	22.2	0.0	0.0	0.0	11.1
. Medullary cystic, inc nephronophthisis	17	0.0	73	58.8	82.4	11.8	5.9	0.0	0.0	29.4
. Alports, other hereditary/familial dis	64	0.0	72	48.4	95.3	3.1	1.6	0.0	3.1	10.9
. Tuberous sclerosis	52	0.0	73	55.8	88.5	7.7	1.9	1.9	0.0	36.5
. Cystinosis	*	0.0	75	0.0	50.0	50.0	0.0	0.0	0.0	50.0
. Primary oxalosis	21	0.0	70	47.6	85.7	14.3	0.0	0.0	0.0	23.8
. Fabrys disease	*	0.0	71	50.0	50.0	50.0	0.0	0.0	0.0	0.0
. Congenital nephrotic syndrome	19	0.0	77	42.1	84.2	5.3	10.5	0.0	0.0	42.1
. Drash syndrome, mesangial sclerosis	*	0.0	72	50.0	83.3	16.7	0.0	0.0	0.0	0.0
. Congenital obstructive uropathy	155	0.1	75	74.8	76.1	18.1	3.2	0.6	0.0	32.3
. Renal hypoplasia, dysplasia	44	0.0	75	50.0	84.1	15.9	0.0	0.0	0.0	18.2
. Prune belly syndrome	*	0.0	80	100.0	100.0	0.0	0.0	0.0	0.0	50.0
Neoplasms/Tumors	3,731	2.3	73	62.6	81.5	15.9	1.4	0.6	0.1	52.6
. Renal or Urological Neoplasms	1,034	0.6	74	75.0	82.5	14.8	1.4	1.0	0.1	43.8
. Multiple myeloma	1,939	1.2	73	58.9	79.3	17.9	1.5	0.6	0.0	58.4
. Light chain nephropathy	166	0.1	75	62.0	83.7	14.5	1.8	0.0	0.0	47.6
. Amyloidosis	592	0.4	72	53.0	86.3	11.8	1.2	0.2	0.5	50.3
Miscellaneous Conditions	3,833	2.3	74	60.6	87.8	9.6	1.6	0.4	0.3	45.0
. Complication post bone marr/other txp	34	0.0	67	67.6	97.1	0.0	0.0	2.9	17.6	26.5
. Sickle cell disease/anemia or trait	21	0.0	71	42.9	19.0	81.0	0.0	0.0	0.0	42.9
. AIDS nephropathy	39	0.0	71	69.2	33.3	61.5	2.6	0.0	0.0	38.5
. Traumatic/surgical loss of kidney(s)	132	0.1	75	70.5	87.9	7.6	2.3	1.5	0.0	36.4
. Hepatorenal syndrome	112	0.1	70	66.1	82.1	9.8	0.9	5.4	2.7	65.2
. Tubular necrosis (no recovery)	2,345	1.4	74	57.7	89.7	8.1	1.4	0.2	0.1	46.0
. Post-Partum Fail, Oth Renal Disorders	1,150	0.7	75	64.8	87.1	10.0	2.0	0.3	0.2	42.9
Etiology Uncertain	7,566	4.6	75	55.9	80.4	15.0	3.1	0.7	0.3	37.5
Missing	6,180	.	73	51.8	70.5	22.7	1.3	0.6	1.9	48.6

\* Values for cells with fewer than 10 patients are suppressed.

Includes all patients: residents of the 50 states, the District of Columbia, Puerto Rico and the Territories.

Table A.18  
Incidence of Reported ESRD Therapy by Detailed Primary Disease and Race  
for Patients Age 65 and Over, 1993-1997

Primary Disease Groups	Total Patients	#				Native Amer.	White (%)	Black (%)	Asian (%)	Native Amer. (%)
		White	Black	Asian	Amer.					
All ESRD, (reference)	170,127	123,283	37,651	5,453	1,727	100.0	100.0	100.0	100.0	
Diabetes	63,441	42,432	16,261	2,593	1,124	35.7	44.9	48.3	66.5	
. Type 1, juvenile type	12,437	8,763	2,986	422	141	7.4	8.2	7.9	8.3	
. Type 2, adult-onset or unspec. type	51,004	33,669	13,275	2,171	983	28.3	36.6	40.4	58.2	
Glomerulonephritis	12,977	10,772	1,467	537	105	9.1	4.0	10.0	6.2	
. Focal glomerulosclerosis, focal GN	1,756	1,474	221	45	*	1.2	0.6	0.8	0.4	
. Membranous nephropathy	639	520	94	17	*	0.4	0.3	0.3	0.2	
. Membranoproliferative GN, types 1&2	303	263	29	*	*	0.2	0.1	0.1	0.2	
. IgA nephropathy, Bergers disease	230	208	*	11	*	0.2	0.0	0.2	0.1	
. IgM nephropathy	27	25	*	*	0	0.0	0.0	0.0	0.0	
. Rapidly progressive GN	656	595	39	12	*	0.5	0.1	0.2	0.4	
. Goodpastures Syndrome	304	283	14	*	*	0.2	0.0	0.1	0.2	
. Post infectious GN, SBE	83	75	*	*	0	0.1	0.0	0.0	0.0	
. Glomerulonephritis (GN)	8,637	7,033	1,024	429	79	5.9	2.8	8.0	4.7	
. Other proliferative GN	342	296	32	11	*	0.2	0.1	0.2	0.1	
Secondary GN/Vasculitis	2,029	1,772	199	33	15	1.5	0.5	0.6	0.9	
. Lupus erythematosus, (SLE nephritis)	378	270	94	*	*	0.2	0.3	0.1	0.1	
. Polyarteritis	91	82	*	*	0	0.1	0.0	0.1	0.0	
. Wegeners granulomatosis	466	449	10	*	*	0.4	0.0	0.1	0.2	
. Henoch-Schonlein syndrome	12	10	*	*	0	0.0	0.0	0.0	0.0	
. Vasculitis and its derivatives	403	374	14	*	*	0.3	0.0	0.1	0.4	
. Scleroderma	244	218	19	*	*	0.2	0.1	0.1	0.1	
. Hemolytic uremic syndrome	171	153	16	0	*	0.1	0.0	0.0	0.1	
. Nephropathy from heroin /related abuse	185	148	32	*	*	0.1	0.1	0.1	0.1	
. Secondary GN, other	79	68	*	*	*	0.1	0.0	0.1	0.1	
Interstitial Nephritis/Pyelonephritis	7,430	6,201	942	190	36	5.2	2.6	3.5	2.1	
. Chronic pyelonephritis, reflux neph.	589	503	59	20	*	0.4	0.2	0.4	0.2	
. Analgesic abuse	318	261	42	10	*	0.2	0.1	0.2	0.1	
. Nephropathy caused by other agents	900	740	127	21	*	0.6	0.4	0.4	0.2	
. Nephrolithiasis, Obstruction, Gouty	2,639	2,165	359	68	17	1.8	1.0	1.3	1.0	
. Nephrocalcinosis	96	77	15	*	0	0.1	0.0	0.1	0.0	
. Chronic interstitial nephritis	2,630	2,228	316	62	11	1.9	0.9	1.2	0.7	
. Acute interstitial nephritis	258	227	24	*	0	0.2	0.1	0.1	0.0	
Hypertensive/large vessel disease	60,192	42,955	14,935	1,593	307	36.1	41.2	29.7	18.2	
. Hypertension, (no primary ren. dis.)	52,731	35,935	14,626	1,506	282	30.2	40.4	28.0	16.7	
. Renal artery stenosis or occlusion	5,550	5,197	254	67	18	4.4	0.7	1.2	1.1	
. Cholesterol emboli, renal emboli	1,911	1,823	55	20	*	1.5	0.2	0.4	0.4	
Cystic/Hereditary/Congenital Diseases	2,748	2,303	343	72	12	1.9	0.9	1.3	0.7	
. Polycystic kidneys, adult (dominant)	2,355	1,977	291	62	10	1.7	0.8	1.2	0.6	
. Polycystic, infantile (recessive)	*	*	*	0	0	0.0	0.0	0.0	0.0	
. Medullary cystic, inc nephronophthisis	17	14	*	*	0	0.0	0.0	0.0	0.0	
. Alports, other hereditary/familial dis	64	61	*	*	0	0.1	0.0	0.0	0.0	
. Tuberous sclerosis	52	46	*	*	*	0.0	0.0	0.0	0.1	
. Cystinosis	*	*	*	0	0	0.0	0.0	0.0	0.0	
. Primary oxalosis	21	18	*	0	0	0.0	0.0	0.0	0.0	
. Fabrys disease	*	*	*	0	0	0.0	0.0	0.0	0.0	
. Congenital nephrotic syndrome	19	16	*	*	0	0.0	0.0	0.0	0.0	
. Drash syndrome, mesangial sclerosis	*	*	*	0	0	0.0	0.0	0.0	0.0	
. Congenital obstructive uropathy	155	118	28	*	*	0.1	0.1	0.1	0.1	
. Renal hypoplasia, dysplasia	44	37	*	0	0	0.0	0.0	0.0	0.0	
. Prune belly syndrome	*	*	0	0	0	0.0	0.0	0.0	0.0	
Neoplasms/Tumors	3,731	3,041	595	53	22	2.6	1.6	1.0	1.3	
. Renal or Urological Neoplasms	1,034	853	153	14	10	0.7	0.4	0.3	0.6	
. Multiple myeloma	1,939	1,538	348	29	11	1.3	1.0	0.5	0.7	
. Light chain nephropathy	166	139	24	*	0	0.1	0.1	0.1	0.0	
. Amyloidosis	592	511	70	*	*	0.4	0.2	0.1	0.1	
Miscellaneous Conditions	3,833	3,364	368	61	17	2.8	1.0	1.1	1.0	
. Complication post bone marr/other txp	34	33	0	0	*	0.0	0.0	0.0	0.1	
. Sickle cell disease/anemia or trait	21	*	17	0	0	0.0	0.0	0.0	0.0	
. AIDS nephropathy	39	13	24	*	0	0.0	0.1	0.0	0.0	
. Traumatic/surgical loss of kidney(s)	132	116	10	*	*	0.1	0.0	0.1	0.1	
. Hepatorenal syndrome	112	92	11	*	*	0.1	0.0	0.0	0.4	
. Tubular necrosis (no recovery)	2,345	2,104	191	33	*	1.8	0.5	0.6	0.3	
. Post-Partum Fail, Oth Renal Disorders	1,150	1,002	115	23	*	0.8	0.3	0.4	0.2	
Etiology Uncertain	7,566	6,085	1,136	238	51	5.1	3.1	4.4	3.0	
Missing	6,180	4,358	1,405	83	38	.	.	.	.	

\* Values for cells with fewer than 10 patients are suppressed.

Includes all patients: residents of the 50 states, the District of Columbia, Puerto Rico and the Territories.

Table A.19  
Incidence of Reported ESRD Therapy and  
Median Age at Incidence by Sex, Race, One Year Transplant and Death Status,  
and Detailed Primary Disease, for Adult Patients Age 20-64, 1993-1997

Primary Disease Groups	Total Patients	% Incid	Median Age	% Males	% White	% Black	% Asian	% Amer. Native	% Tran First Year	% Died First Year
All ESRD, (reference)	181,493	100.0	51	55.2	56.0	36.4	3.3	1.9	10.0	12.8
Diabetes	79,918	45.7	54	50.9	61.1	30.7	2.9	2.8	6.7	14.2
. Type 1, juvenile type	28,838	16.5	48	53.2	70.2	24.8	1.9	1.7	12.5	13.7
. Type 2, adult-onset or unspec. type	51,080	29.2	56	49.6	56.0	34.1	3.5	3.4	3.4	14.5
Glomerulonephritis	22,866	13.1	44	61.8	59.5	30.4	5.9	1.5	17.5	6.2
. Focal glomerulosclerosis, focal GN	4,983	2.9	42	61.7	51.0	43.9	2.5	1.1	17.6	5.6
. Membranous nephropathy	1,040	0.6	49	67.2	64.8	30.3	2.2	1.3	17.5	6.0
. Membranoproliferative GN, types 1&2	939	0.5	43	61.3	71.1	17.9	6.5	2.3	23.9	6.2
. IgA nephropathy, Bergers disease	1,302	0.7	39	67.7	73.4	7.8	12.8	1.6	31.6	2.2
. IgM nephropathy	141	0.1	40	68.8	75.2	7.8	12.1	0.7	36.9	3.5
. Rapidly progressive GN	681	0.4	49	55.9	73.3	17.5	5.4	1.8	12.8	5.9
. Goodpastures Syndrome	318	0.2	48	49.4	84.9	9.1	3.1	1.6	11.6	12.9
. Post infectious GN, SBE	163	0.1	45	62.0	71.2	20.9	3.7	2.5	13.5	9.2
. Glomerulonephritis (GN)	12,610	7.2	45	61.5	57.9	30.5	6.9	1.5	15.5	6.6
. Other proliferative GN	689	0.4	44	58.6	68.8	21.5	6.2	2.0	20.0	6.8
Secondary GN/Vasculitis	6,008	3.4	41	28.5	55.1	37.8	3.6	1.4	9.5	13.0
. Lupus erythematosus, (SLE nephritis)	3,671	2.1	37	17.8	45.1	46.4	4.8	1.2	10.9	10.1
. Polyarteritis	88	0.1	47	60.2	80.7	12.5	5.7	1.1	5.7	13.6
. Wegeners granulomatosis	439	0.3	53	62.4	87.9	8.2	1.4	1.4	10.0	11.4
. Henoch-Schonlein syndrome	85	0.0	33	60.0	78.8	10.6	7.1	3.5	23.5	5.9
. Vasculitis and its derivatives	279	0.2	53	44.1	81.0	12.5	1.4	2.5	5.0	17.6
. Scleroderma	511	0.3	49	21.5	72.4	23.9	1.2	1.4	3.1	28.4
. Hemolytic uremic syndrome	441	0.3	46	30.6	76.0	21.8	1.4	0.5	7.5	17.2
. Nephropathy from heroin /related abuse	333	0.2	44	64.3	39.9	53.5	2.4	2.4	7.5	14.7
. Secondary GN, other	161	0.1	44	59.6	44.1	49.1	1.2	2.5	8.1	15.5
Interstitial Nephritis/Pyelonephritis	6,860	3.9	49	52.4	74.0	19.6	3.1	1.3	13.9	11.7
. Chronic pyelonephritis, reflux neph.	1,239	0.7	41	39.7	83.8	10.2	3.4	1.4	22.8	5.4
. Analgesic abuse	246	0.1	53	32.5	70.3	25.6	1.6	0.8	7.7	10.6
. Nephropathy caused by other agents	817	0.5	51	63.5	72.0	22.9	2.1	0.7	11.3	18.0
. Nephrolithiasis, Obstruction, Gouty	1,626	0.9	53	67.2	72.6	19.7	4.2	0.9	9.3	13.0
. Nephrocalcinosis	83	0.0	50	49.4	72.3	18.1	4.8	1.2	15.7	10.8
. Chronic interstitial nephritis	2,684	1.5	48	48.3	71.2	22.4	2.9	1.7	14.5	11.7
. Acute interstitial nephritis	165	0.1	52	47.3	75.8	20.0	1.2	0.6	5.5	18.2
Hypertensive/large vessel disease	36,084	20.7	51	61.3	36.8	57.5	3.0	1.0	5.3	10.4
. Hypertension, (no primary ren. dis.)	34,589	19.8	51	61.3	34.6	59.5	3.1	1.0	5.4	9.8
. Renal artery stenosis or occlusion	1,128	0.6	60	58.2	86.0	10.7	1.4	1.1	3.5	24.2
. Cholesterol emboli, renal emboli	367	0.2	61	70.8	92.1	5.7	1.1	0.8	1.4	26.7
Cystic/Hereditary/Congenital Diseases	7,869	4.5	48	56.1	82.1	13.2	2.5	0.8	25.6	3.5
. Polycystic kidneys, adult (dominant)	6,323	3.6	50	53.8	82.1	13.2	2.5	0.7	24.5	3.3
. Polycystic, infantile (recessive)	47	0.0	44	51.1	85.1	14.9	0.0	0.0	27.7	10.6
. Medullary cystic, inc nephronophthisis	55	0.0	33	50.9	83.6	10.9	0.0	1.8	40.0	0.0
. Alports, other hereditary/familial dis	569	0.3	36	68.2	86.8	9.1	1.9	0.7	33.2	1.8
. Tuberous sclerosis	68	0.0	42	35.3	70.6	25.0	1.5	1.5	13.2	11.8
. Cystinosis	14	0.0	42	42.9	92.9	0.0	0.0	7.1	21.4	7.1
. Primary oxalosis	46	0.0	53	54.3	95.7	4.3	0.0	0.0	23.9	10.9
. Fabrys disease	68	0.0	41	89.7	91.2	4.4	0.0	2.9	25.0	4.4
. Congenital nephrotic syndrome	47	0.0	33	66.0	57.4	29.8	10.6	2.1	40.4	2.1
. Drash syndrome, mesangial sclerosis	*	0.0	40	60.0	40.0	40.0	0.0	20.0	20.0	0.0
. Congenital obstructive uropathy	400	0.2	34	71.8	77.8	15.3	3.8	1.5	28.0	5.8
. Renal hypoplasia, dysplasia	209	0.1	33	56.9	79.9	18.2	0.5	0.5	31.6	2.4
. Prune belly syndrome	18	0.0	26	100.0	83.3	16.7	0.0	0.0	27.8	0.0
Neoplasms/Tumors	2,202	1.3	56	61.3	72.5	23.2	1.7	1.3	2.1	37.1
. Renal or Urological Neoplasms	591	0.3	56	69.7	75.8	20.8	1.2	1.0	2.0	29.3
. Multiple myeloma	1,054	0.6	57	59.7	69.2	26.1	2.1	1.4	0.5	44.9
. Light chain nephropathy	86	0.0	56	60.5	64.0	25.6	5.8	1.2	2.3	31.4
. Amyloidosis	471	0.3	55	54.6	77.3	19.1	0.8	1.5	5.9	30.4
Miscellaneous Conditions	6,777	3.9	42	68.3	36.7	59.6	0.8	0.8	4.3	34.0
. Complication post bone marr/other txp	152	0.1	52	62.5	83.6	13.2	1.3	0.7	16.4	25.7
. Sickle cell disease/anemia or trait	336	0.2	38	52.7	4.2	93.8	0.3	1.2	1.5	16.1
. AIDS nephropathy	3,560	2.0	38	75.1	8.8	87.9	0.2	0.6	0.1	43.8
. Traumatic/surgical loss of kidney(s)	109	0.1	44	71.6	76.1	18.3	1.8	0.9	7.3	6.4
. Hepatorenal syndrome	310	0.2	51	70.0	82.9	11.0	1.9	1.6	20.0	44.5
. Tubular necrosis (no recovery)	1,396	0.8	54	63.9	75.1	21.5	1.0	0.8	4.3	23.8
. Post-Partum Fail, Oth Renal Disorders	914	0.5	49	54.8	70.7	24.0	2.7	1.1	13.9	18.6
Etiology Uncertain	6,116	3.5	47	59.5	58.4	32.8	4.6	1.3	13.2	11.9
Missing	6,793	.	48	57.2	50.9	38.2	2.6	0.8	33.0	14.8

\* Values for cells with fewer than 10 patients are suppressed.

Includes all patients: residents of the 50 states, the District of Columbia, Puerto Rico and the Territories.

Table A.20  
Incidence of Reported ESRD Therapy by Detailed Primary Disease and Race  
for Adult Patients Age 20-64, 1993-1997

Primary Disease Groups	Total Patients	#				Native Amer.	White (%)	Black (%)	Asian (%)	Native Amer. (%)
		White	Black	Asian	Amer.					
All ESRD, (reference)	181,493	101,661	66,054	5,980	3,378	100.0	100.0	100.0	100.0	
Diabetes	79,918	48,832	24,559	2,357	2,240	49.7	38.7	40.6	67.4	
. Type 1, juvenile type	28,838	20,244	7,166	552	481	20.6	11.3	9.5	14.5	
. Type 2, adult-onset or unspec. type	51,080	28,588	17,393	1,805	1,759	29.1	27.4	31.1	52.9	
Glomerulonephritis	22,866	13,612	6,958	1,356	333	13.9	11.0	23.4	10.0	
. Focal glomerulosclerosis, focal GN	4,983	2,543	2,189	124	55	2.6	3.4	2.1	1.7	
. Membranous nephropathy	1,040	674	315	23	13	0.7	0.5	0.4	0.4	
. Membranoproliferative GN, types 1&2	939	668	168	61	22	0.7	0.3	1.1	0.7	
. IgA nephropathy, Bergers disease	1,302	956	102	167	21	1.0	0.2	2.9	0.6	
. IgM nephropathy	141	106	11	17	*	0.1	0.0	0.3	0.0	
. Rapidly progressive GN	681	499	119	37	12	0.5	0.2	0.6	0.4	
. Goodpastures Syndrome	318	270	29	10	*	0.3	0.0	0.2	0.2	
. Post infectious GN, SBE	163	116	34	*	*	0.1	0.1	0.1	0.1	
. Glomerulonephritis (GN)	12,610	7,306	3,843	868	186	7.4	6.1	15.0	5.6	
. Other proliferative GN	689	474	148	43	14	0.5	0.2	0.7	0.4	
Secondary GN/Vasculitis	6,008	3,313	2,269	218	83	3.4	3.6	3.8	2.5	
. Lupus erythematosus, (SLE nephritis)	3,671	1,654	1,703	175	45	1.7	2.7	3.0	1.4	
. Polyarteritis	88	71	11	*	*	0.1	0.0	0.1	0.0	
. Wegeners granulomatosis	439	386	36	*	*	0.4	0.1	0.1	0.2	
. Henoch-Schonlein syndrome	85	67	*	*	*	0.1	0.0	0.1	0.1	
. Vasculitis and its derivatives	279	226	35	*	*	0.2	0.1	0.1	0.2	
. Scleroderma	511	370	122	*	*	0.4	0.2	0.1	0.2	
. Hemolytic uremic syndrome	441	335	96	*	*	0.3	0.2	0.1	0.1	
. Nephropathy from heroin /related abuse	333	133	178	*	*	0.1	0.3	0.1	0.2	
. Secondary GN, other	161	71	79	*	*	0.1	0.1	0.0	0.1	
Interstitial Nephritis/Pyelonephritis	6,860	5,074	1,345	216	87	5.2	2.1	3.7	2.6	
. Chronic pyelonephritis, reflux neph.	1,239	1,038	126	42	17	1.1	0.2	0.7	0.5	
. Analgesic abuse	246	173	63	*	*	0.2	0.1	0.1	0.1	
. Nephropathy caused by other agents	817	588	187	17	*	0.6	0.3	0.3	0.2	
. Nephrolithiasis, Obstruction, Gouty	1,626	1,180	320	69	15	1.2	0.5	1.2	0.5	
. Nephrocalcinosis	83	60	15	*	*	0.1	0.0	0.1	0.0	
. Chronic interstitial nephritis	2,684	1,910	601	78	45	1.9	0.9	1.3	1.4	
. Acute interstitial nephritis	165	125	33	*	*	0.1	0.1	0.0	0.0	
Hypertensive/large vessel disease	36,084	13,261	20,733	1,088	357	13.5	32.7	18.8	10.7	
. Hypertension, (no primary ren. dis.)	34,589	11,953	20,591	1,068	342	12.2	32.4	18.4	10.3	
. Renal artery stenosis or occlusion	1,128	970	121	16	12	1.0	0.2	0.3	0.4	
. Cholesterol emboli, renal emboli	367	338	21	*	*	0.3	0.0	0.1	0.1	
Cystic/Hereditary/Congenital Diseases	7,869	6,460	1,042	193	61	6.6	1.6	3.3	1.8	
. Polycystic kidneys, adult (dominant)	6,323	5,191	837	160	43	5.3	1.3	2.8	1.3	
. Polycystic, infantile (recessive)	47	40	*	0	0	0.0	0.0	0.0	0.0	
. Medullary cystic, inc nephronophthisis	55	46	*	0	*	0.0	0.0	0.0	0.0	
. Alports, other hereditary/familial dis	569	494	52	11	*	0.5	0.1	0.2	0.1	
. Tuberous sclerosis	68	48	17	*	*	0.0	0.0	0.0	0.0	
. Cystinosis	14	13	0	0	*	0.0	0.0	0.0	0.0	
. Primary oxalosis	46	44	*	0	0	0.0	0.0	0.0	0.0	
. Fabrys disease	68	62	*	0	*	0.1	0.0	0.0	0.1	
. Congenital nephrotic syndrome	47	27	14	*	*	0.0	0.0	0.1	0.0	
. Drash syndrome, mesangial sclerosis	*	*	*	0	*	0.0	0.0	0.0	0.0	
. Congenital obstructive uropathy	400	311	61	15	*	0.3	0.1	0.3	0.2	
. Renal hypoplasia, dysplasia	209	167	38	*	*	0.2	0.1	0.0	0.0	
. Prune belly syndrome	18	15	*	0	0	0.0	0.0	0.0	0.0	
Neoplasms/Tumors	2,202	1,596	510	38	29	1.6	0.8	0.7	0.9	
. Renal or Urological Neoplasms	591	448	123	*	*	0.5	0.2	0.1	0.2	
. Multiple myeloma	1,054	729	275	22	15	0.7	0.4	0.4	0.5	
. Light chain nephropathy	86	55	22	*	*	0.1	0.0	0.1	0.0	
. Amyloidosis	471	364	90	*	*	0.4	0.1	0.1	0.2	
Miscellaneous Conditions	6,777	2,487	4,038	56	53	2.5	6.4	1.0	1.6	
. Complication post bone marr/other txp	152	127	20	*	*	0.1	0.0	0.0	0.0	
. Sickle cell disease/anemia or trait	336	14	315	*	*	0.0	0.5	0.0	0.1	
. AIDS nephropathy	3,560	312	3,130	*	21	0.3	4.9	0.1	0.6	
. Traumatic/surgical loss of kidney(s)	109	83	20	*	*	0.1	0.0	0.0	0.0	
. Hepatorenal syndrome	310	257	34	*	*	0.3	0.1	0.1	0.2	
. Tubular necrosis (no recovery)	1,396	1,048	300	14	11	1.1	0.5	0.2	0.3	
. Post-Partum Fail, Oth Renal Disorders	914	646	219	25	10	0.7	0.3	0.4	0.3	
Etiology Uncertain	6,116	3,570	2,003	280	82	3.6	3.2	4.8	2.5	
Missing	6,793	3,456	2,597	178	53	.	.	.	.	

\* Values for cells with fewer than 10 patients are suppressed.

Includes all patients: residents of the 50 states, the District of Columbia, Puerto Rico and the Territories.



Table A.21  
Incidence of Reported ESRD Therapy and  
Median Age at Incidence by Sex, Race, One Year Transplant and Death Status,  
and Detailed Primary Disease for Pediatric Patients Age < 20, 1993-1997

Primary Disease Groups	Total Patients	% Incid	Median Age	% Males	% White	% Black	% Asian	% Amer. Native	% Tran First Year	% Died First Year
All ESRD, (reference)	5,431	100.0	14	57.1	62.4	27.1	4.1	1.4	44.4	3.2
Diabetes	89	1.8	16	42.7	50.6	39.3	4.5	2.2	12.4	2.2
. Type 1, juvenile type	43	0.9	17	39.5	48.8	44.2	4.7	0.0	18.6	2.3
. Type 2, adult-onset or unspec. type	46	0.9	6	45.7	52.2	34.8	4.3	4.3	6.5	2.2
Glomerulonephritis	1,620	32.5	16	55.2	56.8	32.5	4.9	1.7	38.0	1.5
. Focal glomerulosclerosis, focal GN	555	11.1	15	60.5	46.3	45.2	2.7	0.9	37.8	1.8
. Membranous nephropathy	29	0.6	16	44.8	44.8	51.7	0.0	0.0	24.1	3.4
. Membranoproliferative GN, types 1&2	138	2.8	16	46.4	68.8	22.5	2.9	1.4	42.8	0.0
. IgA nephropathy, Bergers disease	86	1.7	17	68.6	72.1	11.6	4.7	5.8	44.2	0.0
. IgM nephropathy	*	0.1	19	28.6	71.4	28.6	0.0	0.0	28.6	0.0
. Rapidly progressive GN	113	2.3	14	40.7	64.6	17.7	6.2	6.2	38.9	0.9
. Goodpastures Syndrome	37	0.7	16	48.6	89.2	8.1	2.7	0.0	16.2	2.7
. Post infectious GN, SBE	12	0.2	14	41.7	75.0	25.0	0.0	0.0	16.7	8.3
. Glomerulonephritis (GN)	562	11.3	16	54.8	57.1	30.2	7.7	1.6	37.5	1.6
. Other proliferative GN	81	1.6	16	54.3	64.2	25.9	6.2	0.0	44.4	1.2
Secondary GN/Vasculitis	485	9.7	15	35.9	61.4	26.0	7.0	1.2	21.4	6.2
. Lupus erythematosus, (SLE nephritis)	252	5.1	17	23.4	44.4	39.3	9.5	0.8	9.1	7.5
. Polyarteritis	*	0.2	14	0.0	44.4	33.3	22.2	0.0	22.2	22.2
. Wegeners granulomatosis	40	0.8	16	47.5	82.5	7.5	5.0	0.0	30.0	2.5
. Henoch-Schonlein syndrome	45	0.9	14	51.1	88.9	0.0	4.4	2.2	48.9	2.2
. Vasculitis and its derivatives	13	0.3	17	46.2	61.5	30.8	0.0	7.7	23.1	0.0
. Scleroderma	*	0.0	17	0.0	0.0	100.0	0.0	0.0	0.0	0.0
. Hemolytic uremic syndrome	106	2.1	8	55.7	82.1	12.3	2.8	1.9	34.0	6.6
. Nephropathy from heroin /related abuse	12	0.2	15	41.7	66.7	25.0	8.3	0.0	41.7	0.0
. Secondary GN, other	*	0.1	17	42.9	85.7	0.0	0.0	0.0	14.3	0.0
Interstitial Nephritis/Pyelonephritis	494	9.9	14	61.3	76.5	17.4	2.8	0.8	50.0	2.6
. Chronic pyelonephritis, reflux neph.	147	2.9	14	44.2	80.3	13.6	2.0	0.7	47.6	2.0
. Analgesic abuse	*	0.1	17	33.3	66.7	33.3	0.0	0.0	0.0	0.0
. Nephropathy caused by other agents	48	1.0	15	68.8	79.2	12.5	2.1	2.1	52.1	2.1
. Nephrolithiasis, Obstruction, Gouty	176	3.5	12	74.4	76.1	20.5	1.1	0.6	49.4	2.8
. Nephrocalcinosis	*	0.0	15	0.0	100.0	0.0	0.0	0.0	0.0	0.0
. Chronic interstitial nephritis	106	2.1	15	62.3	74.5	16.0	6.6	0.9	58.5	3.8
. Acute interstitial nephritis	13	0.3	17	53.8	46.2	46.2	7.7	0.0	23.1	0.0
Hypertensive/large vessel disease	262	5.3	17	57.3	37.0	54.2	3.1	2.3	26.0	4.6
. Hypertension, (no primary ren. dis.)	244	4.9	18	58.6	34.4	57.0	3.3	2.0	25.0	4.5
. Renal artery stenosis or occlusion	18	0.4	10	38.9	72.2	16.7	0.0	5.6	38.9	5.6
. Cholesterol emboli, renal emboli	0	.	.	.	.	.	.	.	.	.
Cystic/Hereditary/Congenital Diseases	1,410	28.3	10	67.5	72.1	18.6	3.1	1.4	53.7	3.6
. Polycystic kidneys, adult (dominant)	110	2.2	10	47.3	70.9	18.2	5.5	0.9	48.2	2.7
. Polycystic, infantile (recessive)	52	1.0	4	42.3	78.8	17.3	3.8	0.0	28.8	11.5
. Medullary cystic, inc nephronophthisis	60	1.2	13	51.7	80.0	13.3	0.0	3.3	58.3	1.7
. Alports, other hereditary/familial dis	148	3.0	16	87.2	70.3	21.6	2.0	3.4	52.7	0.7
. Tuberous sclerosis	*	0.1	18	60.0	40.0	40.0	20.0	0.0	40.0	0.0
. Cystinosis	38	0.8	12	60.5	89.5	7.9	0.0	0.0	68.4	0.0
. Primary oxalosis	19	0.4	3	47.4	84.2	5.3	10.5	0.0	52.6	0.0
. Fabrys disease	*	0.0	19	100.0	100.0	0.0	0.0	0.0	0.0	0.0
. Congenital nephrotic syndrome	64	1.3	2	43.8	65.6	14.1	9.4	3.1	40.6	7.8
. Drash syndrome, mesangial sclerosis	*	0.2	0	66.7	66.7	22.2	0.0	0.0	33.3	0.0
. Congenital obstructive uropathy	362	7.3	11	81.2	71.8	19.1	2.5	0.3	62.7	3.3
. Renal hypoplasia, dysplasia	481	9.6	8	61.3	70.5	19.8	2.9	1.9	52.4	4.4
. Prune belly syndrome	61	1.2	7	96.7	75.4	19.7	1.6	0.0	49.2	3.3
Neoplasms/Tumors	38	0.8	7	47.4	65.8	23.7	2.6	5.3	23.7	21.1
. Renal or Urological Neoplasms	37	0.7	6	48.6	64.9	24.3	2.7	5.4	24.3	21.6
. Multiple myeloma	0	.	.	.	.	.	.	.	.	.
. Light chain nephropathy	0	.	.	.	.	.	.	.	.	.
. Amyloidosis	*	0.0	11	0.0	100.0	0.0	0.0	0.0	0.0	0.0
Miscellaneous Conditions	204	4.1	12	54.4	57.4	33.8	1.0	1.0	33.3	8.3
. Complication post bone marr/other txp	10	0.2	16	50.0	90.0	10.0	0.0	0.0	60.0	0.0
. Sickle cell disease/anemia or trait	17	0.3	19	58.8	5.9	94.1	0.0	0.0	5.9	0.0
. AIDS nephropathy	23	0.5	16	65.2	13.0	82.6	0.0	0.0	0.0	30.4
. Traumatic/surgical loss of kidney(s)	*	0.1	14	33.3	50.0	33.3	0.0	0.0	0.0	16.7
. Hepatorenal syndrome	*	0.0	13	100.0	50.0	50.0	0.0	0.0	50.0	0.0
. Tubular necrosis (no recovery)	55	1.1	7	52.7	72.7	18.2	1.8	0.0	27.3	7.3
. Post-Partum Fail, Oth Renal Disorders	91	1.8	11	52.7	65.9	22.0	1.1	2.2	49.5	5.5
Etiology Uncertain	387	7.8	15	50.4	60.5	27.1	4.7	1.3	42.4	1.3
Missing	442	.	13	59.5	58.1	25.3	3.8	0.5	82.8	2.5

\* Values for cells with fewer than 10 patients are suppressed.

Includes all patients: residents of the 50 states, the District of Columbia, Puerto Rico and the Territories.

Table A.22  
Incidence of Reported ESRD Therapy by Detailed Primary Disease and Race  
for Pediatric Patients Age < 20, 1993-1997

Primary Disease Groups	Total Patients	#				Native Amer.	White (%)	Black (%)	Asian (%)	Native Amer. (%)
		White	Black	Asian	Amer.					
All ESRD, (reference)	5,431	3,388	1,472	221	77	100.0	100.0	100.0	100.0	
Diabetes	89	45	35	*	*	1.4	2.6	2.0	2.7	
. Type 1, juvenile type	43	21	19	*	0	0.7	1.4	1.0	0.0	
. Type 2, adult-onset or unspec. type	46	24	16	*	*	0.8	1.2	1.0	2.7	
Glomerulonephritis	1,620	920	526	79	28	29.4	38.7	38.7	37.3	
. Focal glomerulosclerosis, focal GN	555	257	251	15	*	8.2	18.5	7.4	6.7	
. Membranous nephropathy	29	13	15	0	0	0.4	1.1	0.0	0.0	
. Membranoproliferative GN, types 1&2	138	95	31	*	*	3.0	2.3	2.0	2.7	
. IgA nephropathy, Bergers disease	86	62	10	*	*	2.0	0.7	2.0	6.7	
. IgM nephropathy	*	*	*	0	0	0.2	0.1	0.0	0.0	
. Rapidly progressive GN	113	73	20	*	*	2.3	1.5	3.4	9.3	
. Goodpastures Syndrome	37	33	*	*	0	1.1	0.2	0.5	0.0	
. Post infectious GN, SBE	12	*	*	0	0	0.3	0.2	0.0	0.0	
. Glomerulonephritis (GN)	562	321	170	43	*	10.3	12.5	21.1	12.0	
. Other proliferative GN	81	52	21	*	0	1.7	1.5	2.5	0.0	
Secondary GN/Vasculitis	485	298	126	34	*	9.5	9.3	16.7	8.0	
. Lupus erythematosus, (SLE nephritis)	252	112	99	24	*	3.6	7.3	11.8	2.7	
. Polyarteritis	*	*	*	*	0	0.1	0.2	1.0	0.0	
. Wegeners granulomatosis	40	33	*	*	0	1.1	0.2	1.0	0.0	
. Henoch-Schonlein syndrome	45	40	0	*	*	1.3	0.0	1.0	1.3	
. Vasculitis and its derivatives	13	*	*	0	*	0.3	0.3	0.0	1.3	
. Scleroderma	*	0	*	0	0	0.0	0.1	0.0	0.0	
. Hemolytic uremic syndrome	106	87	13	*	*	2.8	1.0	1.5	2.7	
. Nephropathy from heroin /related abuse	12	*	*	*	0	0.3	0.2	0.5	0.0	
. Secondary GN, other	*	*	0	0	0	0.2	0.0	0.0	0.0	
Interstitial Nephritis/Pyelonephritis	494	378	86	14	*	12.1	6.3	6.9	5.3	
. Chronic pyelonephritis, reflux neph.	147	118	20	*	*	3.8	1.5	1.5	1.3	
. Analgesic abuse	*	*	*	0	0	0.1	0.1	0.0	0.0	
. Nephropathy caused by other agents	48	38	*	*	*	1.2	0.4	0.5	1.3	
. Nephrolithiasis, Obstruction, Gouty	176	134	36	*	*	4.3	2.6	1.0	1.3	
. Nephrocalcinosis	*	*	0	0	0	0.0	0.0	0.0	0.0	
. Chronic interstitial nephritis	106	79	17	*	*	2.5	1.3	3.4	1.3	
. Acute interstitial nephritis	13	*	*	*	0	0.2	0.4	0.5	0.0	
Hypertensive/large vessel disease	262	97	142	*	*	3.1	10.4	3.9	8.0	
. Hypertension, (no primary ren. dis.)	244	84	139	*	*	2.7	10.2	3.9	6.7	
. Renal artery stenosis or occlusion	18	13	*	0	*	0.4	0.2	0.0	1.3	
. Cholesterol emboli, renal emboli	0	0	0	0	0	.	.	.	.	
Cystic/Hereditary/Congenital Diseases	1,410	1,017	262	44	20	32.5	19.3	21.6	26.7	
. Polycystic kidneys, adult (dominant)	110	78	20	*	*	2.5	1.5	2.9	1.3	
. Polycystic, infantile (recessive)	52	41	*	*	0	1.3	0.7	1.0	0.0	
. Medullary cystic, inc nephronophthisis	60	48	*	0	*	1.5	0.6	0.0	2.7	
. Alports, other hereditary/familial dis	148	104	32	*	*	3.3	2.4	1.5	6.7	
. Tuberous sclerosis	*	*	*	*	0	0.1	0.1	0.5	0.0	
. Cystinosis	38	34	*	0	0	1.1	0.2	0.0	0.0	
. Primary oxalosis	19	16	*	*	0	0.5	0.1	1.0	0.0	
. Fabrys disease	*	*	0	0	0	0.0	0.0	0.0	0.0	
. Congenital nephrotic syndrome	64	42	*	*	*	1.3	0.7	2.9	2.7	
. Drash syndrome, mesangial sclerosis	*	*	*	0	0	0.2	0.1	0.0	0.0	
. Congenital obstructive uropathy	362	260	69	*	*	8.3	5.1	4.4	1.3	
. Renal hypoplasia, dysplasia	481	339	95	14	*	10.8	7.0	6.9	12.0	
. Prune belly syndrome	61	46	12	*	0	1.5	0.9	0.5	0.0	
Neoplasms/Tumors	38	25	*	*	*	0.8	0.7	0.5	2.7	
. Renal or Urological Neoplasms	37	24	*	*	*	0.8	0.7	0.5	2.7	
. Multiple myeloma	0	0	0	0	0	.	.	.	.	
. Light chain nephropathy	0	0	0	0	0	.	.	.	.	
. Amyloidosis	*	*	0	0	0	0.0	0.0	0.0	0.0	
Miscellaneous Conditions	204	117	69	*	*	3.7	5.1	1.0	2.7	
. Complication post bone marr/other txp	10	*	*	0	0	0.3	0.1	0.0	0.0	
. Sickle cell disease/anemia or trait	17	*	16	0	0	0.0	1.2	0.0	0.0	
. AIDS nephropathy	23	*	19	0	0	0.1	1.4	0.0	0.0	
. Traumatic/surgical loss of kidney(s)	*	*	*	0	0	0.1	0.1	0.0	0.0	
. Hepatorenal syndrome	*	*	*	0	0	0.0	0.1	0.0	0.0	
. Tubular necrosis (no recovery)	55	40	10	*	0	1.3	0.7	0.5	0.0	
. Post-Partum Fail, Oth Renal Disorders	91	60	20	*	*	1.9	1.5	0.5	2.7	
Etiology Uncertain	387	234	105	18	*	7.5	7.7	8.8	6.7	
Missing	442	257	112	17	*	.	.	.	.	

\* Values for cells with fewer than 10 patients are suppressed.  
Includes all patients: residents of the 50 states, the District of Columbia, Puerto Rico and the Territories.

Table A.23  
 Incidence Counts of Reported ESRD Therapy  
 by State after Dropping Territories and "Unknown" States  
 All Patients

State	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
Alabama	743	956	845	1,012	1,142	1,092	1,236	1,367	1,479	1,594
Alaska	37	46	36	49	59	52	202	348	70	77
Arizona	571	680	698	779	958	919	1,095	1,164	1,251	1,324
Arkansas	378	379	411	502	522	560	675	728	717	806
California	4,328	5,010	5,423	5,866	5,933	6,210	7,592	8,070	8,320	8,905
Colorado	309	402	407	464	506	511	551	543	659	669
Connecticut	471	547	602	651	688	682	782	900	937	923
Delaware	128	124	143	162	194	176	200	232	221	215
District of Columbia	187	313	289	313	334	355	304	424	441	414
Florida	2,303	2,652	2,835	3,157	3,507	3,530	3,798	4,142	4,696	4,883
Georgia	1,131	1,361	1,379	1,625	1,817	1,813	2,072	2,266	2,435	2,363
Hawaii	214	232	278	274	300	322	420	391	388	413
Idaho	102	124	142	132	127	138	181	183	197	229
Illinois	1,787	1,998	2,316	2,655	2,770	3,024	3,399	3,656	3,633	3,781
Indiana	805	863	927	989	1,150	1,233	1,147	1,505	1,533	1,538
Iowa	319	380	415	446	526	506	571	543	585	618
Kansas	291	365	399	401	424	425	491	498	561	653
Kentucky	475	543	590	693	755	801	743	951	947	1,050
Louisiana	863	996	1,026	1,177	1,308	1,321	1,467	1,619	1,609	1,802
Maine	112	108	147	134	160	153	198	230	210	260
Maryland	739	934	1,050	1,152	1,241	1,291	1,276	1,696	1,846	1,813
Massachusetts	770	865	915	1,009	1,166	1,181	1,358	1,433	1,513	1,546
Michigan	1,408	1,635	1,754	1,852	2,103	2,194	2,458	2,605	2,896	2,902
Minnesota	499	563	622	660	730	740	874	853	934	993
Mississippi	476	557	576	636	748	785	907	914	1,015	1,043
Missouri	775	883	980	1,065	1,140	1,214	1,325	1,463	1,498	1,589
Montana	71	110	113	139	127	136	148	165	139	143
Nebraska	188	221	219	242	292	271	320	343	356	408
Nevada	152	170	166	233	236	247	324	340	357	385
New Hampshire	105	123	139	145	152	138	166	187	159	194
New Jersey	1,383	1,572	1,758	1,920	2,093	2,168	2,443	2,670	2,710	2,849
New Mexico	249	245	259	331	315	319	360	432	477	477
New York	2,805	3,203	3,519	3,721	4,235	4,392	5,000	5,356	5,638	5,855
North Carolina	1,073	1,298	1,362	1,536	1,750	1,862	2,110	2,087	2,364	2,471
North Dakota	73	102	104	94	127	122	145	131	139	139
Ohio	1,655	1,849	1,952	2,040	2,363	2,451	2,569	3,139	3,404	3,323
Oklahoma	467	481	576	537	643	680	728	806	810	939
Oregon	344	395	413	481	466	538	581	561	583	640
Pennsylvania	1,957	2,271	2,626	2,641	2,903	2,826	3,445	3,772	3,838	4,115
Rhode Island	138	162	188	202	206	229	236	245	265	256
South Carolina	672	806	865	918	1,017	1,030	1,282	1,233	1,355	1,395
South Dakota	92	86	93	101	112	121	140	193	191	190
Tennessee	702	983	945	1,097	1,176	1,137	1,380	1,478	1,535	1,675
Texas	2,677	3,023	3,354	3,627	4,121	4,197	4,627	4,926	5,439	5,620
Utah	183	180	179	185	194	255	237	257	244	271
Vermont	53	63	67	91	62	75	79	111	94	118
Virginia	964	1,091	1,184	1,399	1,519	1,536	1,599	1,876	2,067	2,234
Washington	495	640	684	734	744	795	919	964	998	1,030
West Virginia	297	281	315	349	372	404	425	514	537	615
Wisconsin	673	745	757	832	947	925	1,036	1,080	1,158	1,209
Wyoming	50	44	35	49	40	53	45	68	70	76
	37,739	43,660	47,077	51,499	56,520	58,135	65,666	71,658	75,518	79,030

(CONTINUED)

Includes residents of 50 states and District of Columbia only.  
 \* Values for cells with fewer than 10 patients are suppressed.

Table A.23(Continued)  
 Incidence Counts of Reported ESRD Therapy  
 by State after Dropping Territories and "Unknown" States  
 Diabetic ESRD Patients

State	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
Alabama	180	253	217	312	395	377	469	523	578	691
Alaska	9	22	12	15	19	24	60	122	31	44
Arizona	241	291	285	368	476	457	528	603	610	674
Arkansas	103	121	128	168	169	178	227	270	304	304
California	1,380	1,822	2,005	2,287	2,326	2,374	3,050	3,398	3,613	4,046
Colorado	133	165	169	201	207	228	227	258	331	308
Connecticut	137	171	191	218	244	241	285	364	357	401
Delaware	49	52	46	58	57	56	67	74	80	71
District of Columbia	47	72	90	92	118	123	89	131	177	147
Florida	610	742	832	934	1,086	1,105	1,280	1,391	1,667	1,795
Georgia	306	410	459	505	626	605	725	881	1,042	960
Hawaii	99	109	142	147	146	181	239	232	237	232
Idaho	37	46	50	40	56	54	79	72	78	97
Illinois	510	608	697	859	843	919	1,198	1,352	1,424	1,356
Indiana	235	241	326	361	409	413	426	638	648	600
Iowa	98	128	123	152	188	197	208	225	243	244
Kansas	92	106	128	159	146	155	199	193	229	261
Kentucky	140	161	191	242	251	279	275	370	397	432
Louisiana	265	331	323	443	488	443	558	614	702	777
Maine	31	33	37	41	54	58	59	81	74	95
Maryland	216	295	375	418	468	470	477	607	690	723
Massachusetts	184	260	285	342	392	397	492	525	593	550
Michigan	468	570	659	742	831	809	1,002	1,081	1,280	1,248
Minnesota	169	220	231	259	270	284	340	333	351	362
Mississippi	135	157	163	225	271	268	338	372	443	421
Missouri	239	276	318	356	419	453	497	592	632	709
Montana	32	52	53	60	69	57	67	82	64	64
Nebraska	64	84	80	93	114	109	117	171	157	163
Nevada	37	58	66	92	84	78	110	157	132	171
New Hampshire	31	38	43	46	37	42	45	70	56	71
New Jersey	408	454	610	657	678	734	902	1,084	1,105	1,147
New Mexico	119	117	107	187	188	184	197	250	286	264
New York	874	955	1,151	1,257	1,415	1,476	1,735	1,959	2,250	2,307
North Carolina	294	398	468	555	616	670	842	855	1,006	1,057
North Dakota	31	46	48	35	60	48	61	55	52	58
Ohio	568	619	683	708	924	906	1,030	1,332	1,470	1,451
Oklahoma	199	180	243	238	311	294	333	392	376	431
Oregon	106	135	144	160	179	187	216	217	225	242
Pennsylvania	614	718	878	960	1,059	990	1,282	1,528	1,477	1,575
Rhode Island	47	43	59	53	69	70	71	86	99	103
South Carolina	199	245	293	330	372	349	473	488	577	566
South Dakota	41	31	32	54	55	58	61	101	94	88
Tennessee	199	279	259	349	401	411	494	590	608	654
Texas	960	1,254	1,436	1,544	1,711	1,902	2,122	2,374	2,689	2,816
Utah	80	62	79	80	82	109	114	132	117	121
Vermont	15	23	22	34	17	28	38	56	32	50
Virginia	280	348	360	456	518	551	630	675	792	905
Washington	189	219	240	285	299	311	354	378	418	429
West Virginia	92	92	114	122	150	143	161	220	233	258
Wisconsin	204	265	292	330	383	353	392	437	478	513
Wyoming	15	21	12	15	11	22	23	40	30	36
	11,811	14,398	16,254	18,644	20,757	21,230	25,264	29,031	31,634	33,088

(CONTINUED)

Includes residents of 50 states and District of Columbia only.  
 \* Values for cells with fewer than 10 patients are suppressed.

Table A.23(Continued)  
 Incidence Counts of Reported ESRD Therapy  
 by State after Dropping Territories and "Unknown" States  
 Nondiabetic ESRD Patients

State	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
Alabama	556	619	475	661	730	661	748	812	873	834
Alaska	26	24	24	34	40	28	142	223	38	31
Arizona	300	359	372	398	466	425	543	538	620	592
Arkansas	268	253	274	328	349	364	443	453	404	465
California	2,710	2,952	3,198	3,450	3,476	3,526	4,359	4,384	4,442	4,458
Colorado	173	230	219	255	286	264	319	277	315	334
Connecticut	323	362	397	419	431	413	476	516	568	461
Delaware	74	61	86	95	130	100	128	144	126	119
District of Columbia	115	195	185	197	191	197	181	233	225	237
Florida	1,636	1,852	1,958	2,199	2,388	2,268	2,460	2,483	2,843	2,833
Georgia	756	872	882	1,083	1,155	1,124	1,282	1,316	1,355	1,276
Hawaii	113	119	133	124	151	134	176	154	144	162
Idaho	64	76	89	90	70	82	101	109	115	117
Illinois	1,207	1,275	1,423	1,634	1,821	1,850	2,085	2,182	2,084	2,132
Indiana	554	575	573	592	688	727	639	796	835	840
Iowa	209	236	285	288	334	289	351	302	329	332
Kansas	196	240	260	241	271	253	285	303	328	367
Kentucky	308	340	376	419	474	447	400	532	502	549
Louisiana	579	652	690	722	806	838	895	977	894	964
Maine	79	73	104	89	105	95	134	144	135	154
Maryland	458	587	645	708	746	777	737	965	1,010	962
Massachusetts	521	565	604	653	753	750	819	842	898	873
Michigan	914	1,035	1,046	1,081	1,245	1,275	1,426	1,485	1,595	1,561
Minnesota	324	330	380	395	450	419	522	504	558	583
Mississippi	312	368	323	383	462	488	542	514	546	569
Missouri	515	560	641	701	714	720	806	848	842	814
Montana	37	52	60	76	57	76	81	80	72	75
Nebraska	120	133	134	148	177	151	197	167	194	223
Nevada	109	103	91	136	149	159	205	176	219	200
New Hampshire	70	79	94	97	111	92	114	114	102	109
New Jersey	936	1,074	1,108	1,224	1,401	1,321	1,499	1,544	1,569	1,591
New Mexico	117	114	135	139	124	122	161	171	180	196
New York	1,810	2,123	2,303	2,386	2,739	2,707	3,175	3,218	3,282	3,289
North Carolina	738	856	866	964	1,101	1,101	1,232	1,193	1,327	1,293
North Dakota	42	53	56	57	66	70	84	74	86	72
Ohio	1,024	1,111	1,204	1,230	1,330	1,383	1,407	1,688	1,779	1,643
Oklahoma	267	295	329	293	321	362	391	404	417	468
Oregon	236	257	263	317	284	336	359	334	354	368
Pennsylvania	1,250	1,346	1,654	1,599	1,753	1,656	2,069	2,104	2,194	2,311
Rhode Island	90	117	125	147	132	147	157	154	164	137
South Carolina	443	538	547	574	624	629	786	708	750	738
South Dakota	49	53	58	47	57	63	76	90	97	95
Tennessee	476	645	558	724	762	662	870	858	895	933
Texas	1,611	1,646	1,857	2,029	2,349	2,155	2,440	2,429	2,643	2,485
Utah	102	115	92	102	109	140	122	116	119	130
Vermont	37	39	45	56	41	42	38	51	59	62
Virginia	621	702	798	908	973	938	909	1,069	1,157	1,181
Washington	300	405	436	438	439	460	557	569	573	567
West Virginia	193	176	193	224	212	250	252	267	279	311
Wisconsin	441	464	458	493	557	539	630	628	669	653
Wyoming	35	22	22	34	29	29	22	25	40	36
	24,444	27,328	29,128	31,681	34,629	34,104	38,832	40,267	41,844	41,785

Includes residents of 50 states and District of Columbia only.  
 \* Values for cells with fewer than 10 patients are suppressed.

Table A.24  
Incidence Rates per Million Population of Reported ESRD Therapy  
by State Adjusted for Age, Race and Sex  
All Patients

State	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
Alabama	164.08	198.52	162.05	194.69	222.21	204.18	237.59	259.16	275.58	287.60
Alaska	109.39	178.42	123.31	145.99	186.38	190.39	717.19	1159.64	219.02	254.32
Arizona	194.03	222.66	209.19	240.47	286.12	252.01	290.08	294.49	315.72	315.52
Arkansas	159.50	156.39	159.99	199.90	202.31	213.82	250.45	278.52	262.54	298.10
California	178.76	203.83	218.07	231.65	228.24	230.63	278.69	287.30	287.95	304.84
Colorado	118.12	169.72	159.23	186.79	184.23	185.47	195.49	190.83	219.16	224.32
Connecticut	164.53	184.25	195.20	212.60	226.49	219.30	255.72	290.20	301.33	290.88
Delaware	186.31	177.89	216.15	237.09	280.74	232.25	257.26	297.55	279.58	274.92
District of Columbia	216.51	218.33	190.01	169.63	184.57	222.60	203.75	289.72	257.77	257.23
Florida	166.98	186.79	192.80	208.28	225.22	223.11	229.05	249.90	276.38	273.15
Georgia	158.88	182.89	179.85	211.55	232.25	226.25	252.99	330.63	358.46	270.36
Hawaii	104.74	226.17	149.45	131.22	167.06	160.95	185.62	172.90	146.45	177.57
Idaho	101.71	170.44	144.86	172.32	253.20	257.77	297.17	197.96	231.13	391.80
Illinois	159.58	175.68	202.76	228.81	240.12	255.75	285.14	305.46	302.22	312.67
Indiana	168.10	184.23	190.20	198.02	232.12	252.63	228.91	298.22	304.75	289.72
Iowa	159.88	190.38	214.77	214.80	261.38	230.42	296.17	256.36	334.38	279.93
Kansas	142.79	171.13	194.85	197.36	202.45	208.57	228.16	244.91	280.49	310.97
Kentucky	156.98	176.98	185.33	213.64	246.30	240.20	220.40	283.85	275.81	292.79
Louisiana	184.54	194.16	208.14	241.02	261.74	259.90	284.55	303.06	297.21	329.33
Maine	367.49	145.75	158.59	180.74	135.40	104.82	302.89	291.66	307.57	255.13
Maryland	138.71	167.64	193.09	206.74	219.82	222.40	214.13	276.82	294.15	291.18
Massachusetts	155.16	163.48	174.57	189.28	219.87	217.54	256.22	271.80	285.39	276.88
Michigan	159.62	182.84	192.90	201.13	224.80	230.12	260.41	271.41	293.51	293.32
Minnesota	180.36	184.31	211.18	207.41	219.54	226.81	271.32	284.22	291.27	283.64
Mississippi	158.15	161.84	169.77	198.66	222.12	217.54	269.94	277.78	282.14	295.66
Missouri	162.30	185.66	196.05	214.59	228.27	243.68	258.28	284.56	303.08	301.86
Montana	157.12	124.07	309.82	264.67	140.21	145.75	311.61	393.38	140.39	144.46
Nebraska	169.92	193.05	179.83	214.18	236.10	227.16	272.85	263.59	298.89	307.46
Nevada	169.21	203.17	167.91	213.77	197.26	205.59	254.40	248.08	235.48	242.72
New Hampshire	202.14	185.06	206.53	169.91	159.34	153.17	202.75	175.33	193.50	207.30
New Jersey	174.72	197.44	219.92	236.28	255.55	260.85	289.35	313.02	314.85	326.22
New Mexico	192.12	199.07	203.75	230.08	221.44	214.64	229.01	274.46	291.97	301.12
New York	149.68	168.39	183.37	193.92	218.16	223.79	252.10	266.15	279.81	289.16
North Carolina	143.14	169.45	173.65	195.73	216.24	227.38	249.90	271.66	302.14	277.54
North Dakota	111.35	821.46	195.26	135.39	202.86	791.32	421.09	862.72	196.35	347.24
Ohio	167.17	183.35	189.00	193.13	223.49	227.11	232.36	285.19	312.95	302.50
Oklahoma	159.02	163.23	190.68	178.80	207.67	224.04	231.61	253.39	251.13	287.25
Oregon	158.37	195.83	169.43	223.04	186.22	220.59	254.66	233.36	236.83	216.45
Pennsylvania	167.94	190.83	217.95	217.58	236.69	227.44	282.06	311.66	310.68	324.94
Rhode Island	158.18	213.35	232.79	217.88	224.58	234.96	277.89	290.98	312.26	284.81
South Carolina	159.53	186.59	200.61	203.96	243.07	226.17	273.77	396.09	457.55	283.03
South Dakota	154.07	111.49	482.05	445.54	139.71	147.77	190.47	264.77	273.39	261.71
Tennessee	156.12	191.26	188.53	215.54	229.63	213.17	255.25	275.11	274.56	297.08
Texas	196.91	209.55	228.08	243.68	268.95	268.48	289.42	305.25	330.21	332.83
Utah	199.50	128.56	120.21	180.66	163.61	313.27	184.10	190.63	213.80	206.58
Vermont	272.56	608.79	107.29	265.27	101.21	181.52	133.84	273.14	274.36	320.95
Virginia	153.49	167.01	180.70	208.84	222.35	222.62	223.87	258.85	280.24	301.93
Washington	136.14	171.37	186.99	190.16	202.76	202.09	216.72	228.83	231.39	226.71
West Virginia	188.76	167.97	210.74	222.05	222.00	239.30	252.99	325.39	329.32	348.29
Wisconsin	184.25	194.99	202.11	211.76	250.60	239.57	255.32	278.30	289.89	286.98
Wyoming	178.15	169.75	123.36	308.21	132.77	248.01	127.58	151.87	295.01	233.48

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

\* Values for cells with fewer than 10 patients are suppressed.

Rates per million based on July 1, U.S. resident population by state or ESRD Network. The standard population is July 1, 1996, U.S. resident population by 5-year age groups, sex, and White/non-White race groups.

Table A.24(Continued)  
 Incidence Rates per Million Population of Reported ESRD Therapy  
 by State Adjusted for Age, Race and Sex  
 Diabetic ESRD Patients

State	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
Alabama	40.73	51.91	38.19	55.21	72.69	66.90	89.17	97.13	106.22	121.11
Alaska	22.33	93.05	43.11	40.22	52.17	95.84	260.24	367.53	85.48	153.88
Arizona	84.19	94.97	77.18	112.81	142.25	125.53	136.35	150.32	147.49	163.05
Arkansas	42.75	49.99	50.52	65.98	66.78	68.05	87.66	104.32	112.44	111.08
California	56.54	73.22	80.24	89.83	89.16	88.17	111.52	120.20	124.22	138.09
Colorado	50.71	72.76	65.48	81.12	73.57	78.82	83.63	90.33	110.19	97.33
Connecticut	46.78	56.76	61.37	71.85	83.53	79.47	96.47	119.40	118.90	130.83
Delaware	71.93	78.99	67.38	79.39	79.90	72.81	86.63	92.45	102.84	91.01
District of Columbia	39.44	48.51	42.58	37.43	54.56	65.68	42.00	93.31	98.41	92.44
Florida	46.35	55.11	59.72	63.96	73.25	72.48	80.19	86.79	101.20	102.60
Georgia	38.06	54.21	60.69	67.37	79.44	73.99	88.55	126.25	151.79	108.47
Hawaii	24.57	123.42	59.94	55.03	61.85	47.29	100.70	91.73	70.51	84.63
Idaho	40.19	93.92	56.15	39.91	62.27	133.20	93.19	66.58	117.55	164.36
Illinois	44.25	53.03	61.14	73.40	72.31	77.28	99.98	112.73	118.44	112.18
Indiana	48.93	48.52	64.31	69.64	82.97	85.67	85.52	124.06	130.53	114.05
Iowa	58.30	63.41	68.62	80.37	87.77	94.35	116.77	115.23	157.93	133.16
Kansas	47.25	51.45	63.11	82.38	72.58	77.74	96.75	102.65	118.66	133.46
Kentucky	47.15	52.65	63.16	75.19	81.41	87.18	80.96	109.25	113.63	121.16
Louisiana	50.87	61.65	66.07	83.00	92.21	87.47	103.22	112.44	123.86	134.55
Maine	101.44	26.97	26.50	98.10	61.78	39.59	50.31	158.35	122.75	97.49
Maryland	40.06	53.88	64.78	73.10	82.49	79.81	79.43	96.82	110.07	113.73
Massachusetts	39.37	48.83	55.65	65.18	74.89	75.23	94.22	103.91	113.00	100.74
Michigan	51.36	61.59	70.95	79.82	88.50	84.40	105.10	113.10	130.63	127.31
Minnesota	70.40	76.60	85.64	84.17	86.47	100.83	111.06	111.61	114.83	117.27
Mississippi	47.36	47.11	53.25	69.32	84.09	68.92	104.59	123.18	121.64	121.02
Missouri	49.21	60.04	63.82	73.33	86.85	87.72	96.94	116.13	125.86	135.38
Montana	112.48	59.57	243.29	178.21	77.85	61.95	98.31	208.13	64.92	65.95
Nebraska	70.47	80.80	64.50	88.48	104.53	107.06	101.59	151.14	136.98	143.90
Nevada	39.69	65.32	66.45	77.83	67.27	64.47	81.90	113.02	82.35	105.04
New Hampshire	49.30	43.63	78.35	42.87	46.71	72.69	60.49	73.84	81.78	59.53
New Jersey	50.11	55.95	75.33	79.52	81.83	87.68	105.94	126.75	128.15	131.21
New Mexico	82.09	80.11	79.17	123.69	120.00	115.16	120.75	152.79	162.18	159.82
New York	45.51	49.43	59.35	64.51	72.08	74.20	86.96	97.04	110.71	113.47
North Carolina	38.46	52.86	60.26	71.49	76.01	81.57	99.08	111.05	126.22	114.08
North Dakota	49.81	408.79	76.22	57.58	98.42	690.50	260.17	586.18	79.16	239.88
Ohio	57.06	59.26	65.66	65.10	85.89	83.87	91.41	118.14	133.37	133.35
Oklahoma	64.20	55.52	73.91	76.49	96.95	92.62	100.57	121.01	112.45	123.34
Oregon	45.18	79.17	57.67	74.29	74.24	75.37	110.60	93.32	101.84	85.98
Pennsylvania	52.69	58.89	70.19	77.79	86.65	78.61	103.79	124.62	118.08	123.21
Rhode Island	46.38	63.84	80.66	55.23	85.54	76.37	89.46	113.46	128.90	112.58
South Carolina	45.31	51.16	65.37	74.55	82.96	75.03	103.11	148.23	176.76	107.44
South Dakota	55.54	42.24	41.05	319.60	69.21	73.23	77.38	123.48	113.72	145.48
Tennessee	49.88	54.16	52.17	68.20	78.19	76.26	92.54	109.26	108.20	113.37
Texas	72.41	85.72	97.59	103.42	111.48	121.34	132.11	148.16	164.18	166.06
Utah	113.06	43.97	54.85	71.08	72.41	132.89	75.77	104.16	87.11	103.30
Vermont	108.94	312.77	35.11	137.68	28.29	42.78	58.39	177.94	49.29	150.52
Virginia	42.81	49.79	51.33	64.19	73.69	76.77	85.69	91.52	105.15	119.93
Washington	49.55	63.24	74.89	82.34	88.66	86.30	80.16	96.21	98.99	97.13
West Virginia	62.21	62.98	71.60	85.10	85.92	87.36	93.30	143.42	139.31	138.62
Wisconsin	54.93	74.55	80.32	85.43	96.83	96.18	98.34	116.90	128.16	129.32
Wyoming	37.53	58.61	73.43	31.57	29.13	76.14	80.27	88.57	69.82	138.68

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

\* Values for cells with fewer than 10 patients are suppressed.

Rates per million based on July 1, U.S. resident population by state or ESRD Network. The standard population is July 1, 1996, U.S. resident population by 5-year age groups, sex, and White/non-White race groups.

Table A.24(Continued)  
Incidence Rates per Million Population of Reported ESRD Therapy  
by State Adjusted for Age, Race and Sex  
Nondiabetic ESRD Patients

State	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
Alabama	121.27	126.61	93.79	131.35	144.50	124.82	145.33	154.04	163.31	152.11
Alaska	82.78	85.37	80.21	105.77	134.22	94.54	456.95	775.42	130.57	96.43
Arizona	100.58	119.52	116.73	124.26	138.82	116.85	147.87	138.88	162.85	137.68
Arkansas	113.93	102.67	106.19	131.42	134.11	136.15	161.15	172.52	146.98	172.57
California	112.66	121.10	129.06	137.01	134.08	130.31	160.55	156.75	155.19	153.79
Colorado	66.16	93.61	86.16	102.12	105.42	97.80	110.06	97.86	103.71	118.81
Connecticut	113.48	122.88	129.36	136.19	139.21	130.70	152.30	163.28	178.41	139.32
Delaware	108.16	84.65	135.32	139.81	191.60	135.40	164.96	185.18	158.09	152.69
District of Columbia	133.88	136.82	129.34	120.62	101.31	125.32	127.03	157.01	119.25	135.69
Florida	116.18	127.44	129.34	142.63	149.59	141.71	145.26	144.72	162.62	154.45
Georgia	111.12	116.89	113.31	139.08	148.05	140.31	155.69	195.86	202.24	147.73
Hawaii	50.79	96.35	58.89	70.38	102.64	81.68	80.53	72.25	70.80	78.11
Idaho	60.62	74.52	86.01	130.66	190.05	122.91	203.17	129.68	110.73	215.01
Illinois	108.75	112.19	124.67	141.52	158.65	156.77	175.31	182.21	173.25	175.53
Indiana	116.10	122.93	119.96	119.51	135.35	147.33	126.83	157.42	165.18	156.68
Iowa	97.74	121.88	141.19	130.59	172.56	130.44	169.86	133.92	171.27	128.38
Kansas	94.37	110.15	126.43	114.66	126.76	123.83	128.45	140.49	159.75	166.98
Kentucky	101.74	105.46	114.64	126.79	152.25	129.05	118.06	157.16	144.36	152.46
Louisiana	128.25	129.64	139.82	155.14	164.87	162.32	177.68	184.53	170.02	185.73
Maine	264.80	117.16	116.95	79.95	73.00	65.23	249.24	126.77	184.15	126.20
Maryland	86.88	104.04	122.15	128.60	132.45	134.59	124.97	158.59	162.32	156.32
Massachusetts	102.97	106.31	114.00	120.47	140.41	135.74	150.92	153.96	167.53	154.16
Michigan	105.35	117.98	116.34	117.67	132.86	133.96	151.49	153.33	160.78	155.99
Minnesota	108.22	98.54	121.98	121.35	130.60	113.41	156.99	167.60	164.01	156.75
Mississippi	99.01	106.30	87.59	114.64	131.44	140.04	153.46	144.69	153.90	152.98
Missouri	107.52	114.50	128.22	139.26	139.90	145.81	157.21	163.38	172.71	153.94
Montana	42.55	57.88	66.53	83.35	61.21	80.42	213.30	182.35	72.31	74.32
Nebraska	94.35	110.00	110.20	125.14	131.06	109.80	163.04	106.53	157.42	151.04
Nevada	122.07	127.41	92.82	132.21	127.24	132.92	166.20	130.86	149.94	129.62
New Hampshire	149.49	136.65	126.48	125.08	109.25	77.01	132.79	99.13	110.99	134.37
New Jersey	119.60	135.89	139.49	152.00	171.94	159.40	178.50	181.37	182.42	182.15
New Mexico	101.15	109.62	114.34	102.89	99.30	87.54	107.55	112.11	119.44	130.46
New York	97.95	112.44	120.75	125.29	141.97	138.77	160.70	160.05	163.92	163.02
North Carolina	99.38	111.45	109.89	122.04	135.85	134.68	146.11	155.90	171.60	149.97
North Dakota	61.54	408.22	119.03	75.48	103.16	95.53	160.92	274.12	116.27	95.86
Ohio	104.02	110.30	115.25	116.64	126.81	127.07	128.59	155.75	165.08	146.91
Oklahoma	94.50	105.77	115.03	100.02	107.72	125.10	130.07	129.29	133.64	151.17
Oregon	109.81	115.77	110.02	147.58	110.98	138.57	142.43	134.42	133.79	118.47
Pennsylvania	107.60	113.85	140.05	131.44	141.71	134.39	169.80	173.61	176.48	182.26
Rhode Island	110.98	147.83	148.57	161.18	135.07	146.53	177.56	170.97	181.57	152.37
South Carolina	105.56	128.18	129.19	125.68	153.90	139.49	166.05	237.63	274.27	155.36
South Dakota	95.97	66.41	437.90	125.94	70.50	74.55	109.37	138.88	159.67	108.00
Tennessee	101.11	126.41	111.45	140.63	148.90	124.28	159.88	159.21	160.93	166.17
Texas	117.41	114.35	125.95	136.47	153.10	137.65	153.04	149.03	159.29	147.50
Utah	85.98	82.18	59.73	107.64	89.15	158.32	91.40	80.98	121.55	91.68
Vermont	162.48	294.76	72.18	126.01	66.76	130.51	70.82	88.68	187.66	161.05
Virginia	100.35	110.70	125.06	139.10	144.06	138.41	129.52	150.11	159.31	161.93
Washington	84.45	104.72	110.57	104.98	111.90	111.18	135.11	128.83	130.57	123.40
West Virginia	120.68	97.98	126.74	135.69	130.14	142.64	153.33	161.34	162.40	181.99
Wisconsin	120.25	116.33	119.81	124.10	151.94	133.54	153.38	158.77	159.11	146.90
Wyoming	140.62	55.57	44.81	276.64	103.64	167.37	47.31	52.53	225.18	86.26

Includes residents of 50 states and District of Columbia only.

\* Values for cells with fewer than 10 patients are suppressed.

Rates per million based on July 1, U.S. resident population by state or ESRD Network. The standard population is July 1, 1996, U.S. resident population by 5-year age groups, sex, and White/non-White race groups.



Table A.25  
 Standard Errors for Incidence Rates per Million Population of Reported ESRD Therapy  
 by State Adjusted for Age, Race and Sex  
 All Patients

State	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
Alabama	8.40	8.30	6.35	6.88	7.93	7.17	8.14	8.51	8.69	8.37
Alaska	27.23	39.15	32.25	31.96	31.11	32.85	70.14	85.57	37.97	37.15
Arizona	10.72	11.13	9.93	11.28	12.07	10.38	10.93	10.69	11.22	10.75
Arkansas	9.70	9.08	8.26	9.77	9.44	9.76	10.22	11.44	10.34	11.48
California	2.88	3.04	3.13	3.19	3.13	3.11	3.40	3.42	3.39	3.46
Colorado	7.72	10.20	9.26	10.36	9.53	9.62	9.73	9.46	9.84	10.05
Connecticut	8.59	8.39	8.46	8.91	9.25	8.94	9.69	10.19	10.39	10.05
Delaware	17.33	16.72	19.19	20.50	22.00	17.92	18.93	20.25	19.50	19.74
District of Columbia	29.30	26.72	24.68	22.16	23.46	27.30	27.13	29.96	25.63	26.29
Florida	3.77	3.94	3.93	4.02	4.07	4.06	3.92	4.13	4.25	4.09
Georgia	5.81	5.66	5.53	6.19	6.25	6.03	6.44	8.99	9.22	6.34
Hawaii	31.21	70.59	41.94	22.38	31.69	33.59	27.51	28.49	21.48	23.73
Idaho	10.54	43.46	13.02	50.54	118.22	88.49	85.91	42.70	40.49	93.05
Illinois	3.87	4.01	4.30	4.51	4.65	4.71	4.94	5.10	5.06	5.13
Indiana	6.49	7.45	6.90	6.86	7.67	8.26	7.50	8.64	8.72	7.89
Iowa	15.48	17.18	19.09	17.56	19.82	17.29	21.53	18.74	23.14	18.84
Kansas	9.64	10.17	11.09	11.17	11.08	11.46	11.46	12.29	13.21	13.50
Kentucky	9.47	10.35	9.84	9.62	11.56	9.89	9.33	10.87	10.16	9.77
Louisiana	7.78	7.15	7.66	8.44	8.58	8.43	8.73	9.03	8.84	9.09
Maine	144.64	54.18	46.21	51.14	23.98	8.49	81.00	69.43	97.13	42.63
Maryland	5.60	5.97	6.48	6.66	6.79	6.74	6.56	7.38	7.54	7.52
Massachusetts	6.55	6.44	6.65	6.87	7.34	7.15	7.82	8.06	8.21	7.83
Michigan	4.55	4.76	4.87	4.88	5.09	5.13	5.50	5.56	5.59	5.62
Minnesota	14.32	12.68	14.58	12.93	13.32	13.55	14.18	15.28	14.12	13.35
Mississippi	11.43	9.45	10.10	11.62	10.82	9.58	13.20	13.13	12.00	12.32
Missouri	6.42	6.94	6.65	7.17	7.29	7.66	7.49	7.95	8.67	8.03
Montana	75.26	11.91	179.62	109.50	12.50	12.55	88.99	155.42	12.00	12.23
Nebraska	16.48	17.52	15.85	18.07	18.10	17.94	19.63	17.82	20.02	18.85
Nevada	15.79	17.79	14.78	15.97	13.78	14.23	15.38	14.38	13.06	13.01
New Hampshire	54.30	48.34	40.66	38.54	22.24	40.03	35.08	20.80	35.35	31.20
New Jersey	4.78	5.05	5.32	5.45	5.63	5.64	5.88	6.08	6.07	6.13
New Mexico	16.82	19.07	18.63	16.83	16.35	16.53	15.59	17.17	17.18	17.86
New York	2.89	3.03	3.15	3.24	3.41	3.43	3.62	3.70	3.79	3.84
North Carolina	4.83	5.11	5.13	5.55	5.67	5.80	5.97	6.84	7.09	6.05
North Dakota	13.71	385.09	46.22	14.49	21.71	436.63	170.42	461.27	16.98	145.26
Ohio	5.01	4.81	4.79	4.66	5.05	4.96	4.83	5.34	5.78	5.65
Oklahoma	8.03	8.03	8.55	8.27	8.74	9.24	9.14	9.51	9.41	9.97
Oregon	14.31	16.86	13.41	16.74	14.16	15.84	17.88	16.04	16.12	12.99
Pennsylvania	4.45	4.45	4.68	4.68	4.75	4.60	5.20	5.49	5.40	5.36
Rhode Island	17.02	21.93	22.10	19.35	19.58	18.65	22.20	22.65	23.07	21.18
South Carolina	7.64	8.69	9.70	9.02	11.55	9.52	10.09	18.73	21.40	9.68
South Dakota	35.76	12.18	252.01	242.45	13.33	13.55	24.05	31.39	44.27	43.86
Tennessee	8.35	6.32	7.13	7.45	7.78	6.99	7.54	8.25	7.62	7.99
Texas	4.09	3.91	4.05	4.14	4.26	4.22	4.32	4.43	4.54	4.50
Utah	35.94	10.05	9.25	31.80	24.09	52.25	23.32	22.01	29.14	29.21
Vermont	72.63	251.92	13.21	85.07	12.91	53.94	18.19	84.12	65.53	96.16
Virginia	5.34	5.38	5.64	5.94	6.04	5.99	5.90	6.31	6.48	6.71
Washington	8.21	9.22	9.82	9.48	10.25	9.59	9.35	9.67	9.49	9.19
West Virginia	15.01	13.08	17.70	15.55	14.38	15.88	15.74	19.52	18.54	18.37
Wisconsin	9.21	9.04	9.36	9.14	10.26	9.80	9.74	10.32	10.39	9.87
Wyoming	69.18	56.89	45.55	113.06	44.53	73.62	35.79	19.58	86.34	67.47

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

\* Values for cells with fewer than 10 patients are suppressed.

Rates per million based on July 1, U.S. resident population by state or ESRD Network. The standard population is July 1, 1996, U.S. resident population by 5-year age groups, sex, and White/non-White race groups.

Table A.25(Continued)  
Standard Errors for Incidence Rates per Million Population of Reported ESRD Therapy  
by State Adjusted for Age, Race and Sex  
Diabetic ESRD Patients

State	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
Alabama	3.89	4.15	2.82	3.39	4.32	3.73	5.03	5.28	5.28	5.65
Alaska	8.74	31.74	18.88	14.06	13.73	24.49	48.17	48.60	24.34	28.18
Arizona	7.26	7.24	5.24	7.64	8.55	7.47	7.32	7.61	7.42	7.97
Arkansas	4.92	4.99	4.88	5.39	5.40	5.32	6.37	7.13	6.74	6.81
California	1.61	1.80	1.89	1.98	1.95	1.92	2.14	2.21	2.22	2.33
Colorado	5.01	6.98	6.02	7.16	5.89	6.13	6.79	6.54	7.13	6.40
Connecticut	4.67	4.62	4.69	5.14	5.82	5.61	6.13	6.63	6.63	6.88
Delaware	10.84	11.73	10.26	10.82	11.04	10.00	11.03	10.89	11.91	11.40
District of Columbia	11.88	12.28	10.13	9.43	12.25	14.13	10.15	18.00	17.05	16.42
Florida	2.02	2.22	2.24	2.22	2.38	2.32	2.35	2.47	2.61	2.52
Georgia	2.43	2.97	3.29	3.79	3.62	3.34	3.73	5.48	5.94	4.01
Hawaii	7.13	57.40	27.37	14.65	14.24	10.36	22.38	20.68	15.75	16.59
Idaho	7.20	42.54	8.87	6.80	9.24	78.76	20.20	8.43	37.75	52.22
Illinois	2.00	2.20	2.38	2.54	2.53	2.58	2.92	3.10	3.17	3.07
Indiana	3.43	3.32	3.80	3.82	4.56	4.95	4.65	5.55	5.89	5.06
Iowa	10.15	9.96	11.39	11.36	10.92	11.47	14.07	13.08	16.83	14.36
Kansas	5.57	5.76	6.29	7.47	6.82	6.97	7.69	8.27	8.76	9.17
Kentucky	5.35	5.66	6.29	6.05	6.78	6.40	5.68	6.49	6.66	6.52
Louisiana	3.65	3.86	4.57	4.78	4.96	4.96	5.14	5.49	5.73	5.59
Maine	73.79	5.41	4.40	47.59	22.89	5.21	8.78	65.17	70.60	24.11
Maryland	3.00	3.36	3.62	3.85	4.13	3.99	3.95	4.29	4.60	4.64
Massachusetts	3.45	3.51	3.86	4.09	4.34	4.33	4.79	5.12	5.19	4.77
Michigan	2.52	2.70	2.89	3.09	3.21	3.11	3.48	3.63	3.77	3.75
Minnesota	9.60	8.40	9.53	8.65	8.62	9.99	9.47	9.46	9.33	9.58
Mississippi	6.74	5.93	6.37	6.85	7.33	5.22	9.02	9.78	8.07	8.40
Missouri	3.50	4.10	3.79	4.29	4.65	4.32	4.57	5.12	5.43	5.41
Montana	74.91	8.32	179.41	109.06	9.42	8.24	28.38	117.46	8.16	8.31
Nebraska	11.47	11.95	9.46	12.18	12.74	13.12	12.00	14.64	13.73	14.07
Nevada	7.53	9.82	9.21	9.11	7.77	8.06	8.38	9.64	7.50	8.51
New Hampshire	24.68	14.34	27.94	7.70	17.34	39.17	24.88	17.76	29.09	8.03
New Jersey	2.53	2.66	3.10	3.13	3.17	3.26	3.55	3.87	3.87	3.89
New Mexico	9.64	10.67	11.42	11.26	10.70	11.22	11.33	12.44	11.91	12.82
New York	1.57	1.63	1.78	1.85	1.95	1.96	2.12	2.23	2.38	2.41
North Carolina	2.51	2.90	3.08	3.48	3.38	3.51	3.78	4.42	4.57	3.81
North Dakota	9.43	304.41	11.53	10.25	13.25	436.46	162.36	433.01	11.20	144.76
Ohio	3.00	2.64	2.83	2.61	3.10	3.09	2.98	3.36	3.75	3.84
Oklahoma	5.08	4.51	5.17	5.38	5.96	5.92	5.96	6.64	6.28	6.42
Oregon	6.72	11.76	7.40	9.82	8.95	9.01	13.20	10.43	11.33	8.69
Pennsylvania	2.46	2.42	2.52	2.78	2.93	2.70	3.14	3.43	3.29	3.28
Rhode Island	7.58	12.91	13.79	9.44	13.18	11.34	13.11	15.12	15.81	13.00
South Carolina	3.78	3.71	5.01	6.54	6.11	5.19	6.91	11.18	12.56	5.62
South Dakota	8.77	7.69	7.32	233.96	9.42	9.67	9.94	12.33	11.78	42.30
Tennessee	5.72	3.37	3.71	4.07	4.68	4.00	4.84	5.28	4.80	4.81
Texas	2.55	2.47	2.65	2.69	2.74	2.83	2.90	3.09	3.22	3.17
Utah	32.68	6.11	6.38	18.01	18.07	32.44	7.30	18.15	13.15	23.41
Vermont	58.66	188.23	7.54	74.58	6.87	8.11	9.50	82.60	8.73	74.54
Virginia	2.73	2.80	2.82	3.16	3.41	3.43	3.58	3.70	3.92	4.17
Washington	5.04	6.00	7.00	7.07	7.24	6.91	5.60	6.88	6.58	6.22
West Virginia	8.71	9.17	8.61	10.14	8.40	9.71	9.30	13.37	11.93	10.60
Wisconsin	4.95	5.93	5.96	5.90	6.13	6.37	6.09	6.84	7.21	6.91
Wyoming	10.20	14.31	44.22	8.24	9.70	30.55	34.21	14.99	13.51	64.08

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

\* Values for cells with fewer than 10 patients are suppressed.

Rates per million based on July 1, U.S. resident population by state or ESRD Network. The standard population is July 1, 1996, U.S. resident population by 5-year age groups, sex, and White/non-White race groups.

Table A.25(Continued)  
 Standard Errors for Incidence Rates per Million Population of Reported ESRD Therapy  
 by State Adjusted for Age, Race and Sex  
 Nondiabetic ESRD Patients

State	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
Alabama	7.40	6.49	5.03	5.83	6.29	5.66	6.36	6.37	6.74	5.78
Alaska	25.60	22.92	26.15	28.70	27.92	21.90	51.22	70.11	29.00	24.06
Arizona	7.63	8.32	7.78	8.26	8.34	6.95	8.00	7.40	8.31	6.84
Arkansas	8.29	7.16	6.57	8.09	7.71	7.56	7.97	8.92	7.77	8.84
California	2.29	2.35	2.41	2.46	2.41	2.34	2.59	2.53	2.49	2.46
Colorado	5.82	7.30	6.72	7.36	7.30	7.02	6.93	6.76	6.57	7.57
Connecticut	7.08	6.89	6.93	7.17	7.11	6.72	7.34	7.54	7.91	6.77
Delaware	13.22	11.09	15.69	15.60	18.70	13.85	15.17	16.22	14.65	14.73
District of Columbia	22.87	21.19	20.66	19.29	16.84	20.46	22.66	21.60	15.73	18.18
Florida	3.13	3.21	3.16	3.33	3.27	3.24	3.10	3.08	3.21	3.04
Georgia	5.13	4.53	4.33	4.82	5.02	4.79	5.10	7.04	7.02	4.69
Hawaii	12.97	41.18	14.78	16.42	28.20	22.77	15.70	17.56	14.16	15.89
Idaho	7.64	8.77	9.41	50.07	117.86	40.33	83.50	41.85	14.57	76.94
Illinois	3.21	3.20	3.37	3.55	3.80	3.69	3.88	3.94	3.83	3.83
Indiana	5.45	6.03	5.63	5.39	5.50	6.10	5.53	6.12	6.31	5.68
Iowa	11.63	13.94	14.96	13.18	16.54	12.88	15.61	13.05	15.77	11.33
Kansas	7.84	7.98	8.97	8.29	8.64	8.89	8.41	9.01	9.83	9.64
Kentucky	7.64	6.90	7.39	6.87	8.82	6.53	6.74	7.94	6.95	6.85
Louisiana	6.73	5.94	6.11	6.88	6.80	6.59	6.95	7.03	6.67	7.03
Maine	124.40	53.89	45.12	18.69	7.15	6.70	80.51	23.59	66.70	25.05
Maryland	4.46	4.70	5.25	5.33	5.29	5.28	5.05	5.63	5.64	5.55
Massachusetts	5.26	5.18	5.32	5.40	5.82	5.55	5.90	5.93	6.26	5.82
Michigan	3.74	3.87	3.83	3.68	3.87	3.90	4.19	4.11	4.10	4.04
Minnesota	10.60	8.80	10.93	9.59	10.13	8.60	10.50	11.89	9.96	9.21
Mississippi	8.30	7.14	5.77	8.01	7.31	7.81	8.83	8.37	8.61	7.52
Missouri	5.15	5.18	5.39	5.67	5.59	5.98	5.87	5.95	6.70	5.72
Montana	7.07	8.08	8.66	9.61	8.13	9.26	84.34	101.76	8.60	8.72
Nebraska	11.36	12.76	12.35	13.34	12.85	11.50	14.87	9.64	14.35	12.26
Nevada	13.49	14.22	11.15	13.01	11.25	11.40	12.72	10.55	10.62	9.61
New Hampshire	48.35	46.12	29.58	37.73	13.83	8.07	24.26	10.75	20.11	29.84
New Jersey	3.98	4.21	4.25	4.39	4.64	4.41	4.63	4.63	4.62	4.58
New Mexico	13.56	15.60	14.51	12.41	12.33	10.98	10.71	10.98	11.65	11.95
New York	2.35	2.48	2.56	2.61	2.75	2.71	2.90	2.87	2.91	2.89
North Carolina	4.03	4.13	4.04	4.29	4.46	4.44	4.55	5.15	5.35	4.53
North Dakota	9.95	304.36	44.76	10.11	17.15	11.68	51.80	158.95	12.73	11.40
Ohio	3.92	3.67	3.60	3.58	3.80	3.57	3.61	4.00	4.21	3.81
Oklahoma	6.21	6.59	6.75	6.20	6.32	6.97	6.90	6.72	6.91	7.31
Oregon	12.25	12.08	11.17	13.55	10.96	12.72	12.05	11.75	11.47	8.96
Pennsylvania	3.62	3.41	3.85	3.56	3.59	3.52	4.03	4.09	4.05	4.01
Rhode Island	15.22	17.70	17.20	16.86	14.37	14.17	17.38	16.48	16.77	15.68
South Carolina	6.41	7.21	8.20	6.13	9.54	7.77	7.27	14.86	17.38	7.37
South Dakota	34.62	9.24	251.90	63.58	9.43	9.50	21.80	28.82	42.67	11.17
Tennessee	6.02	5.15	5.67	5.78	6.18	5.31	5.73	6.15	5.84	5.95
Texas	3.11	2.88	2.99	3.10	3.22	3.02	3.15	3.08	3.14	2.99
Utah	14.95	7.86	6.39	26.27	15.88	36.57	14.32	12.31	25.95	17.27
Vermont	43.82	167.42	10.85	40.89	10.48	53.20	15.28	15.58	55.00	60.64
Virginia	4.37	4.46	4.81	4.93	4.90	4.77	4.54	4.86	4.93	4.97
Washington	6.38	6.95	6.87	6.23	7.14	6.59	7.47	6.68	6.80	6.67
West Virginia	12.10	9.06	12.64	11.77	11.48	11.44	12.52	13.14	12.27	14.05
Wisconsin	7.47	6.71	7.16	6.91	8.19	7.12	7.51	7.69	7.43	6.78
Wyoming	68.43	12.81	9.66	112.76	43.46	66.90	10.55	10.74	85.28	20.67

Includes residents of 50 states and District of Columbia only.

\* Values for cells with fewer than 10 patients are suppressed.

Rates per million based on July 1, U.S. resident population by state or ESRD Network. The standard population is July 1, 1996, U.S. resident population by 5-year age groups, sex, and White/non-White race groups.

Table A.26  
Incidence Counts of Reported ESRD Therapy  
by Network Before Dropping Territories and "Unknown" Networks

Network	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
(CT) Net. of New England	1,649	1,868	2,058	2,232	2,434	2,458	2,819	3,106	3,178	3,297
(NY) Net. of N.Y.	2,805	3,203	3,519	3,721	4,235	4,392	5,000	5,356	5,638	5,855
(NJ) Trans-Atlantic R. C.	1,874	2,142	2,331	2,543	2,823	2,854	3,317	3,551	3,678	3,878
(PA) ESRD Net. Org. #4	2,085	2,395	2,769	2,803	3,097	3,002	3,645	4,004	4,059	4,330
(VA) Mid Atlantic R. C.	2,187	2,619	2,838	3,213	3,466	3,586	3,604	4,510	4,891	5,076
(NC) Southeastern Kidney Council	2,876	3,465	3,606	4,079	4,584	4,705	5,464	5,586	6,154	6,229
(FL) ESRD Net. of Florida	2,303	2,652	2,835	3,157	3,507	3,530	3,798	4,142	4,696	4,883
(MS) Network 8	1,921	2,496	2,366	2,745	3,066	3,014	3,523	3,759	4,029	4,312
(IN) Tri-state R. N.	2,935	3,255	3,469	3,722	4,268	4,485	4,459	5,595	5,884	5,911
(IL) Renal Net. of Illinois	1,787	1,998	2,316	2,655	2,770	3,024	3,399	3,656	3,633	3,781
(MN) Renal Net. of upper midwest	2,745	3,131	3,330	3,539	4,019	4,102	4,653	4,862	5,318	5,433
(MD) ESRD net. #12	1,573	1,849	2,013	2,154	2,382	2,416	2,707	2,847	3,000	3,268
(OK) ESRD net. #13	1,708	1,856	2,013	2,216	2,473	2,561	2,870	3,153	3,136	3,547
(TX) Net. of Texas	2,677	3,023	3,354	3,627	4,121	4,197	4,627	4,926	5,439	5,620
(CO) Inter-mountain ESRD net.	1,514	1,721	1,744	2,041	2,249	2,304	2,612	2,804	3,058	3,202
(WA) Northwest Renal Net.	1,049	1,315	1,388	1,535	1,523	1,659	2,031	2,221	1,987	2,119
(N-CA) Trans-pacific ESRD Net.	1,947	2,139	2,390	2,510	2,580	2,755	3,235	3,378	3,560	3,736
(S-CA) Southern California Net.	2,624	3,129	3,345	3,664	3,703	3,821	4,829	5,153	5,231	5,676
Unknown Network	173	193	189	259	310	513	1,157	351	147	95
	38,432	44,449	47,873	52,415	57,610	59,378	67,749	72,960	76,716	80,248

Includes all patients: residents of the 50 states, the District of Columbia, Puerto Rico and the Territories for Table A.26.

Includes residents of 50 states and District of Columbia only for Table A.27.

\* Values for cells with fewer than 10 patients are suppressed.

Table A.27  
Incidence Counts of Reported ESRD Therapy  
by Network after Dropping Territories and "Unknown" Networks  
All Patients

Network	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
(CT) Net. of New England	1,649	1,868	2,058	2,232	2,434	2,458	2,819	3,106	3,178	3,297
(NY) Net. of N.Y.	2,805	3,203	3,519	3,721	4,235	4,392	5,000	5,356	5,638	5,855
(NJ) Trans-Atlantic R. C.	1,383	1,572	1,758	1,920	2,093	2,168	2,443	2,670	2,710	2,849
(PA) ESRD Net. Org. #4	2,085	2,395	2,769	2,803	3,097	3,002	3,645	4,004	4,059	4,330
(VA) Mid Atlantic R. C.	2,187	2,619	2,838	3,213	3,466	3,586	3,604	4,510	4,891	5,076
(NC) Southeastern Kidney Council	2,876	3,465	3,606	4,079	4,584	4,705	5,464	5,586	6,154	6,229
(FL) ESRD Net. of Florida	2,303	2,652	2,835	3,157	3,507	3,530	3,798	4,142	4,696	4,883
(MS) Network 8	1,921	2,496	2,366	2,745	3,066	3,014	3,523	3,759	4,029	4,312
(IN) Tri-state R. N.	2,935	3,255	3,469	3,722	4,268	4,485	4,459	5,595	5,884	5,911
(IL) Renal Net. of Illinois	1,787	1,998	2,316	2,655	2,770	3,024	3,399	3,656	3,633	3,781
(MN) Renal Net. of upper midwest	2,745	3,131	3,330	3,539	4,019	4,102	4,653	4,862	5,318	5,433
(MD) ESRD net. #12	1,573	1,849	2,013	2,154	2,382	2,416	2,707	2,847	3,000	3,268
(OK) ESRD net. #13	1,708	1,856	2,013	2,216	2,473	2,561	2,870	3,153	3,136	3,547
(TX) Net. of Texas	2,677	3,023	3,354	3,627	4,121	4,197	4,627	4,926	5,439	5,620
(CO) Inter-mountain ESRD net.	1,514	1,721	1,744	2,041	2,249	2,304	2,612	2,804	3,058	3,202
(WA) Northwest Renal Net.	1,049	1,315	1,388	1,535	1,523	1,659	2,031	2,221	1,987	2,119
(N-CA) Trans-pacific ESRD Net.	1,918	2,113	2,356	2,476	2,530	2,711	3,183	3,308	3,477	3,642
(S-CA) Southern California Net.	2,624	3,129	3,345	3,664	3,703	3,821	4,829	5,153	5,231	5,676
	37,739	43,660	47,077	51,499	56,520	58,135	65,666	71,658	75,518	79,030

(CONTINUED)

Table A.27(Continued)  
Incidence Counts of Reported ESRD Therapy  
by Network after Dropping Territories and "Unknown" Networks  
Diabetic ESRD Patients

Network	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
(CT) Net. of New England	445	568	637	734	813	836	990	1,182	1,211	1,270
(NY) Net. of N.Y.	874	955	1,151	1,257	1,415	1,476	1,735	1,959	2,250	2,307
(NJ) Trans-Atlantic R. C.	408	454	610	657	678	734	902	1,084	1,105	1,147
(PA) ESRD Net. Org. #4	663	770	924	1,018	1,116	1,046	1,349	1,602	1,557	1,646
(VA) Mid Atlantic R. C.	635	807	939	1,088	1,254	1,287	1,357	1,633	1,892	2,033
(NC) Southeastern Kidney Council	799	1,053	1,220	1,390	1,614	1,624	2,040	2,224	2,625	2,583
(FL) ESRD Net. of Florida	610	742	832	934	1,086	1,105	1,280	1,391	1,667	1,795
(MS) Network 8	514	689	639	886	1,067	1,056	1,301	1,485	1,629	1,766
(IN) Tri-state R. N.	943	1,021	1,200	1,311	1,584	1,598	1,731	2,340	2,515	2,483
(IL) Renal Net. of Illinois	510	608	697	859	843	919	1,198	1,352	1,424	1,356
(MN) Renal Net. of upper midwest	913	1,132	1,262	1,420	1,599	1,552	1,856	2,007	2,255	2,269
(MD) ESRD net. #12	493	594	649	760	867	914	1,021	1,181	1,261	1,377
(OK) ESRD net. #13	567	632	694	849	968	915	1,118	1,276	1,382	1,512
(TX) Net. of Texas	960	1,254	1,436	1,544	1,711	1,902	2,122	2,374	2,689	2,816
(CO) Inter-mountain ESRD net.	625	714	718	943	1,048	1,078	1,199	1,440	1,506	1,574
(WA) Northwest Renal Net.	373	474	499	560	622	633	776	871	816	876
(N-CA) Trans-pacific ESRD Net.	619	799	892	943	997	1,075	1,352	1,448	1,600	1,693
(S-CA) Southern California Net.	860	1,132	1,255	1,491	1,475	1,480	1,937	2,182	2,250	2,585
	11,811	14,398	16,254	18,644	20,757	21,230	25,264	29,031	31,634	33,088

(CONTINUED)

Includes all patients: residents of the 50 states, the District of Columbia, Puerto Rico and the Territories for Table A. 26.

Includes residents of 50 states and District of Columbia only for Table A. 27.

\* Values for cells with fewer than 10 patients are suppressed.

Table A.27(Continued)  
 Incidence Counts of Reported ESRD Therapy  
 by Network after Dropping Territories and "Unknown" Networks  
 Nondiabetic ESRD Patients

Network	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
(CT) Net. of New England	1,120	1,235	1,369	1,461	1,573	1,539	1,738	1,821	1,926	1,796
(NY) Net. of N.Y.	1,810	2,123	2,303	2,386	2,739	2,707	3,175	3,218	3,282	3,289
(NJ) Trans-Atlantic R. C.	936	1,074	1,108	1,224	1,401	1,321	1,499	1,544	1,569	1,591
(PA) ESRD Net. Org. #4	1,324	1,407	1,740	1,694	1,883	1,756	2,197	2,248	2,320	2,430
(VA) Mid Atlantic R. C.	1,387	1,660	1,821	2,037	2,122	2,162	2,079	2,534	2,671	2,691
(NC) Southeastern Kidney Council	1,937	2,266	2,295	2,621	2,880	2,854	3,300	3,217	3,432	3,307
(FL) ESRD Net. of Florida	1,636	1,852	1,958	2,199	2,388	2,268	2,460	2,483	2,843	2,833
(MS) Network 8	1,344	1,632	1,356	1,768	1,954	1,811	2,160	2,184	2,314	2,336
(IN) Tri-state R. N.	1,886	2,026	2,153	2,241	2,492	2,557	2,446	3,016	3,116	3,032
(IL) Renal Net. of Illinois	1,207	1,275	1,423	1,634	1,821	1,850	2,085	2,182	2,084	2,132
(MN) Renal Net. of upper midwest	1,770	1,935	1,998	2,073	2,375	2,366	2,738	2,781	3,005	2,964
(MD) ESRD net. #12	1,040	1,169	1,320	1,378	1,496	1,413	1,639	1,620	1,693	1,736
(OK) ESRD net. #13	1,114	1,200	1,293	1,343	1,476	1,564	1,729	1,834	1,715	1,897
(TX) Net. of Texas	1,611	1,646	1,857	2,029	2,349	2,155	2,440	2,429	2,643	2,485
(CO) Inter-mountain ESRD net.	836	943	931	1,064	1,163	1,139	1,372	1,303	1,493	1,488
(WA) Northwest Renal Net.	663	814	872	955	890	982	1,240	1,315	1,152	1,158
(N-CA) Trans-pacific ESRD Net.	1,226	1,255	1,416	1,507	1,503	1,538	1,787	1,811	1,831	1,828
(S-CA) Southern California Net.	1,597	1,816	1,915	2,067	2,124	2,122	2,748	2,727	2,755	2,792
	24,444	27,328	29,128	31,681	34,629	34,104	38,832	40,267	41,844	41,785

Includes all patients: residents of the 50 states, the District of Columbia, Puerto Rico and the Territories for Table A. 26.  
 Includes residents of 50 states and District of Columbia only for Table A. 27.  
 \* Values for cells with fewer than 10 patients are suppressed.

Table A.28  
Incidence Rates per Million Population of Reported ESRD Therapy  
by Network Adjusted for Age, Race and Sex  
All Patients

Network	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
(CT) Net. of New England	158.03	173.08	184.45	196.78	215.38	211.52	251.31	275.05	281.64	277.52
(NY) Net. of N.Y.	149.68	168.39	183.37	193.92	218.16	223.79	252.10	266.15	279.81	289.16
(NJ) Trans-Atlantic R. C.	174.72	197.44	219.92	236.28	255.55	260.85	289.35	313.02	314.85	326.22
(PA) ESRD Net. Org. #4	169.25	190.00	218.32	219.05	239.80	227.68	281.27	310.01	308.73	321.85
(VA) Mid Atlantic R. C.	151.83	172.10	187.50	208.00	221.71	226.65	223.86	274.62	293.03	306.62
(NC) Southeastern Kidney Council	151.94	177.32	180.42	203.05	224.64	225.96	255.00	306.06	337.19	274.92
(FL) ESRD Net. of Florida	166.98	186.79	192.80	208.28	225.22	223.11	229.05	249.90	276.38	273.15
(MS) Network 8	158.87	187.63	175.38	203.35	224.72	210.33	250.49	267.31	275.73	291.62
(IN) Tri-state R. N.	164.66	182.00	188.06	197.43	228.90	235.68	228.35	287.94	304.07	297.27
(IL) Renal Net. of Illinois	159.58	175.68	202.76	228.81	240.12	255.75	285.14	305.46	302.22	312.67
(MN) Renal Net. of upper midwest	167.36	188.79	197.10	203.50	230.36	232.66	260.82	272.85	289.46	290.43
(MD) ESRD net. #12	158.02	181.98	193.52	208.71	229.05	231.89	255.30	267.49	293.11	299.52
(OK) ESRD net. #13	168.71	178.29	194.54	209.70	231.30	235.38	259.79	281.32	276.37	309.39
(TX) Net. of Texas	196.91	209.55	228.08	243.68	268.95	268.48	289.42	305.25	330.21	332.83
(CO) Inter-mountain ESRD net.	167.42	198.71	181.55	215.60	222.77	222.96	242.36	249.80	262.60	266.68
(WA) Northwest Renal Net.	141.57	176.53	180.60	196.17	196.80	209.73	259.93	290.36	228.35	225.98
(N-CA) Trans-pacific ESRD Net.	178.70	198.82	217.34	221.73	219.36	229.20	256.51	257.84	266.38	280.13
(S-CA) Southern California Net.	176.40	205.18	216.77	237.61	233.96	231.60	292.08	304.05	299.83	319.81

(CONTINUED)

Table A.28(Continued)  
Incidence Rates per Million Population of Reported ESRD Therapy  
by Network Adjusted for Age, Race and Sex  
Diabetic ESRD Patients

Network	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
(CT) Net. of New England	42.57	52.37	58.86	66.53	75.03	73.71	91.03	108.62	111.67	110.91
(NY) Net. of N.Y.	45.51	49.43	59.35	64.51	72.08	74.20	86.96	97.04	110.71	113.47
(NJ) Trans-Atlantic R. C.	50.11	55.95	75.33	79.52	81.83	87.68	105.94	126.75	128.15	131.21
(PA) ESRD Net. Org. #4	53.83	60.11	70.19	78.49	86.46	78.49	102.98	122.49	117.26	121.55
(VA) Mid Atlantic R. C.	42.76	51.77	58.76	67.55	78.88	79.10	82.93	98.33	111.80	120.72
(NC) Southeastern Kidney Council	39.89	53.26	61.60	70.27	78.16	77.31	95.31	120.29	140.56	110.26
(FL) ESRD Net. of Florida	46.35	55.11	59.72	63.96	73.25	72.48	80.19	86.79	101.20	102.60
(MS) Network 8	45.46	52.00	47.26	64.09	77.67	71.98	92.87	106.54	110.21	117.51
(IN) Tri-state R. N.	53.11	55.03	64.54	67.97	84.02	84.50	87.42	117.89	128.87	126.13
(IL) Renal Net. of Illinois	44.25	53.03	61.14	73.40	72.31	77.28	99.98	112.73	118.44	112.18
(MN) Renal Net. of upper midwest	57.46	69.81	76.77	83.39	94.20	90.49	106.07	115.11	125.11	124.10
(MD) ESRD net. #12	50.09	60.99	63.63	76.92	88.11	88.14	98.15	116.03	126.63	133.11
(OK) ESRD net. #13	56.93	61.34	69.01	80.15	91.06	85.98	101.88	114.84	121.23	131.55
(TX) Net. of Texas	72.41	85.72	97.59	103.42	111.48	121.34	132.11	148.16	164.18	166.06
(CO) Inter-mountain ESRD net.	68.99	81.30	72.88	96.96	102.23	102.19	108.80	126.50	124.82	129.27
(WA) Northwest Renal Net.	47.52	70.53	71.37	78.41	84.35	85.40	97.42	111.09	96.99	97.85
(N-CA) Trans-pacific ESRD Net.	55.72	72.65	79.58	80.38	84.51	87.94	103.91	106.86	115.88	125.90
(S-CA) Southern California Net.	56.89	73.63	80.62	96.37	92.66	89.34	117.22	128.96	129.51	146.23

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

\* Values for cells with fewer than 10 patients are suppressed.

Rates per million based on July 1, U.S. resident population by state or ESRD Network. The standard population is July 1, 1996, U.S. resident population by 5-year age groups, sex, and White/non-White race groups.

Table A.28(Continued)  
Incidence Rates per Million Population of Reported ESRD Therapy  
by Network Adjusted for Age, Race and Sex  
Nondiabetic ESRD Patients

Network	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
(CT) Net. of New England	107.44	114.52	120.77	126.32	136.23	130.16	151.07	155.80	165.74	145.96
(NY) Net. of N.Y.	97.95	112.44	120.75	125.29	141.97	138.77	160.70	160.05	163.92	163.02
(NJ) Trans-Atlantic R. C.	119.60	135.89	139.49	152.00	171.94	159.40	178.50	181.37	182.42	182.15
(PA) ESRD Net. Org. #4	107.83	111.98	139.90	131.74	144.95	133.97	169.94	174.12	175.36	180.13
(VA) Mid Atlantic R. C.	97.72	110.63	122.97	134.88	137.03	138.70	130.85	156.25	162.13	164.04
(NC) Southeastern Kidney Council	104.43	116.37	113.93	129.15	141.59	137.17	153.40	178.79	191.82	149.76
(FL) ESRD Net. of Florida	116.18	127.44	129.34	142.63	149.59	141.71	145.26	144.72	162.62	154.45
(MS) Network 8	108.14	122.21	100.18	130.20	142.64	126.90	152.73	152.97	159.63	157.07
(IN) Tri-state R. N.	105.93	112.70	116.17	118.69	132.99	132.91	125.97	156.51	161.65	149.98
(IL) Renal Net. of Illinois	108.75	112.19	124.67	141.52	158.65	156.77	175.31	182.21	173.25	175.53
(MN) Renal Net. of upper midwest	106.19	115.20	116.37	117.14	133.33	132.06	151.21	153.38	161.02	155.74
(MD) ESRD net. #12	103.55	112.04	125.58	130.13	139.08	134.55	152.57	147.00	162.27	152.87
(OK) ESRD net. #13	109.08	114.57	123.19	127.34	137.21	141.39	155.80	162.60	151.31	166.09
(TX) Net. of Texas	117.41	114.35	125.95	136.47	153.10	137.65	153.04	149.03	159.29	147.50
(CO) Inter-mountain ESRD net.	93.06	110.31	98.49	115.27	116.38	111.38	129.90	118.32	132.48	126.47
(WA) Northwest Renal Net.	91.36	103.32	107.67	115.43	110.68	119.86	161.22	174.30	129.30	120.21
(N-CA) Trans-pacific ESRD Net.	116.16	120.62	133.40	138.96	132.40	131.84	149.45	147.01	146.90	145.11
(S-CA) Southern California Net.	108.46	119.78	124.78	134.82	134.75	128.32	166.19	160.76	158.59	157.94

Includes residents of 50 states and District of Columbia only.

\* Values for cells with fewer than 10 patients are suppressed.

Rates per million based on July 1, U.S. resident population by state or ESRD Network. The standard population is July 1, 1996, U.S. resident population by 5-year age groups, sex, and White/non-White race groups.



Table A.29  
Standard Errors for Incidence Rates per Million Population of Reported ESRD Therapy  
by Network Adjusted for Age, Race and Sex  
All Patients

Network	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
(CT) Net. of New England	4.74	4.78	4.81	4.91	5.11	4.94	5.47	5.67	5.72	5.49
(NY) Net. of N.Y.	2.89	3.03	3.15	3.24	3.41	3.43	3.62	3.70	3.79	3.84
(NJ) Trans-Atlantic R. C.	4.78	5.05	5.32	5.45	5.63	5.64	5.88	6.08	6.07	6.13
(PA) ESRD Net. Org. #4	4.30	4.28	4.54	4.55	4.67	4.43	5.00	5.26	5.18	5.16
(VA) Mid Atlantic R. C.	3.54	3.62	3.79	3.94	4.03	4.04	3.98	4.37	4.47	4.58
(NC) Southeastern Kidney Council	3.31	3.42	3.44	3.72	3.84	3.78	3.96	5.13	5.36	3.94
(FL) ESRD Net. of Florida	3.77	3.94	3.93	4.02	4.07	4.06	3.92	4.13	4.25	4.09
(MS) Network 8	5.12	4.49	4.30	4.70	4.89	4.39	5.10	5.36	5.09	5.18
(IN) Tri-state R. N.	3.66	3.73	3.62	3.55	3.94	3.91	3.67	4.16	4.34	4.16
(IL) Renal Net. of Illinois	3.87	4.01	4.30	4.51	4.65	4.71	4.94	5.10	5.06	5.13
(MN) Renal Net. of upper midwest	3.48	3.65	3.68	3.63	3.87	3.85	4.03	4.13	4.15	4.11
(MD) ESRD net. #12	4.63	4.85	4.90	5.12	5.31	5.35	5.46	5.60	6.03	5.82
(OK) ESRD net. #13	4.24	4.29	4.49	4.60	4.79	4.79	4.99	5.16	5.08	5.35
(TX) Net. of Texas	4.09	3.91	4.05	4.14	4.26	4.22	4.32	4.43	4.54	4.50
(CO) Inter-mountain ESRD net.	5.44	6.21	5.42	6.05	5.80	5.75	5.78	5.69	5.68	5.63
(WA) Northwest Renal Net.	6.67	7.51	7.44	7.58	7.82	7.82	8.61	9.02	7.51	7.08
(N-CA) Trans-pacific ESRD Net.	4.58	4.83	5.00	5.03	4.95	5.01	5.23	5.19	5.25	5.34
(S-CA) Southern California Net.	3.63	3.85	3.94	4.09	4.02	3.94	4.42	4.47	4.39	4.49

(CONTINUED)

Table A.29(Continued)  
Standard Errors for Incidence Rates per Million Population of Reported ESRD Therapy  
by Network Adjusted for Age, Race and Sex  
Diabetic ESRD Patients

Network	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
(CT) Net. of New England	2.49	2.63	2.80	2.92	3.11	2.98	3.37	3.65	3.70	3.55
(NY) Net. of N.Y.	1.57	1.63	1.78	1.85	1.95	1.96	2.12	2.23	2.38	2.41
(NJ) Trans-Atlantic R. C.	2.53	2.66	3.10	3.13	3.17	3.26	3.55	3.87	3.87	3.89
(PA) ESRD Net. Org. #4	2.39	2.38	2.45	2.70	2.84	2.61	3.02	3.27	3.16	3.16
(VA) Mid Atlantic R. C.	1.84	1.93	2.03	2.17	2.38	2.35	2.39	2.59	2.74	2.84
(NC) Southeastern Kidney Council	1.63	1.84	2.04	2.32	2.24	2.21	2.44	3.23	3.43	2.45
(FL) ESRD Net. of Florida	2.02	2.22	2.24	2.22	2.38	2.32	2.35	2.47	2.61	2.52
(MS) Network 8	3.01	2.42	2.23	2.58	2.92	2.44	3.27	3.54	3.21	3.32
(IN) Tri-state R. N.	2.13	1.94	2.12	2.02	2.36	2.41	2.26	2.61	2.84	2.78
(IL) Renal Net. of Illinois	2.00	2.20	2.38	2.54	2.53	2.58	2.92	3.10	3.17	3.07
(MN) Renal Net. of upper midwest	2.12	2.30	2.37	2.39	2.54	2.47	2.63	2.74	2.78	2.74
(MD) ESRD net. #12	2.60	2.96	2.84	3.18	3.43	3.29	3.42	3.81	4.03	4.01
(OK) ESRD net. #13	2.50	2.54	2.71	2.85	3.02	2.93	3.14	3.31	3.36	3.49
(TX) Net. of Texas	2.55	2.47	2.65	2.69	2.74	2.83	2.90	3.09	3.22	3.17
(CO) Inter-mountain ESRD net.	3.47	3.95	3.35	3.96	3.85	3.83	3.83	4.03	3.81	3.90
(WA) Northwest Renal Net.	3.75	5.19	5.18	5.35	5.32	5.39	5.40	5.79	5.19	4.92
(N-CA) Trans-pacific ESRD Net.	2.54	2.88	3.02	2.99	3.05	3.10	3.30	3.33	3.45	3.58
(S-CA) Southern California Net.	2.05	2.29	2.40	2.60	2.52	2.43	2.79	2.91	2.88	3.04

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

\* Values for cells with fewer than 10 patients are suppressed.

Rates per million based on July 1, U.S. resident population by state or ESRD Network. The standard population is July 1, 1996, U.S. resident population by 5-year age groups, sex, and White/non-White race groups.

Table A.29(Continued)  
 Standard Errors for Incidence Rates per Million Population of Reported ESRD Therapy  
 by Network Adjusted for Age, Race and Sex  
 Nondiabetic ESRD Patients

Network	Year									
	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997
(CT) Net. of New England	3.90	3.89	3.83	3.87	4.00	3.81	4.16	4.17	4.31	3.89
(NY) Net. of N.Y.	2.35	2.48	2.56	2.61	2.75	2.71	2.90	2.87	2.91	2.89
(NJ) Trans-Atlantic R. C.	3.98	4.21	4.25	4.39	4.64	4.41	4.63	4.63	4.62	4.58
(PA) ESRD Net. Org. #4	3.48	3.26	3.73	3.46	3.57	3.38	3.89	3.94	3.88	3.85
(VA) Mid Atlantic R. C.	2.87	2.94	3.11	3.22	3.19	3.18	3.07	3.32	3.35	3.37
(NC) Southeastern Kidney Council	2.79	2.77	2.71	2.87	3.05	2.95	3.05	3.94	4.09	2.94
(FL) ESRD Net. of Florida	3.13	3.21	3.16	3.33	3.27	3.24	3.10	3.08	3.21	3.04
(MS) Network 8	4.06	3.55	3.23	3.61	3.76	3.40	3.80	3.87	3.86	3.63
(IN) Tri-state R. N.	2.92	2.85	2.78	2.72	2.94	2.82	2.73	3.06	3.15	2.86
(IL) Renal Net. of Illinois	3.21	3.20	3.37	3.55	3.80	3.69	3.88	3.94	3.83	3.83
(MN) Renal Net. of upper midwest	2.72	2.79	2.77	2.70	2.88	2.85	3.02	3.04	3.05	2.97
(MD) ESRD net. #12	3.73	3.66	3.93	3.98	4.03	4.04	4.20	4.03	4.44	4.05
(OK) ESRD net. #13	3.39	3.43	3.54	3.58	3.68	3.68	3.86	3.91	3.76	3.93
(TX) Net. of Texas	3.11	2.88	2.99	3.10	3.22	3.02	3.15	3.08	3.14	2.99
(CO) Inter-mountain ESRD net.	4.11	4.65	4.05	4.53	4.25	4.09	4.27	3.95	4.13	3.93
(WA) Northwest Renal Net.	5.40	5.41	5.33	5.33	5.66	5.61	6.70	6.78	5.39	4.98
(N-CA) Trans-pacific ESRD Net.	3.71	3.79	3.93	4.00	3.87	3.79	4.02	3.93	3.90	3.85
(S-CA) Southern California Net.	2.86	2.96	3.00	3.10	3.06	2.93	3.33	3.25	3.19	3.16

Includes residents of 50 states and District of Columbia only.

\* Values for cells with fewer than 10 patients are suppressed.

Rates per million based on July 1, U.S. resident population by state or ESRD Network. The standard population is July 1, 1996, U.S. resident population by 5-year age groups, sex, and White/non-White race groups.

Table A.30  
Incidence Counts  
of Reported ESRD Therapy  
by Age, Sex, and Race

**1992-1994**

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	1006	436	59	21	1522	826	314	60	22	1222	1832	750	119	43	2744
20-44	10514	7747	576	233	19070	7403	4978	516	182	13079	17917	12725	1092	415	32149
45-64	20083	10507	927	595	32112	16158	10608	835	630	28231	36241	21115	1762	1225	60343
65-74	19928	5079	738	259	26004	16884	7711	726	375	25696	36812	12790	1464	634	51700
75 plus	14457	2556	463	118	17594	11652	4232	423	159	16466	26109	6788	886	277	34060
All Age	65988	26325	2763	1226	96302	52923	27843	2560	1368	84694	118911	54168	5323	2594	180996

**1995-1997**

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	1212	548	62	19	1841	882	399	73	24	1378	2094	947	135	43	3219
20-44	11302	8962	585	328	21177	7598	6518	579	277	14972	18900	15480	1164	605	36149
45-64	24600	13439	1347	774	40160	19765	13449	1188	889	35291	44365	26888	2535	1663	75451
65-74	23787	5949	974	288	30998	19431	9032	1074	507	30044	43218	14981	2048	795	61042
75 plus	19801	3395	797	125	24118	15723	5565	758	200	22246	35524	8960	1555	325	46364
All Age	80702	32293	3765	1534	118294	63399	34963	3672	1897	103931	144101	67256	7437	3431	222225

Includes residents of 50 states and District of Columbia only.  
Cases where race is "Other" or "Unknown" are excluded from this table.  
See tables A.4 and A.5 and notes at beginning of this Section.  
\* Values for cells with fewer than 10 patients are suppressed.

**Table A.31**  
**Incidence Rates per Million Population**  
**of Reported ESRD Therapy**  
**Specific Rates by Sex, Race, and Age, and Rates Adjusted for Age, Race, and Sex**

**1992-1994**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	11	25	14	16	*	18	15	18	11	23	15	18	13	11	12
20-44	83	417	103	176	60	242	87	139	70	339	96	168	129	84	106
45-64	321	1569	448	1263	246	1275	351	1233	301	1507	440	1401	524	415	468
65-74	902	2584	1520	2400	612	2780	1135	2812	760	2696	1333	2610	1160	927	1042
75 plus	1050	2330	1809	2000	471	2024	1297	1670	702	2035	1450	1680	1157	666	906
All Age	209	575	218	377	161	549	192	415	185	561	205	396	255	214	234
Age Adj	221	808	346	623	144	667	262	610	177	735	298	616	287	201	238

**1995-1997**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	13	30	13	14	10	23	16	18	12	27	15	17	15	12	14
20-44	90	472	97	240	62	311	90	207	73	393	94	232	139	94	116
45-64	364	1802	540	1485	280	1451	415	1572	353	1773	554	1712	616	490	551
65-74	1071	2905	1766	2487	713	3165	1419	3595	895	3071	1610	3046	1355	1080	1215
75 plus	1311	2869	2577	1791	601	2516	1806	1792	899	2551	2079	1658	1471	858	1158
All Age	249	677	267	450	189	662	245	549	219	669	256	500	304	256	279
Age Adj	261	935	427	691	168	793	331	776	207	862	371	739	336	236	279

Includes residents of 50 states and District of Columbia only.

Cases where race is "Other" or "Unknown" are excluded from this table.

See tables A.4 and A.5 and notes at beginning of this Section.

The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

**Table A.32**  
**Standard Errors for Adjusted Incidence Rates per Million Population**  
**of Reported ESRD Therapy**  
**by Sex, Race, and Age,**  
**Adjusted for Age, Race, and Sex**

**1992-1994**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	0.3	1.2	1.8	3.5	0.3	1.0	1.9	3.7	0.2	0.8	1.4	2.7	0.3	0.3	0.2
20-44	0.8	4.7	4.3	11.6	0.7	3.4	3.8	10.3	0.5	3.0	2.9	8.3	0.9	0.7	0.6
45-64	2.3	15.3	14.7	51.8	1.9	12.4	12.2	49.1	1.6	10.6	10.9	41.3	3.0	2.5	2.0
65-74	6.4	36.3	56.0	149.1	4.7	31.7	42.1	145.2	4.0	24.3	35.5	105.1	7.5	6.0	4.8
75 plus	8.7	46.1	84.1	184.1	4.4	31.1	63.0	132.4	4.8	27.2	52.7	107.6	9.9	5.7	5.6
Age Adj	0.9	5.2	7.1	19.0	0.6	4.0	5.5	16.9	0.5	3.2	4.4	12.6	0.9	0.7	0.6

**1995-1997**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	0.4	1.3	1.7	3.3	0.3	1.1	1.9	3.8	0.3	0.9	1.3	2.5	0.4	0.3	0.2
20-44	0.8	5.0	4.0	13.3	0.7	3.8	3.7	12.4	0.5	3.2	2.8	9.5	1.0	0.8	0.6
45-64	2.3	15.5	14.7	53.4	2.0	12.5	12.0	52.7	1.7	11.2	11.4	43.5	3.2	2.7	2.1
65-74	6.9	37.7	56.6	146.5	5.1	33.3	43.3	159.7	4.3	25.6	36.2	109.0	8.0	6.4	5.1
75 plus	9.3	49.2	91.3	160.2	4.8	33.7	65.6	126.7	5.2	29.5	56.5	96.5	10.7	6.3	6.1
Age Adj	0.9	5.4	7.5	18.6	0.7	4.3	5.7	18.2	0.5	3.4	4.6	13.1	1.0	0.7	0.6

Includes residents of 50 states and District of Columbia only.

Cases where race is "Other" or "Unknown" are excluded from this table.

See tables A.4 and A.5 and notes at beginning of this Section.

The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

Table A.33  
Incidence Counts  
of Reported ESRD Therapy  
by Age, Sex, Race, and Primary Disease Causing ESRD

**1992-1994**

### Diabetes

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	*	*	0	*	16	14	12	*	*	28	22	19	*	*	44
20-44	4287	1172	92	99	5650	3124	1166	74	85	4449	7411	2338	166	184	10099
45-64	9108	4023	462	412	14005	8364	5490	390	508	14752	17472	9513	852	920	28757
65-74	6428	1851	336	145	8760	7649	3781	392	271	12093	14077	5632	728	416	20853
75 plus	2438	565	132	39	3174	2954	1306	159	83	4502	5392	1871	291	122	7676
All Age	22269	7618	1022	696	31605	22105	11755	1016	948	35824	44374	19373	2038	1644	67429

### Hypertension

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	31	57	*	*	92	37	27	*	*	68	68	84	*	*	160
20-44	1174	3124	112	41	4451	614	1397	85	16	2112	1788	4521	197	57	6563
45-64	3926	4232	195	65	8418	2428	3252	162	42	5884	6354	7484	357	107	14302
65-74	7277	2218	221	58	9774	4658	2876	177	47	7758	11935	5094	398	105	17532
75 plus	7092	1396	209	41	8738	5258	2220	155	42	7675	12350	3616	364	83	16413
All Age	19500	11027	739	207	31473	12995	9772	582	148	23497	32495	20799	1321	355	54970

### Glomeruloneph.

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	279	189	25	*	500	276	125	26	10	437	555	314	51	17	937
20-44	2221	1468	249	41	3979	1259	930	203	31	2423	3480	2398	452	72	6402
45-64	2615	785	140	55	3595	1459	553	124	24	2160	4074	1338	264	79	5755
65-74	2088	254	90	24	2456	1302	243	59	16	1620	3390	497	149	40	4076
75 plus	1474	113	49	10	1646	1000	148	45	12	1205	2474	261	94	22	2851
All Age	8677	2809	553	137	12176	5296	1999	457	93	7845	13973	4808	1010	230	20021

(CONTINUED)

Includes residents of 50 states and District of Columbia only.  
Cases where race is "Other" or "Unknown" are excluded from this table.  
See tables A.4 and A.5 and notes at beginning of this Section.  
\* Values for cells with fewer than 10 patients are suppressed.

Table A.33(Continued)  
Incidence Counts  
of Reported ESRD Therapy  
by Age, Sex, Race, and Primary Disease Causing ESRD

1992-1994

**Cystic Kidney**

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	40	*	*	*	47	43	10	*	0	57	83	14	*	*	104
20-44	453	60	11	*	532	362	78	11	*	456	815	138	22	13	988
45-64	1136	150	32	10	1328	1092	183	25	*	1308	2228	333	57	18	2636
65-74	361	50	15	*	429	392	44	*	*	449	753	94	24	*	878
75 plus	187	18	*	*	209	153	26	*	0	184	340	44	*	*	393
All Age	2177	282	62	24	2545	2042	341	54	17	2454	4219	623	116	41	4999

**Other Urologic**

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	107	35	*	0	148	62	*	*	*	69	169	40	*	*	217
20-44	264	50	11	*	326	223	25	*	*	257	487	75	15	*	583
45-64	290	57	10	*	360	244	57	17	*	320	534	114	27	*	680
65-74	382	52	*	*	447	208	33	10	0	251	590	85	19	*	698
75 plus	353	57	12	*	427	160	21	*	0	189	513	78	20	*	616
All Age	1396	251	48	13	1708	897	141	40	*	1086	2293	392	88	21	2794

**Other Cause**

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	400	93	21	*	520	275	95	14	*	391	675	188	35	13	911
20-44	1215	1318	46	25	2604	1211	1080	97	27	2415	2426	2398	143	52	5019
45-64	1722	637	43	29	2431	1592	539	58	26	2215	3314	1176	101	55	4646
65-74	1765	271	34	13	2083	1431	212	33	18	1694	3196	483	67	31	3777
75 plus	1375	192	20	*	1595	952	164	20	*	1143	2327	356	40	15	2738
All Age	6477	2511	164	81	9233	5461	2090	222	85	7858	11938	4601	386	166	17091

(CONTINUED)

Includes residents of 50 states and District of Columbia only.  
Cases where race is "Other" or "Unknown" are excluded from this table.  
See tables A. 4 and A. 5 and notes at beginning of this Section.  
\* Values for cells with fewer than 10 patients are suppressed.

Table A.33(Continued)  
Incidence Counts  
of Reported ESRD Therapy  
by Age, Sex, Race, and Primary Disease Causing ESRD

**1992-1994**

### Unknown Cause

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	95	28	*	*	128	80	23	*	*	114	175	51	12	*	242
20-44	629	389	38	15	1071	404	198	35	13	650	1033	587	73	28	1721
45-64	809	348	33	12	1202	584	246	49	*	888	1393	594	82	21	2090
65-74	994	172	27	11	1204	695	218	32	*	953	1689	390	59	19	2157
75 plus	985	112	34	13	1144	705	156	23	*	887	1690	268	57	16	2031
All Age	3512	1049	135	53	4749	2468	841	148	35	3492	5980	1890	283	88	8241

### Missing Cause

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	46	23	*	*	71	39	17	*	0	58	85	40	*	*	129
20-44	271	166	17	*	457	206	104	*	0	317	477	270	24	*	774
45-64	477	275	12	*	773	395	288	10	11	704	872	563	22	20	1477
65-74	633	211	*	*	851	549	304	14	11	878	1182	515	20	12	1729
75 plus	553	103	*	*	661	470	191	*	12	681	1023	294	12	13	1342
All Age	1980	778	40	15	2813	1659	904	41	34	2638	3639	1682	81	49	5451

(CONTINUED)

Includes residents of 50 states and District of Columbia only.  
Cases where race is "Other" or "Unknown" are excluded from this table.  
See tables A.4 and A.5 and notes at beginning of this Section.  
\* Values for cells with fewer than 10 patients are suppressed.



Table A.33(Continued)  
Incidence Counts  
of Reported ESRD Therapy  
by Age, Sex, Race, and Primary Disease Causing ESRD

1995-1997

**Diabetes**

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	16	*	*	0	25	13	13	*	0	27	29	21	*	0	52
20-44	4520	1454	108	127	6209	3019	1468	89	118	4694	7539	2922	197	245	10903
45-64	12237	5668	676	563	19144	11101	7594	608	691	19994	23338	13262	1284	1254	39138
65-74	9312	2661	485	193	12651	9819	5097	644	383	15943	19131	7758	1129	576	28594
75 plus	4470	1006	290	48	5814	4703	2198	346	121	7368	9173	3204	636	169	13182
All Age	30555	10797	1560	931	43843	28655	16370	1688	1313	48026	59210	27167	3248	2244	91869

**Hypertension**

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	21	53	*	*	77	25	32	*	*	64	46	85	*	*	141
20-44	1089	3022	96	49	4256	502	1750	75	35	2362	1591	4772	171	84	6618
45-64	3742	4434	259	92	8527	2261	3287	210	70	5828	6003	7721	469	162	14355
65-74	7006	2116	248	38	9408	4492	2748	208	65	7513	11498	4864	456	103	16921
75 plus	8318	1599	291	39	10247	6269	2485	265	49	9068	14587	4084	556	88	19315
All Age	20176	11224	896	219	32515	13549	10302	762	222	24835	33725	21526	1658	441	57350

**Glomeruloneph.**

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	289	173	25	*	493	254	131	21	*	415	543	304	46	15	908
20-44	2374	1549	227	74	4224	1320	1062	228	64	2674	3694	2611	455	138	6898
45-64	2951	1052	197	47	4247	1646	697	165	47	2555	4597	1749	362	94	6802
65-74	2250	281	115	17	2663	1308	325	83	17	1733	3558	606	198	34	4396
75 plus	1886	144	88	13	2131	1247	191	61	10	1509	3133	335	149	23	3640
All Age	9750	3199	652	157	13758	5775	2406	558	147	8886	15525	5605	1210	304	22644

(CONTINUED)

Includes residents of 50 states and District of Columbia only.  
Cases where race is "Other" or "Unknown" are excluded from this table.  
See tables A.4 and A.5 and notes at beginning of this Section.  
\* Values for cells with fewer than 10 patients are suppressed.

Table A.33(Continued)  
Incidence Counts  
of Reported ESRD Therapy  
by Age, Sex, Race, and Primary Disease Causing ESRD

1995-1997

Cystic Kidney

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	54	14	*	*	71	59	11	*	0	73	113	25	*	*	144
20-44	534	99	15	*	652	350	82	12	*	445	884	181	27	*	1097
45-64	1250	165	41	*	1463	1063	183	30	*	1285	2313	348	71	16	2748
65-74	410	51	14	*	476	411	64	13	*	489	821	115	27	*	965
75 plus	200	45	*	*	252	194	33	*	*	232	394	78	*	*	484
All Age	2448	374	76	16	2914	2077	373	62	12	2524	4525	747	138	28	5438

Other Urologic

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	74	21	0	0	95	58	10	*	*	71	132	31	*	*	166
20-44	307	54	10	10	381	313	57	16	*	388	620	111	26	12	769
45-64	468	101	18	*	595	364	63	20	*	449	832	164	38	10	1044
65-74	575	125	15	*	720	282	45	19	*	348	857	170	34	*	1068
75 plus	743	84	10	*	843	244	39	*	*	293	987	123	19	*	1136
All Age	2167	385	53	29	2634	1261	214	66	*	1549	3428	599	119	37	4183

Other Cause

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	594	198	25	*	826	339	134	30	10	513	933	332	55	19	1339
20-44	1466	1868	45	41	3420	1388	1567	103	41	3099	2854	3435	148	82	6519
45-64	2379	1063	70	33	3545	2203	867	75	42	3187	4582	1930	145	75	6732
65-74	2517	346	46	16	2925	1914	322	57	17	2310	4431	668	103	33	5235
75 plus	2215	248	52	12	2527	1651	255	35	*	1949	3866	503	87	20	4476
All Age	9171	3723	238	111	13243	7495	3145	300	118	11058	16666	6868	538	229	24301

(CONTINUED)

Includes residents of 50 states and District of Columbia only.  
Cases where race is "Other" or "Unknown" are excluded from this table.  
See tables A.4 and A.5 and notes at beginning of this Section.  
\* Values for cells with fewer than 10 patients are suppressed.

Table A.33(Continued)  
 Incidence Counts  
 of Reported ESRD Therapy  
 by Age, Sex, Race, and Primary Disease Causing ESRD

1995-1997

**Unknown Cause**

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	51	38	*	*	91	62	33	*	0	100	113	71	*	*	191
20-44	427	396	41	13	877	282	199	30	11	522	709	595	71	24	1399
45-64	732	336	45	16	1129	536	272	50	16	874	1268	608	95	32	2003
65-74	981	175	35	15	1206	667	192	36	15	910	1648	367	71	30	2116
75 plus	1268	148	46	*	1465	931	189	29	*	1157	2199	337	75	11	2622
All Age	3459	1093	168	48	4768	2478	885	150	50	3563	5937	1978	318	98	8331

**Missing Cause**

Age At ESRD	Males					Females					Both Sexes				
	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All	White	Black	Asian	NatAm	All
0-19	113	43	*	0	163	72	35	*	*	115	185	78	14	*	278
20-44	585	520	43	10	1158	424	333	26	*	788	1009	853	69	15	1946
45-64	841	620	41	*	1510	591	486	30	12	1119	1432	1106	71	20	2629
65-74	736	194	16	*	949	538	239	14	*	798	1274	433	30	10	1747
75 plus	701	121	15	*	839	484	175	*	*	670	1185	296	24	*	1509
All Age	2976	1498	122	23	4619	2109	1268	86	27	3490	5085	2766	208	50	8109

Includes residents of 50 states and District of Columbia only.  
 Cases where race is "Other" or "Unknown" are excluded from this table.  
 See tables A.4 and A.5 and notes at beginning of this Section.  
 \* Values for cells with fewer than 10 patients are suppressed.

**Table A.34**  
**Incidence Rates per Ten Million Population of Reported ESRD Therapy**  
**by Primary Disease Causing ESRD**  
**Specific Rates by Sex, Race, and Age**  
**and Rates Adjusted for Age, Race, and Sex**

**1992-1994**

**Diabetes**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	*	*	0	*	*	*	*	*	*	*	*	*	*	*	*
20-44	338	631	164	750	252	567	125	649	288	630	149	768	374	289	330
45-64	1455	6006	2231	8744	1272	6597	1641	9944	1455	6827	2193	10570	2282	2199	2241
65-74	2911	9417	6920	13435	2774	13633	6126	20321	2837	11533	6512	16784	3962	4410	4198
75 plus	1770	5150	5158	6610	1193	6245	4874	8717	1271	4965	4376	6629	1977	1822	1901
All Age	721	2418	1295	3453	611	2853	1082	4250	662	2663	1182	3900	915	854	884
Age Adj	721	2418	1295	3453	611	2853	1082	4250	662	2663	1182	3900	915	854	884

**Hypertension**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	*	33	*	*	*	16	*	*	*	26	*	*	*	*	*
20-44	93	1682	199	310	49	679	143	122	70	1220	174	227	310	135	219
45-64	627	6319	942	1380	369	3908	682	822	543	5381	913	1258	1465	895	1170
65-74	3295	11284	4552	5374	1689	10370	2766	3524	2515	10939	3702	4536	4445	2870	3642
75 plus	5150	12725	8166	6949	2124	10616	4752	4411	3439	11166	6278	5526	5942	3191	4539
All Age	682	3501	1066	1207	334	2399	658	731	479	2923	824	940	979	538	726
Age Adj	682	3501	1066	1207	334	2399	658	731	479	2923	824	940	979	538	726

**Glomeruloneph.**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	31	108	59	*	32	74	64	80	32	95	65	71	43	40	42
20-44	175	791	443	310	101	452	342	237	137	628	393	284	266	156	210
45-64	418	1172	676	1167	222	665	522	470	333	912	603	851	546	300	420
65-74	945	1292	1854	2224	472	876	922	1200	709	1087	1391	1712	1041	551	791
75 plus	1070	1030	1915	1695	404	708	1379	1260	671	811	1569	1402	1008	459	728
All Age	286	733	566	638	149	434	402	368	210	578	476	492	350	191	263
Age Adj	286	733	566	638	149	434	402	368	210	578	476	492	350	191	263

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

Cases where race is "Other" or "Unknown" are excluded from this table.

See tables A.4 and A.5 and notes at beginning of this Section.

Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.

The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

Table A.34(Continued)  
 Incidence Rates per Ten Million Population of Reported ESRD Therapy  
 by Primary Disease Causing ESRD  
 Specific Rates by Sex, Race, and Age  
 and Rates Adjusted for Age, Race, and Sex

1992-1994

Cystic Kidney

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	*	*	*	*	*	*	*	0	*	*	*	*	*	*	*
20-44	36	32	20	*	29	38	19	*	32	38	20	52	35	30	33
45-64	181	224	155	212	166	220	105	*	175	222	128	183	188	171	179
65-74	163	254	309	*	142	159	*	*	152	205	232	*	181	146	163
75 plus	136	164	*	*	62	124	*	0	89	131	*	*	125	66	95
All Age	71	87	68	103	60	81	50	67	65	83	59	84	73	62	67
Age Adj	71	87	68	103	60	81	50	67	65	83	59	84	73	62	67

Other Urologic

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	12	20	*	0	*	*	*	*	*	11	*	*	13	*	*
20-44	21	27	20	*	18	12	*	*	19	20	13	*	22	17	19
45-64	46	85	48	*	37	68	72	*	44	84	68	*	57	44	50
65-74	173	265	*	*	75	119	156	0	125	195	178	*	191	84	137
75 plus	256	520	469	*	65	100	*	0	151	320	340	*	299	69	181
All Age	47	83	62	89	25	34	43	*	34	54	50	48	51	26	37
Age Adj	47	83	62	89	25	34	43	*	34	54	50	48	51	26	37

Other Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	44	53	50	*	32	56	35	*	38	56	43	54	46	36	41
20-44	96	710	82	189	98	525	163	206	96	624	123	204	176	155	165
45-64	275	951	208	615	242	648	244	509	274	804	249	642	381	307	343
65-74	799	1379	700	1205	519	764	516	1350	660	1078	603	1324	881	559	716
75 plus	998	1750	781	*	385	784	613	*	636	1190	664	984	1010	423	710
All Age	216	691	182	380	153	450	194	344	179	560	186	359	270	190	224
Age Adj	216	691	182	380	153	450	194	344	179	560	186	359	270	190	224

(CONTINUED)

Includes residents of 50 states and District of Columbia only.  
 Cases where race is "Other" or "Unknown" are excluded from this table.  
 See tables A.4 and A.5 and notes at beginning of this Section.  
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.  
 The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

Table A.34(Continued)  
Incidence Rates per Ten Million Population of Reported ESRD Therapy  
by Primary Disease Causing ESRD  
Specific Rates by Sex, Race, and Age  
and Rates Adjusted for Age, Race, and Sex

1992-1994

Unknown Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	10	16	*	*	*	14	*	*	10	15	16	*	11	11	11
20-44	50	209	68	114	33	96	59	99	41	157	62	110	72	42	57
45-64	129	520	159	255	89	296	206	*	116	432	197	232	193	129	160
65-74	450	875	556	1019	252	786	500	*	354	833	538	848	521	335	426
75 plus	715	1021	1328	2203	285	746	705	*	480	881	957	1040	765	349	553
All Age	120	316	176	298	67	199	146	144	89	254	156	210	143	82	108
Age Adj	120	316	176	298	67	199	146	144	89	254	156	210	143	82	108

Missing Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	*	13	*	*	*	10	*	0	*	12	*	*	*	*	*
20-44	21	89	30	*	17	51	*	0	19	71	22	*	31	20	25
45-64	76	411	58	*	60	346	42	215	73	412	50	219	127	106	116
65-74	287	1073	*	*	199	1096	219	825	243	1088	177	428	382	318	349
75 plus	402	939	*	*	190	913	*	1260	280	882	205	763	441	277	357
All Age	68	252	42	66	44	221	45	173	54	235	45	129	85	61	71
Age Adj	68	252	42	66	44	221	45	173	54	235	45	129	85	61	71

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

Cases where race is "Other" or "Unknown" are excluded from this table.

See tables A.4 and A.5 and notes at beginning of this Section.

Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.

The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

Table A.34(Continued)  
 Incidence Rates per Ten Million Population of Reported ESRD Therapy  
 by Primary Disease Causing ESRD  
 Specific Rates by Sex, Race, and Age  
 and Rates Adjusted for Age, Race, and Sex

1995-1997

**Diabetes**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	*	*	*	0	*	*	*	0	*	*	*	0	*	*	*
20-44	359	765	179	931	246	700	138	881	288	742	161	961	398	296	346
45-64	1809	7602	2708	10799	1572	8193	2122	12215	1869	8939	2923	12988	2963	2834	2899
65-74	4191	12992	8796	16664	3605	17861	8507	27157	3900	15502	8705	21885	5594	5795	5706
75 plus	2960	8501	9375	6876	1797	9937	8242	10843	2086	8310	7986	8045	3415	2876	3144
All Age	960	3271	1793	4220	768	3785	1573	5459	854	3560	1673	4918	1219	1096	1153
Age Adj	960	3271	1793	4220	768	3785	1573	5459	854	3560	1673	4918	1219	1096	1153

**Hypertension**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	*	29	*	*	*	18	*	*	*	24	*	*	*	*	*
20-44	87	1590	159	359	41	834	116	261	61	1217	138	323	283	144	211
45-64	553	5947	1038	1765	320	3546	733	1237	500	5081	1034	1675	1392	837	1105
65-74	3153	10331	4498	3281	1649	9630	2748	4609	2419	10205	3696	4041	4197	2762	3465
75 plus	5508	13511	9408	5587	2395	11234	6312	4391	3828	11989	7667	4785	6470	3607	5010
All Age	680	3371	1140	1073	335	2389	760	964	477	2854	920	1016	964	543	721
Age Adj	680	3371	1140	1073	335	2389	760	964	477	2854	920	1016	964	543	721

**Glomeruloneph.**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	31	96	53	*	29	75	47	*	30	87	52	56	41	36	38
20-44	189	815	377	542	107	506	354	478	146	662	365	515	277	169	222
45-64	436	1411	789	902	233	752	576	831	355	1090	711	923	607	331	465
65-74	1013	1372	2086	1468	480	1139	1096	1205	747	1271	1607	1333	1115	595	850
75 plus	1249	1217	2845	1862	476	863	1453	896	811	985	2059	1202	1235	544	883
All Age	311	800	635	621	158	500	432	520	226	645	519	564	380	207	285
Age Adj	311	800	635	621	158	500	432	520	226	645	519	564	380	207	285

(CONTINUED)

Includes residents of 50 states and District of Columbia only.  
 Cases where race is "Other" or "Unknown" are excluded from this table.  
 See tables A.4 and A.5 and notes at beginning of this Section.  
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.  
 The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

Table A.34(Continued)  
 Incidence Rates per Ten Million Population of Reported ESRD Therapy  
 by Primary Disease Causing ESRD  
 Specific Rates by Sex, Race, and Age  
 and Rates Adjusted for Age, Race, and Sex

1995-1997

Cystic Kidney

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	*	*	*	*	*	*	*	0	*	*	*	*	*	*	*
20-44	42	52	25	*	28	39	19	*	34	46	22	*	42	28	35
45-64	185	221	164	*	151	197	105	*	170	211	141	161	190	158	174
65-74	185	249	254	*	151	224	172	*	167	240	214	*	194	161	177
75 plus	132	380	*	*	74	149	*	*	96	258	*	*	159	80	119
All Age	76	108	73	69	58	82	49	46	66	93	59	55	78	60	68
Age Adj	76	108	73	69	58	82	49	46	66	93	59	55	78	60	68

Other Urologic

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	*	12	0	0	*	*	*	*	*	*	*	*	*	*	*
20-44	24	28	17	73	25	27	25	*	25	28	21	43	25	26	25
45-64	69	135	72	*	52	68	70	*	66	115	85	118	90	58	73
65-74	259	610	272	*	104	158	251	*	182	385	264	*	310	116	211
75 plus	492	710	323	*	93	176	*	*	289	457	295	*	526	106	311
All Age	72	128	61	142	35	47	56	*	50	81	57	81	77	36	53
Age Adj	72	128	61	142	35	47	56	*	50	81	57	81	77	36	53

Other Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	64	110	53	*	38	77	67	77	51	94	62	75	70	45	57
20-44	117	983	75	300	113	747	160	306	113	864	120	311	226	195	210
45-64	352	1426	280	633	312	935	262	742	362	1181	298	718	520	414	465
65-74	1133	1689	834	1381	703	1128	753	1205	920	1426	802	1278	1208	766	982
75 plus	1467	2096	1681	1719	631	1153	834	*	987	1551	1188	1221	1478	674	1068
All Age	296	953	258	473	203	647	237	422	242	789	241	438	371	257	305
Age Adj	296	953	258	473	203	647	237	422	242	789	241	438	371	257	305

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

Cases where race is "Other" or "Unknown" are excluded from this table.

See tables A.4 and A.5 and notes at beginning of this Section.

Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.

The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.



Table A.34(Continued)  
 Incidence Rates per Ten Million Population of Reported ESRD Therapy  
 by Primary Disease Causing ESRD  
 Specific Rates by Sex, Race, and Age  
 and Rates Adjusted for Age, Race, and Sex

1995-1997

Unknown Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	*	21	*	*	*	19	*	0	*	20	*	*	*	*	*	
20-44	34	208	68	95	23	95	47	82	28	151	57	91	58	33	45	
45-64	108	451	180	307	76	293	174	283	102	397	206	343	173	118	145	
65-74	442	854	635	1295	245	673	476	1064	346	777	573	1161	518	319	416	
75 plus	840	1251	1487	*	356	854	691	*	592	1059	1105	499	913	435	669	
All Age	116	314	196	219	64	199	134	208	85	252	158	216	140	80	105	
Age Adj	116	314	196	219	64	199	134	208	85	252	158	216	140	80	105	

Missing Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	12	24	*	0	*	20	*	*	10	22	15	*	14	*	12	
20-44	47	274	71	73	35	159	40	*	39	216	55	54	76	50	62	
45-64	124	832	164	*	84	524	105	212	110	720	143	192	227	152	188	
65-74	331	947	290	*	198	838	185	*	265	900	238	395	413	281	345	
75 plus	464	1022	485	*	185	791	*	*	306	901	355	*	513	257	382	
All Age	96	410	114	93	57	278	66	106	74	341	87	100	129	80	102	
Age Adj	96	410	114	93	57	278	66	106	74	341	87	100	129	80	102	

Includes residents of 50 states and District of Columbia only.

Cases where race is "Other" or "Unknown" are excluded from this table.

See tables A.4 and A.5 and notes at beginning of this Section.

Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.

The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

**Table A.35**  
**Standard Errors for Adjusted Incidence Rates per Ten Million Population**  
**of Reported ESRD Therapy by Primary Disease Causing ESRD**  
**by Sex, Race, and Age**  
**Adjusted for Age, Race, and Sex**

**1992-1994**

**Diabetes**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	*	*	0.0	*	0.4	2.0	*	*	0.3	1.3	*	*	0.3	0.5	0.3
20-44	5.2	18.4	17.1	75.3	4.5	16.6	14.5	70.4	3.4	13.1	11.6	56.9	5.0	4.3	3.3
45-64	15.2	94.7	103.8	430.8	13.9	89.0	83.1	441.2	11.1	71.3	77.4	359.3	20.0	18.4	13.6
65-74	36.3	218.9	377.5	1115.7	31.7	221.7	309.4	1234.4	24.1	156.8	245.9	833.0	44.4	41.5	30.4
75 plus	35.9	216.7	448.9	1058.5	22.0	172.8	386.5	956.8	18.7	124.2	274.3	633.5	39.8	30.2	24.8
Age Adj	4.9	28.3	42.6	136.8	4.1	26.4	35.5	140.5	3.1	19.4	27.5	98.9	5.2	4.5	3.4

**Hypertension**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	0.6	4.3	*	*	0.7	3.1	*	*	0.5	2.8	*	*	0.8	0.8	0.5
20-44	2.7	30.1	18.8	48.5	2.0	18.2	15.5	30.5	1.7	18.3	12.4	30.3	4.7	3.0	2.7
45-64	10.0	97.1	67.4	171.1	7.5	68.5	53.5	126.9	6.9	63.5	50.1	125.9	16.5	11.9	10.0
65-74	38.6	239.6	306.2	705.6	24.8	193.4	207.9	514.1	23.2	156.6	188.8	448.6	47.0	33.6	28.6
75 plus	61.1	340.6	564.9	1085.3	29.3	225.3	381.7	680.6	34.0	204.5	356.8	649.7	72.1	39.9	40.6
Age Adj	4.9	34.8	42.4	90.6	2.9	24.4	29.0	61.4	2.7	20.6	24.2	52.0	5.6	3.5	3.1

**Glomeruloneph.**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	1.8	7.9	11.8	*	1.9	6.6	12.6	25.3	1.4	5.4	9.1	17.3	1.9	1.9	1.4
20-44	3.7	20.6	28.1	48.5	2.9	14.8	24.0	42.5	2.3	12.9	18.5	33.6	4.2	3.2	2.6
45-64	8.2	41.8	57.1	157.4	5.8	28.3	46.8	95.9	5.3	25.5	38.7	99.5	9.4	6.6	5.7
65-74	20.7	81.1	195.4	453.9	13.1	56.2	120.0	299.9	12.3	49.8	115.6	275.1	21.9	14.1	12.9
75 plus	27.9	96.9	273.5	536.0	12.8	58.2	205.6	363.8	14.7	55.0	174.6	317.0	27.9	15.0	15.6
Age Adj	3.1	14.4	26.4	59.0	2.1	9.9	20.1	40.0	1.8	8.6	16.2	34.3	3.2	2.2	1.9

(CONTINUED)

Includes residents of 50 states and District of Columbia only.  
 Cases where race is "Other" or "Unknown" are excluded from this table.  
 See tables A.4 and A.5 and notes at beginning of this Section.  
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.  
 The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

Table A.35(Continued)  
 Standard Errors for Adjusted Incidence Rates per Ten Million Population  
 of Reported ESRD Therapy by Primary Disease Causing ESRD  
 by Sex, Race, and Age  
 Adjusted for Age, Race, and Sex

1992-1994

**Cystic Kidney**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	0.7	*	*	*	0.8	1.9	*	0.0	0.5	1.1	*	*	0.6	0.7	0.5	
20-44	1.7	4.2	5.9	*	1.5	4.3	5.6	*	1.1	3.2	4.3	14.5	1.5	1.4	1.0	
45-64	5.4	18.3	27.3	67.1	5.0	16.3	21.0	*	3.8	12.5	17.6	44.4	5.3	4.8	3.6	
65-74	8.6	36.0	79.8	*	7.2	23.9	*	*	5.6	21.6	48.0	*	9.1	7.1	5.7	
75 plus	9.9	38.7	*	*	5.0	24.4	*	0.0	5.3	21.6	*	*	9.5	5.3	5.4	
Age Adj	1.5	5.3	9.0	22.5	1.3	4.4	7.2	16.7	1.0	3.4	5.7	13.7	1.5	1.3	0.9	

**Other Urologic**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	1.1	3.4	*	0.0	0.9	*	*	*	0.7	1.8	*	*	1.1	0.8	0.7	
20-44	1.3	3.8	5.9	*	1.2	2.4	*	*	0.9	2.3	3.4	*	1.2	1.1	0.8	
45-64	2.7	11.3	15.3	*	2.4	9.1	17.3	*	1.9	8.1	13.5	*	3.1	2.5	2.0	
65-74	8.9	36.7	*	*	5.2	20.7	49.4	0.0	5.2	21.6	41.7	*	9.4	5.5	5.4	
75 plus	13.6	68.8	135.4	*	5.1	21.9	*	0.0	7.3	39.9	83.9	*	16.6	5.5	8.6	
Age Adj	1.3	5.6	10.1	26.3	0.9	2.9	7.1	*	0.7	2.8	5.7	11.4	1.3	0.8	0.7	

**Other Cause**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	2.2	5.5	10.9	*	1.9	5.7	9.2	*	1.5	4.1	7.4	15.0	2.0	1.8	1.4	
20-44	2.7	19.5	12.1	37.9	2.8	16.0	16.6	39.7	2.0	12.8	10.3	28.4	3.5	3.2	2.3	
45-64	6.6	37.7	31.7	114.3	6.1	27.9	32.0	99.8	4.8	24.0	25.6	88.8	8.0	6.6	5.1	
65-74	19.0	83.8	120.1	334.1	13.7	52.5	89.8	318.1	11.8	50.1	75.1	240.9	20.0	13.9	12.1	
75 plus	26.9	126.3	174.7	*	12.5	61.2	137.1	*	14.5	68.8	114.2	269.0	28.4	13.8	15.5	
Age Adj	2.7	14.5	15.7	46.4	2.1	10.0	13.9	39.0	1.6	8.5	10.3	29.6	2.8	2.2	1.7	

(CONTINUED)

Includes residents of 50 states and District of Columbia only.  
 Cases where race is "Other" or "Unknown" are excluded from this table.  
 See tables A.4 and A.5 and notes at beginning of this Section.  
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.  
 The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

Table A.35(Continued)  
 Standard Errors for Adjusted Incidence Rates per Ten Million Population  
 of Reported ESRD Therapy by Primary Disease Causing ESRD  
 by Sex, Race, and Age  
 Adjusted for Age, Race, and Sex

1992-1994

Unknown Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	1.1	3.0	*	*	1.0	2.8	*	*	0.8	2.2	4.6	*	1.0	1.0	0.7
20-44	2.0	10.6	11.0	29.3	1.6	6.8	10.0	27.5	1.3	6.5	7.3	20.8	2.2	1.7	1.4
45-64	4.5	27.9	27.7	73.5	3.7	18.8	29.5	*	3.1	18.1	22.6	52.7	5.7	4.4	3.6
65-74	14.3	66.7	107.0	307.3	9.6	53.2	88.4	*	8.7	43.1	71.2	196.9	15.6	11.2	9.5
75 plus	22.8	96.5	227.8	611.1	10.7	59.7	147.0	*	12.9	59.4	137.3	269.2	25.6	12.9	14.1
Age Adj	2.1	10.3	16.7	44.9	1.4	6.9	12.8	25.5	1.2	6.0	10.0	23.9	2.1	1.4	1.2

Missing Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For						
	Males				Females				Sex				Race		Sex & Race
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race
0-19	0.7	2.8	*	*	0.7	2.4	*	0.0	0.5	1.9	*	*	0.7	0.7	0.5
20-44	1.3	6.9	7.3	*	1.2	5.0	*	0.0	0.9	4.3	4.5	*	1.4	1.1	0.9
45-64	3.5	24.8	16.7	*	3.0	20.4	13.3	64.9	2.5	17.7	11.1	51.1	4.7	4.1	3.1
65-74	11.4	73.9	*	*	8.5	62.9	58.5	248.7	7.1	49.0	40.2	124.9	13.6	11.1	8.7
75 plus	17.1	92.5	*	*	8.8	66.1	*	363.8	9.7	57.0	60.8	224.2	19.3	11.7	11.1
Age Adj	1.5	9.4	7.1	18.7	1.1	7.4	7.6	30.1	0.9	5.8	5.5	19.3	1.6	1.2	1.0

(CONTINUED)

Includes residents of 50 states and District of Columbia only.

Cases where race is "Other" or "Unknown" are excluded from this table.

See tables A.4 and A.5 and notes at beginning of this Section.

Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.

The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

Table A.35(Continued)  
 Standard Errors for Adjusted Incidence Rates per Ten Million Population  
 of Reported ESRD Therapy by Primary Disease Causing ESRD  
 by Sex, Race, and Age  
 Adjusted for Age, Race, and Sex

1995-1997

**Diabetes**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	0.4	*	*	0.0	0.4	2.1	*	0.0	0.3	1.3	*	0.0	0.4	0.4	0.3	
20-44	5.3	20.1	17.3	82.6	4.5	18.3	14.6	81.1	3.3	13.8	11.5	61.6	5.1	4.3	3.3	
45-64	16.4	101.0	104.2	455.1	14.9	94.0	86.0	464.7	12.5	79.8	84.2	379.7	22.3	20.5	15.1	
65-74	43.4	251.9	399.4	1199.5	36.4	250.2	335.2	1387.6	28.3	179.6	263.4	920.0	51.8	47.2	35.0	
75 plus	44.3	268.0	550.5	992.4	26.2	211.9	443.1	985.7	23.4	159.6	339.5	641.4	50.7	36.7	31.1	
Age Adj	5.5	32.3	47.8	143.8	4.6	29.7	39.6	153.5	3.5	21.9	30.7	106.8	5.9	5.0	3.8	

**Hypertension**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	0.5	4.0	*	*	0.6	3.2	*	*	0.4	2.6	*	*	0.7	0.7	0.5	
20-44	2.6	28.9	16.3	51.3	1.8	19.9	13.4	44.2	1.5	17.7	10.6	35.3	4.4	3.0	2.6	
45-64	9.0	89.3	64.5	184.0	6.7	61.9	50.6	147.9	6.6	59.8	49.6	136.9	15.6	11.2	9.5	
65-74	37.7	224.6	285.6	532.2	24.6	183.7	190.5	571.7	22.7	149.5	176.1	401.2	45.0	32.7	27.6	
75 plus	60.4	337.9	551.5	894.6	30.2	225.4	387.8	627.3	34.6	205.4	347.4	535.2	71.8	41.1	40.8	
Age Adj	4.8	33.2	40.5	77.5	2.9	23.7	28.8	66.4	2.6	19.8	23.9	50.4	5.4	3.5	3.0	

**Glomeruloneph.**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	1.8	7.3	10.6	*	1.8	6.5	10.2	*	1.3	5.0	7.7	14.5	1.8	1.8	1.3	
20-44	3.9	20.7	25.0	63.0	3.0	15.5	23.4	59.7	2.4	13.0	17.2	44.0	4.3	3.3	2.7	
45-64	8.0	43.5	56.2	131.5	5.7	28.5	44.8	121.2	5.4	27.1	39.1	99.8	9.7	6.7	5.8	
65-74	21.3	81.8	194.5	356.0	13.3	63.2	120.4	292.3	12.6	52.8	116.0	230.9	22.3	14.6	13.2	
75 plus	28.8	101.4	303.3	516.5	13.5	62.5	186.0	283.4	15.8	59.1	181.1	261.5	29.9	15.3	16.6	
Age Adj	3.2	14.7	27.1	53.7	2.1	10.3	19.2	44.3	1.8	8.8	15.9	34.0	3.3	2.2	1.9	

(CONTINUED)

Includes residents of 50 states and District of Columbia only.  
 Cases where race is "Other" or "Unknown" are excluded from this table.  
 See tables A.4 and A.5 and notes at beginning of this Section.  
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.  
 The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

Table A.35(Continued)  
 Standard Errors for Adjusted Incidence Rates per Ten Million Population  
 of Reported ESRD Therapy by Primary Disease Causing ESRD  
 by Sex, Race, and Age  
 Adjusted for Age, Race, and Sex

1995-1997

Cystic Kidney

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	0.8	2.1	*	*	0.9	1.9	*	0.0	0.6	1.4	*	*	0.7	0.8	0.5	
20-44	1.8	5.2	6.4	*	1.5	4.3	5.4	*	1.1	3.5	4.2	*	1.6	1.3	1.0	
45-64	5.2	17.2	25.7	*	4.6	14.6	19.1	*	3.6	11.7	17.6	41.9	5.1	4.5	3.4	
65-74	9.1	34.9	67.9	*	7.4	28.0	47.6	*	5.9	22.8	41.8	*	9.2	7.4	5.9	
75 plus	9.4	56.7	*	*	5.3	26.0	*	*	5.3	31.9	*	*	11.5	5.7	6.3	
Age Adj	1.5	5.8	8.9	18.7	1.3	4.3	6.4	13.3	1.0	3.5	5.3	10.7	1.5	1.2	0.9	

Other Urologic

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	0.9	2.5	0.0	0.0	0.9	1.8	*	*	0.6	1.6	*	*	0.8	0.8	0.6	
20-44	1.4	3.9	5.3	23.2	1.4	3.6	6.2	*	1.0	2.7	4.1	12.5	1.3	1.3	0.9	
45-64	3.2	13.5	17.0	*	2.7	8.6	15.6	*	2.3	9.3	14.5	38.3	3.8	2.8	2.3	
65-74	10.8	54.6	70.2	*	6.2	23.5	57.6	*	6.2	30.1	45.9	*	12.0	6.4	6.7	
75 plus	18.1	77.4	102.2	*	6.0	28.2	*	*	10.1	44.4	71.7	*	20.2	6.8	10.4	
Age Adj	1.6	6.8	8.9	28.5	1.0	3.3	7.2	*	0.8	3.4	5.5	13.9	1.5	0.9	0.8	

Other Cause

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	2.6	7.8	10.6	*	2.1	6.6	12.1	24.4	1.7	5.2	8.4	17.1	2.4	2.0	1.6	
20-44	3.0	22.7	11.1	46.9	3.0	18.9	15.8	47.8	2.1	14.8	9.9	34.4	3.9	3.5	2.6	
45-64	7.2	43.7	33.5	110.2	6.6	31.8	30.2	114.6	5.5	28.0	26.0	86.6	9.1	7.5	5.8	
65-74	22.6	90.8	123.0	345.4	16.1	62.9	99.7	292.3	13.9	56.4	80.3	224.4	23.0	16.2	14.0	
75 plus	31.2	133.1	233.1	496.2	15.5	72.2	140.9	*	17.4	75.8	137.0	295.5	33.0	16.4	18.1	
Age Adj	3.1	16.3	18.2	48.9	2.4	11.7	14.4	40.2	1.9	9.7	11.1	30.3	3.3	2.5	2.0	

(CONTINUED)

Includes residents of 50 states and District of Columbia only.  
 Cases where race is "Other" or "Unknown" are excluded from this table.  
 See tables A.4 and A.5 and notes at beginning of this Section.  
 Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.  
 The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

Table A.35(Continued)  
 Standard Errors for Adjusted Incidence Rates per Ten Million Population  
 of Reported ESRD Therapy by Primary Disease Causing ESRD  
 by Sex, Race, and Age  
 Adjusted for Age, Race, and Sex

1995-1997

**Unknown Cause**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	0.8	3.4	*	*	0.9	3.3	*	0.0	0.6	2.4	*	*	0.8	0.9	0.6	
20-44	1.6	10.5	10.6	26.4	1.4	6.7	8.5	24.8	1.1	6.2	6.8	18.5	2.0	1.5	1.2	
45-64	4.0	24.6	26.9	76.7	3.3	17.8	24.7	70.7	2.9	16.7	22.0	63.0	5.3	4.1	3.3	
65-74	14.1	64.6	107.3	334.4	9.5	48.6	79.3	274.6	8.6	41.4	68.9	213.9	15.4	10.9	9.3	
75 plus	23.6	102.8	219.3	*	11.7	62.2	128.3	*	13.8	63.1	135.9	151.9	26.7	13.9	14.8	
Age Adj	2.0	10.0	16.4	33.2	1.3	6.8	11.5	30.2	1.1	5.8	9.5	22.7	2.0	1.3	1.1	

**Missing Cause**

Age at ESRD	Specific Rates (Unadjusted)								Rates Adjusted For							
	Males				Females				Sex				Race		Sex & Race	
	White	Black	Asian	NatAm	White	Black	Asian	NatAm	White	Black	Asian	NatAm	Male	Female	Race	
0-19	1.1	3.6	*	0.0	1.0	3.4	*	*	0.7	2.5	4.0	*	1.1	0.9	0.7	
20-44	1.9	12.0	10.9	23.2	1.7	8.7	7.9	*	1.2	7.4	6.7	13.9	2.2	1.8	1.4	
45-64	4.3	33.4	25.7	*	3.4	23.8	19.1	61.2	3.0	22.5	18.0	44.7	6.1	4.7	3.8	
65-74	12.2	68.0	72.5	*	8.5	54.2	49.4	*	7.5	44.2	44.2	125.9	13.9	10.2	8.5	
75 plus	17.5	92.9	125.2	*	8.4	59.8	*	*	9.7	57.3	78.1	*	20.0	10.8	11.2	
Age Adj	1.8	11.1	11.3	21.0	1.2	7.9	7.5	21.1	1.0	6.6	6.5	14.8	1.9	1.4	1.1	

Includes residents of 50 states and District of Columbia only.

Cases where race is "Other" or "Unknown" are excluded from this table.

See tables A.4 and A.5 and notes at beginning of this Section.

Note that rates are per TEN MILLION population rather than per million because of the small cell sizes.

The population base is U.S. resident population on July 1 of each year. The standard population for adjustment is July 1, 1996, U.S. resident population. \* Values for cells with fewer than 10 patients are suppressed.

Table A.36  
 Primary Disease Causing ESRD: New ESRD Patients by Detailed Disease Code and Year of First ESRD Service

Detailed Primary Disease	Year of First ESRD Service																
	ALL	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	1999	%
ALL	906,310	181,404	29,055	31,678	34,775	38,432	44,449	47,873	52,415	57,610	59,378	67,750	72,962	76,718	80,265	31,546	
***UNRECONCILABLE CODE***	63,276	38,707	1,120	1,324	1,138	1,553	2,022	1,761	1,262	1,225	2,958	1,548	1,781	1,649	4,224	1,004	
7900 : ***UNRECONCILABLE CODE***	6												4	2			
7900Z : ***UNRECONCILABLE CODE***	314	106	8	14	16	28	30	28	28	19	20	12	5				
0160Z : RENAL TUBERCULOSIS	20	1						2	4	5	6	2					
0429 : ***UNRECONCILABLE CODE***	5												2	3			
0429A : AIDS nephropathy	3,347	2	1		1	6	5	11	18	39	65	348	943	845	739	324	
0429Z : AIDS, OR HIV INFECTION WITH SPECIFIED OR MALIGNANT N.	361	3			1	10	36	52	74	64	71	45	5				
0439 : ***UNRECONCILABLE CODE***	1												1				
0439D : ***UNRECONCILABLE CODE***	2												1	1			
0439Z : AIDS-LIKE SYNDROME, OR HIV INFECTION WITH OTHER SPEC.	378	2		1	1	7	30	26	33	98	108	71	1				
0449 : ***UNRECONCILABLE CODE***	1												1				
0449Z : HIV INFECTION (DISEASE), OR OTHER HIV INFE.	860	2		1	1	11	35	81	170	178	243	133	5				
0586Z : ***UNRECONCILABLE CODE***	1			1													
135Z : SARCOIDOSIS	50	3		1	1	2		3	12	7	13	8					
18 AN : ***UNRECONCILABLE CODE***	1	1															
1890 : ***UNRECONCILABLE CODE***	3												2		1		
1890B : Renal tumor (malignant)	1,105	33	10	16	15	23	12	16	11	20	20	92	245	225	256	111	
1890Z : CANCER OF KIDNEY, EXCEPT PELVIS	726	3	1	1	4	6	7	56	163	186	175	122	2				
1891Z : CANCER OF RENAL PELVIS (CALYX, HILUS)	50							4	14	17	7	8					
1899A : Urinary tract tumor (malignant)	313												81	95	94	43	
1899Z : ***UNRECONCILABLE CODE***	4											4					
189Z : CANCER OF KIDNEY AND OTHER UNSPECIFIED URINARY ORGAN.	949	204	100	111	96	125	162	116	15	7	6	7					
19Z : ***UNRECONCILABLE CODE***	1							1									
20 : ***UNRECONCILABLE CODE***	1													1			
20280A : Lymphoma of kidneys	119	2	1	3	1	3	1	4		1	1	8	25	23	34	12	
20280Z : ***UNRECONCILABLE CODE***	1											1					
20283Z : LYMPHOMA, INTRA-ABDOMINAL	16							1	5	2	5	3					
20285Z : LYMPHOMA, INGUINAL REGION	12							2	3	5	1	1					
20286Z : LYMPHOMA, INTRAPELVIC	1											1					
2028Z : LYMPHOMAS	65	15	9	7	10	7	8	6		2	1						
2030 : ***UNRECONCILABLE CODE***	3												2	1			
2030A : Multiple myeloma	2,885	101	28	25	33	36	28	34	22	39	55	245	607	669	671	292	
2030B : Light chain nephropathy	293	1		1	1	1	1	3	1	1	1	71	87	92	31		
2030Z : MULTIPLE MYELOMA / LIGHT CHAIN DISEASE	4,102	673	258	280	285	310	356	355	399	449	428	308	1				
203Z : MULTIPLE MYELOMA AND IMMUNOPROLIFERATIVE NEOPLASMS	422	422															
20540Z : ***UNRECONCILABLE CODE***	1						1										
20541Z : ***UNRECONCILABLE CODE***	1											1					
20Z : ***UNRECONCILABLE CODE***	1							1									
21Z : ***UNRECONCILABLE CODE***	2						1	1									
2230A : Renal tumor (benign)	24	1										1	5	8	8	1	
2239A : Urinary tract tumor (benign)	27									1	1		7	9	5	4	
22Z : ***UNRECONCILABLE CODE***	1						1										
23 01Z : ***UNRECONCILABLE CODE***	1									1							

(CONTINUED)

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.



Table A.36 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Detailed Disease Code and Year of First ESRD Service

Detailed Primary Disease	Year of First ESRD Service															
	ALL	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	
, 23 LU : ***UNRECONCILABLE CODE***	1											1				
, 23 SY : ***UNRECONCILABLE CODE***	1			1												
, 2395A : Renal tumor (unspecified)	55		1									13	14	23	4	
, 2395B : Urinary tract tumor (unspecified)	29											5	8	13	3	
, 25000 : ***UNRECONCILABLE CODE***	188											104	81	3		
, 25000A: Type II, adult-onset type or unspecified type diabet	106,543	2,389	891	1,052	1,194	972	704	732	857	1,045	1,730	6,713	21,665	26,222	28,552	11,825
, 25000Z: DIABETES, ADULT / DIABETES TYPE II / NIDDM	29,971	339	126	228	681	2,929	3,685	4,254	4,648	4,742	4,809	3,368	162			
, 25001 : ***UNRECONCILABLE CODE***	178											104	73	1		
, 25001A: Type I, juvenile type, ketosis prone diabetes	31,683	239	106	134	198	685	551	613	669	978	1,432	5,466	7,615	6,027	5,175	1,795
, 25001Z: JUVENILE ONSET DIABETES MELLITUS / DIABETES TYPE I /	23,457	456	185	229	464	1,759	2,422	3,109	3,441	3,916	4,169	3,134	172	1		
, 2500A : ***UNRECONCILABLE CODE***	116	3		4	5	2	5	6	8	51	13	16	2	1		
, 2500Z : DIABETES	15,933	7,290	2,690	2,979	2,924	47	1	2								
, 2501Z : DIABETES (CODE NOT IN HCFA LISTS).	79	79														
, 25040 : ***UNRECONCILABLE CODE***	15											7	7	1		
, 25040Z: DIABETES WITH RENAL MANIFESTATIONS TYPE II	32,265	215	86	143	660	3,267	4,044	4,085	5,153	5,705	4,961	3,928	17	1		
, 25041 : ***UNRECONCILABLE CODE***	25											11	14			
, 25041Z: DIABETES WITH RENAL MANIFESTATIONS TYPE I	27,451	261	84	115	444	2,312	3,275	3,739	4,246	4,848	4,570	3,526	31			
, 2504Z : DIABETES WITH RENAL MANIFESTATIONS	31,918	19,016	4,087	4,646	4,095	69	2	1		2						
, 25090Z: ***UNRECONCILABLE CODE***	1	1														
, 2700 : ***UNRECONCILABLE CODE***	1													1		
, 2700A : Cystinosis	77	12	1	5	4	3	2	3	3	2	3	3	12	8	13	3
, 2700Z : CYSTINOSIS, MALIGNANT	109	37	3	9	6	3	6	8	9	13	6	9				
, 2718B : Primary oxalosis	80	6	1	1	1	2		1	1	2	5	17	13	11	15	4
, 2718Z : OXALATE NEPHROPATHY / OXALOSIS	226	61	16	19	17	17	9	19	20	23	18	7				
, 2727A : Fabry's disease	76	6		3	3	1	2	1	2	4		11	10	18	11	4
, 2727Z : FABRY'S DISEASE	122	27	9	4	12	8	10	9	7	15	10	11				
, 2728Z : ***UNRECONCILABLE CODE***	1					1										
, 2733Z : MACROGLOBULINEMIA	22					1		1	6	5	5	4				
, 27410 : ***UNRECONCILABLE CODE***	1													1		
, 27410A: Gouty nephropathy	199	19	6	2	2	5	3	2		3	2	15	37	37	50	16
, 27410Z: GOUTY NEPHROPATHY, UNSPECIFIED	47						3	4	10	13	10	7				
, 27411Z: URATE NEPHROPATHY / URIC ACID NEPHROLITHIASIS	37							4	7	11	8	7				
, 2741Z : GOUTY NEPHROPATHY / URATE NEPHROPATHY	388	247	30	25	16	20	18	18	8	2	1	3				
, 2754A : Nephrocalcinosis	204	2							1	1	2	2	62	58	56	20
, 2754Z : ***UNRECONCILABLE CODE***	1	1														
, 2773 : ***UNRECONCILABLE CODE***	2												2			
, 2773A : Amyloidosis	1,035	47	12	15	19	20	12	9	13	8	25	85	207	238	241	84
, 2773Z : AMYLOIDOSIS	1,978	538	130	131	140	125	141	151	178	176	145	119	3		1	
, 2820Z : ***UNRECONCILABLE CODE***	1				1											
, 28260 : ***UNRECONCILABLE CODE***	1													1		
, 28260A: Sickle cell disease/anemia	311	2	3	2	4	2	3	1	1	5	6	25	78	77	72	30
, 28260Z: SICKLE-CELL ANEMIA, UNSPECIFIED	157	1		1	3	3		11	26	41	41	30				

(CONTINUED)

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.36 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Detailed Disease Code and Year of First ESRD Service

Detailed Primary Disease	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
28263Z: SICKLE CELL/HB-C DISEASE (HB-S/HB-C DISEASE)	29							3	4	9	6	7				
28269A: Sickle cell trait and other sickle cell (HbS/Hb othe	31	1			1						2	10	2	4	8	3
28269Z: OTHER SICKLE CELL (INCLUDES: HB-S/HB-D DISEASE, HB-S	6									1	2	3				
2826A : ***UNRECONCILABLE CODE***	1										1					
2826Z : SICKLE CELL DISEASE	268	74	31	25	32	16	49	33	6	1		1				
2831 : ***UNRECONCILABLE CODE***	1														1	
2831A: Hemolytic uremic syndrome	699	29	4	3	12	11	8	16	11	9	28	82	149	154	135	48
2831Z: HEMOLYTIC UREMIC SYNDROME	750	150	46	35	46	57	73	58	77	78	73	55	2			
2870 : ***UNRECONCILABLE CODE***	3												1	2		
2870A: Henoch-Schonlein syndrome	174	15	4	4	3	3	3	5	4	10	5	16	31	37	20	14
2870Z: HENOCH-SCHONLEIN SYNDROME	210	55	11	14	11	18	8	20	21	19	21	12				
2873Z: AMYLOIDOSIS (CODE NOT IN CURRENT HCFA LISTS--ASSUMED	11	11														
29 AL : ***UNRECONCILABLE CODE***	1	1														
29Z : ***UNRECONCILABLE CODE***	2								1	1						
30400Z: ***UNRECONCILABLE CODE***	1	1														
4010 : ***UNRECONCILABLE CODE***	1												1			
4010D: ***UNRECONCILABLE CODE***	1												1			
4010Z: MALIGNANT HYPERTENSION	1,643	491	101	118	98	116	122	134	124	132	108	99				
4011 : ***UNRECONCILABLE CODE***	1												1			
4011Z: BENIGN HYPERTENSION	88	5	3	4	3	5	6	10	8	26	9	9				
4019 : ***UNRECONCILABLE CODE***	39												19	20		
4019Z: ESSENTIAL HYPERTENSION, UNSPECIFIED	49,623	5,863	2,454	2,671	3,228	3,474	4,142	4,850	5,632	6,231	6,191	4,857	30			
401Z : ESSENTIAL HYPERTENSION	13,264	13,264														
40301Z: ***UNRECONCILABLE CODE***	1										1					
4030Z: NEPHROSCLEROSIS, MALIGNANT / HYPERTENSIVE RENAL DISE	1,378	178	120	114	133	90	81	66	102	134	183	176	1			
4031Z: NEPHROSCLEROSIS, BENIGN / HYPERTENSIVE RENAL DISEASE	848	87	31	35	46	65	57	55	92	129	131	119	1			
4039 : ***UNRECONCILABLE CODE***	213												110	92	10	1
40391Z: ***UNRECONCILABLE CODE***	6	2					1	1	2							
40399 : ***UNRECONCILABLE CODE***	1													1		
4039A : ***UNRECONCILABLE CODE***	1													1		
4039D: Renal disease due to hypertension (no primary renal	81,413	3,179	903	1,050	1,176	1,418	1,029	1,093	992	1,369	2,143	8,360	16,675	17,141	17,693	7,192
4039Z: NEPHROSCLEROSIS / HYPERTENSIVE RENAL DISEASE / OTHER	69,883	7,975	3,845	4,144	4,649	5,355	6,970	7,359	7,859	8,508	7,494	5,505	217	2	1	
403Z : HYPERTENSIVE RENAL DISEASE	2,243	2,242	1													
4040Z: HYPERTENSIVE HEART AND RENAL DISEASE, MALIGNANT	147	15	19	5	9	11	11	9	12	20	21	15				
4041Z: HYPERTENSIVE HEART AND RENAL DISEASE, BENIGN	60	6	2	2	1	7	3	4	6	12	7	10				
4049Z: CARDIORENAL SYNDROME / HYPERTENSIVE HEART AND RENAL	1,540	204	51	40	56	121	170	139	169	224	192	174				
404Z : HYPERTENSIVE HEART AND RENAL DISEASE	308	308														
4100 : ***UNRECONCILABLE CODE***	1													1		
4280 : ***UNRECONCILABLE CODE***	1												1			
4280Z: ***UNRECONCILABLE CODE***	1											1				
4289A : ***UNRECONCILABLE CODE***	1											1				
4401 : ***UNRECONCILABLE CODE***	3												3			

(CONTINUED)

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.36 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Detailed Disease Code and Year of First ESRD Service

Detailed Primary Disease	Year of First ESRD Service															
	ALL	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	
.4401A : Renal artery stenosis	4,166	21	25	18	18	20	21	29	36	48	64	267	913	1,065	1,159	462
.4401Z : STENOSIS, RENAL ARTERY	2,432	98	75	81	100	102	144	221	350	413	495	352	1			
.4431 : ***UNRECONCILABLE CODE***	1													1		
.44310Z : ***UNRECONCILABLE CODE***	1	1														
.4431Z : BUERGERS (BERGERS) DISEASE	376	30	37	21	34	53	54	50	27	26	28	16				
.4460C : Polyarteritis	200	13	1	1	3	4	2	2	1	7		12	44	39	45	26
.4460Z : POLYARTERITIS, RENAL	306	71	27	24	22	15	22	29	22	26	16	31	1			
.4462 : ***UNRECONCILABLE CODE***	1													1		
.44620Z : ***UNRECONCILABLE CODE***	1					1										
.44621Z : ***UNRECONCILABLE CODE***	1										1					
.44629Z : *** CODE IN ERROR: ASSUMED TO BE 4462.	15	15														
.4462A : Vasculitis and its derivatives	936	59	13	14	18	19	14	14	11	12	14	83	169	222	207	67
.4462Z : ANTI- GLOMERULOBASEMENT MEMBRANE GLOMER. / GOODPASTUR.	2,154	973	75	106	132	129	163	138	124	119	116	78	1			
.4464 : ***UNRECONCILABLE CODE***	4												3	1		
.4464B : Wegeners granulomatosis	939	33	6	9	11	10	9	12	14	17	24	108	181	214	209	82
.4464Z : GRANULOMATOSIS / WEGENERS GRANULOMATOSIS / WEGENERS	1,036	156	52	44	55	70	84	92	141	133	127	80	2			
.4466Z : THROMBOTIC THROMBOCYTOPENIC PURPURA	198	16	8	9	12	16	23	20	20	34	26	14				
.4828Z : ***UNRECONCILABLE CODE***	1	1														
.49007Z : ***UNRECONCILABLE CODE***	1	1														
.50000A : ***UNRECONCILABLE CODE***	1											1				
.53831 : ***UNRECONCILABLE CODE***	1												1			
.5724A : Hepatorenal syndrome	404	3		3	1	2	1	2		3	12	23	82	109	127	36
.5724Z : HEPATORENAL SYNDROME	253	19	9	9	9	15	26	25	35	35	40	31				
.5800C : Post infectious GN, SBE	293	20	2	3	9	4	5	3	2	3	5	19	62	65	62	29
.5800Z : GLOMERULONEPHRITIS, ACUTE	222	40	9	11	17	18	30	25	14	13	26	19				
.5804 : ***UNRECONCILABLE CODE***	29												11	17	1	
.58040Z : ***UNRECONCILABLE CODE***	1	1														
.5804B : Rapidly progressive GN	1,509	77	24	28	14	24	27	25	22	25	36	119	291	377	295	125
.5804Z : GLOMERULONEPHRITIS, ACUTE WITH LESION OF RAPIDLY PRO.	1,945	368	150	150	129	151	162	183	172	148	176	128	28			
.58089 : ***UNRECONCILABLE CODE***	7												2	5		
.58089A : Acute interstitial nephritis	489	7	4	3	3	5	5	3		6	6	24	115	119	121	68
.58089Z : ACUTE INTERSTITIAL NEPHRITIS	191	27	11	9	5	14	13	18	21	22	26	23	2			
.5809Z : ACUTE GLOMERULONEPHRITIS WITH UNSPECIFIED PATHOLOGIC.	272	66	19	16	17	20	19	21	25	24	30	15				
.5810A : ***UNRECONCILABLE CODE***	1													1		
.5811 : ***UNRECONCILABLE CODE***	10												5	4	1	
.5811Z : FOCAL GLOMERULONEPHRITIS / FOCAL GLOMERULOSCLEROSIS	2,173	398	115	113	130	190	224	208	224	217	193	150	10	4		
.5818 : ***UNRECONCILABLE CODE***	1														1	
.5818Z : FOCAL GLOMERULOSCLEROSIS WITH NEPHROTIC SYNDROME	121	4	1	1	1		1	7	17	26	33	28	2			
.5819 : ***UNRECONCILABLE CODE***	3												2		1	
.5819A : ***UNRECONCILABLE CODE***	1										1					
.5819Z : NEPHROTIC SYNDROME / NEPHROSIS	2,294	418	123	124	152	159	175	247	246	262	210	171	6	1		
.5820 : ***UNRECONCILABLE CODE***	1													1		

(CONTINUED)

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.36 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Detailed Disease Code and Year of First ESRD Service

Detailed Primary Disease	Year of First ESRD Service															
	ALL	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	
58200Z: ***UNRECONCILABLE CODE***	1											1				
5820A: Other proliferative GN	1,328	53	10	9	19	18	15	22	28	37	45	222	271	249	238	92
5820Z: ***UNRECONCILABLE CODE***	20	2				1	1	1	4	1	6	1	3			
5821: ***UNRECONCILABLE CODE***	28											15	11	2		
58210Z: ***UNRECONCILABLE CODE***	3	1	1					1								
5821A: Focal glomerulosclerosis, focal sclerosing GN	7,554	221	56	59	66	101	98	117	103	123	172	526	1,653	1,831	1,710	718
5821Z: FOCAL GLOMERULOSCLEROSIS	4,553	625	227	241	302	330	389	403	477	574	592	383	9	1		
5824Z: ***UNRECONCILABLE CODE***	5	4							1							
5826A: ***UNRECONCILABLE CODE***	1												1			
58281Z: ***UNRECONCILABLE CODE***	1											1				
58289: ***UNRECONCILABLE CODE***	5												2	2	1	
58289Z: CHRONIC INTERSTITIAL NEPHRITIS / HEREDITARY INTERSTI	8,795	2,851	649	573	601	504	633	596	684	685	564	451	3	1		
5828Z: ***UNRECONCILABLE CODE***	21	19				1	1									
5829: ***UNRECONCILABLE CODE***	76												43	30	3	
58291A: ***UNRECONCILABLE CODE***	1												1			
5829A: Glomerulonephritis (GN)	23,307	2,534	443	479	509	575	502	491	417	515	795	2,401	4,330	4,059	3,806	1,451
5829Z: CHRONIC GLOMERULONEPHRITIS, INCLUDING WITH UNSPECIFI	26,375	6,426	1,613	1,667	1,760	1,894	1,997	2,209	2,374	2,431	2,246	1,717	40	1		
582Z: ***UNRECONCILABLE CODE***	1	1														
5830B: Radiation nephritis	93				1	1				1			19	35	30	6
5830Z: PROLIFERATIVE GLOMERULONEPHRITIS / RADIATION NEPHRIT	636	171	37	37	43	48	48	67	59	49	45	31	1			
5831: ***UNRECONCILABLE CODE***	3												1	2		
5831A: Membranous nephropathy	1,738	70	27	20	21	32	25	29	19	45	36	129	346	397	395	147
5831Z: MEMBRANOUS GLOMERULONEPHRITIS	2,374	505	123	163	188	157	206	193	229	205	243	157	5			
5832: ***UNRECONCILABLE CODE***	8												4	4		
5832A: Membranoproliferative GN type 1, diffuse MPGN	1,474	90	25	26	20	31	26	34	36	29	51	113	255	335	280	123
5832C: Dense deposit disease, MPGN type 2	99	2					2		1	1	2	1	23	26	25	16
5832Z: MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS / MESANGIOC	1,941	515	135	134	115	133	150	161	161	168	164	101	4			
5834: ***UNRECONCILABLE CODE***	4												1	3		
5834C: Goodpastures Syndrome	416	6	1	1		1	2	10	6	9	19	60	89	91	92	29
5834Z: ANTI-GBN GLOMERULONEPHRITIS	299	13	1	7	5	1	1	15	79	64	73	40				
5836: ***UNRECONCILABLE CODE***	2												2			
5836A: Tubular necrosis (no recovery)	3,945	222	37	30	49	45	42	32	27	28	70	316	752	893	1,016	386
5836Z: ***UNRECONCILABLE CODE***	22	3	1				1			2	12	1	2			
5837Z: NEPHRITIS OR NEPHROPATHY WITH RENAL MEDULLARY LESION	244	15	5	10	9	15	11	25	50	56	25	22	1			
58381: ***UNRECONCILABLE CODE***	4												2	2		
58381B: IgA nephropathy, Bergers disease	1,872	14	7	2	7	2	5	13	7	12	5	8	412	594	555	229
58381C: IgM nephropathy	204	2	1		1				1	1		4	71	50	50	23
58381Z: NEPHRITIS AND NEPHROPATHY, NOT SPECIFIED AS ACUTE OR	1,200	92	21	27	27	38	34	90	232	245	207	184	3			
58389: ***UNRECONCILABLE CODE***	16												10	6		
58389A: ***UNRECONCILABLE CODE***	8												6	2		
58389B: Chronic interstitial nephritis	5,360	459	133	143	137	168	91	95	76	101	150	693	1,121	911	759	323
58389Z: ANALGESIC NEPHROPATHY / OTHER INTERST NEPHRITIS / IN	3,601	545	211	300	197	269	331	327	368	387	368	285	13			

(CONTINUED)

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version. \*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form. Diseases are grouped in two ways: Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR. Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.36 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Detailed Disease Code and Year of First ESRD Service

Detailed Primary Disease	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
5838B : ***UNRECONCILABLE CODE***	9	5				1			1			1	1			
5839 : ***UNRECONCILABLE CODE***	14												10	4		
58398Z : ***UNRECONCILABLE CODE***	1								1							
5839B : Secondary GN, other	300	6	1	1	2	5	2		2	5	4	76	87	75	34	
5839C : Nephropathy due to heroin abuse and related drugs	489	31	21	12	20	26	16	18	9	12	22	73	83	74	52	20
5839D : Drash syndrome, mesangial sclerosis	28			1					1				9	2	9	6
5839Z : GLOMERULON. / NEPHRITIS / NEPHROPATHY / BRIGHTS DISE.	30,840	17,487	1,340	1,330	1,407	1,407	1,635	1,515	1,380	1,358	1,179	793	8	1		
5840Z : ***UNRECONCILABLE CODE***	1									1						
5845 : ***UNRECONCILABLE CODE***	3												3			
5845A : ***UNRECONCILABLE CODE***	1												1			
5845Z : NEPHROTOXINS (VARIOUS) / TOXIC NEPHROPATHY (SPECIFY)	2,213	151	80	78	92	123	198	240	297	312	370	264	8			
58500Z : ***UNRECONCILABLE CODE***	4						4									
585Z : CHRONIC RENAL FAILURE / CHRONIC UREMIA / HEROIN ABUS.	1											1				
58600Z : ***UNRECONCILABLE CODE***	1												1			
586Z : RENAL FAILURE, UNSPECIFIED / UREMIA, NOT OTHERWISE S.	3,272	1,205	365	356	440	354	335	190	12	9	3	3				
587 : ***UNRECONCILABLE CODE***	1												1			
5870Z : ***UNRECONCILABLE CODE***	1									1						
587Z : GLOMERULOSCLEROSIS	1,805	302	136	134	168	153	168	174	178	167	129	96				
5890Z : UNILATERAL SMALL KIDNEY	43	5		2		2		1	7	9	11	6				
5891 : ***UNRECONCILABLE CODE***	1													1		
58910A : ***UNRECONCILABLE CODE***	1												1			
5891Z : BILATERAL SMALL KIDNEY	226			3			2	10	43	52	79	37				
5899Z : SMALL KIDNEY, UNSPECIFIED	88	6				2		5	25	26	17	7				
589Z : SMALL KIDNEY OF UNKNOWN CAUSE	255	82	32	26	29	27	27	28	2	1	1					
5900 : ***UNRECONCILABLE CODE***	1												1			
59000Z : ***UNRECONCILABLE CODE***	2												1	1		
59000Z : CHRONIC PYELONEPHRITIS WITHOUT LESION OF RENAL MEDUL.	696	52	8	4	6	12	11	46	148	145	158	103	3			
59001 : ***UNRECONCILABLE CODE***	2												2			
59001Z : PYELONEPHRITIS, CHRONIC WITH LESION OF RENAL MEDULLA.	466	28	4	3	2	5	6	35	115	109	100	58	1			
5900A : Chronic pyelonephritis, reflux nephropathy	1,948	87	12	19	13	23	19	18	21	25	33	128	455	489	447	159
5900Z : CHRONIC PYELONEPHRITIS	3,033	1,249	307	279	254	263	283	243	55	47	34	18	1			
59080Z : PYELONEPHRITIS, UNSPECIFIED / NECROSIS, RENAL (GANGR.	5,587	4,569	167	199	180	170	174	108	14	3	2	1				
5908Z : ***UNRECONCILABLE CODE***	2	1								1						
5909A : Nephropathy caused by other agents	1,161	13	3	3	3	5		4	3	3	5	21	286	322	346	144
5909Z : INFECTIONS OF KIDNEY	131	30	9	10	4	11	11	7	11	12	17	9				
591 : ***UNRECONCILABLE CODE***	1												1			
5910Z : ***UNRECONCILABLE CODE***	1											1				
5919Z : ***UNRECONCILABLE CODE***	1							1								
591Z : HYDRONEPHROSIS	447	93	26	29	30	26	36	39	48	55	42	23				
5920 : ***UNRECONCILABLE CODE***	2												1	1		
5920C : Nephrolithiasis	654	23	6	14	7	13	8	10	4	8	11	34	149	168	136	63
5920Z : CALCULI (RENAL) / NEPHROLITHIASIS / STAGHORN CALCULI.	877	191	62	54	52	65	84	67	90	92	75	45				

(CONTINUED)

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.36 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Detailed Disease Code and Year of First ESRD Service

Detailed Primary Disease	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
.5929B : Urolithiasis	115	1	1			1	2	1	1	1		22	38	35	11	
.5929Z : URINARY CALCULUS, UNSPECIFIED	23	3	3	1	1	3	1	4	2	3						
.5937Z : ***UNRECONCILABLE CODE***	3	2			1											
.59381 : ***UNRECONCILABLE CODE***	2											1	1			
.59381B: Renal artery occlusion	1,964	16	14	11	10	12	8	12	20	29	33	211	434	484	496	174
.59381E: Cholesterol emboli, renal emboli	2,609		1					4	5	5	3	7	581	781	906	316
.59381Z: THROMBOSIS RENAL ARTERY / KIDNEY ARTERY EMBOLISM / O	2,207	126	77	88	105	90	113	153	328	405	412	307	3			
.59389 : ***UNRECONCILABLE CODE***	10												8	2		
.59389A: Other renal disorders	2,977	226	55	68	98	90	51	29	16	19	18	38	556	644	797	272
.59389Z: OBSTRUCTIVE KIDNEY / OBSTRUCTIVE NEPHROPATHY	1,339	57	10	14	23	89	160	186	222	216	201	158	3			
.5938A : ***UNRECONCILABLE CODE***	1							1								
.5990 : ***UNRECONCILABLE CODE***	3												1	2		
.5990Z : URINARY TRACT INFECTION, SITE NOT SPECIFIED	1,614	30	2	6	11	15	19	101	378	430	354	263	5			
.5996 : ***UNRECONCILABLE CODE***	2												1	1		
.5996A : Acquired obstructive uropathy	3,779	234	54	61	63	66	61	43	40	59	85	357	723	816	788	329
.5996C : ***UNRECONCILABLE CODE***	1												1			
.5996Z : URINARY OBSTRUCTION, UNSPECIFIED / OBSTRUCTIVE UROPA	858	55	4	4	7	12	11	63	170	195	200	136	1			
.599Z : OBSTRUCTIVE UROPATHY, ACQUIRED / URINARY OBSTRUCTION	4,603	2,115	447	443	426	398	400	310	43	7	4	10				
.600Z : HYPERPLASIA OF PROSTATE	12	1	2	1	2	1	1	2	1	1						
.64620A: Post partum renal failure	72	7				1	1	1		4	6	8	11	11	15	7
.64620Z: RENAL FAILURE (IN PREGNANCY, CHILDBIRTH, PUERPERIUM)	31	1	1			2	2	2	7	3	5	8				
.6462Z : RENAL FAILURE (IN PREGNANCY, CHILDBIRTH, PUERPERIUM)	47	18	4	7	3	5	8	2								
.6954Z : LUPUS ERYTHEMATOSUS	476	116	23	21	25	32	46	45	47	58	45	18				
.7100 : ***UNRECONCILABLE CODE***	16												5	10	1	
.71000Z: ***UNRECONCILABLE CODE***	1			1												
.7100E : Lupus erythematosus, (SLE nephritis)	4,407	168	44	68	83	89	71	96	93	91	151	442	863	908	883	357
.7100Z : SYSTEMIC LUPUS ERYTHEMATOSUS / LUPUS NEPHRITIS	5,737	966	361	380	412	434	510	519	567	597	591	390	10			
.7101 : ***UNRECONCILABLE CODE***	5												3	2		
.71010Z: ***UNRECONCILABLE CODE***	1							1								
.7101B : Scleroderma	746	40	12	8	7	11	10	8	4	9	20	71	157	173	158	58
.7101Z : SCLERODERMA	1,476	513	101	82	86	86	100	98	102	131	96	78	3			
.7140Z : RHEUMATOID ARTHRITIS	58	11	5	4	2	3	5	3	9	7	7	2				
.72889Z: RAMBDOMYOLYSIS	101	1					1	5	22	26	30	16				
.73513Z: ***UNRECONCILABLE CODE***	1						1									
.7530 : ***UNRECONCILABLE CODE***	6												4	2		
.7530A : ***UNRECONCILABLE CODE***	4									1		1	1	1		
.7530B : Renal hypoplasia, dysplasia, oligonephronia	939	108	21	23	28	35	34	26	28	33	39	77	138	169	144	36
.7530Z : HYPOPLASIA KIDNEY DISEASE / SOLITARY KIDNEY	595	171	42	34	33	32	60	39	62	43	49	26	4			
.7531 : ***UNRECONCILABLE CODE***	22												13	9		
.75313 : ***UNRECONCILABLE CODE***	23												11	12		
.75313A: Polycystic kidneys, adult type (dominant)	9,129	682	141	180	186	179	126	165	150	197	299	831	1,831	1,750	1,722	690
.75313Z: ***UNRECONCILABLE CODE***	264	51	2	4	7	17	13	21	22	19	69	23	16			

(CONTINUED)

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.36 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Detailed Disease Code and Year of First ESRD Service

Detailed Primary Disease	Year of First ESRD Service															
	ALL	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	
,75314A: Polycystic, infantile (recessive)	145,	6,	1,	2,	2,	1,	2,	1,	2,	1,	27,	41,	39,	21,		
,75316A: Medullary cystic disease, including nephronophthisis,	171,	9,	7,	2,	1,	4,	1,	6,	43,	48,	34,	15,				
,7531A : ***UNRECONCILABLE CODE***	21,	10,	1,	2,	4,	2,	2,	1,	2,	2,	1,	1,	1,			
,7531B : ***UNRECONCILABLE CODE***	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,			
,7531Z : CYSTIC KIDNEY DISEASE / MEDULLARY CYSTIC, MULTICYSTIC,	19,071,	7,325,	1,012,	1,065,	1,081,	1,094,	1,175,	1,291,	1,362,	1,419,	1,272,	943,	28,	4,		
,7532 : ***UNRECONCILABLE CODE***	7,	7,	7,	7,	7,	7,	7,	7,	7,	7,	7,	7,	7,			
,7532A : Congenital obstructive uropathy	1,210,	137,	10,	11,	22,	24,	21,	29,	22,	25,	47,	132,	241,	223,	209,	57,
,7532Z : OBSTRUCTIVE DEFECTS OF RENAL PELVIS AND URETER	306,	62,	16,	15,	23,	10,	17,	29,	35,	49,	30,	13,	7,	1,	1,	
,7533A : Congenital nephrotic syndrome	159,	8,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	
,7533Z : CALCULI RENAL, CONGENITAL / OBSTRUCTIVE UROPATHY, CO,	1,152,	720,	70,	46,	65,	67,	83,	59,	14,	13,	8,	7,	1,	1,	1,	
,7535Z : ***UNRECONCILABLE CODE***	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	
,7536A : ***UNRECONCILABLE CODE***	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	
,7539 : ***UNRECONCILABLE CODE***	2,	2,	2,	2,	2,	2,	2,	2,	2,	2,	2,	2,	2,	2,	2,	
,7539Z : DYSPLASIA (ANOMALY) OF KIDNEY	782,	181,	67,	55,	63,	58,	64,	67,	81,	58,	55,	29,	4,	1,	1,	
,753Z : CONGENITAL ANOMALIES OF URINARY SYSTEM / RENAL AGENE,	336,	124,	34,	37,	38,	28,	38,	35,	2,	1,	1,	1,	1,	1,	1,	
,7564Z : ***UNRECONCILABLE CODE***	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	
,7567 : ***UNRECONCILABLE CODE***	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	
,7567A : Prune belly syndrome	92,	5,	2,	1,	1,	1,	1,	1,	1,	1,	2,	24,	26,	24,	4,	
,7567Z : ***UNRECONCILABLE CODE***	5,	5,	5,	5,	5,	5,	5,	5,	5,	5,	5,	5,	5,	5,	5,	
,7595A : Tuberous sclerosis	118,	1,	1,	1,	1,	1,	2,	1,	1,	4,	3,	10,	26,	29,	24,	17,
,7595Z : TUBEROUS SCLEROSIS	91,	1,	1,	1,	1,	1,	6,	16,	34,	20,	13,	1,	1,	1,	1,	
,7598 : ***UNRECONCILABLE CODE***	5,	5,	5,	5,	5,	5,	5,	5,	5,	5,	5,	5,	5,	5,	5,	
,7598A : Hereditary nephritis, Alports syndrome	740,	80,	15,	16,	18,	16,	9,	20,	15,	19,	22,	58,	121,	142,	126,	63,
,7598B : Hereditary/familial nephropathy	194,	3,	1,	2,	1,	1,	1,	1,	1,	1,	1,	59,	67,	45,	15,	
,7598Z : ALPORTS SYNDROME	1,020,	320,	47,	57,	55,	75,	89,	68,	91,	79,	78,	60,	1,	1,	1,	
,7777Z : ***UNRECONCILABLE CODE***	3,	3,	3,	3,	3,	3,	3,	3,	3,	3,	3,	3,	3,	3,	3,	
,7999 : ***UNRECONCILABLE CODE***	56,	56,	56,	56,	56,	56,	56,	56,	56,	56,	56,	56,	56,	56,	56,	
,7999A : Etiology uncertain	15,336,	1,226,	233,	311,	376,	403,	241,	237,	244,	333,	512,	1,427,	2,654,	2,979,	2,949,	1,211,
,7999Z : CAUSE UNKNOWN	24,687,	8,735,	1,141,	1,274,	1,507,	1,570,	1,583,	1,731,	2,000,	2,214,	1,783,	1,131,	17,	1,	1,	
,8660A : Traumatic or surgical loss of kidney(s)	293,	6,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	
,8660Z : ***UNRECONCILABLE CODE***	2,	2,	2,	2,	2,	2,	2,	2,	2,	2,	2,	2,	2,	2,	2,	
,8888Z : ***UNRECONCILABLE CODE***	3,	3,	3,	3,	3,	3,	3,	3,	3,	3,	3,	3,	3,	3,	3,	
,8888Z : DIAGNOSIS NOT ON CODING LIST	29,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	
,8999Z : CAUSE UNKNOWN [CODE IN ERROR--ASSUMED TO BE 7999]	3,773,	3,773,	3,773,	3,773,	3,773,	3,773,	3,773,	3,773,	3,773,	3,773,	3,773,	3,773,	3,773,	3,773,	3,773,	
,935Z : ***UNRECONCILABLE CODE***	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	
,9654Z : AROMATIC ANALGESICS, PHENACETIN (ACETOPHENETIDIN)	459,	450,	1,	2,	1,	1,	2,	2,	2,	2,	2,	2,	2,	2,	2,	
,9659A : Analgesic abuse	663,	33,	3,	3,	6,	2,	2,	2,	2,	4,	3,	22,	148,	179,	182,	72,
,9659Z : ANALGESIC ABUSE (SPECIFY)	372,	129,	29,	27,	32,	25,	29,	21,	22,	27,	23,	8,	1,	1,	1,	
,9778Z : RHABDOMYOLYSIS (X-RAY DYE REACTION)	84,	1,	1,	1,	1,	1,	6,	21,	21,	19,	16,	1,	1,	1,	1,	
,982B : ***UNRECONCILABLE CODE***	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	
,9828Z : ETHYLENE GLYCOL INGESTION	34,	1,	2,	1,	1,	2,	5,	7,	7,	6,	2,	1,	1,	1,	1,	
,9849A : Lead nephropathy	61,	1,	1,	1,	1,	1,	1,	1,	1,	1,	1,	14,	17,	19,	8,	

(CONTINUED)

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.36 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Detailed Disease Code and Year of First ESRD Service

Detailed Primary Disease	Year of First ESRD Service															
	ALL	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	
99680A: Complication post bone marrow or other transplant	306	51	4	5	7	5	8	5	1	2	7	3	41	63	79	25
99680Z: ***UNRECONCILABLE CODE***	4	..	..	1	1	1	..	1	..	..	..	..	..	..	..	..
99681Z: REJECTION, TRANSPLANT, KIDNEY	708	470	80	63	37	24	23	6	2	..	3	..	..	..	..	..
9968A: ***UNRECONCILABLE CODE***	1	1	..	..	..	..	..	..	..	..	..	..	..	..	..	..
9968Z: REJECTION, TRANSPLANT	306	277	12	7	9	1	..	..	..	..	..	..	..	..	..	..
99985Z: ***UNRECONCILABLE CODE***	9	9	..	..	..	..	..	..	..	..	..	..	..	..	..	..
99999Z: CAUSE UNKNOWN	1,558	1,106	93	80	125	57	7	24	14	18	25	8	1	..	..	..
OTHER: ***UNRECONCILABLE CODE***	88	40	1	2	1	4	2	6	8	4	10	4	4	2	..	..
RNS: ***UNRECONCILABLE CODE***	15	6	2	..	3	1	..	2	1	..	..	..	..	..	..	..
UNK: ***UNRECONCILABLE CODE***	58	14	..	6	2	9	9	14	2	1	..	1	..	..	..	..
UUUUUZ: ***UNRECONCILABLE CODE***	413	413	..	..	..	..	..	..	..	..	..	..	..	..	..	..
UZ: ***UNRECONCILABLE CODE***	204	204	..	..	..	..	..	..	..	..	..	..	..	..	..	..

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version. \*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form. Diseases are grouped in two ways: Table A. 37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR. Tables A. 38-A. 39 use the two levels of disease groups used only in Reference Tables A. 15-A. 22.



Table A.37  
 Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service  
 Using 8-Group Classification Used in Most ADR Tables

Primary Disease Group 1: Diabetes

Detailed Primary Disease	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
ALL	299,300	30,284	8,255	9,526	10,660	12,040	14,684	16,533	19,016	21,234	21,673	26,135	29,662	32,251	33,727	13,620
,25000A: Type II, adult-onset type or unspecified type diabet	106,543	2,389	891	1,052	1,194	972	704	732	857	1,045	1,730	6,713	21,665	26,222	28,552	11,825
,25000Z: DIABETES, ADULT / DIABETES TYPE II / NIDDM	29,971	339	126	228	681	2,929	3,685	4,254	4,648	4,742	4,809	3,368	162	..	..	..
,25001A: Type I, juvenile type, ketosis prone diabetes	31,683	239	106	134	198	685	551	613	669	978	1,432	5,466	7,615	6,027	5,175	1,795
,25001Z: JUVENILE ONSET DIABETES MELLITUS / DIABETES TYPE I /	23,457	456	185	229	464	1,759	2,422	3,109	3,441	3,916	4,169	3,134	172	1	..	..
,2500Z : DIABETES	15,933	7,290	2,690	2,979	2,924	47	1	..	2	..	..	..	..	..	..	..
,2501Z : DIABETES (CODE NOT IN HCFA LISTS).	79	79	..	..	..	..	..	..	..	..	..	..	..	..	..	..
,25040Z: DIABETES WITH RENAL MANIFESTATIONS TYPE II	32,265	215	86	143	660	3,267	4,044	4,085	5,153	5,705	4,961	3,928	17	1	..	..
,25041Z: DIABETES WITH RENAL MANIFESTATIONS TYPE I	27,451	261	84	115	444	2,312	3,275	3,739	4,246	4,848	4,570	3,526	31	..	..	..
,2504Z : DIABETES WITH RENAL MANIFESTATIONS	31,918	19,016	4,087	4,646	4,095	69	2	1	..	..	2	..	..	..	..	..

Primary Disease Group 2: Hypertension

Detailed Primary Disease	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
ALL	235,816	34,078	7,722	8,381	9,632	10,886	12,877	14,138	15,735	17,685	17,486	20,468	18,856	19,473	20,255	8,144
,4010Z : MALIGNANT HYPERTENSION	1,643	491	101	118	98	116	122	134	124	132	108	99	..	..	..	..
,4011Z : BENIGN HYPERTENSION	88	5	3	4	3	5	6	10	8	26	9	9	..	..	..	..
,4019Z : ESSENTIAL HYPERTENSION, UNSPECIFIED	49,623	5,863	2,454	2,671	3,228	3,474	4,142	4,850	5,632	6,231	6,191	4,857	30	..	..	..
,401Z : ESSENTIAL HYPERTENSION	13,264	13,264	..	..	..	..	..	..	..	..	..	..	..	..	..	..
,4030Z : NEPHROSCLEROSIS, MALIGNANT / HYPERTENSIVE RENAL DISE.	1,378	178	120	114	133	90	81	66	102	134	183	176	1	..	..	..
,4031Z : NEPHROSCLEROSIS, BENIGN / HYPERTENSIVE RENAL DISEASE	848	87	31	35	46	65	57	55	92	129	131	119	1	..	..	..
,4039D: Renal disease due to hypertension (no primary renal)	81,413	3,179	903	1,050	1,176	1,418	1,029	1,093	992	1,369	2,143	8,360	16,675	17,141	17,693	7,192
,4039Z: NEPHROSCLEROSIS / HYPERTENSIVE RENAL DISEASE / OTHER	69,883	7,975	3,845	4,144	4,649	5,355	6,970	7,359	7,859	8,508	7,494	5,505	217	2	1	..
,403Z : HYPERTENSIVE RENAL DISEASE	2,243	2,242	1	..	..	..	..	..	..	..	..	..	..	..	..	..
,4040Z : HYPERTENSIVE HEART AND RENAL DISEASE, MALIGNANT	147	15	19	5	9	11	11	9	12	20	21	15	..	..	..	..
,4041Z : HYPERTENSIVE HEART AND RENAL DISEASE, BENIGN	60	6	2	2	1	7	3	4	6	12	7	10	..	..	..	..
,4049Z: CARDIORENAL SYNDROME / HYPERTENSIVE HEART AND RENAL	1,540	204	51	40	56	121	170	139	169	224	192	174	..	..	..	..
,404Z : HYPERTENSIVE HEART AND RENAL DISEASE	308	308	..	..	..	..	..	..	..	..	..	..	..	..	..	..
,4401A: Renal artery stenosis	4,166	21	25	18	18	20	21	29	36	48	64	267	913	1,065	1,159	462
,4401Z: STENOSIS, RENAL ARTERY	2,432	98	75	81	100	102	144	221	350	413	495	352	1	..	..	..
,59381B: Renal artery occlusion	1,964	16	14	11	10	12	8	12	20	29	33	211	434	484	496	174
,59381E: Cholesterol emboli, renal emboli	2,609	..	1	..	..	..	..	4	5	5	3	7	581	781	906	316
,59381Z: THROMBOSIS RENAL ARTERY / KIDNEY ARTERY EMBOLISM / 0	2,207	126	77	88	105	90	113	153	328	405	412	307	3	..	..	..

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.  
 \*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form  
 Diseases are grouped in two ways:  
 Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.  
 Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.37 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service  
 Using 8-Group Classification Used in Most ADR Tables

Primary Disease Group 3: Glomeruloneph.

Detailed Primary Disease	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
ALL	116,404	31,145	4,601	4,748	5,098	5,479	5,962	6,187	6,254	6,485	6,526	7,430	7,920	8,079	7,508	2,982
,4431Z : BUERGERS (BERGERS) DISEASE	376	30	37	21	34	53	54	50	27	26	28	16	..	..	..	..
,44629Z: *** CODE IN ERROR: ASSUMED TO BE 4462.	15	15	..	..	..	..	..	..	..	..	..	..	..	..	..	..
,4462Z : ANTI- GLOMERULOBASEMENT MEMBRANE GLOMER. / GOODPASTUR	2,154	973	75	106	132	129	163	138	124	119	116	78	1	..	..	..
,5800C : Post infectious GN, SBE	293	20	2	3	9	4	5	3	2	3	5	19	62	65	62	29
,5800Z : GLOMERULONEPHRITIS, ACUTE	222	40	9	11	17	18	30	25	14	13	26	19	..	..	..	..
,5804B : Rapidly progressive GN	1,509	77	24	28	14	24	27	25	22	25	36	119	291	377	295	125
,5804Z : GLOMERULONEPHRITIS, ACUTE WITH LESION OF RAPIDLY PRO	1,945	368	150	150	129	151	162	183	172	148	176	128	28	..	..	..
,5809Z : ACUTE GLOMERULONEPHRITIS WITH UNSPECIFIED PATHOLOGIC	272	66	19	16	17	20	19	21	25	24	30	15	..	..	..	..
,5811Z : FOCAL GLOMERULONEPHRITIS / FOCAL GLOMERULOSCLEROSIS	2,173	398	115	113	130	190	224	208	224	217	193	150	10	1	..	..
,5818Z : FOCAL GLOMERULOSCLEROSIS WITH NEPHROTIC SYNDROME	121	4	1	1	1	..	1	7	17	26	33	28	2	..	..	..
,5819Z : NEPHROTIC SYNDROME / NEPHROSIS	2,294	418	123	124	152	159	175	247	246	262	210	171	6	1	..	..
,5820A : Other proliferative GN	1,328	53	10	9	19	18	15	22	28	37	45	222	271	249	238	92
,5820Z : ***UNRECONCILABLE CODE***	20	2	..	..	..	1	1	1	4	1	6	1	3	..	..	..
,5821A : Focal glomerulosclerosis, focal sclerosing GN	7,554	221	56	59	66	101	98	117	103	123	172	526	1,653	1,831	1,710	718
,5821Z : FOCAL GLOMERULOSCLEROSIS	4,553	625	227	241	302	330	389	403	477	574	592	383	9	1	..	..
,5829A : Glomerulonephritis (GN)	23,307	2,534	443	479	509	575	502	491	417	515	795	2,401	4,330	4,059	3,806	1,451
,5829Z : CHRONIC GLOMERULONEPHRITIS, INCLUDING WITH UNSPECIFI	26,375	6,426	1,613	1,667	1,760	1,894	1,997	2,209	2,374	2,431	2,246	1,717	40	1	..	..
,5830Z : PROLIFERATIVE GLOMERULONEPHRITIS / RADIATION NEPHRIT	636	171	37	37	43	48	48	67	59	49	45	31	1	..	..	..
,5831A : Membranous nephropathy	1,738	70	27	20	21	32	25	29	19	45	36	129	346	397	395	147
,5831Z : MEMBRANOUS GLOMERULONEPHRITIS	2,374	505	123	163	188	157	206	193	229	205	243	157	5	..	..	..
,5832A : Membranoproliferative GN type 1, diffuse MPGN	1,474	90	25	26	20	31	26	34	36	29	51	113	255	335	280	123
,5832C : Dense deposit disease, MPGN type 2	99	2	..	..	..	..	2	..	1	1	2	1	23	26	25	16
,5832Z : MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS / MESANGIOC	1,941	515	135	134	115	133	150	161	161	168	164	101	4	..	..	..
,5834C : Goodpastures Syndrome	416	6	1	1	..	1	2	10	6	9	19	60	89	91	92	29
,5834Z : ANTI- GBN GLOMERULONEPHRITIS	299	13	1	7	5	1	1	15	79	64	73	40	..	..	..	..
,58381B: IgA nephropathy, Bergers disease	1,872	14	7	2	7	2	5	13	7	12	5	8	412	594	555	229
,58381C: IgM nephropathy	204	2	1	..	1	..	..	..	1	1	..	4	71	50	50	23
,5839Z : GLOMERULON. / NEPHRITIS / NEPHROPATHY / BRIGHTS DISE	30,840	17,487	1,340	1,330	1,407	1,407	1,635	1,515	1,380	1,358	1,179	793	8	1	..	..

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.  
 \*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form  
 Diseases are grouped in two ways:  
 Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.  
 Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.37 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service  
 Using 8-Group Classification Used in Most ADR Tables

Primary Disease Group 4: Cystic Kidney

Detailed Primary Disease	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
ALL	28,780	8,073	1,155	1,257	1,276	1,292	1,316	1,479	1,540	1,638	1,642	1,803	1,945	1,843	1,795	726
,75313A: Polycystic kidneys, adult type (dominant)	9,129	682	141	180	186	179	126	165	150	197	299	831	1,831	1,750	1,722	690
,75313Z: ***UNRECONCILABLE CODE***	264	51	2	4	7	17	13	21	22	19	69	23	16			
,75314A: Polycystic, infantile (recessive)	145	6		1		2	2	1	2	2	1			27	41	39
,75316A: Medullary cystic disease, including nephronophthisis	171	9		7	2			1	4	1	1	6	43	48	34	15
,7531Z: CYSTIC KIDNEY DISEASE / MEDULLARY CYSTIC, MULTICYSTI	19,071	7,325	1,012	1,065	1,081	1,094	1,175	1,291	1,362	1,419	1,272	943	28	4		

Primary Disease Group 5: Other Urologic

Detailed Primary Disease	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
ALL	15,868	2,941	639	647	632	714	800	824	905	916	913	1,054	1,369	1,528	1,419	567
,2230A: Renal tumor (benign)	24	1										1	5	8	8	1
,2239A: Urinary tract tumor (benign)	27									1	1		7	9	5	4
,59000Z: CHRONIC PYELONEPHRITIS WITHOUT LESION OF RENAL MEDUL	696	52	8	4	6	12	11	46	148	145	158	103	3			
,59001Z: PYELONEPHRITIS, CHRONIC WITH LESION OF RENAL MEDULLA	466	28	4	3	2	5	6	35	115	109	100	58	1			
,5900A: Chronic pyelonephritis, reflux nephropathy	1,948	87	12	19	13	23	19	18	21	25	33	128	455	489	447	159
,591Z: HYDRONEPHROSIS	447	93	26	29	30	26	36	39	48	55	42	23				
,5920C: Nephrolithiasis	654	23	6	14	7	13	8	10	4	8	11	34	149	168	136	63
,5920Z: CALCULI (RENAL) / NEPHROLITHIASIS / STAGHORN CALCULU	877	191	62	54	52	65	84	67	90	92	75	45				
,5929B: Urolithiasis	115	1	1			1	2	1	1	1		1	22	38	35	11
,5929Z: URINARY CALCULUS, UNSPECIFIED	23	3	3	1	1	3	1	4	2	2	3					
,59389Z: OBSTRUCTIVE KIDNEY / OBSTRUCTIVE NEPHROPATHY	1,339	57	10	14	23	89	160	186	222	216	201	158	3			
,5996A: Acquired obstructive uropathy	3,779	234	54	61	63	66	61	43	40	59	85	357	723	816	788	329
,5996Z: URINARY OBSTRUCTION, UNSPECIFIED / OBSTRUCTIVE UROPA	858	55	4	4	7	12	11	63	170	195	200	136	1			
,599Z: OBSTRUCTIVE UROPATHY, ACQUIRED / URINARY OBSTRUCTION	4,603	2,115	447	443	426	398	400	310	43	7	4	10				
,600Z: HYPERPLASIA OF PROSTATE	12	1	2	1	2	1	1	2	1	1						

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.37 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service  
 Using 8-Group Classification Used in Most ADR Tables

Primary Disease Group 6: Other Cause Detailed Primary Disease	Year of First ESRD Service																
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	
ALL	93,935	19,093	3,666	3,691	3,804	3,962	4,502	4,570	5,069	5,480	5,443	6,445	8,123	8,438	8,358	3,291	
,0160Z : RENAL TUBERCULOSIS	20	1	..	..	..	..	..	2	4	5	6	2	..	..	..	..	
,0429A : AIDS nephropathy	3,347	2	1	..	1	6	5	11	18	39	65	348	943	845	739	324	
,0429Z : AIDS, OR HIV INFECTION WITH SPECIFIED OR MALIGNANT N.	361	3	..	..	1	10	36	52	74	64	71	45	5	..	..	..	
,0439Z : AIDS-LIKE SYNDROME, OR HIV INFECTION WITH OTHER SPEC.	378	2	..	1	1	7	30	26	33	98	108	71	1	..	..	..	
,0449Z : HIV INFECTION (DISEASE) (ILLNESS), OR OTHER HIV INFE.	860	2	..	1	1	11	35	81	170	178	243	133	5	..	..	..	
,135Z : SARCOIDOSIS	50	3	..	1	1	2	..	3	12	7	13	8	..	..	..	..	
,1890B : Renal tumor (malignant)	1,105	33	10	16	15	23	12	16	11	20	20	92	245	225	256	111	
,1890Z : CANCER OF KIDNEY, EXCEPT PELVIS	726	3	1	1	4	6	7	56	163	186	175	122	2	..	..	..	
,1891Z : CANCER OF RENAL PELVIS (CALYX, HILUS)	50	..	..	..	..	..	..	4	14	17	7	8	..	..	..	..	
,1899A : Urinary tract tumor (malignant)	313	..	..	..	..	..	..	..	..	..	..	81	95	94	43	..	
,1899Z : ***UNRECONCILABLE CODE***	4	..	..	..	..	..	..	..	..	..	4	..	..	..	..	..	
,189Z : CANCER OF KIDNEY AND OTHER UNSPECIFIED URINARY ORGAN,	949	204	100	111	96	125	162	116	15	7	6	7	..	..	..	..	
,20280A : Lymphoma of kidneys	119	2	1	3	1	3	1	4	..	1	1	8	25	23	34	12	
,20283Z : LYMPHOMA, INTRA-ABDOMINAL	16	..	..	..	..	..	..	1	5	2	5	3	..	..	..	..	
,20285Z : LYMPHOMA, INGUINAL REGION	12	..	..	..	..	..	..	2	3	5	1	1	..	..	..	..	
,20286Z : LYMPHOMA, INTRAPELVIC	1	..	..	..	..	..	..	..	..	..	1	..	..	..	..	..	
,2028Z : LYMPHOMAS	65	15	9	7	10	7	8	6	..	2	1	..	..	..	..	..	
,2030A : Multiple myeloma	2,885	101	28	25	33	36	28	34	22	39	55	245	607	669	671	292	
,2030B : Light chain nephropathy	293	1	..	1	1	1	1	1	3	1	1	1	71	87	92	31	
,2030Z : MULTIPLE MYELOMA / LIGHT CHAIN DISEASE	4,102	673	258	280	285	310	356	355	399	449	428	308	1	..	..	..	
,203Z : MULTIPLE MYELOMA AND IMMUNOPROLIFERATIVE NEOPLASMS	422	422	..	..	..	..	..	..	..	..	..	..	..	..	..	..	
,2395A : Renal tumor (unspecified)	55	..	..	1	..	..	..	..	..	..	..	..	13	14	23	4	
,2395B : Urinary tract tumor (unspecified)	29	..	..	..	..	..	..	..	..	..	..	..	5	8	13	3	
,2700A : Cystinosis	77	12	1	5	4	3	2	3	3	2	3	3	12	8	13	3	
,2700Z : CYSTINOSIS, MALIGNANT	109	37	3	9	6	3	6	8	9	13	6	9	..	..	..	..	
,2718B : Primary oxalosis	80	6	1	1	1	2	..	1	1	2	5	17	13	11	15	4	
,2718Z : OXALATE NEPHROPATHY / OXALOSIS	226	61	16	19	17	17	9	19	20	23	18	7	..	..	..	..	
,2727A : Fabry's disease	76	6	..	3	3	1	2	1	2	4	..	11	10	18	11	4	
,2727Z : FABRY'S DISEASE	122	27	9	4	12	8	10	9	7	15	10	11	..	..	..	..	
,2733Z : MACROGLOBULINEMIA	22	..	..	..	..	1	..	1	6	5	5	4	..	..	..	..	
,27410A : Gouty nephropathy	199	19	6	2	2	5	3	2	..	3	2	15	37	37	50	16	
,27410Z : GOUTY NEPHROPATHY, UNSPECIFIED	47	..	..	..	..	..	3	4	10	13	10	7	..	..	..	..	
,27411Z : URATE NEPHROPATHY / URIC ACID NEPHROLITHIASIS	37	..	..	..	..	..	4	7	11	8	7	7	..	..	..	..	
,2741Z : GOUTY NEPHROPATHY / URATE NEPHROPATHY	388	247	30	25	16	20	18	18	8	2	1	3	..	..	..	..	
,2754A : Nephrocalcinosis	204	2	..	..	..	..	..	..	1	1	2	2	62	58	56	20	
,2773A : Amyloidosis	1,035	47	12	15	19	20	12	9	13	8	25	85	207	238	241	84	
,2773Z : AMYLOIDOSIS	1,978	538	130	131	140	125	141	151	178	176	145	119	3	..	1	..	
,28260A : Sickle cell disease/anemia	311	2	3	2	4	2	3	1	1	5	6	25	78	77	72	30	
,28260Z : SICKLE-CELL ANEMIA, UNSPECIFIED	157	1	..	1	3	3	..	11	26	41	41	30	..	..	..	..	
,28263Z : SICKLE-CELL/HB-C DISEASE (HB-S/HB-C DISEASE)	29	..	..	..	..	..	..	3	4	9	6	7	..	..	..	..	
,28269A : Sickle cell trait and other sickle cell (HbS/Hb othe.	31	1	..	1	..	..	..	..	..	..	2	10	2	4	8	3	
,28269Z : OTHER SICKLE-CELL (INCLUDES: HB-S/HB-D DISEASE, HB-S,	6	..	..	..	..	..	..	..	..	1	2	3	..	..	..	..	

(CONTINUED)

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.37 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service  
 Using 8-Group Classification Used in Most ADR Tables

Primary Disease Group 6: Other Cause

Detailed Primary Disease	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
2826Z : SICKLE CELL DISEASE	268,	74,	31,	25,	32,	16,	49,	33,	6,	1,	..	1,	..	..	..	..
2831A : Hemolytic uremic syndrome	699,	29,	4,	3,	12,	11,	8,	16,	11,	9,	28,	82,	149,	154,	135,	48,
2831Z : HEMOLYTIC UREMIC SYNDROME	750,	150,	46,	35,	46,	57,	73,	58,	77,	78,	73,	55,	2,	..	..	..
2870A : Henoch-Schonlein syndrome	174,	15,	4,	4,	3,	3,	3,	5,	4,	10,	5,	16,	31,	37,	20,	14,
2870Z : HENOCH-SCHONLEIN SYNDROME	210,	55,	11,	14,	11,	18,	8,	20,	21,	19,	21,	12,	..	..	..	..
2873Z : AMYLOIDOSIS (CODE NOT IN CURRENT HCFA LISTS--ASSUMED)	11,	11,	..	..	..	..	..	..	..	..	..	..	..	..	..	..
4460C : Polyarteritis	200,	13,	1,	1,	3,	4,	2,	2,	1,	7,	..	12,	44,	39,	45,	26,
4460Z : POLYARTERITIS, RENAL	306,	71,	27,	24,	22,	15,	22,	29,	22,	26,	16,	31,	1,	..	..	..
4462A : Vasculitis and its derivatives	936,	59,	13,	14,	18,	19,	14,	14,	11,	12,	14,	83,	169,	222,	207,	67,
4464B : Wegeners granulomatosis	939,	33,	6,	9,	11,	10,	9,	12,	14,	17,	24,	108,	181,	214,	209,	82,
4464Z : GRANULOMATOSIS / WEGENERS GRANULOMATOSIS / WEGENERS	1,036,	156,	52,	44,	55,	70,	84,	92,	141,	133,	127,	80,	2,	..	..	..
4466Z : THROMBOTIC THROMBOCYTOPENIC PURPURA	198,	16,	8,	9,	12,	16,	23,	20,	20,	34,	26,	14,	..	..	..	..
5724A : Hepatorenal syndrome	404,	3,	..	3,	1,	2,	1,	2,	..	3,	12,	23,	82,	109,	127,	36,
5724Z : HEPATORENAL SYNDROME	253,	19,	9,	9,	9,	15,	26,	25,	35,	35,	40,	31,	..	..	..	..
58089A : Acute interstitial nephritis	489,	7,	4,	3,	3,	5,	5,	3,	..	6,	6,	24,	115,	119,	121,	68,
58089Z : ACUTE INTERSTITIAL NEPHRITIS	191,	27,	11,	9,	5,	14,	13,	18,	21,	22,	26,	23,	2,	..	..	..
58289Z : CHRONIC INTERSTITIAL NEPHRITIS / HEREDITARY INTERSTI	8,795,	2,851,	649,	573,	601,	504,	633,	596,	684,	685,	564,	451,	3,	1,	..	..
5830B : Radiation nephritis	93,	..	..	..	1,	1,	..	..	..	1,	..	..	19,	35,	30,	6,
5836A : Tubular necrosis (no recovery)	3,945,	222,	37,	30,	49,	45,	42,	32,	27,	28,	70,	316,	752,	893,	1,016,	386,
5836Z : ***UNRECONCILABLE CODE***	22,	3,	1,	..	..	..	1,	..	..	2,	12,	1,	2,	..	..	..
5837Z : NEPHRITIS OR NEPHROPATHY WITH RENAL MEDULLARY LESION	244,	15,	5,	10,	9,	15,	11,	25,	50,	56,	25,	22,	1,	..	..	..
58389B : Chronic interstitial nephritis	5,360,	459,	133,	143,	137,	168,	91,	95,	76,	101,	150,	693,	1,121,	911,	759,	323,
58389Z : ANALGESIC NEPHROPATHY / OTHER INTERST NEPHRITIS / IN	3,601,	545,	211,	300,	197,	269,	331,	327,	368,	387,	368,	285,	13,	..	..	..
5839B : Secondary GN, other	300,	6,	1,	1,	..	2,	5,	2,	..	2,	5,	4,	76,	87,	75,	34,
5839C : Nephropathy due to heroin abuse and related drugs	489,	31,	21,	12,	20,	26,	16,	18,	9,	12,	22,	73,	83,	74,	52,	20,
5839D : Drash syndrome, mesangial sclerosis	28,	..	..	1,	..	..	..	1,	..	..	..	..	9,	2,	9,	6,
5845Z : NEPHROTOXINS (VARIOUS) / TOXIC NEPHROPATHY (SPECIFY)	2,213,	151,	80,	78,	92,	123,	198,	240,	297,	312,	370,	264,	8,	..	..	..
585Z : CHRONIC RENAL FAILURE / CHRONIC UREMIA / HEROIN ABUS	1,	..	..	..	..	..	..	..	..	..	..	1,	..	..	..	..
587Z : GLOMERULOSCLEROSIS	1,805,	302,	136,	134,	168,	153,	168,	174,	178,	167,	129,	96,	..	..	..	..
5900Z : CHRONIC PYELONEPHRITIS	3,033,	1,249,	307,	279,	254,	263,	283,	243,	55,	47,	34,	18,	1,	..	..	..
59080Z : PYELONEPHRITIS, UNSPECIFIED / NECROSIS, RENAL (GANGR	5,587,	4,569,	167,	199,	180,	170,	174,	108,	14,	3,	2,	1,	..	..	..	..
5909A : Nephropathy caused by other agents	1,161,	13,	3,	3,	3,	5,	..	4,	3,	3,	5,	21,	286,	322,	346,	144,
5909Z : INFECTIONS OF KIDNEY	131,	30,	9,	10,	4,	11,	11,	7,	11,	12,	17,	9,	..	..	..	..
59389A : Other renal disorders	2,977,	226,	55,	68,	98,	90,	51,	29,	16,	19,	18,	38,	556,	644,	797,	272,
5990Z : URINARY TRACT INFECTION, SITE NOT SPECIFIED	1,614,	30,	2,	6,	11,	15,	19,	101,	378,	430,	354,	263,	5,	..	..	..
64620A : Post partum renal failure	72,	7,	..	..	..	1,	1,	1,	..	4,	6,	8,	11,	11,	15,	7,
64620Z : RENAL FAILURE (IN PREGNANCY, CHILDBIRTH, PUERPERIUM)	31,	1,	1,	..	..	2,	2,	2,	7,	3,	5,	8,	..	..	..	..
6462Z : RENAL FAILURE (IN PREGNANCY, CHILDBIRTH, PUERPERIUM)	47,	18,	4,	7,	3,	5,	8,	2,	..	..	..	..	..	..	..	..
6954Z : LUPUS ERYTHEMATOSUS	476,	116,	23,	21,	25,	32,	46,	45,	47,	58,	45,	18,	..	..	..	..
7100E : Lupus erythematosus, (SLE nephritis)	4,407,	168,	44,	68,	83,	89,	71,	96,	93,	91,	151,	442,	863,	908,	883,	357,
7100Z : SYSTEMIC LUPUS ERYTHEMATOSUS / LUPUS NEPHRITIS	5,737,	966,	361,	380,	412,	434,	510,	519,	567,	597,	591,	390,	10,	..	..	..

(CONTINUED)

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.37 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service  
 Using 8-Group Classification Used in Most ADR Tables

Primary Disease Group 6: Other Cause Detailed Primary Disease	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
, 7101B : Scleroderma	, 746,	40,	12,	8,	7,	11,	10,	8,	4,	9,	20,	71,	157,	173,	158,	58,
, 7101Z : SCLERODERMA	, 1,476,	513,	101,	82,	86,	86,	100,	98,	102,	131,	96,	78,	3,	..	..	..
, 7140Z : RHEUMATOID ARTHRITIS	, 58,	11,	5,	4,	2,	3,	5,	3,	9,	7,	7,	2,	..	..	..	..
, 72889Z : RANBDMYOLYSIS	, 101,	1,	..	..	..	..	1,	5,	22,	26,	30,	16,	..	..	..	..
, 7530B : Renal hypoplasia, dysplasia, oligonephronia	, 939,	108,	21,	23,	28,	35,	34,	26,	28,	33,	39,	77,	138,	169,	144,	36,
, 7530Z : HYPOPLASIA KIDNEY DISEASE / SOLITARY KIDNEY	, 595,	171,	42,	34,	33,	32,	60,	39,	62,	43,	49,	26,	4,	..	..	..
, 7532A : Congenital obstructive uropathy	, 1,210,	137,	10,	11,	22,	24,	21,	29,	22,	25,	47,	132,	241,	223,	209,	57,
, 7532Z : OBSTRUCTIVE DEFECTS OF RENAL PELVIS AND URETER	, 306,	62,	16,	15,	23,	10,	17,	29,	35,	49,	30,	13,	7,	..	..	..
, 7533A : Congenital nephrotic syndrome	, 159,	8,	..	..	1,	1,	..	..	1,	..	2,	..	41,	44,	43,	18,
, 7533Z : CALCULI RENAL, CONGENITAL / OBSTRUCTIVE UROPATHY, CO	, 1,152,	720,	70,	46,	65,	67,	83,	59,	14,	13,	8,	7,	..	..	..	..
, 7539Z : DYSPLASIA (ANOMALY) OF KIDNEY	, 782,	181,	67,	55,	63,	58,	64,	67,	81,	58,	55,	29,	4,	..	..	..
, 753Z : CONGENITAL ANOMALIES OF URINARY SYSTEM / RENAL AGENE	, 336,	124,	34,	37,	38,	28,	38,	35,	2,	..	..	..	..	..	..	..
, 7567A : Prune belly syndrome	, 92,	5,	2,	1,	..	1,	1,	1,	1,	..	..	2,	24,	26,	24,	4,
, 7567Z : ***UNRECONCILABLE CODE***	, 5,	..	..	..	..	..	..	..	..	..	1,	3,	1,	..	..	..
, 7595A : Tuberous sclerosis	, 118,	1,	..	..	..	..	2,	1,	1,	4,	3,	10,	26,	29,	24,	17,
, 7595Z : TUBEROUS SCLEROSIS	, 91,	1,	..	..	..	1,	..	6,	16,	34,	20,	13,	..	..	..	..
, 7598A : Hereditary nephritis, Alports syndrome	, 740,	80,	15,	16,	18,	16,	9,	20,	15,	19,	22,	58,	121,	142,	126,	63,
, 7598B : Hereditary/familial nephropathy	, 194,	3,	..	..	2,	1,	..	..	..	..	1,	1,	59,	67,	45,	15,
, 7598Z : ALPORTS SYNDROME	, 1,020,	320,	47,	57,	55,	75,	89,	68,	91,	79,	78,	60,	1,	..	..	..
, 8660A : Traumatic or surgical loss of kidney(s)	, 293,	6,	..	..	..	..	1,	..	..	1,	2,	..	68,	107,	70,	38,
, 9654Z : AROMATIC ANALGESICS, PHENACETIN (ACETOPHENETIDIN)	, 459,	450,	..	..	2,	..	1,	..	2,	2,	2,	..	..	..	..	..
, 9659A : Analgesic abuse	, 663,	33,	3,	3,	6,	2,	2,	2,	2,	4,	3,	22,	148,	179,	182,	72,
, 9659Z : ANALGESIC ABUSE (SPECIFY)	, 372,	129,	29,	27,	32,	25,	29,	21,	22,	27,	23,	8,	..	..	..	..
, 9778Z : RHABDOMYOLYSIS (X-RAY DYE REACTION)	, 84,	1,	..	..	..	..	..	6,	21,	21,	19,	16,	..	..	..	..
, 9828Z : ETHYLENE GLYCOL INGESTION	, 34,	1,	..	2,	1,	1,	2,	5,	7,	7,	6,	2,	..	..	..	..
, 9849A : Lead nephropathy	, 61,	..	..	..	..	..	..	..	..	..	1,	2,	14,	17,	19,	8,
, 99680A : Complication post bone marrow or other transplant	, 306,	51,	4,	5,	7,	5,	8,	5,	1,	2,	7,	3,	41,	63,	79,	25,
, 99681Z : REJECTION, TRANSPLANT, KIDNEY	, 708,	470,	80,	63,	37,	24,	23,	6,	2,	..	3,	..	..	..	..	..
, 9968Z : REJECTION, TRANSPLANT	, 306,	277,	12,	7,	9,	1,	..	..	..	..	..	..	..	..	..	..

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.37 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service  
 Using 8-Group Classification Used in Most ADR Tables

Primary Disease Group 7: Unknown Cause

Detailed Primary Disease	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
ALL	50,469	16,231	1,885	2,079	2,504	2,453	2,229	2,318	2,580	2,910	2,647	2,814	2,679	2,980	2,949	1,211
58381Z: NEPHRITIS AND NEPHROPATHY, NOT SPECIFIED AS ACUTE OR	1,200	92	21	27	27	38	34	90	232	245	207	184	3			
586Z : RENAL FAILURE, UNSPECIFIED / UREMIA, NOT OTHERWISE S	3,272	1,205	365	356	440	354	335	190	12	9	3	3				
5890Z : UNILATERAL SMALL KIDNEY	43	5		2		2		1	7	9	11	6				
5891Z : BILATERAL SMALL KIDNEY	226			3			2	10	43	52	79	37				
5899Z : SMALL KIDNEY, UNSPECIFIED	88	6				2		5	25	26	17	7				
589Z : SMALL KIDNEY OF UNKNOWN CAUSE	255	82	32	26	29	27	27	28	2	1	1					
7999A : Etiology uncertain	15,336	1,226	233	311	376	403	241	237	244	333	512	1,427	2,654	2,979	2,949	1,211
7999Z : CAUSE UNKNOWN	24,687	8,735	1,141	1,274	1,507	1,583	1,731	2,000	2,214	1,783	1,131	17	1			
8660Z : ***UNRECONCILABLE CODE***	2										2					
8888Z : DIAGNOSIS NOT ON CODING LIST	29	1						2	1	3	7	11	4			
8999Z : CAUSE UNKNOWN [CODE IN ERROR--ASSUMED TO BE 7999]	3,773	3,773														
9999Z : CAUSE UNKNOWN	1,558	1,106	93	80	125	57	7	24	14	18	25	8	1			

Primary Disease Group 8: Missing Cause

Detailed Primary Disease	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
ALL	65,738	39,559	1,132	1,349	1,169	1,606	2,079	1,824	1,316	1,262	3,048	1,601	2,408	2,126	4,254	1,005
***UNRECONCILABLE CODE***	63,276	38,707	1,120	1,324	1,138	1,553	2,022	1,761	1,262	1,225	2,958	1,548	1,781	1,649	4,224	1,004
7900 : ***UNRECONCILABLE CODE***	6												4	2		
7900Z : ***UNRECONCILABLE CODE***	314	106	8	14	16	28	30	28	28	19	20	12	5			
0429 : ***UNRECONCILABLE CODE***	5												2	3		
0439 : ***UNRECONCILABLE CODE***	1												1			
0439D : ***UNRECONCILABLE CODE***	2												1	1		
0449 : ***UNRECONCILABLE CODE***	1												1			
0586Z : ***UNRECONCILABLE CODE***	1			1												
18 AN : ***UNRECONCILABLE CODE***	1	1														
1890 : ***UNRECONCILABLE CODE***	3												2		1	
19Z : ***UNRECONCILABLE CODE***	1							1								
20 : ***UNRECONCILABLE CODE***	1													1		
20280Z : ***UNRECONCILABLE CODE***	1											1				
2030 : ***UNRECONCILABLE CODE***	3												2	1		
20540Z : ***UNRECONCILABLE CODE***	1						1									
20541Z : ***UNRECONCILABLE CODE***	1											1				
20Z : ***UNRECONCILABLE CODE***	1								1							
21Z : ***UNRECONCILABLE CODE***	2							1	1							
22Z : ***UNRECONCILABLE CODE***	1						1									
23 01Z : ***UNRECONCILABLE CODE***	1									1						

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.37 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service  
 Using 8-Group Classification Used in Most ADR Tables

Primary Disease Group 8: Missing Cause

Detailed Primary Disease	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
.23 LU : ***UNRECONCILABLE CODE***	1											1				
.23 SY : ***UNRECONCILABLE CODE***	1				1											
.25000 : ***UNRECONCILABLE CODE***	188											104	81	3		
.25001 : ***UNRECONCILABLE CODE***	178											104	73	1		
.2500A : ***UNRECONCILABLE CODE***	116	3			4	5	2	5	6	8	51	13	16	2	1	
.25040 : ***UNRECONCILABLE CODE***	15												7	7	1	
.25041 : ***UNRECONCILABLE CODE***	25												11	14		
.25090Z : ***UNRECONCILABLE CODE***	1	1														
.2700 : ***UNRECONCILABLE CODE***	1													1		
.2728Z : ***UNRECONCILABLE CODE***	1					1										
.27410 : ***UNRECONCILABLE CODE***	1												1			
.2754Z : ***UNRECONCILABLE CODE***	1	1														
.2773 : ***UNRECONCILABLE CODE***	2												2			
.2820Z : ***UNRECONCILABLE CODE***	1					1										
.28260 : ***UNRECONCILABLE CODE***	1													1		
.2826A : ***UNRECONCILABLE CODE***	1										1					
.2831 : ***UNRECONCILABLE CODE***	1													1		
.2870 : ***UNRECONCILABLE CODE***	3												1	2		
.29 AL : ***UNRECONCILABLE CODE***	1	1														
.29Z : ***UNRECONCILABLE CODE***	2								1	1						
.30400Z : ***UNRECONCILABLE CODE***	1	1														
.4010 : ***UNRECONCILABLE CODE***	1												1			
.4010D : ***UNRECONCILABLE CODE***	1												1			
.4011 : ***UNRECONCILABLE CODE***	1												1			
.4019 : ***UNRECONCILABLE CODE***	39												19	20		
.40301Z : ***UNRECONCILABLE CODE***	1											1				
.4039 : ***UNRECONCILABLE CODE***	213												110	92	10	1
.40391Z : ***UNRECONCILABLE CODE***	6	2					1	1	2							
.40399 : ***UNRECONCILABLE CODE***	1													1		
.4039A : ***UNRECONCILABLE CODE***	1												1			
.4100 : ***UNRECONCILABLE CODE***	1													1		
.4280 : ***UNRECONCILABLE CODE***	1												1			
.4280Z : ***UNRECONCILABLE CODE***	1											1				
.4289A : ***UNRECONCILABLE CODE***	1											1				
.4401 : ***UNRECONCILABLE CODE***	3												3			
.4431 : ***UNRECONCILABLE CODE***	1													1		
.44310Z : ***UNRECONCILABLE CODE***	1	1														
.4462 : ***UNRECONCILABLE CODE***	1													1		
.44620Z : ***UNRECONCILABLE CODE***	1						1									
.44621Z : ***UNRECONCILABLE CODE***	1											1				
.4464 : ***UNRECONCILABLE CODE***	4												3	1		

(CONTINUED)

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.



Table A.37 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service  
 Using 8-Group Classification Used in Most ADR Tables

Primary Disease Group 8: Missing Cause Detailed Primary Disease	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
.4828Z : ***UNRECONCILABLE CODE***	1	1														
.49007Z: ***UNRECONCILABLE CODE***	1	1														
.50000A: ***UNRECONCILABLE CODE***	1											1				
.53831 : ***UNRECONCILABLE CODE***	1												1			
.5804 : ***UNRECONCILABLE CODE***	29												11	17	1	
.58040Z: ***UNRECONCILABLE CODE***	1	1														
.58089 : ***UNRECONCILABLE CODE***	7												2	5		
.5810A : ***UNRECONCILABLE CODE***	1													1		
.5811 : ***UNRECONCILABLE CODE***	10												5	4	1	
.5818 : ***UNRECONCILABLE CODE***	1														1	
.5819 : ***UNRECONCILABLE CODE***	3												2		1	
.5819A : ***UNRECONCILABLE CODE***	1										1					
.5820 : ***UNRECONCILABLE CODE***	1													1		
.58200Z: ***UNRECONCILABLE CODE***	1												1			
.5821 : ***UNRECONCILABLE CODE***	28												15	11	2	
.58210Z: ***UNRECONCILABLE CODE***	3	1	1					1								
.5824Z : ***UNRECONCILABLE CODE***	5	4						1								
.5826A : ***UNRECONCILABLE CODE***	1												1			
.58281Z: ***UNRECONCILABLE CODE***	1											1				
.58289 : ***UNRECONCILABLE CODE***	5												2	2	1	
.5828Z : ***UNRECONCILABLE CODE***	21	19				1	1									
.5829 : ***UNRECONCILABLE CODE***	76												43	30	3	
.58291A: ***UNRECONCILABLE CODE***	1												1			
.582Z : ***UNRECONCILABLE CODE***	1	1														
.5831 : ***UNRECONCILABLE CODE***	3												1	2		
.5832 : ***UNRECONCILABLE CODE***	8												4	4		
.5834 : ***UNRECONCILABLE CODE***	4												1	3		
.5836 : ***UNRECONCILABLE CODE***	2												2			
.58381 : ***UNRECONCILABLE CODE***	4												2	2		
.58389 : ***UNRECONCILABLE CODE***	16												10	6		
.58389A: ***UNRECONCILABLE CODE***	8											6	2			
.5838B : ***UNRECONCILABLE CODE***	9	5				1		9	1			1	1			
.5839 : ***UNRECONCILABLE CODE***	14												10	4		
.58398Z: ***UNRECONCILABLE CODE***	1							1								
.5840Z : ***UNRECONCILABLE CODE***	1									1						
.5845 : ***UNRECONCILABLE CODE***	3												3			
.5845A : ***UNRECONCILABLE CODE***	1											1				
.58500Z: ***UNRECONCILABLE CODE***	4						4									
.58600Z: ***UNRECONCILABLE CODE***	1											1				
.587 : ***UNRECONCILABLE CODE***	1												1			
.5870Z : ***UNRECONCILABLE CODE***	1							1								

(CONTINUED)

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.  
 \*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form  
 Diseases are grouped in two ways:  
 Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.  
 Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.37 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service  
 Using 8-Group Classification Used in Most ADR Tables

Primary Disease Group 8: Missing Cause Detailed Primary Disease	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
.5891 : ***UNRECONCILABLE CODE***	1														1	
.58910A : ***UNRECONCILABLE CODE***	1											1				
.5900 : ***UNRECONCILABLE CODE***	1											1				
.59000 : ***UNRECONCILABLE CODE***	2												1	1		
.59001 : ***UNRECONCILABLE CODE***	2												2			
.5908Z : ***UNRECONCILABLE CODE***	2	1								1						
.591 : ***UNRECONCILABLE CODE***	1												1			
.5910Z : ***UNRECONCILABLE CODE***	1											1				
.5919Z : ***UNRECONCILABLE CODE***	1							1								
.5920 : ***UNRECONCILABLE CODE***	2												1	1		
.5937Z : ***UNRECONCILABLE CODE***	3	2			1											
.59381 : ***UNRECONCILABLE CODE***	2												1	1		
.59389 : ***UNRECONCILABLE CODE***	10												8	2		
.5938A : ***UNRECONCILABLE CODE***	1							1								
.5990 : ***UNRECONCILABLE CODE***	3												1	2		
.5996 : ***UNRECONCILABLE CODE***	2												1	1		
.5996C : ***UNRECONCILABLE CODE***	1											1				
.7100 : ***UNRECONCILABLE CODE***	16												5	10	1	
.71000Z : ***UNRECONCILABLE CODE***	1			1												
.7101 : ***UNRECONCILABLE CODE***	5												3	2		
.71010Z : ***UNRECONCILABLE CODE***	1							1								
.73513Z : ***UNRECONCILABLE CODE***	1							1								
.7530 : ***UNRECONCILABLE CODE***	6												4	2		
.7530A : ***UNRECONCILABLE CODE***	4									1		1	1	1		
.7531 : ***UNRECONCILABLE CODE***	22												13	9		
.75313 : ***UNRECONCILABLE CODE***	23												11	12		
.7531A : ***UNRECONCILABLE CODE***	21	10			1		2				4	2	2			
.7531B : ***UNRECONCILABLE CODE***	1												1			
.7532 : ***UNRECONCILABLE CODE***	7												5	2		
.7535Z : ***UNRECONCILABLE CODE***	1							1								
.7536A : ***UNRECONCILABLE CODE***	1											1				
.7539 : ***UNRECONCILABLE CODE***	2													2		
.7564Z : ***UNRECONCILABLE CODE***	1	1														
.7567 : ***UNRECONCILABLE CODE***	1												1			
.7598 : ***UNRECONCILABLE CODE***	5												2	3		
.7777Z : ***UNRECONCILABLE CODE***	3						1	1	1							
.7999 : ***UNRECONCILABLE CODE***	56												31	23	2	
.88888 : ***UNRECONCILABLE CODE***	3												2	1		
.935Z : ***UNRECONCILABLE CODE***	1	1														
.9828 : ***UNRECONCILABLE CODE***	1													1		
.99680Z : ***UNRECONCILABLE CODE***	4			1	1	1		1								

(CONTINUED)

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.37 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service  
 Using 8-Group Classification Used in Most ADR Tables

Primary Disease Group 8: Missing Cause

Detailed Primary Disease	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
9968A : ***UNRECONCILABLE CODE***	1	1	..	..	..	..	..	..	..	..	..	..	..	..	..	..
99985Z: ***UNRECONCILABLE CODE***	9	9	..	..	..	..	..	..	..	..	..	..	..	..	..	..
OTHER : ***UNRECONCILABLE CODE***	88	40	1	2	1	4	2	6	8	4	10	4	4	2	..	..
RNS : ***UNRECONCILABLE CODE***	15	6	2	..	3	1	..	2	1	..	..	..	..	..	..	..
UNK : ***UNRECONCILABLE CODE***	58	14	..	6	2	9	9	14	2	1	..	1	..	..	..	..
UUUUUZ: ***UNRECONCILABLE CODE***	413	413	..	..	..	..	..	..	..	..	..	..	..	..	..	..
UZ : ***UNRECONCILABLE CODE***	204	204	..	..	..	..	..	..	..	..	..	..	..	..	..	..

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.  
 \*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form  
 Diseases are grouped in two ways:  
 Table A. 37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.  
 Tables A. 38-A. 39 use the two levels of disease groups used only in Reference Tables A. 15-A. 22.

Table A.38  
 Primary Disease Causing ESRD: New ESRD Patients by Disease Group and Year of First ESRD Service  
 Using Using Level 1 and 2 disease groups reported in Tables A15-A22

Disease Group Level 1 01: Diabetes

Disease Group Level 2	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
ALL	299,300	30,284	8,255	9,526	10,660	12,040	14,684	16,533	19,016	21,234	21,673	26,135	29,662	32,251	33,727	13,620
Disease Group Level 2																
01A: Type I, juvenile type, ketosis prone	82,670	1,035	375	478	1,106	4,756	6,248	7,461	8,356	9,742	10,171	12,126	7,818	6,028	5,175	1,795
01B: Type II, adult-onset or unspec. type	216,630	29,249	7,880	9,048	9,554	7,284	8,436	9,072	10,660	11,492	11,502	14,009	21,844	26,223	28,552	11,825

Disease Group Level 1 02: Glomerulonephritis

Disease Group Level 2	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
ALL	116,404	31,145	4,601	4,748	5,098	5,479	5,962	6,187	6,254	6,485	6,526	7,430	7,920	8,079	7,508	2,982
Disease Group Level 2																
02A: Focal glomerulosclerosis, focal GN	14,401	1,248	399	414	499	621	712	735	821	940	990	1,087	1,674	1,833	1,710	718
02B: Membranous nephropathy	4,112	575	150	183	209	189	231	222	248	250	279	286	351	397	395	147
02C: Membranoproliferative GN, types 1&2	3,514	607	160	160	135	164	178	195	198	198	217	215	282	361	305	139
02E: IgA nephropathy, Bergers disease	2,248	44	44	23	41	55	59	63	34	38	33	24	412	594	555	229
02F: IgM nephropathy	204	2	1		1				1	1		4	71	50	50	23
02G: Rapidly progressive GN	3,454	445	174	178	143	175	189	208	194	173	212	247	319	377	295	125
02H: Goodpastures Syndrome	2,884	1,007	77	114	137	131	166	163	209	192	208	178	90	91	92	29
02I: Post infectious GN, SBE	515	60	11	14	26	22	35	28	16	16	31	38	62	65	62	29
02J: Glomerulonephritis (GN)	83,088	26,931	3,538	3,616	3,845	4,055	4,328	4,483	4,442	4,590	4,460	5,097	4,384	4,062	3,806	1,451
02K: Other proliferative GN	1,984	226	47	46	62	67	64	90	91	87	96	254	275	249	238	92

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.38 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Disease Group and Year of First ESRD Service  
 Using Using Level 1 and 2 disease groups reported in Tables A15-A22

Disease Group Level 1 03: Secondary GN/Vasculitis																
Disease Group Level 2	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
ALL	20,885	2,739	871	863	994	1,056	1,172	1,228	1,322	1,412	1,394	1,665	1,771	1,908	1,784	706
Disease Group Level 2																
,03A: Lupus erythematosus, (SLE nephritis)	10,620	1,250	428	469	520	555	627	660	707	746	787	850	873	908	883	357
,03B: Polyarteritis	506	84	28	25	25	19	24	31	23	33	16	43	45	39	45	26
,03C: Wegeners granulomatosis	1,975	189	58	53	66	80	93	104	155	150	151	188	183	214	209	82
,03D: Henoch-Schonlein syndrome	384	70	15	18	14	21	11	25	25	29	26	28	31	37	20	14
,03E: Vasculitis and its derivatives	936	59	13	14	18	19	14	14	11	12	14	83	169	222	207	67
,03F: Scleroderma	2,222	553	113	90	93	97	110	106	106	140	116	149	160	173	158	58
,03G: Hemolytic uremic syndrome	1,647	195	58	47	70	84	104	94	108	121	127	151	151	154	135	48
,03H: Nephropathy from heroin /related abuse	2,295	333	157	146	188	179	184	192	187	179	152	169	83	74	52	20
,03I: Secondary GN, other	300	6	1	1	.	2	5	2	.	2	5	4	76	87	75	34
Disease Group Level 1 04: Interstitial Nephritis/Pyonephritis																
Disease Group Level 2	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
ALL	42,959	9,046	2,041	2,040	1,915	2,036	2,253	2,294	2,603	2,728	2,513	2,928	3,184	3,190	2,969	1,219
Disease Group Level 2																
,04A: Chronic pyelonephritis, reflux neph.	3,110	167	24	26	21	40	36	99	284	279	291	289	459	489	447	159
,04B: Analgesic abuse	1,494	612	32	30	40	27	32	23	26	33	28	30	148	179	182	72
,04C: Nephropathy caused by other agents	3,060	73	14	19	19	32	30	112	392	446	377	295	324	374	395	158
,04F: Nephrolithiasis, Obstruction, Gouty	13,378	3,039	651	648	629	699	788	753	646	665	642	796	935	1,059	1,009	419
,04G: Nephrocalcinosis	204	2	.	.	.	.	.	.	1	1	2	2	62	58	56	20
,04J: Chronic interstitial nephritis	21,033	5,119	1,305	1,305	1,198	1,219	1,349	1,286	1,233	1,276	1,141	1,469	1,139	912	759	323
,04K: Acute interstitial nephritis	680	34	15	12	8	19	18	21	21	28	32	47	117	119	121	68

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.38 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Disease Group and Year of First ESRD Service  
 Using Using Level 1 and 2 disease groups reported in Tables A15-A22

Disease Group Level 1 05: Hypertensive/large vessel disease

Disease Group Level 2	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
ALL	235,816	34,078	7,722	8,381	9,632	10,886	12,877	14,138	15,735	17,685	17,486	20,468	18,856	19,473	20,255	8,144
Disease Group Level 2																
05A: Hypertension, (no primary ren. dis.)	222,438	33,817	7,530	8,183	9,399	10,662	12,591	13,719	14,996	16,785	16,479	19,324	16,924	17,143	17,694	7,192
05B: Renal artery stenosis or occlusion	10,769	261	191	198	233	224	286	415	734	895	1,004	1,137	1,351	1,549	1,655	636
05D: Cholesterol emboli, renal emboli	2,609		1					4	5	5	3	7	581	781	906	316

Disease Group Level 1 06: Cystic/Hereditary/Congenital Diseases

Disease Group Level 2	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
ALL	37,237	10,143	1,509	1,594	1,667	1,675	1,763	1,901	1,951	2,054	2,039	2,292	2,656	2,582	2,458	953
Disease Group Level 2																
06A: Polycystic kidneys, adult (dominant)	28,464	8,058	1,155	1,249	1,274	1,290	1,314	1,477	1,534	1,635	1,640	1,797	1,875	1,754	1,722	690
06B: Polycystic, infantile (recessive)	145	6		1		2	2	1	2	1			27	41	39	21
06C: Medullary cystic, inc nephronophthisis	171	9		7	2			1	4	1	1	6	43	48	34	15
06D: Alports, other hereditary/familial dis	1,954	403	62	73	75	92	98	88	106	98	101	119	181	209	171	78
06E: Tuberos sclerosis	209	2				1	2	7	17	38	23	23	26	29	24	17
06G: Cystinosis	186	49	4	14	10	6	8	11	12	15	9	12	12	8	13	3
06H: Primary oxalosis	306	67	17	20	18	19	9	20	21	25	23	24	13	11	15	4
06I: Fabrys disease	198	33	9	7	15	9	12	10	9	19	10	22	10	18	11	4
06J: Congenital nephrotic syndrome	159	8			1	1			1		2		41	44	43	18
06K: Drash syndrome, mesangial sclerosis	28			1				1					9	2	9	6
06L: Congenital obstructive uropathy	2,668	919	96	72	110	101	121	117	71	87	85	152	248	223	209	57
06M: Renal hypoplasia, dysplasia	2,652	584	164	149	162	153	196	167	173	134	143	132	146	169	144	36
06N: Prune belly syndrome	97	5	2	1		1	1	1	1		1	5	25	26	24	4

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.38 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Disease Group and Year of First ESRD Service  
 Using Using Level 1 and 2 disease groups reported in Tables A15-A22

Disease Group Level 1 07: Neoplasms/Tumors

Disease Group Level 2	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
ALL	14,243	2,051	549	591	604	657	728	756	832	919	880	1,005	1,272	1,376	1,438	585
Disease Group Level 2																
,07C: . Renal or Urological Neoplasms	3,495	258	121	139	126	164	190	205	211	241	221	243	383	382	433	178
,07H: . Multiple myeloma	7,431	1,196	286	305	318	347	384	390	427	493	488	557	608	669	671	292
,07I: . Light chain nephropathy	293	1		1	1	1	1	1	3	1	1	1	71	87	92	31
,07J: . Amyloidosis	3,024	596	142	146	159	145	153	160	191	184	170	204	210	238	242	84

Disease Group Level 1 08: Miscellaneous Conditions

Disease Group Level 2	Year of First ESRD Service															
	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
ALL	23,259	6,128	490	507	532	544	702	694	806	921	1,172	1,412	2,554	2,753	2,923	1,121
Disease Group Level 2																
,08A: . Complication post bone marr/other txp	1,320	798	96	75	53	30	31	11	3	2	10	3	41	63	79	25
,08C: . Sickle cell disease/anemia or trait	802	78	34	29	39	21	52	48	37	57	57	76	80	81	80	33
,08E: . AIDS nephropathy	4,946	9	1	2	4	34	106	170	295	379	487	597	954	845	739	324
,08F: . Traumatic/surgical loss of kidney(s)	293	6					1			1	2		68	107	70	38
,08G: . Hepatorenal syndrome	657	22	9	12	10	17	27	27	35	38	52	54	82	109	127	36
,08H: . Tubular necrosis (no recovery)	11,986	4,948	285	309	322	339	418	396	388	399	509	616	762	893	1,016	386
,08I: . Post-Partum Fail, Oth Renal Disorders	3,255	267	65	80	104	103	67	42	48	45	55	66	567	655	812	279

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.  
 \*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form  
 Diseases are grouped in two ways:  
 Table A. 37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.  
 Tables A. 38-A. 39 use the two levels of disease groups used only in Reference Tables A. 15-A. 22.

Table A.38 (Continued)  
 Primary Disease Causing ESRD: New ESRD Patients by Disease Group and Year of First ESRD Service  
 Using Level 1 and 2 disease groups reported in Tables A15-A22

Disease Group Level 1 09: Etiology Uncertain												
-----+-----												
, Disease Group Level 2												
, Year of First ESRD Service												
, ALL , <1985 , 1985 , 1986 , 1987 , 1988 , 1989 , 1990 , 1991 , 1992 , 1993 , 1994 , 1995 , 1996 , 1997 , 1998 ,												
-----+-----												
, ALL , 50,469 , 16,231 , 1,885 , 2,079 , 2,504 , 2,453 , 2,229 , 2,318 , 2,580 , 2,910 , 2,647 , 2,814 , 2,679 , 2,980 , 2,949 , 1,211 ,												
, Disease Group Level 2												
, 09 : Etiology Uncertain , 50,469 , 16,231 , 1,885 , 2,079 , 2,504 , 2,453 , 2,229 , 2,318 , 2,580 , 2,910 , 2,647 , 2,814 , 2,679 , 2,980 , 2,949 , 1,211 ,												
-----+-----												

Disease Group Level 1 10: Missing												
-----+-----												
, Disease Group Level 2												
, Year of First ESRD Service												
, ALL , <1985 , 1985 , 1986 , 1987 , 1988 , 1989 , 1990 , 1991 , 1992 , 1993 , 1994 , 1995 , 1996 , 1997 , 1998 ,												
-----+-----												
, ALL , 65,738 , 39,559 , 1,132 , 1,349 , 1,169 , 1,606 , 2,079 , 1,824 , 1,316 , 1,262 , 3,048 , 1,601 , 2,408 , 2,126 , 4,254 , 1,005 ,												
, Disease Group Level 2												
, 10 : Missing , 65,738 , 39,559 , 1,132 , 1,349 , 1,169 , 1,606 , 2,079 , 1,824 , 1,316 , 1,262 , 3,048 , 1,601 , 2,408 , 2,126 , 4,254 , 1,005 ,												
-----+-----												

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.  
 \*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form  
 Diseases are grouped in two ways:  
 Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.  
 Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.



Table A.39

Detailed Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service Using Using Level 1 and 2 disease groups reported in Tables A15-A22

Disease Group Level 1 01: Diabetes

Disease Group Level 2	Detailed Disease Code	CYEAR																
		ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	
.01A: . Type I, juvenile type, ketosis prone	25001A	31,683	239	106	134	198	685	551	613	669	978	1,432	5,466	7,615	6,027	5,175	1,795	
	25001Z	23,457	456	185	229	464	1,759	2,422	3,109	3,441	3,916	4,169	3,134	172	1			
	2501Z	79	79															
	25041Z	27,451	261	84	115	444	2,312	3,275	3,739	4,246	4,848	4,570	3,526	31				
.01B: . Type II, adult-onset or unspec. type	25000A	106,543	2,389	891	1,052	1,194	972	704	732	857	1,045	1,730	6,713	21,665	26,222	28,552	11,825	
	25000Z	29,971	339	126	228	681	2,929	3,685	4,254	4,648	4,742	4,809	3,368	162				
	2500Z	15,933	7,290	2,690	2,979	2,924	47	1		2								
	25040Z	32,265	215	86	143	660	3,267	4,044	4,085	5,153	5,705	4,961	3,928	17	1			
	2504Z	31,918	19,016	4,087	4,646	4,095	69	2	1			2						

Disease Group Level 1 02: Glomerulonephritis

Disease Group Level 2	Detailed Disease Code	CYEAR																
		ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	
.02A: . Focal glomerulosclerosis, focal GN	5811Z	2,173	398	115	113	130	190	224	208	224	217	193	150	10	1			
	5818Z	121	4	1	1	1		1	7	17	26	33	28	2				
	5821A	7,554	221	56	59	66	101	98	117	103	123	172	526	1,653	1,831	1,710	718	
	5821Z	4,553	625	227	241	302	330	389	403	477	574	592	383	9	1			
.02B: . Membranous nephropathy	5831A	1,738	70	27	20	21	32	25	29	19	45	36	129	346	397	395	147	
	5831Z	2,374	505	123	163	188	157	206	193	229	205	243	157	5				
.02C: . Membranoproliferative GN, types 1&2	5832A	1,474	90	25	26	20	31	26	34	36	29	51	113	255	335	280	123	
	5832C	99	2					2		1	1	2	1	23	26	25	16	
	5832Z	1,941	515	135	134	115	133	150	161	161	168	164	101	4				
.02E: . IgA nephropathy, Bergers disease	4431Z	376	30	37	21	34	53	54	50	27	26	28	16					
	58381B	1,872	14	7	2	7	2	5	13	7	12	5	8	412	594	555	229	
.02F: . IgM nephropathy	58381C	204	2	1		1				1	1		4	71	50	50	23	
.02G: . Rapidly progressive GN	5804B	1,509	77	24	28	14	24	27	25	22	25	36	119	291	377	295	125	
	5804Z	1,945	368	150	150	129	151	162	183	172	148	176	128	28				
.02H: . Goodpastures Syndrome	44629Z	15	15															
	4462Z	2,154	973	75	106	132	129	163	138	124	119	116	78	1				
	5834C	416	6	1	1		1	2	10	6	9	19	60	89	91	92	29	
	5834Z	299	13	1	7	5	1	1	15	79	64	73	40					
.02I: . Post infectious GN, SBE	5800C	293	20	2	3	9	4	5	3	2	3	5	19	62	65	62	29	
	5800Z	222	40	9	11	17	18	30	25	14	13	26	19					
.02J: . Glomerulonephritis (GN)	5809Z	272	66	19	16	17	20	19	21	25	24	30	15					
	5819Z	2,294	418	123	124	152	159	175	247	246	262	210	171	6	1			
	5829A	23,307	2,534	443	479	509	575	502	491	417	515	795	2,401	4,330	4,059	3,806	1,451	
	5829Z	26,375	6,426	1,613	1,667	1,760	1,894	1,997	2,209	2,374	2,431	2,246	1,717	40	1			
	5839Z	30,840	17,487	1,340	1,330	1,407	1,407	1,635	1,515	1,380	1,358	1,179	793	8	1			

(CONTINUED) Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version. \*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form. Diseases are grouped in two ways: Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR. Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.39 (Continued)

Detailed Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service Using Using Level 1 and 2 disease groups reported in Tables A15-A22

Disease Group Level 1 02: Glomerulonephritis

Disease Group Level 2	Detailed Disease Code	CYEAR																
		ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	
.02K: . Other proliferative GN	5820A	1,328	53	10	9	19	18	15	22	28	37	45	222	271	249	238	92	
	5820Z	20	2	..	..	..	1	1	1	4	1	6	1	3	..	..	..	
	5830Z	636	171	37	37	43	48	48	67	59	49	45	31	1	..	..	..	

Disease Group Level 1 03: Secondary GN/Vasculitis

Disease Group Level 2	Detailed Disease Code	CYEAR																
		ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	
.03A: . Lupus erythematosus, (SLE nephritis)	6954Z	476	116	23	21	25	32	46	45	47	58	45	18	..	..	..	..	
	7100E	4,407	168	44	68	83	89	71	96	93	91	151	442	863	908	883	357	
	7100Z	5,737	966	361	380	412	434	510	519	567	597	591	390	10	..	..	..	
.03B: . Polyarteritis	4460C	200	13	1	1	3	4	2	2	1	7	..	12	44	39	45	26	
	4460Z	306	71	27	24	22	15	22	29	22	26	16	31	1	..	..	..	
.03C: . Wegeners granulomatosis	4464B	939	33	6	9	11	10	9	12	14	17	24	108	181	214	209	82	
	4464Z	1,036	156	52	44	55	70	84	92	141	133	127	80	2	..	..	..	
.03D: . Henoch-Schonlein syndrome	2870A	174	15	4	4	3	3	3	5	4	10	5	16	31	37	20	14	
	2870Z	210	55	11	14	11	18	8	20	21	19	21	12	..	..	..	..	
.03E: . Vasculitis and its derivatives	4462A	936	59	13	14	18	19	14	14	11	12	14	83	169	222	207	67	
	7101B	746	40	12	8	7	11	10	8	4	9	20	71	157	173	158	58	
	7101Z	1,476	513	101	82	86	86	100	98	102	131	96	78	3	..	..	..	
.03G: . Hemolytic uremic syndrome	2831A	699	29	4	3	12	11	8	16	11	9	28	82	149	154	135	48	
	2831Z	750	150	46	35	46	57	73	58	77	78	73	55	2	..	..	..	
	4466Z	198	16	8	9	12	16	23	20	20	34	26	14	..	..	..	..	
.03H: . Nephropathy from heroin /related abuse	5839C	489	31	21	12	20	26	16	18	9	12	22	73	83	74	52	20	
	585Z	1	..	..	..	..	..	..	..	..	..	..	1	..	..	..	..	
	587Z	1,805	302	136	134	168	153	168	174	178	167	129	96	..	..	..	..	
.03I: . Secondary GN, other	5839B	300	6	1	1	..	2	5	2	..	2	5	4	76	87	75	34	

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.39 (Continued)

Detailed Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service Using Using Level 1 and 2 disease groups reported in Tables A15-A22

Disease Group Level 1 04: Interstitial Nephritis/Pyelonephritis		CYEAR																
Disease Group Level 2	Detailed Disease Code	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	
.04A: . Chronic pyelonephritis, reflux neph.	59000Z	696,	52,	8,	4,	6,	12,	11,	46,	148,	145,	158,	103,	3,	..	..	..	
	59001Z	466,	28,	4,	3,	2,	5,	6,	35,	115,	109,	100,	58,	1,	..	..	..	
	5900A	1,948,	87,	12,	19,	13,	23,	19,	18,	21,	25,	33,	128,	455,	489,	447,	159,	
.04B: . Analgesic abuse	9654Z	459,	450,	..	..	2,	..	1,	..	2,	2,	2,	..	..	..	..	..	
	9659A	663,	33,	3,	3,	6,	2,	2,	2,	4,	3,	22,	148,	179,	182,	72,	..	
	9659Z	372,	129,	29,	27,	32,	25,	29,	21,	22,	27,	23,	8,	..	..	..	..	
.04C: . Nephropathy caused by other agents	5830B	93,	..	..	..	1,	1,	..	..	..	1,	..	..	19,	35,	30,	6,	
	5909A	1,161,	13,	3,	3,	3,	5,	..	4,	3,	3,	5,	21,	286,	322,	346,	144,	
	5909Z	131,	30,	9,	10,	4,	11,	11,	7,	11,	12,	17,	9,	..	..	..	..	
	5990Z	1,614,	30,	2,	6,	11,	15,	19,	101,	378,	430,	354,	263,	5,	..	..	..	
	9849A	61,	..	..	..	..	..	..	..	..	1,	2,	14,	17,	19,	8,	..	
.04F: . Nephrolithiasis, Obstruction, Gouty	27410A	199,	19,	6,	2,	2,	5,	3,	2,	..	3,	2,	15,	37,	37,	50,	16,	
	27410Z	47,	..	..	..	..	..	3,	4,	10,	13,	10,	7,	..	..	..	..	
	27411Z	37,	..	..	..	..	..	..	4,	7,	11,	8,	7,	..	..	..	..	
	2741Z	388,	247,	30,	25,	16,	20,	18,	18,	8,	2,	1,	3,	..	..	..	..	
	591Z	447,	93,	26,	29,	30,	26,	36,	39,	48,	55,	42,	23,	..	..	..	..	
	5920C	654,	23,	6,	14,	7,	13,	8,	10,	4,	8,	11,	34,	149,	168,	136,	63,	
	5920Z	877,	191,	62,	54,	52,	65,	84,	67,	90,	92,	75,	45,	..	..	..	..	
	5929B	115,	1,	1,	..	..	1,	2,	1,	1,	1,	..	1,	22,	38,	35,	11,	
	5929Z	23,	3,	3,	1,	1,	3,	1,	4,	2,	2,	3,	..	..	..	..	..	
	59389Z	1,339,	57,	10,	14,	23,	89,	160,	186,	222,	216,	201,	158,	3,	..	..	..	
	5996A	3,779,	234,	54,	61,	63,	66,	61,	43,	40,	59,	85,	357,	723,	816,	788,	329,	
	5996Z	858,	55,	4,	4,	7,	12,	11,	63,	170,	195,	200,	136,	1,	..	..	..	
	599Z	4,603,	2,115,	447,	443,	426,	398,	400,	310,	43,	7,	4,	10,	..	..	..	..	
	600Z	12,	1,	2,	1,	2,	1,	1,	2,	1,	1,	..	..	..	..	..	..	
.04G: . Nephrocalcinosis	2754A	204,	2,	..	..	..	..	..	..	1,	1,	2,	2,	62,	58,	56,	20,	
.04J: . Chronic interstitial nephritis	58289Z	8,795,	2,851,	649,	573,	601,	504,	633,	596,	684,	685,	564,	451,	3,	1,	..	..	
	5837Z	244,	15,	5,	10,	9,	15,	11,	25,	50,	56,	25,	22,	1,	..	..	..	
	58389B	5,360,	459,	133,	143,	137,	168,	91,	95,	76,	101,	150,	693,	1,121,	911,	759,	323,	
	58389Z	3,601,	545,	211,	300,	197,	269,	331,	327,	368,	387,	368,	285,	13,	..	..	..	
	5900Z	3,033,	1,249,	307,	279,	254,	263,	283,	243,	55,	47,	34,	18,	1,	..	..	..	
.04K: . Acute interstitial nephritis	58089A	489,	7,	4,	3,	3,	5,	5,	3,	..	6,	6,	24,	115,	119,	121,	68,	
	58089Z	191,	27,	11,	9,	5,	14,	13,	18,	21,	22,	26,	23,	2,	..	..	..	

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.39 (Continued)

Detailed Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service Using Using Level 1 and 2 disease groups reported in Tables A15-A22

Disease Group Level 1 05: Hypertensive/large vessel disease		CYEAR																
Disease Group Level 2	Detailed Disease Code	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	
.05A: Hypertension, (no primary ren. dis.)	4010Z	1,643	491	101	118	98	116	122	134	124	132	108	99	..	..	..	..	
	4011Z	88	5	3	4	3	5	6	10	8	26	9	9	..	..	..	..	
	4019Z	49,623	5,863	2,454	2,671	3,228	3,474	4,142	4,850	5,632	6,231	6,191	4,857	30	..	..	..	
	401Z	13,264	13,264	..	..	..	..	..	..	..	..	..	..	..	..	..	..	
	4030Z	1,378	178	120	114	133	90	81	66	102	134	183	176	1	..	..	..	
	4031Z	848	87	31	35	46	65	57	55	92	129	131	119	1	..	..	..	
	4039D	81,413	3,179	903	1,050	1,176	1,418	1,029	1,093	992	1,369	2,143	8,360	16,675	17,141	17,693	7,192	
	4039Z	69,883	7,975	3,845	4,144	4,649	5,355	6,970	7,359	7,859	8,508	7,494	5,505	217	2	1	..	
	403Z	2,243	2,242	1	..	..	..	..	..	..	..	..	..	..	..	..	..	
	4040Z	147	15	19	5	9	11	11	9	12	20	21	15	..	..	..	..	
	4041Z	60	6	2	2	1	7	3	4	6	12	7	10	..	..	..	..	
	4049Z	1,540	204	51	40	56	121	170	139	169	224	192	174	..	..	..	..	
	404Z	308	308	..	..	..	..	..	..	..	..	..	..	..	..	..	..	
.05B: Renal artery stenosis or occlusion	4401A	4,166	21	25	18	18	20	21	29	36	48	64	267	913	1,065	1,159	462	
	4401Z	2,432	98	75	81	100	102	144	221	350	413	495	352	1	..	..	..	
	59381B	1,964	16	14	11	10	12	8	12	20	29	33	211	434	484	496	174	
	59381Z	2,207	126	77	88	105	90	113	153	328	405	412	307	3	..	..	..	
.05D: Cholesterol emboli, renal emboli	59381E	2,609	..	1	..	..	..	..	4	5	5	3	7	581	781	906	316	

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.39 (Continued)

Detailed Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service Using Using Level 1 and 2 disease groups reported in Tables A15-A22

Disease Group Level 1 06: Cystic/Hereditary/Congenital Diseases		CYEAR															
Disease Group Level 2	Detailed Disease Code	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
.06A: . Polycystic kidneys, adult (dominant)	75313A 75313Z 7531Z	9,129, 264, 19,071,	682, 51, 7,325,	141, 2, 1,012,	180, 4, 1,065,	186, 7, 1,081,	179, 17, 1,094,	126, 13, 1,175,	165, 21, 1,291,	150, 22, 1,362,	197, 19, 1,419,	299, 69, 1,272,	831, 23, 943,	1,831, 16, 28,	1,750, .., 4,	1,722, .., ..,	690, .., ..,
.06B: . Polycystic, infantile (recessive)	75314A	145,	6,	..,	1,	..,	2,	2,	1,	2,	2,	1,	..,	27,	41,	39,	21,
.06C: . Medullary cystic, inc nephronophthisis	75316A	171,	9,	..,	7,	2,	..,	..,	1,	4,	1,	1,	6,	43,	48,	34,	15,
.06D: . Alports, other hereditary/familial dis	7598A 7598B 7598Z	740, 194, 1,020,	80, 3, 320,	15, .., 47,	16, .., 57,	18, 2, 55,	16, 1, 75,	9, .., 89,	20, .., 68,	15, .., 91,	19, .., 79,	22, 1, 78,	58, 1, 60,	121, 59, 1,	142, 67, ..,	126, 45, ..,	63, 15, ..,
.06E: . Tuberosus sclerosis	7595A 7595Z	118, 91,	1, 1,	.., ..,	.., ..,	.., ..,	.., 1,	2, ..,	1, 6,	1, 16,	4, 34,	3, 20,	10, 13,	26, ..,	29, ..,	24, ..,	17, ..,
.06G: . Cystinosis	2700A 2700Z	77, 109,	12, 37,	1, 3,	5, 9,	4, 6,	3, 3,	2, 6,	3, 8,	3, 9,	2, 13,	3, 6,	3, 9,	12, ..,	8, ..,	13, ..,	3, ..,
.06H: . Primary oxalosis	2718B 2718Z	80, 226,	6, 61,	1, 16,	1, 19,	1, 17,	2, 17,	.., 9,	1, 19,	1, 20,	2, 23,	5, 18,	17, 7,	13, ..,	11, ..,	15, ..,	4, ..,
.06I: . Fabrys disease	2727A 2727Z	76, 122,	6, 27,	.., 9,	3, 4,	3, 12,	1, 8,	2, 10,	1, 9,	2, 7,	4, 15,	.., 10,	11, 11,	10, ..,	18, ..,	11, ..,	4, ..,
.06J: . Congenital nephrotic syndrome	7533A	159,	8,	..,	..,	1,	1,	..,	..,	1,	..,	2,	..,	41,	44,	43,	18,
.06K: . Drash syndrome, mesangial sclerosis	5839D	28,	..,	..,	1,	..,	..,	..,	1,	..,	..,	..,	..,	9,	2,	9,	6,
.06L: . Congenital obstructive uropathy	7532A 7532Z 7533Z	1,210, 306, 1,152,	137, 62, 720,	10, 16, 70,	11, 15, 46,	22, 23, 65,	24, 10, 67,	21, 17, 83,	29, 29, 59,	22, 35, 14,	25, 49, 13,	47, 30, 8,	132, 13, 7,	241, 7, ..,	223, ..,	209, ..,	57, ..,
.06M: . Renal hypoplasia, dysplasia	7530B 7530Z 7539Z 753Z	939, 595, 782, 336,	108, 171, 181, 124,	21, 42, 67, 34,	23, 34, 55, 37,	28, 33, 63, 38,	35, 32, 58, 28,	34, 60, 64, 38,	26, 39, 67, 35,	28, 39, 81, 2,	33, 62, 58, ..,	39, 43, 55, ..,	77, 26, 29, ..,	138, 4, 4,	169, ..,	144, ..,	36, ..,
.06N: . Prune belly syndrome	7567A 7567Z	92, 5,	5, ..,	2, ..,	1, ..,	.., ..,	1, ..,	1, ..,	1, ..,	1, ..,	1, ..,	.., 1,	2, 3,	24, 1,	26, ..,	24, ..,	4, ..,

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.39 (Continued)

Detailed Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service Using Using Level 1 and 2 disease groups reported in Tables A15-A22

Disease Group Level 1 07: Neoplasms/Tumors		CYEAR															
Disease Group Level 2	Detailed Disease Code	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
.07C: . Renal or Urological	1890B	1,105.	33.	10.	16.	15.	23.	12.	16.	11.	20.	20.	92.	245.	225.	256.	111.
. Neoplasms	1890Z	726.	3.	1.	1.	4.	6.	7.	56.	163.	186.	175.	122.	2.	..	..	..
	1891Z	50.	..	..	..	..	..	..	4.	14.	17.	7.	8.	..	..	..	..
	1899A	313.	..	..	..	..	..	..	..	..	..	..	..	81.	95.	94.	43.
	1899Z	4.	..	..	..	..	..	..	..	..	..	4.	..	..	..	..	..
	189Z	949.	204.	100.	111.	96.	125.	162.	116.	15.	7.	6.	7.	..	..	..	..
	20280A	119.	2.	1.	3.	1.	3.	1.	4.	..	1.	1.	8.	25.	23.	34.	12.
	20283Z	16.	..	..	..	..	..	..	1.	5.	2.	5.	3.	..	..	..	..
	20285Z	12.	..	..	..	..	..	..	2.	3.	5.	1.	1.	..	..	..	..
	20286Z	1.	..	..	..	..	..	..	..	..	..	..	1.	..	..	..	..
	2028Z	65.	15.	9.	7.	10.	7.	8.	6.	..	2.	1.	..	..	..	..	..
	2230A	24.	1.	..	..	..	..	..	..	..	..	..	1.	5.	8.	8.	1.
	2239A	27.	..	..	..	..	..	..	..	..	1.	1.	..	7.	9.	5.	4.
	2395A	55.	..	..	1.	..	..	..	..	..	..	..	..	13.	14.	23.	4.
	2395B	29.	..	..	..	..	..	..	..	..	..	..	..	5.	8.	13.	3.
.07H: . Multiple myeloma	2030A	2,885.	101.	28.	25.	33.	36.	28.	34.	22.	39.	55.	245.	607.	669.	671.	292.
	2030Z	4,102.	673.	258.	280.	285.	310.	356.	355.	399.	449.	428.	308.	1.	..	..	..
	203Z	422.	422.	..	..	..	..	..	..	..	..	..	..	..	..	..	..
	2733Z	22.	..	..	..	..	1.	..	1.	6.	5.	5.	4.	..	..	..	..
.07I: . Light chain nephropathy	2030B	293.	1.	..	1.	1.	1.	1.	1.	3.	1.	1.	1.	71.	87.	92.	31.
.07J: . Amyloidosis	2773A	1,035.	47.	12.	15.	19.	20.	12.	9.	13.	8.	25.	85.	207.	238.	241.	84.
	2773Z	1,978.	538.	130.	131.	140.	125.	141.	151.	178.	176.	145.	119.	3.	..	1.	..
	2873Z	11.	11.	..	..	..	..	..	..	..	..	..	..	..	..	..	..

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.39 (Continued)

Detailed Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service Using Using Level 1 and 2 disease groups reported in Tables A15-A22

Table with columns for Disease Group Level 1, Disease Group Level 2, Detailed Disease Code, and CYEAR (1985-1998). Rows include categories like '08A: . Complication post bone marr/other txp', '08C: . Sickle cell disease/anemia or trait', '08E: . AIDS nephropathy', '08F: . Traumatic/surgical loss of kidney(s)', '08G: . Hepatorenal syndrome', '08H: . Tubular necrosis (no recovery)', and '08I: . Post-Partum Fail, Oth Renal Disorders'.

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.39 (Continued)  
 Detailed Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service  
 Using Level 1 and 2 disease groups reported in Tables A15-A22

Disease Group Level 1 09: Etiology Uncertain		CYEAR																
Disease Group Level 2	Detailed Disease Code	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	
09 : Etiology Uncertain	58381Z	1,200	92	21	27	27	38	34	90	232	245	207	184	3				
	586Z	3,272	1,205	365	356	440	354	335	190	12	9	3	3					
	5890Z	43	5		2		2		1	7	9	11	6					
	5891Z	226			3			2	10	43	52	79	37					
	5899Z	88	6				2		5	25	26	17	7					
	589Z	255	82	32	26	29	27	27	28	2	1	1						
	7999A	15,336	1,226	233	311	376	403	241	237	244	333	512	1,427	2,654	2,979	2,949	1,211	
	7999Z	24,687	8,735	1,141	1,274	1,507	1,570	1,583	1,731	2,000	2,214	1,783	1,131	17	1			
	8660Z	2										2						
	88888Z	29	1						2	1	3	7	11	4				
	8999Z	3,773	3,773															
	99999Z	1,558	1,106	93	80	125	57	7	24	14	18	25	8	1				

Disease Group Level 1 10: Missing		CYEAR																
Disease Group Level 2	Detailed Disease Code	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	
10 : Missing	7900	63,276	38,707	1,120	1,324	1,138	1,553	2,022	1,761	1,262	1,225	2,958	1,548	1,781	1,649	4,224	1,004	
	7900Z	6												4	2			
	0429	314	106	8	14	16	28	30	28	28	19	20	12	5				
	0439	5												2	3			
	0439D	1												1				
	0449	2												1	1			
	0586Z	1			1									1				
	18 AN	1	1															
	1890	3												2		1		
	19Z	1							1									
	20	1														1		
	20280Z	1											1					
	2030	3												2	1			
	20540Z	1						1										
	20541Z	1											1					
	20Z	1								1								
	21Z	2							1	1								
	22Z	1						1										
	23 01Z	1									1							
	23 LU	1											1					
	23 SY	1				1												

(CONTINUED)  
 Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.  
 \*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form  
 Diseases are grouped in two ways:  
 Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.  
 Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.



Table A.39 (Continued)

Detailed Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service Using Using Level 1 and 2 disease groups reported in Tables A15-A22

Disease Group Level 1 10: Missing	Disease Group Level 2	Detailed Disease Code	CYEAR															
			ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
		25000	188,	..	..	..	..	..	..	..	..	..	..	..	104,	81,	3,	..
		25001	178,	..	..	..	..	..	..	..	..	..	..	..	104,	73,	1,	..
		2500A	116,	3,	..	..	4,	5,	2,	5,	6,	8,	51,	13,	16,	2,	1,	..
		25040	15,	..	..	..	..	..	..	..	..	..	..	..	7,	7,	1,	..
		25041	25,	..	..	..	..	..	..	..	..	..	..	..	11,	14,	..	..
		25090Z	1,	1,	..	..	..	..	..	..	..	..	..	..	..	..	..	..
		2700	1,	..	..	..	..	..	..	..	..	..	..	..	..	1,	..	..
		2728Z	1,	..	..	..	..	1,	..	..	..	..	..	..	..	..	..	..
		27410	1,	..	..	..	..	..	..	..	..	..	..	..	1,	..	..	..
		2754Z	1,	1,	..	..	..	..	..	..	..	..	..	..	..	..	..	..
		2773	2,	..	..	..	..	..	..	..	..	..	..	..	2,	..	..	..
		2820Z	1,	..	..	..	1,	..	..	..	..	..	..	..	..	..	..	..
		28260	1,	..	..	..	..	..	..	..	..	..	..	..	..	1,	..	..
		2826A	1,	..	..	..	..	..	..	..	..	..	1,	..	..	..	..	..
		2831	1,	..	..	..	..	..	..	..	..	..	..	..	..	1,	..	..
		2870	3,	..	..	..	..	..	..	..	..	..	..	..	1,	2,	..	..
		29 AL	1,	1,	..	..	..	..	..	..	..	..	..	..	..	..	..	..
		29Z	2,	..	..	..	..	..	..	..	1,	1,	..	..	..	..	..	..
		30400Z	1,	1,	..	..	..	..	..	..	..	..	..	..	..	..	..	..
		4010	1,	..	..	..	..	..	..	..	..	..	..	..	1,	..	..	..
		4010D	1,	..	..	..	..	..	..	..	..	..	..	..	1,	..	..	..
		4011	1,	..	..	..	..	..	..	..	..	..	..	..	1,	..	..	..
		4019	39,	..	..	..	..	..	..	..	..	..	..	..	19,	20,	..	..
		40301Z	1,	..	..	..	..	..	..	..	..	..	1,	..	..	..	..	..
		4039	213,	..	..	..	..	..	..	..	..	..	..	..	110,	92,	10,	1,
		40391Z	6,	2,	..	..	..	1,	1,	2,	..	..	..	..	..	..	..	..
		40399	1,	..	..	..	..	..	..	..	..	..	..	..	..	1,	..	..
		4039A	1,	..	..	..	..	..	..	..	..	..	..	..	1,	..	..	..
		4100	1,	..	..	..	..	..	..	..	..	..	..	..	..	1,	..	..
		4280	1,	..	..	..	..	..	..	..	..	..	..	..	1,	..	..	..
		4280Z	1,	..	..	..	..	..	..	..	..	..	..	1,	..	..	..	..
		4289A	1,	..	..	..	..	..	..	..	..	..	..	1,	..	..	..	..
		4401	3,	..	..	..	..	..	..	..	..	..	..	..	3,	..	..	..
		4431	1,	..	..	..	..	..	..	..	..	..	..	..	..	1,	..	..
		44310Z	1,	1,	..	..	..	..	..	..	..	..	..	..	..	..	..	..
		4462	1,	..	..	..	..	..	..	..	..	..	..	..	..	1,	..	..
		44620Z	1,	..	..	..	1,	..	..	..	..	..	..	..	..	..	..	..
		44621Z	1,	..	..	..	..	..	..	..	..	..	1,	..	..	..	..	..
		4464	4,	..	..	..	..	..	..	..	..	..	..	..	3,	1,	..	..
		4828Z	1,	1,	..	..	..	..	..	..	..	..	..	..	..	..	..	..
		49007Z	1,	1,	..	..	..	..	..	..	..	..	..	..	..	..	..	..

(CONTINUED)

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.



Table A.39 (Continued)

Detailed Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service Using Using Level 1 and 2 disease groups reported in Tables A15-A22

Disease Group Level 1	Disease Group Level 2	Detailed Disease Code	CYEAR																
			ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998	
.10 : Missing	5900		1														1		
	59000		2														1	1	
	59001		2														2		
	5908Z		2	1									1						
	591		1														1		
	5910Z		1														1		
	5919Z		1								1								
	5920		2														1	1	
	5937Z		3	2			1												
	59381		2														1	1	
	59389		10														8	2	
	5938A		1								1								
	5990		3														1	2	
	5996		2														1	1	
	5996C		1														1		
	7100		16														5	10	1
	71000Z		1				1												
	7101		5														3	2	
	71010Z		1								1								
	73513Z		1								1								
	7530		6														4	2	
	7530A		4										1				1	1	
	7531		22														13	9	
	75313		23														11	12	
	7531A		21	10			1		2				4	2	2		2		
	7531B		1														1		
	7532		7														5	2	
	7535Z		1							1									
	7536A		1														1		
	7539		2															2	
	7564Z		1	1															
	7567		1														1		
	7598		5														2	3	
	7777Z		3					1	1	1									
	7999		56														31	23	2
	88888		3														2	1	
	935Z		1	1															
	9828		1															1	
	99680Z		4				1	1	1		1								
	9968A		1	1															
	99985Z		9	9															

(CONTINUED)

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A.37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A.38-A.39 use the two levels of disease groups used only in Reference Tables A.15-A.22.

Table A.39 (Continued)

Detailed Primary Disease Causing ESRD: New ESRD Patients by Disease Group, Detailed Disease Code, and Year of First ESRD Service Using Using Level 1 and 2 disease groups reported in Tables A15-A22

Disease Group Level 1 10: Missing		CYEAR															
Disease Group Level 2	Detailed Disease Code	ALL	<1985	1985	1986	1987	1988	1989	1990	1991	1992	1993	1994	1995	1996	1997	1998
, 10 : Missing	OTHER	88,	40,	1,	2,	1,	4,	2,	6,	8,	4,	10,	4,	4,	2,	..	..
	RNS	15,	6,	2,	..	3,	1,	..	2,	1,	..	..	..	..	..	..	..
	UNK	58,	14,	..	6,	2,	9,	9,	14,	2,	1,	..	1,	..	..	..	..
	UUUUUZ	413,	413,	..	..	..	..	..	..	..	..	..	..	..	..	..	..
	UZ	204,	204,	..	..	..	..	..	..	..	..	..	..	..	..	..	..

Detailed primary disease codes ending in Z are from the pre-1995 version of the Medical Evidence Form (HCFA-2728). Other codes are from the current (1995) version.

\*\*\*UNRECONCILABLE CODE\*\*\* indicates a code that is not in the list of codes used for either version of the Form

Diseases are grouped in two ways:

Table A. 37 shows the eight categories used in most tables and graphics in the text and Reference Tables of the ADR.

Tables A. 38-A. 39 use the two levels of disease groups used only in Reference Tables A. 15-A. 22.